WO2005117909A2 - Kinase modulators and methods of use - Google Patents

Kinase modulators and methods of use Download PDF

Info

Publication number
WO2005117909A2
WO2005117909A2 PCT/US2005/013860 US2005013860W WO2005117909A2 WO 2005117909 A2 WO2005117909 A2 WO 2005117909A2 US 2005013860 W US2005013860 W US 2005013860W WO 2005117909 A2 WO2005117909 A2 WO 2005117909A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
pyrazolo
esi
mhz
Prior art date
Application number
PCT/US2005/013860
Other languages
French (fr)
Other versions
WO2005117909A3 (en
Inventor
Neel K. Anand
Charles M. Blazey
Owen Joseph Bowles
Joerg Bussenius
Lynne Canne Bannen
Diva Sze-Ming Chan
Baili Chen
Erick Wang Co
Simona Costanzo
Steven Charles Defina
Larisa Dubenko
Maurizio Franzini
Ping Huang
Vasu Jammalamadaka
Richard George Khoury
Moon Hwan Kim
Rhett Ronald Klein
Donna Tra Le
Morrison B. Mac
John M. Nuss
Jason Jevious Parks
Kenneth D. Rice
Tsze H. Tsang
Amy Lew Tsuhako
Yong Wang
Wei Xu
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Priority to EP20050804792 priority Critical patent/EP1750727A2/en
Priority to AU2005249380A priority patent/AU2005249380C1/en
Priority to US11/568,173 priority patent/US8076338B2/en
Priority to JP2007509678A priority patent/JP5213229B2/en
Priority to CA2563699A priority patent/CA2563699C/en
Publication of WO2005117909A2 publication Critical patent/WO2005117909A2/en
Publication of WO2005117909A3 publication Critical patent/WO2005117909A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Even more specifically, the invention relates to compounds which inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
  • Protein kinases are enzymes that catalyze the phosphorylation of proteins at the hydroxy groups of tyrosine, serine and threonine residues of proteins.
  • the kinase complement of the human genome contains 518 putative protein kinase genes [Manning et al, Science, (2002), 298, 1912].
  • the consequences of this activity include effects on cell differentiation, proliferation, transcription, translation, metabolism, cell cycle progression, apoptosis, metabolism cytoskeletal rearrangement and movement; i.e., protein kinases mediate the majority of signal transduction in eukaryotic cells.
  • Tyrosine kinases can be categorized as receptor type or non-receptor type. Receptor-type tyrosine kinases have an extracellular, a transmembrane, and an intracellular portion, while non-receptor type tyrosine kinases are wholly intracellular.
  • Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. In fact, about 20 different subfamilies of receptor-type tyrosine kinases have been identified.
  • Ligands of this subfamily of receptors identified so far include epithelial growth factor, TGF-alpha, amphiregulin, HB-EGF, betacellulin and heregulin.
  • the insulin subfamily includes LNS-R, IGF- IR, and IR-R.
  • the PDGF subfamily includes the PDGF-alpha and -beta receptors, CSFIR, c-kit and FLK-II.
  • the FLK family which is comprised of the kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (Flt-1).
  • KDR kinase insert domain receptor
  • FLK-1 fetal liver kinase-1
  • FLK-4 fetal liver kinase-4
  • Flt-1 fms-like tyrosine kinase-1
  • the non-receptor type of tyrosine kinases is also comprised of numerous subfamilies, including Src, Frk, Btk, Csk, Abl, Syk Zap70, Fes Fps, Fak, Jak, and Ack. Each of these subfamilies is further sub-divided into varying receptors.
  • the Src subfamily is one of the largest and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr, and Yrk.
  • the Src subfamily of enzymes has been linked to oncogenesis.
  • Serine-theoronine kinases play critical roles in intracellular signal transduction and include the multiple families, including STE, CKI, AGC, CAMK, and CMGC. Important subfamilies include, the MAP kinases, p38, JNK and ERK, which modulate signal transduction resulting from such diverse stimuli as mitogenic, stress, proinflammatory and antiapoptotic pathways. Members of the MAP kinase subfamily have been targeted for therapeutic intervention, including p38a, JNK isozymes and Raf.
  • kinase modulation relates to oncological indications.
  • modulation of protein kinase activity for the treatment of cancer has been demonstrated successfully with the FDA approval of Gleevec® (imatinib mesylate, produced by Novartis Pharmaceutical Corporation of East Hanover, NJ) for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stroma cancers.
  • Gleevec is a selective Abl kinase inhibitor.
  • p70S6 kinase is a serine-theoronine kinase that is a component of the phosphatidylinositol 3 kinase (PI3K)/Akt kinase (AktK) pathway. Both Akt and p70S6K are downstream of phosphatidylinositol-3 kinase (PI3K), and undergo phosphorylation and activation in response to growth factors such as IGF-1, EGF, TGF- and HGF. The enzyme p70S6K modulates protein synthesis by phosphorylation of the S6 ribosomal protein promoting translation.
  • the present invention provides compounds for modulating kinase activity and methods of treating, diseases mediated by kinase activity, in particular p70S6 and/or Akt kinase activity, utilizing the compounds and pharmaceutical compositions thereof.
  • Diseases mediated by kinase activity are from herein referred to as "kinase-dependent diseases or conditions" (see definition in detailed description of invention below).
  • Inhibitors that are selective for p70S6 and or Akt kinase are included in this invention.
  • the invention provides methods of screening for modulators of kinase activity.
  • the methods comprise combining a composition of the invention, a kinase, and at least one candidate agent and determining the effect of the candidate agent on the kinase activity.
  • kits comprising one or more containers filled with one or more of the ingredients of pharmaceutical compounds and/or compositions of the present invention, including, one or more kinase enzyme activity modulators as described herein.
  • kits can also include, for example, other compounds and/or compositions (e.g., diluents, permeation enhancers, lubricants, and the like), a device(s) for administering the compounds and/or compositions, and written instructions in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflects approval by the agency of manufacture, use or sale for human administration.
  • the invention also provides a diagnostic agent comprising a compound of the invention and, optionally, pharmaceutically acceptable adjuvants and excipients.
  • compositions of the invention are used to treat diseases associated with abnormal and/or unregulated cellular activities.
  • Disease states which can be treated by the methods and compositions provided herein include, but are not limited to, cancer (further discussed below), immunological disorders such as rheumatoid arthritis, graft-host diseases, multiple , sclerosis, psoriasis; cardiovascular diseases such as atherosclerosis, myocardioinfarction, ischemia, pulmonary hypertension, stroke and restenosis; other inflammatory and degenerative diseases such as interbowel diseases, osteoarthritus, macular degeneration, diabetic retinopathy.
  • cancer cancer
  • immunological disorders such as rheumatoid arthritis, graft-host diseases, multiple , sclerosis, psoriasis
  • cardiovascular diseases such as atherosclerosis, myocardioinfarction, ischemia, pulmonary hypertension, stroke and restenosis
  • other inflammatory and degenerative diseases such as interbowel diseases, osteoarthritus, macular de
  • the cells may not be in a hyper- or hypo- proliferative and/or migratory state (abnormal state) and still require treatment.
  • the cells may be proliferating "normally,” but proliferation and migration enhancement may be desired.
  • reduction in "normal” cell proliferation and/or migration rate may be desired.
  • the present invention comprises a compound for modulating kinase activity, particularly p70S6 and/or Akt kinase activity, of Formula I,
  • X 21 is N or CR 22 ;
  • X 22 is N or CR 23 ;
  • X 23 is N or CR 2 , but when X 22 is N then X 23 is CR 24 ;
  • each of R 2i , R 22 , R 23 , R 2 , R 25 , R 2 6, R27, R28, R29 and R 30 , and each R 3 ⁇ , R 32 and R 33 is independently selected from -H, halogen, trihalomethyl, -CN, -N0 2 ,
  • R is selected from -H, halogen, trihalomethyl, -S(O) 0-2 R 35 , -S0 2 NR 35 R 35a ,
  • -CO 2 R 35 -C(O)NR 35 R 35 a, -OR35, -C(O)R 35 , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or
  • each of R 5 and R 3 s a is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or
  • R 35 and R 35a together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl;
  • m is an integer from 0 to 5;
  • n is an integer from 1 to 2;
  • R is not optional substituted aryl or heteroaryl and R 2 ⁇ is not -NR 5 R 35a , and that when X 22 is CR 23 and X 23 is CR 24 then R 2) is not optionally substituted aryl, and that compounds with CAS Registration Nos.
  • the compound is according to Embodiment A, wherein n is 1.
  • the compound is according to paragraph [0037], wherein X 22 is CR 23 .
  • the compound is according to paragraph [0038], wherein R is optionally substituted alkyl.
  • the compound is according to paragraph [0039], wherein R 21 is optionally substituted alkyl.
  • the compound is according to paragraph [0045], wherein R 30 is optionally substituted alkyl.
  • R 30 is -C(O)R 35 .
  • the compound is according to paragraph [0045], wherein R 30 is -C(O)NR 35 R 35a .
  • the compound is according to paragraph [0046], wherein R 31 is -H.
  • the compound is according to paragraph [0050], wherein R 32 is -H.
  • the compound is according to paragraph [0050], wherein R 32 is -C(O)R 35 .
  • the compound is according to paragraph [0050], wherein R 29 , R3o > R31. and R 32 are -H.
  • the compound is according to paragraph [0051], wherein R 23 is optionally substituted alkyl.
  • the compound is according to paragraph [0051], wherein R 23 is halogen, preferably F, Cl, or Br, and more preferably Br.
  • the compound is according to paragraph [0051], wherein R 33 is halogen.
  • the compound is according to paragraph [0051], wherein R 33 is optionally substituted alkyl.
  • the compound is according to paragraph [0051], wherein R 33 is -NR 35 R 35a .
  • the compound is according to paragraph [0051], wherein R 33 is -C(O)R 35 .
  • the compound is according to paragraph [0051], wherein R 33 is trihalomethyl.
  • the present invention also comprises a compound for modulating kinase activity, particularly p70S6 and or Akt kinase activity according to Formula II,
  • each R22, R23, R24, R25, R26, R27, R28, R29 and R 30 and each of R 3 ⁇ , R 32 and R 3 is independently selected from -H, halogen, trihalomethyl, -CN, -N0 2 , -NR 35 R 35a , -S(O) 0 - 2 R 35 , -SO 2 NR 35 R 35a , -CO 2 R 35 , -C(0)NR 35 R 35a , -N(R 35 )S0 2 R 35 , -N(R 35 )C(0)R 35 , -N(R 35 )CO 2
  • the compound is according to Embodiment B, wherein n is 1.
  • the compound is according to paragraph [0080], wherein X 22 is CR 23 .
  • the compound is according to paragraph [0081], wherein R is - H.
  • R is optionally substituted alkyl.
  • the compound is according to paragraph [0082], wherein R 21 is optionally substituted alkyl.
  • the compound is according to paragraph [0088], wherein R 30 is optionally substituted alkyl.
  • the compound is according to paragraph [0088], wherein R 30 is -C(O)R 35 .
  • the compound is according to paragraph [0088], wherein R 30 is -C(O)NR 35 R 35a .
  • the compound is according to paragraph [0094], wherein R 32 is -C(O)R 35 .
  • the compound is according to paragraph [0094], wherein R 3 is optionally substituted alkyl. [0098] In another example, the compound is according to paragraph [0094], wherein R 3 is halogen.
  • the compound is according to paragraph [0099], wherein Qi is a substituted heterocyclyl wherein the heterocyclyl has at least one nitrogen.
  • the compound is according to paragraph [0099], wherein Q ⁇ is a substituted heterocyclyl wherein the heterocyclyl has at least one oxygen.
  • each R 33 is independently selected from: [0103] (a) H, halo, -OH, NO 2 -, CN; [0104] (b) Ci-C 6 - alkyl, optionally substituted with 1-5 moieties independently selected from halo, -OH, -Ci-C 3 -alkoxy optionally substituted with 1-3 halo, or aryl; [0105] (c) Ci-C ⁇ -alkoxy optionally substituted with 1-3 moieties independently selected from halo and -C 3 -a ⁇ koxy; [0106] (d) Rgo-Co- -alkyl, wherein R 90 is N(R 73 )(R 74 ), heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, C ⁇ -C 3 -alkyl, Ci-C 3 -alkoxy, aryl
  • Table A gives particular examples of R 33 of groups (b)-(j) (paragraphs [0104] - [0112]), above: Table A
  • each of R 25 -R 32 is H.
  • R 21 is H.
  • X 22 is CR 23 and R 23 is lower alkyl or halo, preferably Br.
  • R 33 in these examples includes lower alkyl (preferably methyl), Rso- - - alkyl-(Z) s -C 0 -C 3 -alkyl (preferably wherein R 80 is heterocyclyl such as pyrrolidinyl; the - C 3 -alkyl is ethyl; s is 1; Z is ⁇ H; and C 0 -C 3 -alkyl is Co, i.e., a bond), and R 8 ⁇ -Co-C 6 -alkyl- (Z) s -CO- (preferably wherein: R 81 is C ⁇ -C 6 -alkyl optionally substituted with 1-3 halo, more preferably wherein the - -alkyl optionally substituted with 1-3 halo is trihalopropyl (preferably trifluoropropyl, and even more preferably 3,3,3-trifluoroprop
  • R 8 o-C 1 -C 3 -alkyl-(Z) s -C 0 - C 3 -alkyl and the R 81 -Co-C 6 -alkyl-(Z) s -CO- groups are meta to each other and to X 21 .
  • Embodiments A and C with R 1 according to paragraph [0123], R 25 -R 32 according to paragraph [0122], X 21 and X 23 are according to paragraph [0124], X 22 according to paragraph [0125] and m and R 33 according to paragraph [0126].
  • R 25 -R 28 and R 3 o-R 32 are H and R 29 is other than H.
  • the annular carbon atom to which R 29 is bonded is chiral.
  • that chiral center is enantiomerically enriched (greater than 60%, 70%, 80%, 90%, or 95%) or pure.
  • Examples of R 29 when the annular carbon is chiral in this embodiment include methyl and hydroxymethyl.
  • R 33 is selected from: [0130] (i) C ⁇ -C 6 - alkyl 1-5 moieties independently selected from -OH and - C t - -alkoxy optionally substituted with 1-3 halo, or aryl; [0131] (ii) .Cs-alkoxy optionally substituted with 1-3 - -alkoxy moieties; [0132] (iii) R 90 -Co-C 3 -alkyl, wherein R 90 is N(R 73 )(R 7 ) if the alkyl moiety is C ⁇ -C 3 -alkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, C ⁇ -C 3 -alkyl, - C 3 -alkoxy, aryl, and hetero
  • X 22 is CR 23
  • X 23 is CR ⁇
  • X 21 is nitrogen
  • R 21 is hydrogen
  • m is 1, 2, 3, 4, or 5 and at least one R 33 is not hydrogen.
  • X 22 is N
  • X 23 is CR 24
  • X 2 ⁇ is nitrogen and R 21 is hydrogen
  • m is 1, 2, 3, 4, or 5 and at least one R 33 is not hydrogen.
  • X 22 is N
  • X 23 is CR 2
  • X21 is N
  • n is 1
  • R 25 -R 32 are the same and are H, or only one of R 25 -R 3 is alkyl, and R is H or alkyl, then R 24 is H or alkyl.
  • X 22 is CR 23
  • X 23 is CR 24
  • X21 is N
  • n is 1
  • R25-R 3 2 are the same and are H, or only one of R 25 -R 32 is alkyl
  • R is H or alkyl
  • R ⁇ is H or alkyl.
  • Qi is not pyrid-2-yl, i.e., when Qi is pyridyl it is not attached to the X 21 group at postion ortho to the pyridyl nitrogen.
  • X 2 is CR 23
  • X 23 is CR 2
  • R 21 is halogen
  • X 22 is N
  • X 23 is CR 24
  • R 21 is halogen
  • X 22 is CR 23
  • X 23 is CR 24
  • X21 is nitrogen
  • R 21 is hydrogen
  • m is 1, 2, 3, 4, or 5 and at least one R 33 is not hydrogen
  • X 22 is N
  • X 23 is CR 24
  • X 21 is nitrogen
  • R 21 is hydrogen
  • m is 1, 2, 3, 4, or 5 and at least one R 33 is not hydrogen
  • Qi is not pyrimidyl or triazinyl.
  • the compound is according to paragraphs [0022]-[0151], wherein the compound is a pharmaceutically acceptable salt.
  • the compound is according to paragraphs [0022]-[0151], wherein the compound is a prodrug.
  • the compound is according to any one of paragraphs [0022]-[0151], selected from Tables 1 or 2 below.
  • compositions comprising the compound according to any one of paragraphs [0022]-[0154] and at least one pha ⁇ naceutically acceptable carrier or excipient.
  • Another aspect of the invention is a metabolite of the compound according to any one of paragraphs [0022] -[0154].
  • Another aspect of the invention is a method of modulating the in vivo activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising at least one of the compound according to any of paragraphs [0022]-[0154
  • Another aspect of the invention is the method according to paragraph [0157], wherein the kinase is p70S6 and/or Akt.
  • Another aspect of the invention is the method according to paragraph [0158], wherein modulating the in vivo activity of p70S6K and/or AktK comprises inhibition of p70S6K and/or AktK.
  • Another aspect of the invention is a method of treating and/or inhibiting diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155] and the CAS Registration Nos.
  • Another aspect of the invention is a method of screening for modulator of a p70S6K and/or AktK, the method comprising combining either a composition comprising at least one of the compound according to any of paragraphs [0022] -[0154] and the pharmaceutical composition according to paragraph [0155], and the CAS Registration Nos.
  • Another aspect of the invention is a method of inhibiting proliferative activity in a cell or a plurality of cells, the method comprising administering an effective amount of at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155], and the CAS Registration Nos.
  • Another aspect of the invention is a method of preparing the compounds according to any of paragraphs [0022]-[-0154].
  • the symbol "-" means a single bond
  • " ⁇ ” means a triple bond
  • the symbol “ ⁇ wvr” refers to a group on a double-bond as occupying either position on the terminus of a double bond to which the symbol is attached; that is, the geometry, E- or Z-, of the double bond is ambiguous.
  • the " ⁇ ⁇ " symbol will be used at the end of the bond which was theoretically cleaved in order to separate the group from its parent structural formula.
  • a substituent "R” may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.
  • the "R” group may reside on either the 5-membered or the 6-membered ring of the fused ring system.
  • the two "R's" may reside on any two atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.
  • Alkyl is intended to include saturated and non-saturated (but not aromatic) linear, branched, and cyclic hydrocarbon structures and combinations thereof, inclusively.
  • C 8 alkyl may refer to an n-octyl, ⁇ o-octyl, cyclohexylethyl, 3-octenyl, - octa-2,4-dienyl, cyclooctane, cyclooctene, and the like.
  • Lower alkyl refers to alkyl groups of from one to six carbon atoms.
  • lower alkyl groups include methyl, ethyl, propyl, propenyl, isopropyl, butyl, s-butyl, t-butyl, isobutyl, pentyl, hexyl, hex-3-ynyl, and the like.
  • Higher alkyl refers to alkyl groups containing more that eight carbon atoms.
  • Exemplary alkyl groups are those of C 20 or below.
  • Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms.
  • alkyl refers to alkanyl, alkenyl, and alkynyl residues (and combinations thereof); it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like.
  • alkyl residue having a specific number of carbons when named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, either “butyl” or “ alkyl” is meant to include n-butyl, sec-butyl, isobutyl, t-butyl, isobutenyl and but-2-yne radicals; and for example, "propyl” or “C 3 alkyl” each include n- propyl, propenyl, and isopropyl.
  • alkenyl and/or alkynyl descriptors are used in a particular definition of a group, for example "Qalkyl” along with “C 4 alkenyl,” then C 4 alkenyl geometric isomers are not meant to be included in “C 4 alkyl,” but other 4-carbon isomers are, for example C 4 alkynyl.
  • C 1-8 alkyl a particular group as “C 1-8 alkyl” while a preferred species may describe the same group as including, “C 1-8 alkyl,” “C 1-6 alkenyl” and “C 1-5 alkynyl.”
  • Co is a bond. So, for example NH 2 -Co-C 3 -alkyl includes amino as well as aminomethyl, 2-aminoethyl, 1 aminoethyl, etc.
  • Alkylene refers to straight or branched chain divalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, n-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), dimethylpropylene (-CH 2 C(CH 3 ) 2 CH 2 -), and cyclohexylpropylene (-CH 2 CH 2 CH(C 6 H 13 )).
  • Alkylidene refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, n-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, double bond unsaturation. The unsaturation present includes at least one double bond.
  • Alkylidyne refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, ⁇ -butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond.
  • alkylene when optionally substituted, may contain alkyl substitution which itself contains unsaturation.
  • 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an n-butylid-3-ynyl radical with a vinyl substituent at the 2-position of said radical.
  • Alkoxy refers to the group -O-alkyl, for example including from one to eight carbon atoms of a straight, branched, cyclic configuration, unsaturated chains, and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to six carbons.
  • Substituted alkoxy refers to the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy).
  • One exemplary substituted alkoxy group is "polyalkoxy” or -O-optionally substituted alkylene-optionally substituted alkoxy, and includes groups such as -OCH 2 CH 2 OCH 3 , and glycol ethers such as polyethyleneglycol and -O(CH 2 CH 2 O) x CH 3 , where x is an integer of between about two and about twenty, in another example, between about two and about ten, and in a further example between about two and about five.
  • Another exemplary substituted alkoxy group is hydroxyalkoxy or -OCH 2 (CH 2 ) y OH, where y is for example an integer of between about one and about ten, in another example y is an integer of between about one and about four.
  • Acyl refers to groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to six carbons.
  • -Amino Acids refer to naturally occurring and commercially available amino acids and optical isomers thereof. Typical natural and commercially available - amino acids are glycine, alanine, serine, homoserine, threonine, valine, norvaline, leucine, isoleucine, norleucine, aspartic acid, glutamic acid, lysine, omithine, histidine, arginine, cysteine, homocysteine, methionine, phenylalanine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan, glutamine, asparagine, proline and hydroxyproline.
  • a "side chain of an -amino acid” refers to the radical found on the ⁇ -carbon of an -amino acid as defined above, for example, hydrogen (for glycine), methyl (for alanine), benzyl (for phenylalanine), and the like.
  • Amino refers to the group -NH 2 .
  • Substituted amino refers to the group -N(H)R or -N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl, sulfanyl, sulfinyl and sulfonyl, for example, diethylamino, methylsulfonylamino, and furanyl-oxy-sulfonamino.
  • Aryl refers to aromatic six- to fourteen-membered carbocyclic ring, for example, benzene, naphthalene, indane, tetralin, fluorene and the like, univalent radicals.
  • univalent radicals the aforementioned ring examples are named, phenyl, naphthyl, indanyl, tetralinyl, and fluorenyl.
  • Arylene generically refers to any aryl that has at least two non-hydrogen groups attached thereto.
  • phenylene refers to a divalent phenyl ring radical.
  • a phenylene thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto.
  • the terms "ortho- arylene,” “meta-arylene” or “para-arylene” refer to geometrical isomers of a particular arylene wherein, two groups attached to an aryl as depicted in a formula are situated in an ortho, meta or para geometrical relationship about the aryl, respectively.
  • Arylalkyl refers to a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Both the aryl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of an arylalkyl group may be optionally substituted.
  • “Lower arylalkyl” refers to an arylalkyl where the "alkyl" portion of the group has one to six carbons; this can also be refered to as aryl C 1-6 alkyl.
  • Exo-alkenyl refers to a double bond that emanates from an annular carbon, and is not within the ring system, for example the double bond depicted in the formula below.
  • two adjacent groups on an aromatic system may be fused together to form a ring structure.
  • the fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups.
  • saturated carbons of such fused groups i.e. saturated ring structures
  • fused-polycyclic or "fused ring system” refers to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures.
  • fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems.
  • fused- polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro- naphthalene.
  • a spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.
  • Halogen refers to fluorine, chlorine, bromine or iodine.
  • Haloalkyl and haloaryl refer generically to alkyl and aryl radicals that are substituted with one or more halogens, respectively.
  • dihaloaryl refers to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.
  • Heteroarylene generically refers to any heteroaryl that has at least two groups attached thereto.
  • pyridylene refers to a divalent pyridyl ring radical.
  • a pyridylene thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto.
  • ortho-heteroarylene refers to a geometrical isomer of a particular heteroarylene wherein two groups attached to a heteroaryl as depicted in a formula are situated on contiguous atoms of the heteroaryl.
  • Heteroatom refers to O, S, N, or P.
  • Heterocyclyl refers to a stable three- to fifteen-membered ring radical that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur.
  • the heterocyclyl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems as well as spirocyclic systems; and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized to various oxidation states.
  • the group -S(O) 0-2 - refers to -S- (sulfide), -S(O)- (sulfoxide), and -SO 2 - (sulfone).
  • nitrogens particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include their corresponding N-oxide form, although not explicitly defined as such in a particular example.
  • annular nitrogen atoms may be optionally quaternized; and the ring radical may be partially or fully saturated or aromatic.
  • heterocyclyl radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, > 2,5-dioxopyrrolidin-l
  • Heteroalicyclic refers specifically to a non-aromatic heterocyclyl radical.
  • a heteroalicyclic may contain unsaturation, but is not aromatic.
  • Heteroaryl refers specifically to an aromatic heterocyclyl radical.
  • Heterocyclylalkyl refers to a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include (4-methylpiperazin-l-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpi ⁇ erazin-l-yl)-2-butenyl, and the like. Both the heterocyclyl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of a heterocyclylalkyl group may be optionally substituted.
  • “Lower heterocyclylalkyl” refers to a heterocyclylalkyl where the “alkyl” portion of the group has one to six carbons.
  • “Heteroalicyclylalkyl” refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is non-aromatic; and “heteroarylalkyl” refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is aromatic
  • Such terms may be described in more than one way, for example, “lower heterocyclylalkyl” and “heterocyclyl C 1-6 alkyl” are equivalent terms.
  • Optionally substituted refers to all subsequent modifiers in a term, for example in the term “optionally substituted aryl C 1-8 alkyl,” optional substitution may occur on both the “C 1-8 alkyl” portion and the “aryl” portion of the molecule; and for example, optionally substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups.
  • optionally substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups.
  • a list of exemplary optional substitutions is included below in the definition of "substituted.”
  • saturated bridged ring system refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro- lH-indene, 7-aza-bicyclo[2.2.1]heptane, and l,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system.
  • Spirocyclyl or "spirocyclic ring” refers to a ring originating from a particular annular carbon of another ring.
  • a ring atom of a saturated bridged ring system (rings B and B'), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocyclyl (ring A) attached thereto.
  • a spirocyclyl can be carbocyclic or heteroalicyclic.
  • Substituted alkyl, aryl, and heterocyclyl refer respectively to alkyl, aryl, and heterocyclyl, wherein one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent.
  • Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is - C(O)-) nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, sulfonamido, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, alkylthio, ureido, and ureidoalkyl groups.
  • Preferred substituents which are themselves not further substituted (unless expressly stated otherwise) are: [0199] (a) halo, cyano, oxo, alkyl, alkoxy, alkylthio, haloalkoxy, aminoalkyl, aminoalkoxy, carboxy, formyl, nitro, amino, amidino, carbamoyl, guanidino, C 3 -C 7 heterocycle, heterocyclylalkyl, heterocyclylcarbonyl, hydroxyalkyl, alkoxyalkyl, [0200] (b) Ci-C 5 alkyl or alkenyl or arylalkyl imino, carbamoyl, carbamate, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, -Cs alkyl, - alkenyl, - alkoxy, - alkoxycarbonyl, aryloxycarbonyl, C 2
  • substituents on cyclic moieties include 5-6 membered mono- and 9-14 membered bi-cyclic moieties fused to the parent cyclic moiety to form a bi- or tri-cyclic fused ring system.
  • an optionally substituted phenyl includes, but not limited to, the following:
  • Preferred substituents on cyclic moieties also include groups of the formula -K1-N(H)(R36), wherein [0204] Ki is a chemical bond or C 1 -C 4 alkylene; [0205] R 36 is selected from the group consisting of Z' and -Ak 2 -Z', wherein [0206] Ak 2 is C 1 -C4 alkylene; and [0207] Z' is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which optionally is substituted, and each of which optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings.
  • substituents on cyclic moieties include 1, 2, or 3 groups independently selected from the following: [0209] a) alkoxy, cyano, amino, oxo, haloalkyl, halo, alkyl, R 35 -C(O)-N(R 35 )-, R 35 -O-C(O)-N(R 35 )-, R 35 -NH-C(O)-N(R 35 )-, R 35 -NH-C(O)-O-, (R 35a )(R 35 )N-alkyl-, (R 35a )(R 35 )N-alkyl-O-, (R 35 )(R 35a )N-alkyl-O-, (R 35 )(R 35a )N-alkeny
  • Sulfanyl refers to the groups: -S-(optionally substituted alkyl), -S-(optionally substituted aryl), and -S- (optionally substituted heterocyclyl).
  • Sulfinyl refers to the groups: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-optionally substituted aryl), and -S(O)-(optionally substituted heterocyclyl).
  • Sulfonyl refers to the groups: -S(O 2 )-H, -S(O )-(optionally substituted alkyl), -S(O 2 )-optionally substituted aryl), -S(O2)-(optionally substituted heterocyclyl), -S(O 2 )-(optionally substituted alkoxy), -S(O 2 )-optionally substituted aryloxy), and -S(O 2 )-(optionally substituted heterocyclyloxy).
  • Yield for each of the reactions described herein is expressed as a percentage of the theoretical yield.
  • Some of the compounds of the invention may have imino, amino, oxo or hydroxy substituents off aromatic heterocyclyl systems.
  • imino, amino, oxo or hydroxy substituents may exist in their corresponding tautomeric form, i.e., amino, imino, hydroxy or oxo, respectively.
  • the compounds of the invention may have asymmetric carbon atoms, oxidized sulfur atoms or quaternized nitrogen atoms in their structure.
  • the compounds of the invention and their pharmaceutically acceptable salts may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers.
  • the compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.
  • a particular group with its bonding structure is denoted as being bonded to two partners; that is, a divalent radical, for example, -OCH 2 -, then it is understood that either of the two partners may be bound to the particular group at one end, and the other partner is necessarily bound to the other end of the particular group, unless stated explicitly otherwise.
  • divalent radicals are not to be construed as limited to the depicted orientation, for example "-OCH 2 -" is meant to mean not only "-OCH 2 -" as drawn, but also "-CH 2 O-.”
  • optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • Enantiomers may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas- liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting on enantiomer to the other by asymmetric transformation.
  • enantiomers enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystalhzation.
  • Patient for the pu ⁇ oses of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a preferred embodiment the patient is a mammal, and in a most preferred embodiment the patient is human.
  • Kinase-dependent diseases or conditions refer to pathologic conditions that depend on the activity of one or more protein kinases.
  • Kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities including proliferation, adhesion, migration, differentiation and invasion.
  • Diseases associated with kinase activities include tumor growth, the pathologic neovascularization that supports solid tumor growth, and associated with other diseases where excessive local vascularization is involved such as ocular diseases (diabetic retinopathy, age-related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like).
  • phosphatases can also play a role in "kinase-dependent diseases or conditions" as cognates of kinases; that is, kinases phosphorylate and phosphatases dephosphorylate, for example protein substrates. Therefore compounds of the invention, while modulating kinase activity as described herein, may also modulate, either directly or indirectly, phosphatase activity. This additional modulation, if present, may be synergistic (or not) to activity of compounds of the invention toward a related or otherwise interdependent kinase or kinase family. In any case, as stated previously, the compounds of the invention are useful for treating diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth.
  • abnormal levels of cell proliferation i.e. tumor growth
  • apoptosis programmed cell death
  • “Therapeutically effective amount” is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease.
  • the amount of a compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like.
  • the therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • Carrier refers to cellular-proliferative disease states, including but not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hanlartoma, inesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancre
  • “Pharmaceutically acceptable acid addition salt” refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like
  • organic acids such as acetic acid, trifluoro
  • “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
  • salts of primary, secondary, and tertiary amines substituted amines including naturally occurring substituted amines, cyclic amines
  • Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
  • “Prodrug” refers to compounds that are transformed (typically rapidly) in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety.
  • esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) wherein the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl.
  • pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons). Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V.
  • Methodabolite refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics” ⁇ .sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of biotransformation).
  • the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body.
  • a prodrug may be used such that the biologically active form, a metabolite, is released in vivo.
  • a biologically active metabolite is discovered serendipitously, that is, no prodrug design per se was undertaken.
  • An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure.
  • the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the pu ⁇ oses of the present invention.
  • the present invention cover compounds made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.
  • Treating covers the treatment of a disease-state in a human, which disease-state is characterized by abnormal cellular proliferation, and invasion and includes at least one of: (i) preventing the disease-state from occurring in a human, in particular, when such human is predisposed to the disease-state but has not yet been diagnosed as having it; (ii) inhibiting the disease-state, i.e., arresting its development; and (iii) relieving the disease-state, i.e., causing regression of the disease-state.
  • Such suitable x- ray quality crystals can be used as part of a method of identifying a candidate agent capable of binding to and modulating the activity of kinases.
  • Such methods may be characterized by the following aspects: a) introducing into a suitable computer program, information defining a ligand binding domain of a kinase in a conformation (e.g.
  • aspects a-d are not necessarily carried out in the aforementioned order. Such methods may further entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling.
  • Such methods may further entail: employing a candidate agent, so-determined to fit spatially into the ligand binding domain, in a biological activity assay for kinase modulation, and determining whether said candidate agent modulates kinase activity in the assay. Such methods may also include administering the candidate agent, determined to modulate kinase activity, to a mammal suffering from a condition treatable by kinase modulation, such as those described above.
  • compounds of the invention can be used in a method of evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a kinase.
  • a method may be characterized by the following aspects: a) creating a computer model of a kinase binding pocket using structure coordinates obtained from suitable x-ray quality crystals of the kinase, b) employing computational algorithms to perform a fitting operation between the test agent and the computer model of the binding pocket, and c) analyzing the results of the fitting operation to quantify the association between the test agent and the computer model of the binding pocket.
  • CAS a division of the American Chemical Society
  • CAS produces one of the world's largest and most comprehensive databases of chemical information, indexing abstracts, patents, articles from approximately 9,000 scientific journals, conference proceedings, and other documents pertinent to chemistry, life sciences and many other fields.
  • Certain compounds are set forth in this application using a CAS Registration identifier. The structures of these compounds, as they correspond to the CAS Registration identifier, are set forth below:
  • Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition can be carried out via any of the accepted modes of administration or agents for serving similar utilities.
  • administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
  • compositions will include a compound of the invention as the/an active agent, and, in addition, may include at least one other conventional pharmaceutical carrier or excipient, such as medicinal agents, pharmaceutical agents, adjuvants, etc.
  • Compositions of the invention may be used in combination with anticancer or other agents that are generally administered to a patient being treated for cancer.
  • Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents for example sugars, sodium chloride, and the like.
  • Prolonged abso ⁇ tion of the injectable pharmaceutical form can be brought about by the use of agents delaying abso ⁇ tion, for example, aluminum monostearate and gelatin.
  • a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene, etc.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene, etc.
  • compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
  • fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
  • binders as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia
  • humectants as for example, glycerol
  • disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate
  • solution retarders as for example paraffin
  • abso ⁇ tion accelerators as for example, quaternary ammonium compounds
  • wetting agents as for example, cetyl alcohol,
  • Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3- butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol
  • Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • suspending agents as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.
  • Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants.
  • the active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required.
  • Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
  • the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient.
  • the composition will be between about 5% and about 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.
  • composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention.
  • the compounds of the invention are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy.
  • the compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary.
  • the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used.
  • the determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.
  • the protein is bound to a support, and a compound of the invention is added to the assay.
  • the compound of the invention is bound to the support and the protein is added.
  • Classes of candidate agents among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells.
  • assays may be used for this pu ⁇ ose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.
  • the determination of the binding of the candidate agent to, for example, p70S6K and/or AktK protein may be done in a number of ways.
  • the candidate agent (the compound of the invention) is labeled, for example, with a fluorescent or radioactive moiety and binding determined directly.
  • a labeled agent for example a compound of the invention in which at least one atom has been replaced by a detectable isotope
  • washing off excess reagent for example a compound of the invention in which at least one atom has been replaced by a detectable isotope
  • Various blocking and washing steps may be utilized as is known in the art.
  • label herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, for example, radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic particles, chemilummescent tag, or specific binding molecules, and the like.
  • Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin, and the like.
  • the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above.
  • the label can directly or indirectly provide a detectable signal.
  • p70S6K and/or AktK protein may be labeled at tyrosine positions using 125 I, or with fluorophores.
  • more than one component may be labeled with different labels; using 125 I for the proteins, for example, and a fluorophor for the candidate agents.
  • the compounds of the invention may also be used as competitors to screen for additional drug candidates, "candidate bioactive agent” or “drug candidate” or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. In the case where protein binding or activity is screened, some embodiments exclude molecules already known to bind to that particular protein.
  • exogenous agents include candidate agents, which do not bind the target protein in its endogenous native state, termed herein as "exogenous" agents.
  • exogenous agents further exclude antibodies to p70S6K and/or AktK.
  • Candidate agents can encompass numerous chemical classes, though typically they are organic molecules having a molecular weight of more than about 100 and less than about 2,500 daltons.
  • Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl, hydroxyl, ether, or carboxyl group, for example at least two of the functional chemical groups.
  • the candidate agents often comprise cyclical carbon or heterocyclyl structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
  • Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs, or combinations thereof.
  • Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs
  • the binding of the candidate agent is determined through the use of competitive binding assays.
  • the competitor is a binding moiety known to bind to p70S6K and/or AktK, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.
  • the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to p70S6K and/or AktK protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature that facilitates optimal activity, typically between 4°C and 40°C.
  • Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.
  • the competitor is added first, followed by the candidate agent.
  • Displacement of the competitor is an indication the candidate agent is binding to p70S6K and/or AktK and thus is capable of binding to, and potentially modulating, the activity of the p70S6K and/or AktK.
  • either component can be labeled.
  • the presence of label in the wash solution indicates displacement by the agent.
  • the candidate agent is labeled, the presence of the label on the support indicates displacement.
  • the candidate agent is added first, with incubation and washing, followed by the competitor.
  • the absence of binding by the competitor may indicate the candidate agent is bound to p70S6K and/or AktK with a higher affinity.
  • the candidate agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate the candidate agent is capable of binding to p70S6K and/or AktK.
  • Modulation is tested by screening for candidate agents capable of modulating the activity of p70S6K and/or AktK comprising the steps of combining a candidate agent with p70S6K and/or AktK, as above, and determining an alteration in the biological activity of the p70S6K and/or AktK.
  • the candidate agent should both bind to (although this may not be necessary), and alter its biological or biochemical activity as defined herein.
  • the methods include both in vitro screening methods and in vivo screening of cells for alterations in cell viability, mo ⁇ hology, and the like.
  • differential screening may be used to identify drug candidates that bind to native p70S6K and/or AktK, but cannot bind to modified p70S6K and/or AktK.
  • Positive controls and negative controls can be used in the assays. For example, all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples can be counted in a scintillation counter to determine the amount of bound compound.
  • a variety of other reagents can be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components can be added in any order that provides for the requisite binding.
  • Such suitable x- ray quality crystals can be used as part of a method of identifying a candidate agent capable of binding to and modulating the activity of p70S6K and/or AktKs.
  • Such methods may be characterized by the following aspects: a) introducing into a suitable computer program, information defining a ligand binding domain of a p70S6K and/or AktK in a conformation (e.g.
  • aspects a-d are not necessarily carried out in the aforementioned order. Such methods may further entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling.
  • Such methods may further entail: employing a candidate agent, so-determined to fit spatially into the ligand binding domain, in a biological activity assay for p70S6K and/or AktK modulation, and determining whether said candidate agent modulates p70S6K and/or AktK activity in the assay. Such methods may also include administering the candidate agent, determined to modulate p70S6K and/or AktK activity, to a mammal suffering from a condition treatable by p70S6K and/or AktK modulation, such as those described above.
  • compounds of the invention can be used in a method of evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a p70S6K and/or AktK.
  • Such a method may be characterized by the following aspects: a) creating a computer model of a p70S6K and/or AktK binding pocket using structure coordinates obtained from suitable x-ray quality crystals of the p70S6K and/or AktK, b) employing computational algorithms to perform a fitting operation between the test agent and the computer model of the binding pocket, and c) analyzing the results of the fitting operation to quantify the association between the test agent and the computer model of the binding pocket.
  • Scheme 1 depicts a general synthetic route for compounds of the invention and is not intended to be limiting. Specific examples are described subsequently to this general synthetic description. In the generalizations below, specific reaction conditions or details, for example, added reagents, catalysts, solvents, reaction temperature, and the like are not described. The general routes depicted in conjunction with the specific examples provided contain sufficient information to allow one of ordinary skill in the art to synthesize compounds of the invention.
  • Scheme 1 shows that in general, compounds of Formulas I and II can be made, for example via a linear route.
  • an amino-substituted pyrazolopyrimidine (or purine or pyrrolopyrimidine) of 1 having leaving group "L" is reacted with a substituted piperazine/piperidine of 2, substituted with B which can be an optionally substituted as in Formulas I and ⁇ , in an anhydrous solvent such that the leaving group is displaced by the substituted piperazine/piperidine.
  • B can be an optionally substituted as in Formulas I and ⁇
  • the reaction gives compounds of 3, wherein L is an amine and X 21 , X 22 , X 23 , n, R and R 2 ⁇ -R 32 are as descibed above.
  • EXAMPLE 7 4-[4-(5-chloro-2-methylphenyl)pi ⁇ erazin-l-yl]-3-( ⁇ [2-
  • EXAMPLE 12 3- ⁇ 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidin-3-yl Jpropan- 1 -ol trifluroacetate
  • the reaction was quenched with water (5 mL), concentrated, diluted with ethyl acetate (5 mL), washed with water and brine solution (5 mL each), dried over sodium sulfate, and concentrated.
  • the residue was dissolved in T ⁇ F (2 mL), and a solution of lithium aluminum hydride in T ⁇ F (1.0 M, 37 uL, 0.037 mmol) was added.
  • the resulting mixture was stirred at room temperature for 1 h, and then quenched with 2N aqueous sodium hydroxide (0.2 mL), diluted with ethyl ether (10 mL), and filtered through celite. The filtrate was washed with brine (2 mL), dried over sodium sulfate, and concentrated.
  • EXAMPLE 13 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(3- pyrrolidin-l-ylprop-l-yn-l-yl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate
  • EXAMPLE 14 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-piperazin-l- yl-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate
  • EXAMPLE 15 2-[(5-chloro-2-methyl-3- ⁇ 4-[3-(trifluoromethyl)-lH- pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-l-yl ⁇ phenyl)oxy]-N,N-diethylethanamine trifluoroacetate
  • EXAMPLE 16 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-6-methyl-lH- pyrazolo[3,4-d]pyrimidine
  • 6-Methyl-l,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 134 mg, 0.89 mmol. was taken into thionyl chloride (3 mL) followed by addition of DMF (0.2 mL) and the mixture was brought to reflux over 30 minutes. The resulting solution was concentrated and the residue partitioned with ethyl acetate and saturated aqueous sodium bicarbonate. The organic phase was washed with brine then dried over anhydrous sodium sulfate, filtered and concentrated to afford a yellow oil.
  • EXAMPLE 20 1,1-dimethylethyl 4-(3-chlorophenyl)-3- ⁇ [(2-mo ⁇ holin-4- ylethyl)amino]carbonyl ⁇ piperazine- 1 -carboxylate
  • EXAMPLE 21 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(3- methylbut-2-en-l-yl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride
  • EXAMPLE 24 l-[5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4- yl)piperazin-l-yl]-2-(methyloxy)phenyl]-N,N-dimethylmethanamine
  • EXAMPLE 28 N'-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N,N- dimethylethane- 1 ,2-diamine hydrochloride
  • EXAMPLE 30 2-[(5-chloro-2-methyl-3-piperazin-l-ylphenyl)oxy]-N,N- dimethylethanamine hydrochloride
  • EXAMPLE 34 5-bromo-2-methyl-3-pi ⁇ erazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline hydrochloride
  • Trifluoroacetic anhydride (3.56 g, 16.95 mmol) was added dropwise, and the mixture was stirred at 0 °C for 30 min and then at room temperature for 1 h.
  • the reaction mixture was diluted with ethyl acetate (300 mL), washed with water (100 mL), saturated sodium bicarbonate (100 mL), water (100 mL), and brine (100 mL), dried with sodium sulfate, and concentrated.
  • EXAMPLE 38 l- ⁇ 4-methyl-3-piperazin-l-yl-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl ⁇ butan- 1 -one hydrochloride
  • EXAMPLE 40 2-Methyl-5-(3-phenyl-l,2,4-oxadiazol-5-yl)-3-piperazin-l-yl- N-(2-pyrrolidin- 1 -ylethyl)aniline hydrochloride
  • EXAMPLE 42 3-Bromo-4- ⁇ 4-[5-chloro-2-methyl-3-(3-pyrrolidin-l-yl- propyl)-phenyl] -piperazin- 1 -yl ⁇ - lH-pyrazolo[3 ,4-d]pyrimidine.
  • EXAMPLE 43 3 ⁇ Bromo-4- ⁇ 4-[5-Chloro-2-methyl-3-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-piperazin-l-yl ⁇ -lH-pyrazolo[3,4-d] pyrimidine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to compounds of the Formula (I) and (II) wherein R, R21, R25-R33, m, n, X21-X23, and Q1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.

Description

PATENT APPLICATION
Kinase Modulators and Method of Use
Assignee: Exelixis, Inc. Entity: Large
Kinase Modulators and Method of Use BACKGROUND OF THE INVENTION Reference to Related Applications
[0001] This application claims priority to U.S. provisional patent application 60/564,908 filed April 23, 2004. The contents of the prior application are hereby incorporated in their entirety. Field of the Invention
[0002] This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Even more specifically, the invention relates to compounds which inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. Summary of Related Art
[0003] Improvements in the specificity of agents used to treat cancer is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms.
[0004] Protein kinases are enzymes that catalyze the phosphorylation of proteins at the hydroxy groups of tyrosine, serine and threonine residues of proteins. The kinase complement of the human genome contains 518 putative protein kinase genes [Manning et al, Science, (2002), 298, 1912]. The consequences of this activity include effects on cell differentiation, proliferation, transcription, translation, metabolism, cell cycle progression, apoptosis, metabolism cytoskeletal rearrangement and movement; i.e., protein kinases mediate the majority of signal transduction in eukaryotic cells. Furthermore, abnormal protein kinase activity has been related to a host of disorders, ranging from relatively non- life threatening diseases such as psoriasis to cancer. Chromosomal mapping has revealed that over 200 kinases map to disease loci, including cancer, inflammatory and metabolic disease. [0005] Tyrosine kinases can be categorized as receptor type or non-receptor type. Receptor-type tyrosine kinases have an extracellular, a transmembrane, and an intracellular portion, while non-receptor type tyrosine kinases are wholly intracellular.
[0006] Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. In fact, about 20 different subfamilies of receptor-type tyrosine kinases have been identified. One tyrosine kinase subfamily, designated the HER subfamily, is comprised of EGFR (HER1), HER2, HER3, and HER4. Ligands of this subfamily of receptors identified so far include epithelial growth factor, TGF-alpha, amphiregulin, HB-EGF, betacellulin and heregulin. Another subfamily of these receptor-type tyrosine kinases is the insulin subfamily, which includes LNS-R, IGF- IR, and IR-R. The PDGF subfamily includes the PDGF-alpha and -beta receptors, CSFIR, c-kit and FLK-II. Then there is the FLK family, which is comprised of the kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (Flt-1). The PDGF and FLK families are usually considered together due to the similarities of the two groups. For a detailed discussion of the receptor- type tyrosine kinases, see Plowman et al., DN&P 7(6): 334-339, 1994, which is hereby incorporated by reference.
[0007] The non-receptor type of tyrosine kinases is also comprised of numerous subfamilies, including Src, Frk, Btk, Csk, Abl, Syk Zap70, Fes Fps, Fak, Jak, and Ack. Each of these subfamilies is further sub-divided into varying receptors. For example, the Src subfamily is one of the largest and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr, and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. For a more detailed discussion of the non-receptor type of tyrosine kinases, see Bolen, Oncogene, 8:2025-2031 (1993), which is hereby incorporated by reference.
[0008] Serine-theoronine kinases play critical roles in intracellular signal transduction and include the multiple families, including STE, CKI, AGC, CAMK, and CMGC. Important subfamilies include, the MAP kinases, p38, JNK and ERK, which modulate signal transduction resulting from such diverse stimuli as mitogenic, stress, proinflammatory and antiapoptotic pathways. Members of the MAP kinase subfamily have been targeted for therapeutic intervention, including p38a, JNK isozymes and Raf.
[0009] Since protein kinases and their ligands play critical roles in various cellular activities, deregulation of protein kinase enzymatic activity can lead to altered cellular properties, such as uncontrolled cell growth associated with cancer. In addition to oncological indications, altered kinase signaling is implicated in numerous other pathological diseases. These include, but are not limited to: immunological disorders, cardiovascular diseases, inflammatory diseases, and degenerative diseases. Therefore, both receptor and non-receptor protein kinases are attractive targets for small molecule drug discovery.
[0010] One particularly attractive goal for therapeutic use of kinase modulation relates to oncological indications. For example, modulation of protein kinase activity for the treatment of cancer has been demonstrated successfully with the FDA approval of Gleevec® (imatinib mesylate, produced by Novartis Pharmaceutical Corporation of East Hanover, NJ) for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stroma cancers. Gleevec is a selective Abl kinase inhibitor.
[0011] Modulation (particularly inhibition) of cell proliferation and angiogenesis, two key cellular processes needed for tumor growth and survival (Matter A. Drug Disc Technol 2001 6, 1005-1024), is an attractive goal for development of small-molecule drugs. Anti- angiogenic therapy represents a potentially important approach for the treatment of solid tumors and other diseases associated with dysregulated vascularization, including ischemic coronary artery disease, diabetic retinopathy, psoriasis and rheumatoid arthritis. As well, cell antiproliferative agents are desirable to slow or stop the growth of tumors.
[0012] The enzyme, p70S6 kinase (p70S6K) is a serine-theoronine kinase that is a component of the phosphatidylinositol 3 kinase (PI3K)/Akt kinase (AktK) pathway. Both Akt and p70S6K are downstream of phosphatidylinositol-3 kinase (PI3K), and undergo phosphorylation and activation in response to growth factors such as IGF-1, EGF, TGF- and HGF. The enzyme p70S6K modulates protein synthesis by phosphorylation of the S6 ribosomal protein promoting translation. A role for p70S6K in tumor cell proliferation and protection of cells from apoptosis is supported based on its participation in growth factor receptor signal transduction, overexpression and activation in tumor tissues [Pene et al (2002) Oncogene 21, 6587; Miyakawa et al (2003) Endocrin J. 50, 77, 83; Le et al (2003) Oncogene 22, 484]. Clinical inhibition of p70S6K activation was observed in renal carcinoma patients treated with CCI-779 (rapamycin ester), an inhibitor of the upstream activating kinase, mTOR. A significant linear association between disease progression and inhibition of p70S6K activity was reported [Peralba et al (2003) Clinical Cancer Research 9, 2887]. [0013] Recently, the enzyme ρ70S6K was found to be implicated in metabolic diseases and disorders. It was reported that the absence of p70S6K protects against age- and diet- induced obesity while enhancing insulin sensitivity [Um et al (2004) Nature 431, 200-205 and Pende et al (2000) Nature 408, 994-997]. A role for p70S6K in metabolic diseases and disorders such as obesity, diabetes, metabolic syndrome, insulin resistance, hyperglycemia, hyperaminoacidemia, and hyperlipidemia is supported based upon the findings.
[0014] Accordingly, the identification of small-molecule compounds that specifically inhibit, regulate and/or modulate the signal transduction of kinases, particularly p70S6K and/or Akt, is desirable as a means to treat or prevent disease states associated with abnormal cell proliferation and metabolism is an object of this invention. SUMMARY OF THE INVENTION
[0015] The present invention provides compounds for modulating kinase activity and methods of treating, diseases mediated by kinase activity, in particular p70S6 and/or Akt kinase activity, utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by kinase activity are from herein referred to as "kinase-dependent diseases or conditions" (see definition in detailed description of invention below). Inhibitors that are selective for p70S6 and or Akt kinase are included in this invention.
[0016] In another aspect, the invention provides methods of screening for modulators of kinase activity. The methods comprise combining a composition of the invention, a kinase, and at least one candidate agent and determining the effect of the candidate agent on the kinase activity.
[0017] In yet another aspect, the invention also provides pharmaceutical kits comprising one or more containers filled with one or more of the ingredients of pharmaceutical compounds and/or compositions of the present invention, including, one or more kinase enzyme activity modulators as described herein. Such kits can also include, for example, other compounds and/or compositions (e.g., diluents, permeation enhancers, lubricants, and the like), a device(s) for administering the compounds and/or compositions, and written instructions in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflects approval by the agency of manufacture, use or sale for human administration. [0018] In still yet another aspect, the invention also provides a diagnostic agent comprising a compound of the invention and, optionally, pharmaceutically acceptable adjuvants and excipients.
[0019] These and other features and advantages of the present invention will be described in more detail below. DETAILED DESCRIPTION OF THE INVENTION
[0020] The compositions of the invention are used to treat diseases associated with abnormal and/or unregulated cellular activities. Disease states which can be treated by the methods and compositions provided herein include, but are not limited to, cancer (further discussed below), immunological disorders such as rheumatoid arthritis, graft-host diseases, multiple , sclerosis, psoriasis; cardiovascular diseases such as atherosclerosis, myocardioinfarction, ischemia, pulmonary hypertension, stroke and restenosis; other inflammatory and degenerative diseases such as interbowel diseases, osteoarthritus, macular degeneration, diabetic retinopathy.
[0021] It is appreciated that in some cases the cells may not be in a hyper- or hypo- proliferative and/or migratory state (abnormal state) and still require treatment. For example, during wound healing, the cells may be proliferating "normally," but proliferation and migration enhancement may be desired. Alternatively, reduction in "normal" cell proliferation and/or migration rate may be desired.
[0022] In embodiment A, the present invention comprises a compound for modulating kinase activity, particularly p70S6 and/or Akt kinase activity, of Formula I,
Figure imgf000008_0001
I
[0023] or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,
[0024] X21 is N or CR22;
[0025] X22 is N or CR23;
[0026] X23 is N or CR2 , but when X22 is N then X23 is CR24;
[0027] each of R2i, R22, R23, R2 , R25, R26, R27, R28, R29 and R30, and each R3ι, R32 and R33 is independently selected from -H, halogen, trihalomethyl, -CN, -N02,
-NR35R35a, -S(O)o-2R35, -SO2NR35R35a, -CO2R35, -C(O)NR35R35a, -N(R35)SO2R35,
-N(R35)C(O)R35, -N(R35)CO2R35, -OR35, -C(O)R35, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;
[0028] R is selected from -H, halogen, trihalomethyl, -S(O)0-2R35, -S02NR35R35a,
-CO2R35, -C(O)NR35R35a, -OR35, -C(O)R35, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or
[0029] two of R25, R26, R27, R28, R29, 3o; R3ι or R32, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted spirocyclic ring system, optionally substituted fused ring system, and optionally substituted saturated bridged ring system;
[0030] each of R 5 and R3sa is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or
[0031] R35 and R35a, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl; and
[0032] m is an integer from 0 to 5;
[0033] n is an integer from 1 to 2; and
[0034] with the provisos that when X22 is CR2 and X2 is N then R is not optionally substituted aryl, aralkyl or heteroaryl, and that when X22 is N and X23 is
CR2 then R is not optional substituted aryl or heteroaryl and R2ι is not -NR 5R35a, and that when X22 is CR23 and X23 is CR24 then R2) is not optionally substituted aryl, and that compounds with CAS Registration Nos. 732271-60-2, 565169-26-8, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14- 4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-34-2, 47281- 43-6, 37425-49-3, 37425-48-2, 24932-89-6 and 24932-78-3 are not included in Formula I.
[0035] In one example, the compound is according to Embodiment A, wherein n is 1.
[0036] In another example, the compound is according to paragraph [0035], wherein X21 is N.
[0037] In another example, the compound is according to paragraph [0036], wherein X23 is N.
[0038] In another example, the compound is according to paragraph [0037], wherein X22 is CR23.
[0039] In another example, the compound is according to paragraph [0038], wherein R is - H.
[0040] In another example, the compound is according to paragraph [0038], wherein R is optionally substituted alkyl.
[0041] In another example, the compound is according to paragraph [0039], wherein R21 is -H.
[0042] In another example, the compound is according to paragraph [0039], wherein R21 is optionally substituted alkyl.
[0043] In another example, the compound is according to paragraph [0041], wherein R 5 and R26 are -H.
[0044] In another example, the compound is according to paragraph [0043], wherein R2 and R28 are -H.
[0045] In another example, the compound is according to paragraph [0044], wherein R29 is -H.
[0046] In another example, the compound is according to paragraph [0045], wherein R30 is -H.
[0047] In another example, the compound is according to paragraph [0045], wherein R30 is optionally substituted alkyl. [0048] In another example, the compound is according to paragraph [0045], wherein R30 is -C(O)R35.
[0049] In another example, the compound is according to paragraph [0045], wherein R30 is -C(O)NR35R35a.
[0050] In another example, the compound is according to paragraph [0046], wherein R31 is -H.
[0051] In another example, the compound is according to paragraph [0050], wherein R32 is -H.
[0052] In another example, the compound is according to paragraph [0050], wherein R32 is -C(O)R35.
[0053] In another example, the compound is according to paragraph [0050], wherein R29, R3o> R31. and R32 are -H.
[0054] In another example, the compound is according to paragraph [0051], wherein R23 is optionally substituted alkyl.
[0055] In another example, the compound is according to paragraph [0051], wherein R23 is halogen, preferably F, Cl, or Br, and more preferably Br.
[0056] In another example, the compound is according to paragraph [0051], wherein R23 is -H.
[0057] In another example, the compound is according to paragraph [0051], wherein m is 2.
[0058] In another example, the compound is according to paragraph [0051], wherein m is 3.
[0059] In another example, the compound is according to paragraph [0051], wherein R33 is -H.
[0060] In another example, the compound is according to paragraph [0051], wherein R33 is halogen.
[0061] In another example, the compound is according to paragraph [0051], wherein R33 is optionally substituted alkyl.
[0062] In another example, the compound is according to paragraph [0051], wherein R33 is -NR35R35a. [0063] In another example, the compound is according to paragraph [0051], wherein R33 is -C(O)R35.
[0064] In another example, the compound is according to paragraph [0051], wherein R33 is trihalomethyl.
[0065] In embodiment B, the present invention also comprises a compound for modulating kinase activity, particularly p70S6 and or Akt kinase activity according to Formula II,
Figure imgf000012_0001
II [0066] or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, [0067] X2ι is N or CR22; [0068] X22 is N or CR23; [0069] X23 is N or CR24, but when X22 is N then X23 is CR24; [0070] each
Figure imgf000012_0002
R22, R23, R24, R25, R26, R27, R28, R29 and R30 and each of R3ι, R32 and R 3 is independently selected from -H, halogen, trihalomethyl, -CN, -N02, -NR35R35a, -S(O)0-2R35, -SO2NR35R35a, -CO2R35, -C(0)NR35R35a, -N(R35)S02R35, -N(R35)C(0)R35, -N(R35)CO2R35, -OR35, -C(O)R35, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; [0071] R is selected from -H, halogen, trihalomethyl, -S(O)0-2R35, -S02NR35R35a, -CO2R35, -C(O)NR35R35a, -OR35, -C(O)R35, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or [0072] two of R25, R 6, R27, R28, R2g, R30, R31 or R32, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted spirocyclic ring system, optionally substituted fused ring system, and optionally substituted saturated bridged ring system; [0073] each R35 and R35a is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or [0074] R35 and R35a, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl; [0075] Qi optionally substituted heterocyclyl; [0076] n is an integer from 1 to 2; and [0077] with the provisos that when X22 is CR 3 and X23 is N then R is not optionally substituted aryl, aralkyl or heteroaryl, and that when X22 is N and X23 is CR24 then R is not optional substituted aryl or heteroaryl and R21 is not -NR35R35a, and that when X22 is CR23 and X23 is CR24 then R21 is not optionally substituted aryl and X21 is N, and that compounds with CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 537667-22-4, 252722-35- 3, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 24932-90-9, and 24932-77-2 are not included in Formula II.
[0078] In one example, the compound is according to Embodiment B, wherein n is 1.
[0079] In another example, the compound is according to paragraph [0078], wherein X21 is N.
[0080] In another example, the compound is according to paragraph [0079], wherein X23 is N.
[0081] In another example, the compound is according to paragraph [0080], wherein X22 is CR23.
[0082] In another example, the compound is according to paragraph [0081], wherein R is - H. [0083] In another example, the compound is according to paragraph [0081], wherein R is optionally substituted alkyl.
[0084] In another example, the compound is according to paragraph [0082], wherein R21 is -H.
[0085] In another example, the compound is according to paragraph [0082], wherein R21 is optionally substituted alkyl.
[0086] In another example, the compound is according to paragraph [0084], wherein R^ and R26 are -H.
[0087] In another example, the compound is according to paragraph [0086], wherein R2 and R28 are -H.
[0088] In another example, the compound is according to paragraph [0087], wherein R29 is -H.
[0089] In another example, the compound is according to paragraph [0088], wherein R30 is -H.
[0090] In another example, the compound is according to paragraph [0088], wherein R30 is optionally substituted alkyl.
[0091] In another example, the compound is according to paragraph [0088], wherein R30 is -C(O)R35.
[0092] In another example, the compound is according to paragraph [0088], wherein R30 is -C(O)NR35R35a.
[0093] In another example, the compound is according to paragraph [0089], wherein R31 is -H.
[0094] In another example, the compound is according to paragraph [0093], wherein R32 is -H.
[0095] In another example, the compound is according to paragraph [0094], wherein R32 is -C(O)R35.
[0096] In another example, the compound is according to paragraph [0094], wherein R29,
Figure imgf000014_0001
[0097] In another example, the compound is according to paragraph [0094], wherein R 3 is optionally substituted alkyl. [0098] In another example, the compound is according to paragraph [0094], wherein R 3 is halogen.
[0099] In another example, the compound is according to paragraph [0094], wherein R23 is -H.
[0100] In another example, the compound is according to paragraph [0099], wherein Qi is a substituted heterocyclyl wherein the heterocyclyl has at least one nitrogen.
[0101] In another example, the compound is according to paragraph [0099], wherein Qα is a substituted heterocyclyl wherein the heterocyclyl has at least one oxygen.
[0102] In embodiment C, the present invention comprises molecules of embodiment A except that each R33 is independently selected from: [0103] (a) H, halo, -OH, NO2-, CN; [0104] (b) Ci-C6- alkyl, optionally substituted with 1-5 moieties independently selected from halo, -OH, -Ci-C3-alkoxy optionally substituted with 1-3 halo, or aryl; [0105] (c) Ci-Cβ-alkoxy optionally substituted with 1-3 moieties independently selected from halo and -C3-aιkoxy; [0106] (d) Rgo-Co- -alkyl, wherein R90 is N(R73)(R74), heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, Cι-C3-alkyl, Ci-C3-alkoxy, aryl, and heteroaryl; or R90 is R91- aryl optionally substituted with 1-3 halo; [0107] (e) R95-Ci-C3-alkoxy, wherein R95 is N(R 3)(R74), heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, - -alkyl, aryl, and heteroaryl; [0108] (f) R8o-C1-C3-alkyl-(Z)s-C0-C3-alkyl, wherein Rg0 is N(R75)(R76)- or aryl optionally substituted with Ci-C3-alkyl; [0109] (g) R81-C0-C6-alkyl-(Z)s-CO-, wherein R81 is H, Ci-Qs-alkyl optionally substituted with 1-3 halo, -C6-alkyloxy, N(R70)(R 1)-, heteroaryl, or aryl optionally substituted with 1-3 groups independently selected form halo and C1-C3- alkyl; [0110] (h) N(R73)(R74)-C(O)-C0-C3-alkoxy; [0111] (i) trimethylsilyl-Cι-C3-alkyl; or [0112] (j) - -alkylS O),-; [0113] and wherein [0114] R70 and R71 are independently H, CrC3-alkyl, or -Cralkoxy, or R70 and R 1 together with the nitrogen to which they are attached form a heterocyclyl optionally substituted with 1-3 -Cβ-alkyl, provided two oxygen atoms are not adjacent; [0115] R72 is H or Cι-C6-alkyl; [0116] R73 and R74 are independently H or Cr -alkyl; [0117] R 5 and R76 are independently H or -Cό-alkyl or, together with the nitrogen to which they are attached, form a 5- or 6- membered heterocyclyl optionally substituted with Ci-C3-alkyl; [0118] R9ι is N(R75)(R76)-Cι-C3-alkyl-Z-; [0119] Z is -NR72- or -O-; and [0120] s is O or l.
[0121] Table A gives particular examples of R33 of groups (b)-(j) (paragraphs [0104] - [0112]), above: Table A
(b) methyl, trifluoromethyl,ethyl, propyl, 2,2-dimethylbutyl, 1,1-difluorobutyl, trifluoromethyl, hydroxymethyl, phenylethyl, styryl, ethynyl, 3,3-dimethylbut-l- ynyl, difluoromethoxymethyl, ethoxymethyl, 3-hydroxypropyl, 1-hydroxybutyl, (2,2,2-trifluoroethoxy)methyl, 4,4,4-trifluoro- 1 , 1 -dimethoxybutyl
(c) methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-methoxyethoxy, 4- methylbutoxy, 2-ethylbutoxy, 2,2-dimethylpropoxy, 2-fluoro-2-methylpropoxy, difluromefhoxy, 2,3-difluoro-2-(fluoromethyl)propoxy, (2,2- difluorocyclopropyl)methoxy, ethoxymethoxy, 3,3,3-trifluroethoxy, 3,3,3- trifluropropoxy
( phenyl, 3,4-difluorphenyl, 3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazin-6-yl, furan- 2-yl, thiazol-2-yl, morpholino, pyrrolidinylpropyl, 3-methyl-l,2,4-oxadiazol-5-yl, 3-phenyl-l,2,4-oxadiazol-5-yl, diethylamino, isopentylamino, 2-(2-(pyrrolidin-l- yl)ethoxy)phenyl, 3-(2-(pyrrolidin-l-yl)ethoxy)phenyl, 4-fluoro-2-(2-(pyrrolidin-l- yl)ethoxy)phenyl, 2-(3-(dimethylamino)propoxy)phenyl, 2-(2- morpholinoethoxy)phenyl, 2-(2-(2,5-dioxopyrrolidin- 1 -yl)ethoxy)phenyl, 3-fluoro- 2-(2-(pyrrolidin-l-yl)ethoxy)phenyl
(e) morpholino-propoxy, piperidinyl-propoxy, (tetrahydrofuran-2-yl)methoxy (f) (2-(dimethylamino)ethylamino)methyl, 2-(dimethylamino)ethoxy, 2- (diethylamino)ethoxy, 3-(diethylamino)propyl, 3-(diethylamino)proρoxy, 3- (dimethylamino)propoxy, 3-(dimethylamino)-prop-l-enyl, 2- (dimethylamino)ethylamino, 2-(diethylamino)ethylamino, 2-(pyrrolidin- 1 - yl)ethoxy, 3-(pyrrolidin-l-yl)propyl, 3-(pyrrolidin-l-yl)propoxy, 2-(ρyrrolidin-l- yl)ethylamino, 2-(piperidin-l-yl)ethoxy, 3-(piperidin-l-yl)propyl, 3-(piperidin-l- yl)propoxy , 2-( 1 -methylpiperidin-4-yl)ethoxy, ( 1 -methylpiperidin-4-yl)methoxy, (l-methylpiρeridin-4-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 3- morpholinopropyl, 3-(4-methylpiperazin-l-yl)propyl, 3-(4-methylpiperazin-l- yl)propoxy, 3-(4-ethylpiperazin-l-yl)propoxy, 2-(4-methylpiperazin-l-yl)ethoxy, 2- (4-ethylpiperazin-l-yl)ethoxy, phenylmethoxy, 3-methylbenzyloxy, 2- (isopropyl(methyl)amino)ethylamino
(g) 2-(dimethylamino)ethylcarbamoyl, N-methylpiperizinylcarbonyl, (2- (dimethylamino)ethoxy)carbonyl, methylcarbamoyl, ethylcarbamoyl, isopropylcarbamoyl, isopropyl(methyl)carbamoyl, isobutylcarbamoyl, t- butylcarbamoyl, phenylcarbamoyl, benyzlcarbamoyl, 2-chlorophenylcarbamoyl, methoxycarbonyl, pyridin-3-ylcarbamoyl, 4,4,4-trifluorobutanoyl, dimethylcarbamoyl, pyrrolidine- 1 -carbonyl, 2-(dimethylamino)ethylcarbamoyl, acetyl, propionyl, butyryl, 4,4,4-trifluorobutanoyl, pentoyl, benzoyl, cyclopropylmethoxycarbamoyl, cyclopropanecarbonyl
(h) 2-(ethylamino)-2-oxoethoxy, 2-(cyclopropylamino)-2-oxoethoxy
(i) 2-(trimethylsilyl)ethyl
G) methylsulfonyl, ethylsulfonyl
[0122] In some examples of Embodiments A-C, each of R25-R32 is H.
[0123] In some examples according to paragraph [0122], R21 is H.
[0124] In some examples according to paragraph [0122], X21 and X23 are Ν.
[0125] In some examples according to paragraph [0122] X22 is CR23 and R23 is lower alkyl or halo, preferably Br.
[0126] In some examples of embodiments A and C according to paragraph[0122], m is 3. Preferred R33 in these examples includes lower alkyl (preferably methyl), Rso- - - alkyl-(Z)s-C0-C3-alkyl (preferably wherein R80 is heterocyclyl such as pyrrolidinyl; the - C3-alkyl is ethyl; s is 1; Z is ΝH; and C0-C3-alkyl is Co, i.e., a bond), and R8ι-Co-C6-alkyl- (Z)s-CO- (preferably wherein: R81 is Cι-C6-alkyl optionally substituted with 1-3 halo, more preferably wherein the - -alkyl optionally substituted with 1-3 halo is trihalopropyl (preferably trifluoropropyl, and even more preferably 3,3,3-trifluoropropyl); the Co-C6-alkyl is Co (i . e. , a bond); and s is 0). Preferably the R8o-C1-C3-alkyl-(Z)s-C0- C3-alkyl and the R81-Co-C6-alkyl-(Z)s-CO- groups are meta to each other and to X21.
[0127] Another preferred embodiment includes Embodiments A and C with R 1 according to paragraph [0123], R25-R32 according to paragraph [0122], X21 and X23 are according to paragraph [0124], X22 according to paragraph [0125] and m and R33 according to paragraph [0126].
[0128] In other examples of embodiments A-C, R25-R28 and R3o-R32 are H and R29 is other than H. In such embodiments the annular carbon atom to which R29 is bonded is chiral. In some examples of this embodiment, that chiral center is enantiomerically enriched (greater than 60%, 70%, 80%, 90%, or 95%) or pure. Examples of R29 when the annular carbon is chiral in this embodiment include methyl and hydroxymethyl.
[0129] In a particular embodiment of Embodiment C, when X23 is CR24, m is 1-5, and at least one R33 is selected from: [0130] (i) Cι-C6- alkyl 1-5 moieties independently selected from -OH and - Ct- -alkoxy optionally substituted with 1-3 halo, or aryl; [0131] (ii) .Cs-alkoxy optionally substituted with 1-3 - -alkoxy moieties; [0132] (iii) R90-Co-C3-alkyl, wherein R90 is N(R73)(R7 ) if the alkyl moiety is Cι-C3-alkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, Cι-C3-alkyl, - C3-alkoxy, aryl, and heteroaryl; or R 0 is R91-aryl optionally substituted with 1-3 halo; [0133] (iv) R95-Ci-C3-alkoxy, wherein R95 is N(R7 )(R74), heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, - -alkyl, aryl, and heteroaryl; [0134] (v) R80-C1-C3-alkyl-(Z)s-C0-C3-alkyl, wherein R80 is N(R75)(R76)- or aryl optionally substituted with -Cs-alkyl; [0135] (vi) R81-C0-C6-alkyl-(Z)s-CO-, wherein R81 is H, -Ce-alkyl optionally substituted with lr3 halo, -Cό-aikyloxy, N(R7o)(R7ι)-, heteroaryl, or aryl optionally substituted with 1-3 groups independently selected form halo and -C3- alkyl; [0136] (vii) N(R73)(R74)-C(O)-C0-C3-alkoxy; [0137] (viii) trimethylsilyl- -Cralkyl; or [0138] (ix) C1-C3-alkylS(O)2-; [0139] In each of the aspects, examples, and embodiments of the compounds of the invention, R is preferably H or optionally substituted Cι-C6-alkyl, more preferably H or unsubstituted -Cδ-alkyl, and even more preferably H.In one particular embodiment of embodiments A or C, X22 is CR23, X23 is CR^, and R21 is halogenln another particular embodiment of embodiments A or C, X22 is N, X23 is CR24, and R21 is halogen
[0142] In yet another particular embodiment of embodiments A or C, X22 is CR23, X23 is CR^, X21 is nitrogen R21 is hydrogen, m is 1, 2, 3, 4, or 5 and at least one R33 is not hydrogen.
[0143] In still another particular embodiment of embodiments A or C, X22 is N, X23 is CR24, X2ι is nitrogen and R21 is hydrogen, then m is 1, 2, 3, 4, or 5 and at least one R33 is not hydrogen.
[0144] In yet still another particular embodiment of embodiments A or C, X22 is N, X23 is CR2 , X21 is N, n is 1, R25-R32 are the same and are H, or only one of R25-R3 is alkyl, and R is H or alkyl, then R24 is H or alkyl.
[0145] In another particular embodiment of embodiments A or C, X22 is CR23, X23 is CR24, X21 is N, n is 1, R25-R32 are the same and are H, or only one of R25-R32 is alkyl, R is H or alkyl, and R^ is H or alkyl.
[0146] In one particular embodiment of embodiment C, Qi is not pyrid-2-yl, i.e., when Qi is pyridyl it is not attached to the X21 group at postion ortho to the pyridyl nitrogen.
[0147] In another particular embodiment of embodiment C, X 2 is CR23, X23 is CR2 , and R21 is halogen
[0148] In still another particular embodiment of embodiment C, X22 is N, X23 is CR24, and R21 is halogen
[0149] In yet another particular embodiment of embodiment C, X22 is CR23, X23 is CR24, X21 is nitrogen, R21 is hydrogen, m is 1, 2, 3, 4, or 5 and at least one R33 is not hydrogen
[0150] In yet still another particular embodiment of embodiment C, X22 is N, X23 is CR24, X21 is nitrogen, R21 is hydrogen, m is 1, 2, 3, 4, or 5 and at least one R33 is not hydrogen
[0151] In another particular embodiment of embodiment C, Qi is not pyrimidyl or triazinyl. [0152] In one example, the compound is according to paragraphs [0022]-[0151], wherein the compound is a pharmaceutically acceptable salt.
[0153] In one example, the compound is according to paragraphs [0022]-[0151], wherein the compound is a prodrug.
[0154] In another example, the compound is according to any one of paragraphs [0022]-[0151], selected from Tables 1 or 2 below.
[0155] Another aspect of the invention is a composition comprising the compound according to any one of paragraphs [0022]-[0154] and at least one phaπnaceutically acceptable carrier or excipient.
[0156] Another aspect of the invention is a metabolite of the compound according to any one of paragraphs [0022] -[0154].
[0157] Another aspect of the invention is a method of modulating the in vivo activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising at least one of the compound according to any of paragraphs [0022]-[0154| and the pharmaceutical composition according to paragraph [0155] and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908- 34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X22 is CR23 and X23 is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X22 is N and X23 is CR2 then R21 is -NR35R35, and when X22 is CR23 and X23 is CR24 then R21 is optionally substituted aryl and X21 is N.
[0158] Another aspect of the invention is the method according to paragraph [0157], wherein the kinase is p70S6 and/or Akt.
[0159] Another aspect of the invention is the method according to paragraph [0158], wherein modulating the in vivo activity of p70S6K and/or AktK comprises inhibition of p70S6K and/or AktK.
[0160] Another aspect of the invention is a method of treating and/or inhibiting diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155] and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281- 43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X22 is CR23 and X23 is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X22 is N and X23 is CR24 then R ι is - NR35R35, and when X22 is CR23 and X23 is CR24 then R21 is optionally substituted aryl and X21 is N.
[0161] Another aspect of the invention is a method of screening for modulator of a p70S6K and/or AktK, the method comprising combining either a composition comprising at least one of the compound according to any of paragraphs [0022] -[0154] and the pharmaceutical composition according to paragraph [0155], and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495- 50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X22 is CR23 and X23 is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X22 is N and X23 is CR24 then R 1 is -NR35R35, and when X22 is CR23 and X23 is CR2 then R21 is optionally substituted aryl and X2ϊ is N, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
[0162] Another aspect of the invention is a method of inhibiting proliferative activity in a cell or a plurality of cells, the method comprising administering an effective amount of at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155], and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495- 50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and U when X22 is CR23 and X23 is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X22 is N and X23 is CR 4 then R21 is -NR35R35, and when X22 is CR23 and X23 is CR24 then R21 is optionally substituted aryl and X21 is N, to said cell or plurality of cells.
[0163] Another aspect of the invention is a method of preparing the compounds according to any of paragraphs [0022]-[-0154].
Definitions
[0164] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise or they are expressly defined to mean something different.
[0165] The symbol "-" means a single bond, "=" means a double bond, "≡" means a triple bond. The symbol "αwvr" refers to a group on a double-bond as occupying either position on the terminus of a double bond to which the symbol is attached; that is, the geometry, E- or Z-, of the double bond is ambiguous. When a group is depicted removed from its parent formula, the "^^" symbol will be used at the end of the bond which was theoretically cleaved in order to separate the group from its parent structural formula.
[0166] Chemical formulae use descriptors such as "R1" accompanied by a list of formulae or verbage describing the scope of what is meant by the descriptor. A subsequent descriptor such as "Rla" is used to describe some subset of the scope of R1, and "Rlb" is used to describe another subset of the scope of R1, and so on. In such subsequent cases, all other formulae containing simply "R1" are meant to include the entire scope of the descriptor.
[0167] When chemical structures are depicted or described, unless explicitly stated otherwise, all carbons are assumed to have hydrogen substitution to conform to a valence of four. For example, in the structure on the left-hand side of the schematic below there are nine hydrogens implied. The nine hydrogens are depicted in the right-hand structure. Sometimes a particular atom in a structure is described in textual formula as having a hydrogen or hydrogens as substitution (expressly defined hydrogen), for example, -CH2CH2-. It is understood by one of ordinary skill in the art that the aforementioned descriptive techniques are common in the chemical arts to provide brevity and simplicity to description of otherwise complex structures.
Figure imgf000023_0001
[0168] In this application, some ring structures are depicted generically and will be described textually. For example, in the schematic below, if in the structure on the left, ring A is used to describe a "spirocyclyl," then if ring A is cyclopropyl, there are at most four hydrogens on ring A (when "R" can also be -H). In another example, as depicted on the right side of the schematic below, if ring B is used to describe a "phenylene" then there can be at most four hydrogens on ring B (assuming depicted cleaved bonds are not C-H bonds).
Figure imgf000023_0002
[0169] If a group "R" is depicted as "floating" on a ring system, as for example in the formula:
Figure imgf000023_0003
then, unless otherwise defined, a substituent "R" may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.
[0170] If a group "R" is depicted as floating on a fused ring system, as for example in the formulae:
Figure imgf000023_0004
then, unless otherwise defined, a substituent "R" may reside on any atom of the fused ring system, assuming replacement of a depicted hydrogen (for example the -NH- in the formula above), implied hydrogen (for example as in the formula above, where the hydrogens are not shown but understood to be present), or expressly defined hydrogen (for example where in the formula above, "X" equals =CH-) from one of the ring atoms, so long as a stable structure is formed. In the example depicted, the "R" group may reside on either the 5-membered or the 6-membered ring of the fused ring system. In the formula depicted above, when y is 2 for example, then the two "R's" may reside on any two atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.
[0171] When a group "R" is depicted as existing on a ring system containing saturated carbons, as for example in the formula:
Figure imgf000024_0001
where, in this example, "y" can be more than one, assuming each replaces a currently depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined, where the resulting structure is stable, two "R's" may reside on the same carbon. A simple example is when R is a methyl group; there can exist a geminal dimethyl on a carbon of the depicted ring (an "annular" carbon). In another example, two R's on the same carbon, including that carbon, may form a ring, thus creating a spirocyclic ring (a "spirocyclyl" group) structure with the depicted ring as for example in the formula:
Figure imgf000024_0002
[0172] "Alkyl" is intended to include saturated and non-saturated (but not aromatic) linear, branched, and cyclic hydrocarbon structures and combinations thereof, inclusively. For example, "C8 alkyl" may refer to an n-octyl, ώo-octyl, cyclohexylethyl, 3-octenyl, - octa-2,4-dienyl, cyclooctane, cyclooctene, and the like. Lower alkyl refers to alkyl groups of from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, propenyl, isopropyl, butyl, s-butyl, t-butyl, isobutyl, pentyl, hexyl, hex-3-ynyl, and the like. Higher alkyl refers to alkyl groups containing more that eight carbon atoms. Exemplary alkyl groups are those of C20 or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In this application, alkyl refers to alkanyl, alkenyl, and alkynyl residues (and combinations thereof); it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus, when an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, either "butyl" or " alkyl" is meant to include n-butyl, sec-butyl, isobutyl, t-butyl, isobutenyl and but-2-yne radicals; and for example, "propyl" or "C3alkyl" each include n- propyl, propenyl, and isopropyl. Otherwise, if alkenyl and/or alkynyl descriptors are used in a particular definition of a group, for example "Qalkyl" along with "C4alkenyl," then C4alkenyl geometric isomers are not meant to be included in "C4alkyl," but other 4-carbon isomers are, for example C4alkynyl. For example, a more general description, intending to encompass the invention as a whole may describe a particular group as "C1-8alkyl" while a preferred species may describe the same group as including, "C1-8alkyl," "C1-6alkenyl" and "C1-5alkynyl." As used herein, Co is a bond. So, for example NH2-Co-C3-alkyl includes amino as well as aminomethyl, 2-aminoethyl, 1 aminoethyl, etc.
[0173] "Alkylene" refers to straight or branched chain divalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, n-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), dimethylpropylene (-CH2C(CH3)2CH2-), and cyclohexylpropylene (-CH2CH2CH(C6H13)).
[0174] "Alkylidene" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, n-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, double bond unsaturation. The unsaturation present includes at least one double bond.
[0175] "Alkylidyne" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, π-butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond.
[0176] Any of the above radicals, "alkylene," "alkylidene" and "alkylidyne," when optionally substituted, may contain alkyl substitution which itself contains unsaturation. For example, 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an n-butylid-3-ynyl radical with a vinyl substituent at the 2-position of said radical.
[0177] "Alkoxy" or "alkoxyl" refers to the group -O-alkyl, for example including from one to eight carbon atoms of a straight, branched, cyclic configuration, unsaturated chains, and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to six carbons.
[0178] "Substituted alkoxy" refers to the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy). One exemplary substituted alkoxy group is "polyalkoxy" or -O-optionally substituted alkylene-optionally substituted alkoxy, and includes groups such as -OCH2CH2OCH3, and glycol ethers such as polyethyleneglycol and -O(CH2CH2O)xCH3, where x is an integer of between about two and about twenty, in another example, between about two and about ten, and in a further example between about two and about five. Another exemplary substituted alkoxy group is hydroxyalkoxy or -OCH2(CH2)yOH, where y is for example an integer of between about one and about ten, in another example y is an integer of between about one and about four.
[0179] "Acyl" refers to groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to six carbons.
[0180] " -Amino Acids" refer to naturally occurring and commercially available amino acids and optical isomers thereof. Typical natural and commercially available - amino acids are glycine, alanine, serine, homoserine, threonine, valine, norvaline, leucine, isoleucine, norleucine, aspartic acid, glutamic acid, lysine, omithine, histidine, arginine, cysteine, homocysteine, methionine, phenylalanine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan, glutamine, asparagine, proline and hydroxyproline. A "side chain of an -amino acid" refers to the radical found on the α-carbon of an -amino acid as defined above, for example, hydrogen (for glycine), methyl (for alanine), benzyl (for phenylalanine), and the like.
[0181] "Amino" refers to the group -NH2. "Substituted amino," refers to the group -N(H)R or -N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl, sulfanyl, sulfinyl and sulfonyl, for example, diethylamino, methylsulfonylamino, and furanyl-oxy-sulfonamino.
[0182] "Aryl" refers to aromatic six- to fourteen-membered carbocyclic ring, for example, benzene, naphthalene, indane, tetralin, fluorene and the like, univalent radicals. As univalent radicals, the aforementioned ring examples are named, phenyl, naphthyl, indanyl, tetralinyl, and fluorenyl.
[0183] "Arylene" generically refers to any aryl that has at least two non-hydrogen groups attached thereto. For a more specific example, "phenylene" refers to a divalent phenyl ring radical. A phenylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto. The terms "ortho- arylene," "meta-arylene" or "para-arylene" refer to geometrical isomers of a particular arylene wherein, two groups attached to an aryl as depicted in a formula are situated in an ortho, meta or para geometrical relationship about the aryl, respectively.
[0184] "Arylalkyl" refers to a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Both the aryl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of an arylalkyl group may be optionally substituted. "Lower arylalkyl" refers to an arylalkyl where the "alkyl" portion of the group has one to six carbons; this can also be refered to as aryl C1-6alkyl.
[0185] "Exo-alkenyl" refers to a double bond that emanates from an annular carbon, and is not within the ring system, for example the double bond depicted in the formula below.
Figure imgf000027_0001
[0186] In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (i.e. saturated ring structures) can contain two substitution groups.
[0187] "Fused-polycyclic" or "fused ring system" refers to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused- polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro- naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.
[0188] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. "Haloalkyl" and "haloaryl" refer generically to alkyl and aryl radicals that are substituted with one or more halogens, respectively. Thus, "dihaloaryl," "dihaloalkyl," "trihaloaryl" etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.
[0189] "Heteroarylene" generically refers to any heteroaryl that has at least two groups attached thereto. For a more specific example, "pyridylene" refers to a divalent pyridyl ring radical. A pyridylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto. For the purposes of this application, the term "ortho-heteroarylene" refers to a geometrical isomer of a particular heteroarylene wherein two groups attached to a heteroaryl as depicted in a formula are situated on contiguous atoms of the heteroaryl.
[0190] "Heteroatom" refers to O, S, N, or P.
[0191] "Heterocyclyl" refers to a stable three- to fifteen-membered ring radical that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclyl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems as well as spirocyclic systems; and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized to various oxidation states. In a specific example, the group -S(O)0-2-, refers to -S- (sulfide), -S(O)- (sulfoxide), and -SO2- (sulfone). For convenience, nitrogens, particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include their corresponding N-oxide form, although not explicitly defined as such in a particular example. Thus, for a compound of the invention having, for example, a pyridyl ring; the corresponding pyridyl-N-oxide is meant to be included as another compound of the invention. In addition, annular nitrogen atoms may be optionally quaternized; and the ring radical may be partially or fully saturated or aromatic. Examples of heterocyclyl radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, > 2,5-dioxopyrrolidin-l-yl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, moφholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothieliyl, thiamorpholinyl, thiamoφholinyl sulfoxide, thiamoφholinyl sulfone, dioxaphospholanyl, and oxadiazolyl.
[0192] "Heteroalicyclic" refers specifically to a non-aromatic heterocyclyl radical. A heteroalicyclic may contain unsaturation, but is not aromatic.
[0193] "Heteroaryl" refers specifically to an aromatic heterocyclyl radical.
[0194] "Heterocyclylalkyl" refers to a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include (4-methylpiperazin-l-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpiρerazin-l-yl)-2-butenyl, and the like. Both the heterocyclyl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of a heterocyclylalkyl group may be optionally substituted. "Lower heterocyclylalkyl" refers to a heterocyclylalkyl where the "alkyl" portion of the group has one to six carbons. "Heteroalicyclylalkyl" refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is non-aromatic; and "heteroarylalkyl" refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is aromatic Such terms may be described in more than one way, for example, "lower heterocyclylalkyl" and "heterocyclyl C1-6alkyl" are equivalent terms.
[0195] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that, with respect to any molecule described as containing one or more optional substituents, that only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted" refers to all subsequent modifiers in a term, for example in the term "optionally substituted aryl C1-8alkyl," optional substitution may occur on both the "C1-8alkyl" portion and the "aryl" portion of the molecule; and for example, optionally substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups. A list of exemplary optional substitutions is included below in the definition of "substituted."
[0196] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro- lH-indene, 7-aza-bicyclo[2.2.1]heptane, and l,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system.
[0197] "Spirocyclyl" or "spirocyclic ring" refers to a ring originating from a particular annular carbon of another ring. For example, as depicted below, a ring atom of a saturated bridged ring system (rings B and B'), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocyclyl (ring A) attached thereto. A spirocyclyl can be carbocyclic or heteroalicyclic.
Figure imgf000030_0001
[0198] "Substituted" alkyl, aryl, and heterocyclyl, refer respectively to alkyl, aryl, and heterocyclyl, wherein one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent. Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is - C(O)-) nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, sulfonamido, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, alkylthio, ureido, and ureidoalkyl groups. Preferred substituents, which are themselves not further substituted (unless expressly stated otherwise) are: [0199] (a) halo, cyano, oxo, alkyl, alkoxy, alkylthio, haloalkoxy, aminoalkyl, aminoalkoxy, carboxy, formyl, nitro, amino, amidino, carbamoyl, guanidino, C3-C7 heterocycle, heterocyclylalkyl, heterocyclylcarbonyl, hydroxyalkyl, alkoxyalkyl, [0200] (b) Ci-C5 alkyl or alkenyl or arylalkyl imino, carbamoyl, carbamate, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, -Cs alkyl, - alkenyl, - alkoxy, - alkoxycarbonyl, aryloxycarbonyl, C2-C8 acyl, C2-C8 acylamino, - alkylthio, arylalkylthio, arylthio, heteroarylthio, - C8 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, Cι-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, Co-C6 N-alkyl carbamoyl, C2-C15 N,N- dialkylcarbamoyl, C3-C cycloalkyl, aroyl, aryloxy, heteroaryloxy, arylalkyl ether, C3-C7 heterocyclylalkylether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, heteroaryl, arylcarbamoyl, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclyl, or aryl, wherein any of the foregoing which are additionally substitutable is further optionally substituted with one more moieties listed in (a), above; and [0201] (c) -(CH2)s-NR35R35a, wherein s is from 0 (in which case the nitrogen is directly bonded to the moiety that is substituted) to 6, and R35 and R35a are each independently hydrogen, cyano, oxo, carboxamido, amidino, - hydroxyalkyl, d-C3 alkylaryl, aryl-Ci-C3 alkyl, Q-C8 alkyl, - alkenyl, Q-C8 alkoxy, CrC8 alkoxycarbonyl, aryloxycarbonyl, aryl-Cι-C3 alkoxycarbonyl, C2- acyl, - alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, cycloalkyl, heterocyclyl, or heteroaryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above; or R35 and R35a taken together with the N to which they are attached form a heterocyclyl or heteroaryl, each of which is optionally substituted with from 1 to 3 substituents from (a), above.
[0202] In addition, substituents on cyclic moieties (i.e., cycloalkyl, heterocyclyl, aryl, heteroaryl) include 5-6 membered mono- and 9-14 membered bi-cyclic moieties fused to the parent cyclic moiety to form a bi- or tri-cyclic fused ring system. For example, an optionally substituted phenyl includes, but not limited to, the following:
Figure imgf000032_0001
[0203] Preferred substituents on cyclic moieties (i.e., cycloalkyl, heterocyclyl, aryl, heteroaryl) also include groups of the formula -K1-N(H)(R36), wherein [0204] Ki is a chemical bond or C1-C4 alkylene; [0205] R36 is selected from the group consisting of Z' and -Ak2-Z', wherein [0206] Ak2 is C1-C4 alkylene; and [0207] Z' is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which optionally is substituted, and each of which optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings.
[0208] Particularly preferred substituents on cyclic moieties (such as aryl, heteroaryl, cycloalkyl, heterocyclyl, or any of these rings fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings), include 1, 2, or 3 groups independently selected from the following: [0209] a) alkoxy, cyano, amino, oxo, haloalkyl, halo, alkyl, R35-C(O)-N(R35)-, R35-O-C(O)-N(R35)-, R35-NH-C(O)-N(R35)-, R35-NH-C(O)-O-, (R35a)(R35)N-alkyl-, (R35a)(R35)N-alkyl-O-, (R35)(R35a)N-alkenylene-N(R35)-, N(R35)-aryl-N(R35)-C(O)- aryl-alkyl-N(R35)-; wherein R35 is cycloakyl, heterocyclyl- -Ce alkyl-, or alkyl; [0210] b) aryl-C0-C6 alkyl-, heteroaryl-C0-C6 alkyl-, cycloalkyl-C0-C6 alkyl-, heterocyclyl-Co-C6 alkyl-, aryl-C0-C6 alkyl-N(R35)-, aryl-C(O)-, heteroaryl-C0-C6 alkyl-N(R35)-, heterocyclyl-Co-C6 alkyl-N(R35)-, aryl-O-, heteroaryl-O-, aryl-S-, heteroaryl-S-, aryl-SO2-, heteroaryl-SO2, aryl-C(O)N(R35)-, heteroaryl-C(O)N(R35)-, heteroaryl-C(H)(SO2-heteroaryl)-N(R35)-; wherein R35 and R35a are independently H or - s alkyl, or R35 and R35a taken together with the N to which they are attached form a heterocyclyl or heteroaryl; [0211] c) and wherein any of the rings described in paragraphs (a) and (b) immediately above are further optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkoxy, thioalkoxy, alkyl-SO2-, amino, halo, cyano, haloalkyl, hydroxyalkyl, alkoxyalkoxyalkyl, COOH, alkanoyl, alkanoate, NO2, hydroxy, haloalkoxy, (R35a)(R35)N~C0-C6 alkyl-, (R35a)(R35)N-Co-C6 alkyl-O-, (R35a)(R35)N-C(O)-, heteroaryl, alkyl-C(O)N(R35 , aryl-O-, (R35a)(R35)N-SO2-, aryl, and (R35a)(R35)N-alkyl-C(O)N(R35)-.
[0212] "Sulfanyl" refers to the groups: -S-(optionally substituted alkyl), -S-(optionally substituted aryl), and -S- (optionally substituted heterocyclyl).
[0213] "Sulfinyl" refers to the groups: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-optionally substituted aryl), and -S(O)-(optionally substituted heterocyclyl).
[0214] "Sulfonyl" refers to the groups: -S(O2)-H, -S(O )-(optionally substituted alkyl), -S(O2)-optionally substituted aryl), -S(O2)-(optionally substituted heterocyclyl), -S(O2)-(optionally substituted alkoxy), -S(O2)-optionally substituted aryloxy), and -S(O2)-(optionally substituted heterocyclyloxy).
[0215] "Yield" for each of the reactions described herein is expressed as a percentage of the theoretical yield.
[0216] Some of the compounds of the invention may have imino, amino, oxo or hydroxy substituents off aromatic heterocyclyl systems. For puφoses of this disclosure, it is understood that such imino, amino, oxo or hydroxy substituents may exist in their corresponding tautomeric form, i.e., amino, imino, hydroxy or oxo, respectively.
[0217] Compounds of the invention are named according to systematic application of the nomenclature rules agreed upon by the International Union of Pure and Applied Chemistry (IUPAC), International Union of Biochemistry and Molecular Biology (IUBMB), and the Chemical Abstracts Service (CAS). Compounds were named using the nomenclature engine published by ACD/Labs of Toronto Canada - ACD/Name Batch 7.00 Release, Product v.7.10, Build 15 Sep 2003.
[0218] The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms, oxidized sulfur atoms or quaternized nitrogen atoms in their structure. [0219] The compounds of the invention and their pharmaceutically acceptable salts may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.
[0220] It is assumed that when considering generic descriptions of compounds of the invention for the puφose of constructing a compound, such construction results in the creation of a stable structure. That is, one of ordinary skill in the art would recognize that there can theoretically be some constructs which would not normally be considered as stable compounds (that is, sterically practical and/or synthetically feasible, supra).
[0221] When a particular group with its bonding structure is denoted as being bonded to two partners; that is, a divalent radical, for example, -OCH2-, then it is understood that either of the two partners may be bound to the particular group at one end, and the other partner is necessarily bound to the other end of the particular group, unless stated explicitly otherwise. Stated another way, divalent radicals are not to be construed as limited to the depicted orientation, for example "-OCH2-" is meant to mean not only "-OCH2-" as drawn, but also "-CH2O-."
[0222] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas- liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystalhzation.
[0223] "Patient" for the puφoses of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a preferred embodiment the patient is a mammal, and in a most preferred embodiment the patient is human.
[0224] "Kinase-dependent diseases or conditions" refer to pathologic conditions that depend on the activity of one or more protein kinases. Kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities including proliferation, adhesion, migration, differentiation and invasion. Diseases associated with kinase activities include tumor growth, the pathologic neovascularization that supports solid tumor growth, and associated with other diseases where excessive local vascularization is involved such as ocular diseases (diabetic retinopathy, age-related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like).
[0225] While not wishing to be bound to theory, phosphatases can also play a role in "kinase-dependent diseases or conditions" as cognates of kinases; that is, kinases phosphorylate and phosphatases dephosphorylate, for example protein substrates. Therefore compounds of the invention, while modulating kinase activity as described herein, may also modulate, either directly or indirectly, phosphatase activity. This additional modulation, if present, may be synergistic (or not) to activity of compounds of the invention toward a related or otherwise interdependent kinase or kinase family. In any case, as stated previously, the compounds of the invention are useful for treating diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth.
[0226] "Therapeutically effective amount" is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
[0227] "Cancer" refers to cellular-proliferative disease states, including but not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hanlartoma, inesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinorna, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaφosi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [neplrroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis defornians), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastorna multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, SertoliLeydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaφosi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal lands: neuroblastoma. Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above-identified conditions.
[0228] "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
[0229] "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. (See, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19 which is incoφorated herein by reference.) [0230] "Prodrug" refers to compounds that are transformed (typically rapidly) in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) wherein the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl. Examples of pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons). Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B: Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incoφorated herein by reference for all purposes.
[0231] "Metabolite" refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics" δ.sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of biotransformation). As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In one example, a prodrug may be used such that the biologically active form, a metabolite, is released in vivo. In another example, a biologically active metabolite is discovered serendipitously, that is, no prodrug design per se was undertaken. An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure.
[0232] In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the puφoses of the present invention. [0233] In addition, it is intended that the present invention cover compounds made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.
[0234] "Treating" or "treatment" as used herein covers the treatment of a disease-state in a human, which disease-state is characterized by abnormal cellular proliferation, and invasion and includes at least one of: (i) preventing the disease-state from occurring in a human, in particular, when such human is predisposed to the disease-state but has not yet been diagnosed as having it; (ii) inhibiting the disease-state, i.e., arresting its development; and (iii) relieving the disease-state, i.e., causing regression of the disease-state. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.
[0235] One of ordinary skill in the art would understand that certain crystallized, protein-ligand complexes, in particular p70S6- or Akt-4-ligand complexes, and their corresponding x-ray structure coordinates can be used to reveal new structural information useful for understanding the biological activity of kinases as described herein. As well, the key structural features of the aforementioned proteins, particularly, the shape of the ligand binding site, are useful in methods for designing or identifying selective modulators of kinases and in solving the structures of other proteins with similar features. Such protein-ligand complexes, having compounds of the invention as their ligand component, are an aspect of the invention.
[0236] As well, one of ordinary skill in the art would appreciate that such suitable x- ray quality crystals can be used as part of a method of identifying a candidate agent capable of binding to and modulating the activity of kinases. Such methods may be characterized by the following aspects: a) introducing into a suitable computer program, information defining a ligand binding domain of a kinase in a conformation (e.g. as defined by x-ray structure coordinates obtained from suitable x-ray quality crystals as described above) wherein the computer program creates a model of the three dimensional structures of the ligand binding domain, b) introducing a model of the three dimensional structure of a candidate agent in the computer program, c) superimposing the model of the candidate agent on the model of the ligand binding domain, and d) assessing whether the candidate agent model fits spatially into the ligand binding domain. Aspects a-d are not necessarily carried out in the aforementioned order. Such methods may further entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling. [0237] Additionally, one of ordinary skill in the art would appreciate that such methods may further entail: employing a candidate agent, so-determined to fit spatially into the ligand binding domain, in a biological activity assay for kinase modulation, and determining whether said candidate agent modulates kinase activity in the assay. Such methods may also include administering the candidate agent, determined to modulate kinase activity, to a mammal suffering from a condition treatable by kinase modulation, such as those described above. [0238] Also, one of ordinary skill in the art would appreciate that compounds of the invention can be used in a method of evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a kinase. Such a method may be characterized by the following aspects: a) creating a computer model of a kinase binding pocket using structure coordinates obtained from suitable x-ray quality crystals of the kinase, b) employing computational algorithms to perform a fitting operation between the test agent and the computer model of the binding pocket, and c) analyzing the results of the fitting operation to quantify the association between the test agent and the computer model of the binding pocket. [0239] CAS, a division of the American Chemical Society, is one of the world's leader in providing scientists online and web access to chemistry-related research data. CAS produces one of the world's largest and most comprehensive databases of chemical information, indexing abstracts, patents, articles from approximately 9,000 scientific journals, conference proceedings, and other documents pertinent to chemistry, life sciences and many other fields. Certain compounds are set forth in this application using a CAS Registration identifier. The structures of these compounds, as they correspond to the CAS Registration identifier, are set forth below:
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
General Administration
[0240] Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
[0241] The compositions will include a compound of the invention as the/an active agent, and, in addition, may include at least one other conventional pharmaceutical carrier or excipient, such as medicinal agents, pharmaceutical agents, adjuvants, etc. Compositions of the invention may be used in combination with anticancer or other agents that are generally administered to a patient being treated for cancer. Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absoφtion of the injectable pharmaceutical form can be brought about by the use of agents delaying absoφtion, for example, aluminum monostearate and gelatin.
[0242] If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene, etc.
[0243] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
[0244] One preferable route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated. [0245] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absoφtion accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
[0246] Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
[0247] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3- butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension. [0248] Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
[0249] Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.
[0250] Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
[0251] Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.
[0252] Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention.
[0253] The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.
Utility of compounds of the invention as screening agents
[0254] To employ the compounds of the invention in a method of screening for candidate agents that bind to, for example p70S6 and/or Akt receptor kinase, the protein is bound to a support, and a compound of the invention is added to the assay. Alternatively, the compound of the invention is bound to the support and the protein is added. Classes of candidate agents among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells. A wide variety of assays may be used for this puφose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.
[0255] The determination of the binding of the candidate agent to, for example, p70S6K and/or AktK protein may be done in a number of ways. In one example, the candidate agent (the compound of the invention) is labeled, for example, with a fluorescent or radioactive moiety and binding determined directly. For example, thus may be done by attaching all or a portion of the p70S6K and/or AktK protein to a solid support, adding a labeled agent (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing off excess reagent, and determining whether the amount of the label is that present on the solid support. Various blocking and washing steps may be utilized as is known in the art.
[0256] By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, for example, radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic particles, chemilummescent tag, or specific binding molecules, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin, and the like. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.
[0257] In some embodiments, only one of the components is labeled. For example, p70S6K and/or AktK protein may be labeled at tyrosine positions using 125I, or with fluorophores. Alternatively, more than one component may be labeled with different labels; using 125I for the proteins, for example, and a fluorophor for the candidate agents.
[0258] The compounds of the invention may also be used as competitors to screen for additional drug candidates, "candidate bioactive agent" or "drug candidate" or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. In the case where protein binding or activity is screened, some embodiments exclude molecules already known to bind to that particular protein. Exemplary embodiments of assays described herein include candidate agents, which do not bind the target protein in its endogenous native state, termed herein as "exogenous" agents. In one example, exogenous agents further exclude antibodies to p70S6K and/or AktK.
[0259] Candidate agents can encompass numerous chemical classes, though typically they are organic molecules having a molecular weight of more than about 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl, hydroxyl, ether, or carboxyl group, for example at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclyl structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs, or combinations thereof.
[0260] Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs
[0261] In one example, the binding of the candidate agent is determined through the use of competitive binding assays. In this example, the competitor is a binding moiety known to bind to p70S6K and/or AktK, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.
[0262] In some embodiments, the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to p70S6K and/or AktK protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature that facilitates optimal activity, typically between 4°C and 40°C.
[0263] Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.
[0264] In one example, the competitor is added first, followed by the candidate agent. Displacement of the competitor is an indication the candidate agent is binding to p70S6K and/or AktK and thus is capable of binding to, and potentially modulating, the activity of the p70S6K and/or AktK. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate agent is labeled, the presence of the label on the support indicates displacement.
[0265] In an alternative embodiment, the candidate agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate the candidate agent is bound to p70S6K and/or AktK with a higher affinity. Thus, if the candidate agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate the candidate agent is capable of binding to p70S6K and/or AktK.
[0266] It may be of value to identify the binding site of p70S6K and/or AktK. This can be done in a variety of ways. In one embodiment, once p70S6K and/or AktK has been identified as binding to the candidate agent, the p70S6K and or AktK is fragmented or modified and the assays repeated to identify the necessary components for binding.
[0267] Modulation is tested by screening for candidate agents capable of modulating the activity of p70S6K and/or AktK comprising the steps of combining a candidate agent with p70S6K and/or AktK, as above, and determining an alteration in the biological activity of the p70S6K and/or AktK. Thus, in this embodiment, the candidate agent should both bind to (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods and in vivo screening of cells for alterations in cell viability, moφhology, and the like.
[0268] Alternatively, differential screening may be used to identify drug candidates that bind to native p70S6K and/or AktK, but cannot bind to modified p70S6K and/or AktK.
[0269] Positive controls and negative controls can be used in the assays. For example, all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples can be counted in a scintillation counter to determine the amount of bound compound.
[0270] A variety of other reagents can be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components can be added in any order that provides for the requisite binding.
[0271] One of ordinary skill in the art would understand that certain crystallized, protein-ligand complexes, in particular p70S6K- and/or AktK-ligand complexes, and their corresponding x-ray structure coordinates can be used to reveal new structural information useful for understanding the biological activity of p70S6K and/or AktK's as described herein. As well, the key structural features of the aforementioned proteins, particularly, the shape of the ligand binding site, are useful in methods for designing or identifying selective modulators of p70S6K and/or AktK's and in solving the structures of other proteins with similar features. Ligands of such complexes may include compounds of the invention as described herein.
[0272] As well, one of ordinary skill in the art would appreciate that such suitable x- ray quality crystals can be used as part of a method of identifying a candidate agent capable of binding to and modulating the activity of p70S6K and/or AktKs. Such methods may be characterized by the following aspects: a) introducing into a suitable computer program, information defining a ligand binding domain of a p70S6K and/or AktK in a conformation (e.g. as defined by x-ray structure coordinates obtained from suitable x-ray quality crystals as described above) wherein the computer program creates a model of the three dimensional structures of the ligand binding domain, b) introducing a model of the three dimensional structure of a candidate agent in the computer program, c) superimposing the model of the candidate agent on the model of the ligand binding domain, and d) assessing whether the candidate agent model fits spatially into the ligand binding domain. Aspects a-d are not necessarily carried out in the aforementioned order. Such methods may further entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling.
[0273] Additionally, one of ordinary skill in the art would appreciate that such methods may further entail: employing a candidate agent, so-determined to fit spatially into the ligand binding domain, in a biological activity assay for p70S6K and/or AktK modulation, and determining whether said candidate agent modulates p70S6K and/or AktK activity in the assay. Such methods may also include administering the candidate agent, determined to modulate p70S6K and/or AktK activity, to a mammal suffering from a condition treatable by p70S6K and/or AktK modulation, such as those described above.
[0274] Also, one of ordinary skill in the art would appreciate that compounds of the invention can be used in a method of evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a p70S6K and/or AktK. Such a method may be characterized by the following aspects: a) creating a computer model of a p70S6K and/or AktK binding pocket using structure coordinates obtained from suitable x-ray quality crystals of the p70S6K and/or AktK, b) employing computational algorithms to perform a fitting operation between the test agent and the computer model of the binding pocket, and c) analyzing the results of the fitting operation to quantify the association between the test agent and the computer model of the binding pocket.
Abbreviations and their Definitions
[0275] The following abbreviations and terms have the indicated meanings throughout: Abbreviation Meaning
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Synthesis of Compounds
[0276] Scheme 1 depicts a general synthetic route for compounds of the invention and is not intended to be limiting. Specific examples are described subsequently to this general synthetic description. In the generalizations below, specific reaction conditions or details, for example, added reagents, catalysts, solvents, reaction temperature, and the like are not described. The general routes depicted in conjunction with the specific examples provided contain sufficient information to allow one of ordinary skill in the art to synthesize compounds of the invention.
[0277] Scheme 1 shows that in general, compounds of Formulas I and II can be made, for example via a linear route. For example, an amino-substituted pyrazolopyrimidine (or purine or pyrrolopyrimidine) of 1 having leaving group "L" is reacted with a substituted piperazine/piperidine of 2, substituted with B which can be an optionally substituted as in Formulas I and π, in an anhydrous solvent such that the leaving group is displaced by the substituted piperazine/piperidine. After heating for a sufficient period of time, the reaction gives compounds of 3, wherein L is an amine and X21, X22, X23, n, R and R2ι-R32 are as descibed above. Scheme 1
Figure imgf000055_0001
[0278] One of ordinary skill in the art would recognize that the descriptions associated with Scheme 1 is a generalization, and that there are other combinations of steps and approaches that can be used to make compounds of the invention. The examples that follow provide much more detailed descriptions of making exemplary compounds of the invention. Examples
[0279] The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative puφoses. All references cited herein are incoφorated by reference in their entirety. Generally, each example is set out below with a corresponding multi-step synthesis scheme. Following specific examples are lists of compounds that were made in a similar way.
[0280] EXAMPLE 1: 6-(4-phenylpiperazin-l-yl)-9H-purine
[0281] To 6-chloro-9H-purine (60 mg, 0.39 mmol) in ethanol (2 mL) was added diisopropylethylamine (50 mg, 0.39 mmol) and 1-phenylpiperazine (63 mg, 0.39 mmol). The reaction mixture was stirred at 70 °C for 3 h, and then cooled to room temperature. The precipitation was filtered, washed with ethanol, and dried to give 6-(4- phenylpiperazin-l-yl)-9H-purine (77 mg, 71% yield) as a colorless solid. 1H NMR (400 MHz, de-DMSO) δ 13.09 (br s, IH), 8.25 (s, IH), 8.16 (s, IH), 7.24 (m, 2H), 7.01 (m, 2H), 6.82 (m, IH), 4.37 (br s, 4H), 3.26 (m, 4H); MS (ESI) for Cι5Hι6N6: 281 (MH+). [0282] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0283] 6-[4-(3-chlorophenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6- DMSO) δ 13.10 (br s, IH), 8.25 (s, IH), 8.17 (s, IH), 7.24 (m, IH), 7.03 (m, IH), 6.97 (m, IH), 6.82 (m, IH), 4.36 (br s, 4H), 3.32 (m, 4H); MS (ESI) for C15H16N6: 281 (MH+).; MS (ESI) for Cι5Hι5ClN6: 315 (MH+).
[0284] 6-[4-(2-chlorophenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6- DMSO) δ 13.05 (br s, IH), 8.22 (s, IH), 8.13 (s, IH), 7.43 (d, IH), 7.31-7.27 (m, IH), 7.18 (s, IH), 7.07-7.03 (m, IH), 4.39 (br s, 4H), 3.09 (m, 4H); MS (ESI) for C15H15C1N6: 315 (MH+).
[0285] 6-[4-(2-fluorophenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6- DMSO) δ 13.05 (br s, IH), 8.22 (s, IH), 8.14 (s, IH), 7.17-6.96 (m, 4H), 4.38 (br s, 4H), 3.12 (m, 4H); MS (ESI) for C15H15FN6: 299 (MH+).
[0286] 6-[4-(4-methoxyphenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6- DMSO) δ 13.05 (br s, IH), 8.22 (s, IH), 8.13 (s, IH), 6.95 (d, 2H), 6.83 (d, 2H), 4.35 (br s, 4H), 3.68 (s, 3H), 3.12 (m, 4H); MS (ESI) for C16H18N6O: 311 (MH+).
[0287] 6-[4-(2-methoxyphenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6- DMSO) δ 13.03 (br s, IH), 8.21 (s, IH), 8.12 (s, IH), 6.99-6.84 (m, 4H), 4.35 (br s, 4H), 3.81 (s, 3H), 3.06 (m, 4H); MS (ESI) for Cι6H18N6O: 311 (MH+).
[0288] 6-[4-(4-chlorophenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6- DMSO) δ 13.05 (br s, IH), 8.22 (s, IH), 8.14 (s, IH), 7.24 (d, 2H), 7.01 (d, 2H), 4.35 (br s, 4H), 3.26 (m, 4H); MS (ESI) for Cι5H15ClN6: 315 (MH+).
[0289] 6-[4-(4-fluorophenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6- DMSO) δ 13.05 (br s, IH), 8.22 (s, IH), 8.14 (s, IH), 7.09-6.99 (m, 4H), 4.35 (br s, 4H), 3.20 (m, 4H); MS (ESI) for C15H15FN6: 299 (MIT).
[0290] 6-[4-(3-trifluoromethylphenyl)piperazin-l-yl]-9H-purine: 1H NMR (400 MHz, d6-DMSO) δ 13.11 (br s, IH), 8.26 (s, IH), 8.18 (s, IH), 7.45 (m, IH), 7.30 (d, IH), 7.26 (s, IH), 7.11 (d, IH), 4.38 (br s, 4H), 3.38 (m, 4H); MS (ESI) for C16H15F3N6: 349 (MET").
[0291] 6-(4-o-tolylpiperazin-l-yl)-9H-purine: 1H NMR (400 MHz, d6-DMSO) δ 13.09 (br s, IH), 8.24 (s, IH), 8.15 (s, IH), 7.20 (d, IH), 7.15 (m, IH), 7.04 (d, IH), 6.98 (m, IH), 4.38 (br s, 4H), 2.97-2.94 (m, 4H), 2.33 (s, 3H); MS (ESI) for C16Hι8N6: 295 (MH+).
[0292] EXAMPLE 2: 4-(4-phenylρiperazin-l-yl)-7H-pyrrolo[2,3-d]pyrimidine
[0293] To 4-chloro-7H-ρyrrolo[2,3-d]pyrimidine (60 mg, 0.39 mmol) in ethanol (2 mL) was added diisopropylethylamine (50 mg, 0.39 mmol) and 1-phenylρiρerazine (63 mg, 0.39 mmol). The reaction mixture was stirred at 70 °C for 16 h, and then cooled to room temperature. The precipitation was filtered, washed with methanol, and dried to give 4-(4-phenylpiperazin-l-yl)-7H-pyrrolo[2,3-d]pyrimidine (74 mg, 68% yield) as a colorless solid. 1H NMR (400 MHz, de-DMSO) δ 11.76 (br s, IH), 8.18 (s, IH), 7.24 (m, 3H), 6.98 (m, 2H), 6.81 (m, IH), 6.68 (d, IH), 4.03 (m, 4H), 3.29 (m, 4H); MS (ESI) for C16H17N5: 280 (MH+).
[0294] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0295] 4-[4-(3-chloroρhenyl)piperazin-l-yl]-7H-pyrrolo[2,3-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 11.76 (br s, IH), 8.18 (s, IH), 7.24 (m, 2H), 6.98 (m, IH), 6.94 (m, IH), 6.81 (m, IH), 6.64 (d, IH), 4.02 (m, 4H), 3.35 (m, 4H); MS (ESI) for C16H16C1N5: 314 (MH+).
[0296] 4-[4-(2-methylρhenyl)ρiperazin-l-yl]-7H-ρyrrolo[2,3-d]pyrimidine: 1H NMR (400 MHz, dδ-DMSO) δ 11.71 (br s, IH), 8.15 (s, IH), 7.21-7.11 (m, 3H), 7.02 (m, IH), 6.96 (m, IH), 6.46 (m, IH), 4.02 (m, 4H), 2.95 (m, 4H), 2.32 (s, 3H); MS (ESI) for C17Hι9N5: 294 (MIT).
[0297] 4- { 4-[2-(methyloxy)phenyl]piperazin- 1 -yl } -7H-pyrrolo[2,3-d]pyrimidine: H NMR (400 MHz, d6-DMSO) δ 11.70 (br s, IH), 8.14 (s, IH), 7.18 (m, IH), 7.00-6.84 (m, 4H), 6.64 (m, IH), 4.00 (m, 4H), 3.81 (s, 3H), 3.07 (m, 4H); MS (ESI) for C17H19N5O: 310 (MlTft).
[0298] 4-{4-[3-(methyloxy)phenyl]ρiperazin-l-yl}-7H-pyrrolo[2,3-d]pyrimidine: H NMR (400 MHz, d6-DMSO) δ 11.71 (br s, IH), 8.15 (s, IH), 7.20 (m, IH), 7.11 (m, IH), 6.63 (m, IH), 6.55 (m, IH), 6.48 (m, IH), 6.38 (m, IH), 4.00 (m, 4H), 3.27 (s, 3H), 3.28 (m, 4H); MS (ESI) for C17H19N5O: 310 (MH+).
[0299] 4-{4-[4-(methyloxy)phenyl]piperazin-l-yl}-7H-pyrrolo[2,3-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 11.71 (br s, IH), 8.15 (s, IH), 7.20 (m, IH), 6.93 (m, 2H), 6.83 (m, 2H), 6.63 (m, IH), 3.99 (m, 4H), 3.68 (s, 3H), 3.13 (m, 4H); MS (ESI) for Cι7H19N5O: 310 (MH+).
[0300] 4-{ 4-[3-(trifluoromethyl)phenyl]piperazin- 1 -yl } -7H-pyrrolo[2,3-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 11.73 (br s, IH), 8.16 (s, IH), 7.44 (m, IH), 7.26-7.17 (m, 3H), 7.08 (m, IH), 6.63 (m, IH), 4.03 (m, 4H), 3.41 (m, 4H); MS (ESI) for Cι7H16F3N5: 314 (MH+).
[0301] 4-[4-(4-fluorophenyl)piperazin-l-yl]-7H-pyrrolo[2,3-d]pyrimidine: 1H NMR (400 MHz, de-DMSO): δ 11.75 (s, IH), 8.20 (s, IH), 7.42-7.00 (m, 5H), 6.60 (s, IH), 4.08-3.98 (t, 4H), 3.26-3.18 (t, 4H); MS (ESI) for d6Hι6FN5 : 298 (MH+).
[0302] 4-[4-(4-chlorophenyl)piperazin-l-yl]-7H-pyrrolo[2,3-d]pyrimidine: 1H NMR (400 MHz, dg-DMSO): δ 11.70 (s, IH), 8.40 (s, IH), 7.30-7.20 (m, 3H), 7.02-6.92 (d, 2H), 6.62 (s, IH), 4.00 (s, 4H), 3.20 (s, 4H); MS (ESI) for C16Hι6ClN5: 314 (MH+).
[0303] 4-[4-(2-chlorophenyl)ρiperazin-l-yl]-7H-pyrrolo[2,3-d]pyrimidine: 1H NMR (400 MHz, de-DMSO): δ 11.65 (s, IH), 8.18 (s, IH), 7.48-7.42 (s, IH), 7.34-7.26 (m, IH), 7.22- 7.16 (m, 2H), 7.10-7.04 (m, IH), 6.68 (s, IH), 4.04 (t, 4H), 3.12 (t, 4H); MS (ESI) for Cι6H16ClN5: 314 (MH+).
[0304] 4-[4-(2-fluorophenyl)piperazin-l-yl]-7H-pyrrolo[2,3-d]ρyrimidine: 1H NMR (400 MHz, de-DMSO): δ 11.70 (s, IH), 8.20 (s, IH), 7.22 -6.84 (m, 5H), 6.50 (s, IH), 4.08 (s, 4H), 3.18 (s, 4H); MS (ESI) for C16Hι6FN5: 298 (Mt ).
[0305] EXAMPLE 3: 4-(4-phenylpiperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine
[0306] To 4-choro-lH-pyrazolo[3,4-d]pyrimidine (60 mg, 0.39 mmol, R.K. Robins, /. Am. Chem. Soc. 1956, 78, 784-790) in ethanol (2 mL) was added diisopropylethylamine (50 mg, 0.39 mmol) and 1-phenylpiperazine (63 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 4 h. The precipitation was filtered, washed with methanol, and dried to give 4-(4-phenylpiperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine (68 mg, 62% yield) as a colorless solid. 1H NMR (400 MHz, de-DMSO) δ 13.59 (br s, IH), 8.33 (s, IH), 8.28 (s, IH), 7.26 (m, 2H), 6.98 (m, 2H), 6.82 (m, IH), 4.09 (m, 4H), 3.33 (m, 4H); MS (ESI) for C15H16N6: 281 (MH+).
[0307] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared: [0308] 4-[4-(3-chlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: *H NMR (400 MHz, d6-DMSO) δ 13.59 (br s, IH), 8.31 (s, IH), 8.28 (s, IH), 7.25 (m, IH), 6.98 (m, IH), 6.93 (m, IH), 6.81 (m, IH), 4.09 (m, 4H), 3.41 (m, 4H); MS (ESI) for C15Hι5ClN6: 281 (MH+).
[0309] 4- { 4- [3-(trifluoromethyl)phenyl]piperazin- 1 -yl } - 1 H-pyrazolo [3 ,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 13.60 (br s, IH), 8.31 (s, IH), 8.29 (s, IH), 7.47 (m, IH), 7.26 (m, IH), 7.20 (m, IH), 7.10 (m, IH), 4.11 (m, 4H), 3.47 (m, 4H); MS (ESI) for C16Hι5F3N6: 349 (MH+).
[0310] 4-[4-(2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 13.59 (br s, IH), 8.33 (s, IH), 8.28 (s, IH), 7.21 (m, IH), 7.16 (m, IH), 7.05 (m, IH), 6.99 (m, IH), 4.09 (m, 4H), 2.98 (m, 4H), 2.33 (s, 3H); MS (ESI) for Ci6H18N6: 295 (MET).
[0311] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 13.60 (br s, IH), 8.32 (s, IH), 8.28 (s, IH), 7.23 (m, IH), 7.05 (m, 2H), 4.08 (m, 4H), 3.01 (m, 4H), 2.30 (s, 3H); MS (ESI) for Cι6HI7ClN6: 329 (MH+).
[0312] EXAMPLE 4: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-methyl-lH- pyrazolo[3,4-d]pyrimidine
[0313] To 4-hydroxy-3-methyl-lH-pyrazolo[3,4-d]pyrimidine (270 mg, 1.80 mmol, R. Badger, Aust. J. Chem. 1965, 18, 1267-1270) in chloroform (5 mL) was added oxalyl chloride (0.23 mL, 2.68 mmol) and DMF (0.05 mL), and the mixture was refluxed for 8 h. Over the first 4 h reaction time, more oxalyl chloride (1.7 mL) and DMF (1.0 mL) was added in portions. The mixture was added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford 4-chloro-3-methyl-lH-pyrazolo[3,4-d]pyrimidine (130 mg, 43% yield) as a brown solid. 1H NMR (400 MHz, d6-DMSO) δ 8.75 (s, IH), 2.64 (s, 3H); MS (ESI) for C6H5C1N4: 169 (MH+).
[0314] To 4-chloro-3-methyl-lH-pyrazolo[3,4-d]pyrimidine (125 mg, 0.74 mmol) in THF (5 mL) was added diisopropylethylamine ( 96 mg, 0.75 mmol) and l-(5-chloro-2- methylphenyl)piperazine (156 mg, 0.74 mmol). The reaction mixture was stirred at room temperature for 2 h. The precipitation was filtered, washed with methanol, and dried to give 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-methyl-lH-pyrazolo[3,4-d]- pyrimidine (36 mg, 14% yield) as an off-white solid. 1H NMR (400 MHz, de-DMSO) δ 13.27 (br s, IH), 8.27 (s, IH), 7.20 (m, IH), 7.03 (m, 2H), 3.86 (m, 4H), 3.00 (m, 4H), 2.59 (s, 3H), 2.29 (s, 3H); MS (ESI) for Cι7H19ClN6: 343 (MH+).
[0315] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0316] 4-[4-(3-chlorophenyl)piperazin-l-yl]-3-methyl-lH-pyrazolo[3,4-d]pyrimidine: *H NMR (400 MHz, dθ-DMSO): δ 8.40 (br s, IH), 7.23 (t, IH), 6.99 (m, IH), 6.90 (dd, IH), 6.80 (dd, IH), 3.98 (s, 4H), 3.40 (s, 4H), 2.68 (s, 3H), MS (ESI) for C16H17C1N6: 390 (MH+)
[0317] 3-methyl-4-[4-(2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d4-methanol): δ 8.50 (s, IH ), 7.22-6.88 (m, 5H), 4.22 (s, 4H), 3.22 (s, 4H), 2.80 (s, 3H), 2.40 (s, 3H); MS (ESI) for C17H20N6: 310 (MH*).
[0318] EXAMPLE 5: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-ethyl-lH- pyrazolo[3,4-d]pyrimidine
[0319] To 3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-ol (82 mg, 0.50 mmol, DE 1966640, 1973) in thionyl chloride (5 mL) was added DMF (76 mg, 1.02 mmol) and the reaction mixture was refluxed for 3 h. The mixture was concentrated, the residue added to saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford 4-chloro-3-ethyl-lH- pyrazolo[3,4-d]pyrimidine (65 mg, 90% yield) as a yellow solid. 1H NMR (400 MHz, de- DMSO) δ 8.73 (s, IH), 3.05 (q, 2H), 1.32 (t, 3H); MS (ESI) for C7H7C1N4: 183 (MH+).
[0320] To 4-chloro-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine (60 mg, 0.33 mmol) in THF (5 mL) was added diisopropylethylamine ( 45 mg, 0.34 mmol) and l-(5-chloro-2-methyl- phenyl)piperazine (83 mg, 0.39 mmol) and the reaction mixture was stirred at 50 °C for 5 h. The mixture was concentrated, and the remaining solid washed with methanol and dried to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4- d]pyrimidine (53 mg, 45% yield) as an off-white solid. 1H NMR (400 MHz, d6-DMSO) δ 13.35 (br s, IH), 8.32 (s, IH), 7.22 (m, IH), 7.05 (m, 2H), 3.81 (m, 4H), 3.00 (m, 6H), 2.28 (s, 3H), 1.30 (t, 3H); MS (ESI) for C18H21C1N6: 357 (MH+). [0321] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0322] 4-[4-(3-chlorophenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 13.36 (s, IH), 8.32 (s, IH), 7.25 (t, IH), 7.01 (t, IH), 6.96 (dd, IH), 6.83 (dd, IH), 3.80 (m, 4H), 3.34 (m, 4H), 2.98 (q, 2H), 1.29 (t, 3H); MS (ESI) for C17H19C1N6: 343 (MH1").
[0323] 4-{4-[5-chloro-2-(methyloxy)phenyl]piperazin-l-yl}-3-ethyl-lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 13.34 (s, IH), 8.31 (s, IH), 7.03 (dd, IH), 6.98 (d, IH), 6.93 (d, IH), 3.82 (s, 3H), 3.79 (m, 4H), 3.14 (m, 4H) 2.97 (q, 2H), 1.29 (t, 3H); MS (ESI) for Cι8H2ιClN6O: 373 (MH+).
[0324] 4-[4-(3-chlorophenyl)-l,4-diazepan-l-yl]-3-ethyl-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, CDC13) δ 12.36 (br s, IH), 8.36 (s, IH), 7.09 (t, IH), 6.67 (t, IH), 6.62 (dd, IH), 6.58 (dd, IH), 4.08 (m, 2H), 3.85 (m, 2H), 3.75 (m, 2H), 3.50 (m, 2H), 3.04(q, 2H), 2.16 (m, 2H), 1.38 (t, 3H); MS (ESI) for C18H21C1N6: 357 (MH+).
[0325] 4-[5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-ethyl-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, CDC13) δ 12.52 (br s, IH), 8.39 (s, IH), 7.08 (m, IH), 6.63 (dd, IH), 6.53 (m, IH), 6.42 (dd, IH), 5.30 (s, IH), 4.55 (s, IH), 4.06 (dd, IH), 3.72 (m, 2H), 3.43 (d, IH), 3.09-2.91 (m, 2H), 2.16 (q, 2H), 1.36 (t, 3H); MS (ESI) for Cι8H19ClN6: 356 (MH*).
[0326] 4-(4-[3-chloro-4-[(2-moφholin-4-yl-ethyl)oxy]phenyl}piperazin-l-yl)-3-ethyl- lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d4-methanol) δ 8.48 (s, IH), 7.21 (d, IH), 7.16 (d, IH), 7.07 (dd, IH), 4.43 (m, 2H), 4.35 (m, 4H), 4.10 (m, 2H), 3.88-3.81 (m, 2H), 3.73-3.65 (m, 4H), 3.42-3.37 (m, 6H), 3.23 (q, 2H), 1.44 (t, 3H).
[0327] 2-chloro-4-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- methylphenol: 1H NMR (400 MHz, CDC13) δ 8.36 (s, IH), 6.96 (s, IH), 6.73 (s, IH), 4.08 (br s, 4H), 3.02 (q, 2H), 2.99 (m, 4H), 2.30 (s, 3H), 1.39 (t, 3H); MS (ESI) for C18H2ιClN6O: 373 (MET).
[0328] 3-({2-chloro-4-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 5-methylρhenyl}oxy)-N,N-dimethylpropan-l-amine trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.43 (s, IH), 7.12 (s, IH), 6.99 (s, IH), 4.20 (br s, 4H), 4.15 (t, 2H), 3.39 (t, 2H), 3.16 (q, 2H), 3.02 (t, 4H), 2.96 (s, 6H), 2.38 (s, 3H), 2.25 (m, 2H), 1.40 (t, 3H); MS (ESI) for C23H32ClN7O: 458 (MET).
[0329] 2-({2-chloro-4-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 5-methylphenyl}oxy)-N,N-dimethylethanamine trifluoroacetate: 1H NMR (400 MHz, d4- methanol) δ 8.43 (s, IH), 7.14 (s, IH), 7.07 (s, IH), 4.38 (t, 2H), 4.21 (br s, 4H), 3.63 (t, 2H), 3.16 (q, 2H), 3.02 (m, 10H), 2.40 (s, 3H), 1.40 (t, 3H); MS (ESI) for C22H30C1N7O: 444 (MH1").
[0330] 4- { 4-[5-chloro-2-methyl-4-(methyloxy)phenyl]piperazin- 1 -yl } -3-ethyl-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d4-methanol) δ 8.44 (s, IH), 7.08 (s, IH), 6.94 (s, IH), 4.25 (br s, 4H), 3.83 (s, 3H), 3.18 (q, 2H), 3.02 (t, 4H), 2.39 (s, 3H), 1.41 (t, 3H); MS (ESI) for C19H23ClN6O: 387 (MH+).
[0331] 4-[4-(3,6-dimethylpyrazin-2-yl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 13.35 (s, IH), 8.35 (s, IH), 8.00 (s, IH), 3.81 (m, 4H), 3.30 (m, 4H), 2.99 (q, 2H), 2.47 (s, 3H), 2.35 (s, 3H) 1.29 (t, 3H); MS (ESI) for C17H22N8: 339 (MH+).
[0332] l-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]isoquinoline: 1H NMR (400 MHz, d6-DMSO) δ 13.31 (s, IH), 8.31 (s, IH), 8.18 (d, IH), 8.12 (d, IH),
7.89 (d, IH), 7.71 (m, IH), 7.62 (m, IH), 7.41 (d, IH), 3.94 (m, 4H), 3.48 (m, 4H), 3.00 (q, 2H), 1.30 (t, 3H); MS (ESI) for C20H2ιN7: 360 (MH+).
[0333] 4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 13.34 (s, IH), 8.31 (s, IH), 6.46 (s, IH),
3.90 (m, 4H), 3.72 (m, 4H), 2.99 (q, 2H), 2.26 (s, 6H), 1.29 (t, 3H); MS (ESI) for Cι7H22N8: 339 (MIT).
[0334] 2-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]pyridine-3- carboxamide: 1H NMR (400 MHz, d6-DMSO) δ 8.46 (s, IH), 8.26 (m, IH), 7.96 (s, IH), 7.81 (m, IH), 7.62 (s, IH), 6.95 (dd, IH), 3.96 (br s, 4H), 3.52 (br s, 4H), 3.05 (br s, 2H), 1.29 (t, 3H); C17H20N8O: 353 (MH+).
[0335] N'-{5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 2-methylphenyl}-N-methyl-N-(l-methylethyl)ethane-l,2-diamine trifluoroacetate: !H NMR (400 MHz, αVmethanol) δ 8.41 (s, IH), 6.55 (s, 2H), 4.20 (br s, 4H), 3.69 (m, IH), 3.58 (m, 2H), 3.48 (m, IH), 3.24 (m, IH), 3.16 (q, 2H), 3.04 (br s, 4H), 2.88 (s, 3H), 2.24 (s, 3H), 1.42 (t, 3H), 1.36 (m, 6H); MS (ESI) for C24H35C1N8: 471 (MH4).
[0336] N*-{5-chloro-3-[4-(3-ethyl-lH-ρyrazolo[3,4-d]pyrimidin-4-yl)ρiρerazin-l-yl]- 2-methylphenyl}-N-ethyl-N-methylethane-l,2-diamine trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.42 (s, IH), 6.55 (s, 2H), 4.17 (br s, 4H), 3.57 (m, 2H), 3.47 (m, IH), 3.35 (m, IH), 3.25 (m, 2H), 3.15 (q, 2H), 3.02 (br s, 4H), 2.93 (s, 3H), 2.21 (s, 3H), 1.40 (t, 3H), 1.34 (t, 3H); MS (ESI) for C23H33C1N8: 457 (MH+).
[0337] methyl 4-(3-chlorophenyl)-l-(3-ethyl-lH-ρyrazolo[3,4-d]pyrimidin-4- yl)ρiperazine-2-carboxylate: H NMR (400 MHz, d4-methanol) δ 8.47 (s, IH), 7.24 (t, IH), 6.98 (m, IH), 6.89 (dd, IH), 5.97 (br s, IH), 4.43-4.30 (m, 2H), 4.12 (m, IH), 3.79 (s, 3H), 3.75 (m, IH), 3.33-3.14 (m, 4H), 3.03 (dt, IH), 1.43 (t, 3H); MS (ESI) for C19H21ClN6O2: 401 (MIT).
[0338] 4-(3-chlorophenyl)-l-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-N- methylpiperazine-2-carboxamide: 1H NMR (400 MHz, CDC13) δ 12.44 (br s, IH), 8.51 (s,lH), 7.20 (t, IH), 6.99 (br m, IH), 6.94 (dd, IH), 6.86 (dd, IH), 6.72-6.65 (br m, IH), 5.24 (br s, IH), 4.33 (d, IH), 4.26 (d, IH), 3.81-3.70 (m, IH), 3.58-3.51 (m, IH), 3.18- 2.96 (m, 4H), 2.89 (m, 3H), 1.47 (t, 3H); MS (ESI) for C19H22ClN7O: 400 (MH+).
[0339] 4-(4-{5-chloro-2-methyl-3-[(2-moφholin-4-ylethyl)oxy]phenyl}piperazin-l- yl)-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, αV methanol) δ 8.36 (s,lH), 6.78 (br s, IH), 6.73 (br s, IH), 4.34 (t, 2H), 4.15 (br s, 4H), 4.05-3.69 (br m, 4H), 3.62 (t, 2H), 3.58-3.26 (br m, 4H), 3.09 (q, 2H), 3.03-2.96 (br m, 4H), 2.19 (s, 3H), 1.32 (t, 3H); MS (ESI) for C24H32ClN7O2: 486 (Mtf).
[0340] 4-(4- { 5-chloro-2-methyl-3-[(2-piperidin- 1 -ylethyl)oxy]phenyl }piperazin- 1 -yl)- 3-efhyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.36 (s,lH), 6.76 (m, IH), 6.71 (m, IH), 4.30 (t, 2H), 4.24-4.11 (br m, 4H), 3.62-3.50 (br m, 4H), 3.17-2.95 (br m, 8H), 2.18 (s, 3H), 1.94-1.71 (br m, 5H), 1.54-1.41 (br m, IH), 1.32 (t, 3H); MS (ESI) for C25H34ClN7O: 484 (MH+).
[0341] 4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-l-yl)ethyl]oxy}-2- methylphenyl)piperazin- 1 -yl] -3-ethyl- 1 H-pyrazolo [3 ,4-d]pyrimidine hydrochloride: !H NMR (400 MHz, d4-methanol) δ 8.38 (s,lH), 6.74 (m, IH), 6.68 (m, IH), 4.30 (t, 2H), 4.23 (br m, 6H), 3.70-2.88 (m, 18H), 2.18 (s, 3H), 1.37-1.25 (m, 6H); MS (ESI) for C26H37ClN8O: 513 (MPT). [0342] 4-(4-{5-chloro-2-methyl-3-[(3-moφholin-4-ylpropyl)oxy]phenyl}piperazin-l- yl)-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4- methanol) δ 8.38 (s,lH), 6.70 (m, IH), 6.67 (m, IH), 4.20 (br m, 4H), 4.08-3.92 (m, 4H), 3.82-3.65 (br m, 2H), 3.56-3.43 (br m, 2H), 3.40-3.27 (br m, 2H), 3.20-3.06 (br m., 4H), 3.03-2.95 (br m, 4H), 2.28-2.18 (br m, 2H), 2.18-2.14 (br m, 3H), 1.39-1.28 (t, 3H); MS (ESI) for C25H34ClN7O2: 500 (MH+).
[0343] 4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-l-ylpropyl)oxy]phenyl}piperazin-l- yl)-3-ethyl-lH-pyrazolo[3,4-d]ρyrimidine hydrochloride: 1H NMR (400 MHz, dj- methanol) δ 8.44 (s,lH), 6.78 (m, IH), 6.75 (m, IH), 4.33-4.16 (br m, 4H), 4.15-4.07 (m, 2H), 3.79-3.67 (m, 2H), 3.49-3.38 (m, 2H), 3.24-3.04 (m, 8H), 2.35-1.98 (m, 9H), 1.42 (t, 3H); MS (ESI) for C25H34ClN7O: 484 (MH+).
[0344] 4-[4-(5-chloro-2-methyl-3-{ [3-(4-methylpiperazin-l- yl)propyl]oxy}phenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: XH NMR (400 MHz, d4-methanol) δ 8.36 (s,lH), 6.67 (m, IH), 6.63 (m, IH), 4.26-4.15 (br m, 4H), 4.04-3.96 (m, 2H), 3.60-3.27 (m, 6H), 3.20-3.07 (m, 4H), 3.03- 2.92 (m, 4H), 2.88-2.85 (m, 3H), 2.22-2.10 (m, 4H), 1.33 (t, 3H); MS (ESI) for C26H37ClN8O: 513 (MH+).
[0345] 4-(4- { 5-chloro-2-mefhyl-3-[(3-piperidin- 1 -ylpropyl)oxy]phenyl }piperazin- 1 - yl)-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: !H NMR (400 MHz, d - methanol) δ 8.33 (s,lH), 6.69 (m, IH), 6.67 (m, IH), 4.18-4.04 (br m, 4H), 4.02 (t, 2H), 3.57-3.49 (m, 2H), 3.27-3.23 (m, 2H), 3.12-3.02 (m, 2H), 3.01-2.86 (m, 6H), 2.24-2.17 (m, 2H), 2.15 (br s, 3H), 1.94-1.84 (m, 2H), 1.82-1.64 (m, 3H), 1.52-1.40 (m, IH), 1.32 (t, 3H); MS (ESI) for C26H36ClN7O: 498 (MH+).
[0346] 4-[4-(5-chlqro-3- { [3-(4-ethylpiperazin- 1 -yl)propyl] oxy } -2- methylphenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: H NMR (400 MHz, d4-methanol) δ 8.37 (s,lH), 6.68 (m, IH), 6.64 (m, IH), 4.27-4.13 (br m, 4H), 4.00 (t, 2H), 3.54-3.23 (m, 6H), 3.20-3.05 (m, 8H), 3.01-2.94 (m, 4H), 2.19-2.07 (m, 5H), 1.35-1.24 (m, 6H); MS (ESI) for C27H39ClN8O: 527 (MH+).
[0347] 3-({5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 2-methylphenyl}oxy)-N,N-diethylpropan-l -amine hydrochloride: !H NMR (400 MHz, d4-methanol) δ 8.46 (s,lH), 6.79 (m, IH), 6.76 (m, IH), 4.33-4.21 (m, 4H), 4.11 (t, 2H), 3.42-3.35 (m, 2H), 3.24-3.15 (m, 2H), 3.10-3.03 (m, 4H), 2.32-2.19 (m, 5H), 1.46-1.30 (m, 9H); MS (ESI) for C25H36ClN7O: 486 (MH*).
[0348] N-{5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 2-methylphenyl}-N,N',N'-trimethylethane-l,2-diamine: 1H NMR (400 MHz, d4-methanol) δ 8.30 (s,lH), 6.83 (m, IH), 6.77 (m, IH), 4.06-3.81 (br m, 4H), 3.11-3.01 (m, 8H), 2.69 (s, 3H), 2.53 (m, 2H), 2.31 (s, 3H), 2.27 (s, 6H), 1.37 (t, 3H); MS (ESI) for C23H33C1N8: 457 (MH ).
[0349] 3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- [(2-methylpropyl)oxy]-N-(2-pyrrolidin-l-ylethyl)aniline trifluoroacetate: !H NMR (400 MHz, άVmethanol) δ 8.33 (s,lH), 6.02 (m, IH), 5.99 (m, IH), 4.34-3.92 (m, 4H), 3.69- 3.55 (m, 4H), 3.47 (t, 2H), 3.36 (t, 2H), 3.12-2.99 (m, 4H), 2.98-2.88 (m, 4H), 2.12-1.84 (m, 8H), 1.31 (t, 3H), 0.91 (d, 6H); MS (ESI) for C23H33C1N8: 457 (MH+).
[0350] 3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- [(2-methylpropyl)oxy]-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, d - methanol) δ 8.30 (s,lH), 7.15 (m, IH), 7.04 (m, IH), 4.09-3.80 (br m, 4H), 3.51 (t, 2H), 3.16-2.94 (m, 14H), 2.26 (s, 3H), 2.00-1.93 (m, 4H), 1.71-1.61 (m, 2H), 1.46-1.33 (m, 5H), 0.95 (t, 3H); MS (ESI) for C^H^ClNsO: 519 (MH*).
[0351] N,N-diethyl-2-({3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piρerazin-l- yl)phenyl}oxy)ethanamine: 1H NMR (400 MHz, CD3OD) δ 8.43 (s, IH), 7.24- 7.20 (t, IH), 6.70 (dd, IH), 6.64 (t, IH), 6.55(dd, IH), 4.33 (t, 2H), 4.20( br s, 4H), 3.59 (t, 2H), 3.41(t, 4H), 3.35 (t, 4H), 3.18 (m, 2H), 1.42- 1.35 (m, 9H); MS (ESI) for C23H33N7O: 424 (MH1").
[0352] N,N-diethyl-2-({3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]-2-mefhylphenyl}oxy)ethanamine: 1H NMR (400 MHz, dt-methanol) δ 8.44 (s, IH), 7.17 (t, IH), 6.81 (d, IH), 6.80 (d, IH), 4.31 (t, 2H), 4.26 (br s, 4H), 3.68 (t, 2H), 3.40 (m, 4H), 3.18 (m, 2H), 3.08(t, 4H), 2.31 (s, 3H), 1.40 (m, 9H); MS (ESI) for C^H^O: 438 (MET*).
[0353] 3-ethyl-4-(4-phenylpiperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 13.35 (s, IH), 8.32 (s, IH), 7.18 (m, 2H), 7.10 (d, IH), 7.07 (s, IH), 6.94 (m, IH), 3.81 (t, 3H), 3.31 (t, 4H), 2.98 (m, 2H), 1.29 (t, 3H); MS ( El) for C17H20N6: 309 (MBft). [0354] 3-ethyl-4-{4-[3-(methyloxy)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, t-methanol) δ 8.43 (s, IH), 7.17 (t, IH), 6.61 (dd, IH), 6.55 (t, IH), 6.48 (dd, IH), 4.24 (br s, 4H), 3.78 (s, 3H), 3.41 (t, 4H), 3.20 (m, 2H), 1.42 ( t, 3H); MS (ESI) for Cι8H22N6O: 339 (MET*).
[0355] Ethyl-4-[4-(3-ethyl-lH-pyrazolo]3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- (trifluoromethyl)pyrimidine-5-carboxylate: 1H NMR (400 MHz, (^-methanol) δ 8.81 (s, IH), 8.48 ( s, IH), 4.43 (m, 2H), 4.30 (t, 4H), 3.96 (t, 4H), 3.21 (q, 2H), 1.42 (m, 6H); MS (ESI) for C19H2ιF3N8O2: 451 (MH*).
[0356] 4-{4-[3-chloro-5-(methyloxy)phenylpiperazin-l-yl)-3-ethyl-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, αVmethanol) δ 8.44 (s, IH), 6.61 (s, IH), 6.46 (t, 3H), 4.23 (br s, 4H), 3.78 (s, 3H), 3.44 (t, 4H), 3.19 (q, 2H), 1.42 (t, 3H); MS (ESI) for C18H21ClN6O: 373 (MH*).
[0357] 3 -ethyl-4- { 4- [4-trifluoromethyl)pyridin-2-yl]piperazin- 1 -yl } - 1 H-pyrazolo[3 ,4- djpyrimidine: XH NMR (400 MHz, c -methanol) δ 8.46 (s, IH), 8.34 (d, IH), 7.08 (s, IH), 6.93 (dd, IH), 4.27 (t, 4H), 3.92 (m, 4H), 3.21 (q, 2H), 1.43 (t, 3H); MS (ESI) for
[0358] 4-{4-[5-chloro-2-methyl-3-(methyloxy)phenyl]piperazin-lyl}-3-ethyl-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400MHz, d4-methanol) δ 8.43 (s, IH), 6.75 (d, IH), 4.25 (br s, 4H), 3.83 (s, 3H), 3.19 (q, 2H), 3.07 (t, 4H), 2.21 (s, 3H), 1.42 (t, 3H); MS (ESI) for C19H23ClN6O: 388 (MH*").
[0359] 3-ethyl-4-{4-[2-methyl-3-(methyloxy)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, dt-methanol) δ 8.45 (s, IH), 7.11 (t, IH), 6.71 (t, 2H), 4.28 (br s, 4H), 3.81 (s, 3H), 3.19 (q, 2H), 3.07 (t, 4H), 2.24 (s, 3H), 1.41 (t, 3H); MS (ESI) for C19H24N6O: 353 (MH*).
[0360] 2-([3-chloro-5-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin- lyl]phenyl}oxy)-N,N-diethylethanamine: 1H NMR (400 MHz, c -methanol) δ 8.42 (s, IH), 6.70 (s, IH), 6.55 (m, 2H), 487 (t, 2H), 3.60 (br s, 4H), 3.60- 3.43 (t, 2H), 3.31(m, 4H), 1.42-1.35 (m, 6H); MS ( El) for C23H32ClN7O: 458 (MH*).
[0361] 4-(4-{3-chloro-4-[(2-piperidin-l-ylethyl)oxy]phenyl}piperazin-l-yl)-3-ethyl- lH-pyrazolo[3,4-c(]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.42 (s, IH), 7.13 (d, IH), 7.10 (d, IH), 6.98 (dd, IH), 4.36 (m, 2H), 4.19 (br s, 4H), 3.74 (m, 2H), 3.59 (m, 2H), 3.33 (m, 4H), 3.20-3.11 (m, 4H), 2.00 (m, 2H), 1.88-1.81 (m, 3H), 1.57 (m, IH), 1.41 (t, 3H); MS (ESI) for C24H3ιClN7O: 470 (MH*).
[0362] 4-[4-(5-chloro-2-methyl-3-moφholin-4-ylphenyl)piperazin-l-yl]-3-ethyl-lH-
Figure imgf000067_0001
1H NMR (400 MHz, d6-DMSO) δ 13.31 (s, IH), 8.29 (s, IH), 6.78 (d, IH), 6.74 (d, IH), 3.79 (m, 4H), 3.73 (m, 4H), 3.01 (m, 4H), 2.96 (q, 2H), 2.85 (m, 4H), 2.25 (s, 3H), 1.29 (t, 3H); MS (ESI) for C22H28ClN7O: 442 (MET).
[0363] 2-{[5-chloro-3-[4-(3-ethyl-lH-ρyrazolo[3,4-cT|pyrimidm-4-yl)piperazin-l-yl]- 2-(methyloxy)phenyl]oxy}-N,N-dimethylethanamine trifluoroacetate: !H NMR (400 MHz, d6-DMSO) δ 9.65 (br s, IH), 8.36 (br s, IH), 6.90 (d, IH), 6.69 (d, IH), 4.33 (m, 2H), 3.87 (br s, 2H), 3.77 (s, 3H), 3.48 (4H buried under water peak), 3.20 (br s, 4H), 3.00 (q, 2H), 2.90 (m, 6H), 1.30 (t, 3H); MS (ESI) for C22H30C1N7O2: 260 (MH*).
[0364] 3-{5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-^]pyrimidin-4-yl)piperazin-l-yl]-2- methylphenyl}-N,N-dimethylprop-2-yn-l -amine trifluoroacetate: 1H NMR (400 MHz, d6- DMSO) δ 8.35 (br s, IH), 7.32 (d, IH), 7.20 (d, IH), 4.39 (s, 2H), 3.87 (br s, 2H), 3.46 (2H buried under water peak), 3.07-2.99 (m, 6H), 2.90 (s, 6H), 2.40 (s, 3H), 1.30 (t, 3H); MS (ESI) for C23H27C1N7: 438 (MH*).
[0365] N'-{5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 2-methylphenyl}-N,N-dimethylethane-l,2-diamine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.48 (s, IH), 6.56 (m, 2H), 4.34 (br s, 4H), 3.58 (t, 2H), 3.41 (t, 2H), 3.21 (q, 2H), 3.07 (br s, 4H), 2.96 (s, 6H), 2.24 (s, 3H), 1.42 (t, 3H); MS (ESI) for C22H30C1N8: 443 (MH+).
[0366] 3-{5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- methylphenyl}-N,N-diethylpropan-l -amine hydrochloride: 1H NMR (400 MHz, d4- methanol) δ 8.48 (s, IH), 7.06 (d, IH), 7.00 (d, IH), 4.34 (br s, 4H), 3.28-3.20 (m, 8H), 3.09 (m, 4H), 2.76 (m, 2H), 2.40 (s, 3H), 2.00 (m, 2H), 1.44 (t, 3H), 1.33 (t, 6H); MS (ESI) for C25H36C1N7: 470 (MH*).
[0367] 4- { 4-[5-chloro-2-methyl-3-(3-pyrrolidin- 1 -ylpropyl)phenyl]piperazin- 1 -yl }-3- ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d -methanol) δ 8.47 (s, IH), 7.04 (d, IH), 6.99 (d, IH), 4.34 (br s, 4H), 3.67 (m, 2H), 3.29-3.19 (m, 6H), 3.14-3.06 (m, 6H), 2.76 (m, 2H), 2.39 (s, 3H), 2.19-2.14 (m, 2H), 2.06-1.98 (m, 4H), 1.44 (t, 3H); MS (ESI) for C25H34C1N7: 468 (MIT). [0368] 2-({5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 2-methylphenyl}oxy)-N,N-dimethylethanamine hydrochloride: 1H NMR (400 MHz, d4- methanol) δ 8.47 (s, IH), 6.87 (d, IH), 6.81 (d, IH), 4.38 (m, 2H), 4.33 (br s, 4H), 3.67 (m, 2H), 3.22 (q, 2H), 3.10 (m, 4H), 3.04 (s, 6H), 2.30 (s, 3H), 1.43 (t, 3H); MS (ESI) for C22H30C1N7O: 444 (MH*).
[0369] 2-({5-chloro-3-[4-(3-efhyl-lH-ρyrazolo[3,4-d]ρyrimidin-4-yl)ρiρerazin-l-yl]- 2-methylphenyl}oxy)-N,N-diethylethanamine hydrochloride: 1H NMR (400 MHz, d - methanol) δ 8.47 (s, IH), 6.87 (d, IH), 6.81 (d, IH), 4.38 (m, 2H), 4.34 (br s, 4H), 3.69 (m, 2H), 3.43-3.37 (m, 4H), 3.22 (q, 2H), 3.10 (m, 4H), 2.29 (s, 3H), 1.45-1.39 (m, 9H); MS (ESI) for C24H34ClN7O: 472 (MH*).
[0370] 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-l-ylethyl)oxy]phenyl}piperazin-l- yl)-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4- methanol) 8.47 (s, IH), 6.86 (d, IH), 6.81 (d, IH), 4.36-4.30 (m, 6H), 3.79 (m, 2H), 3.73 (m, 2H), 3.27 (m, 2H), 3.22 (q, 2H), 3.10 (m, 4H), 2.31 (s, 3H), 2.22 (m, 2H), 2.08 (m, 2H),1.43 (t, 3H); MS (ESI) for C24H32ClN7O: 470 (MH*).
[0371] 5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- methyl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: H NMR (400 MHz, d4- methanol) δ 8.47 (s, IH), 6.53 (s, 2H), 3.71 (m, 2H), 3.57 (t, 2H), 3.46 (t, 2H), 3.23-3.13 (m, 4H), 3.04 (br s, 4H), 2.23 (s, 3H), 2.18 (m, 2H), 2.05 (m, 2H), 1.42 (t, 3H); MS (ESI) for C24H33C1N8: 469 (MH*).
[0372] 4-[4-[5-chloro-2-methyl-3-(3-moφholin-4-ylpropyl)phenyl]piperazin-l-yl}-3- ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, άVmethanol) δ 8.47 (s, IH), 7.05 (s, IH), 6.99 (s, IH), 4.33 (br s, 4H), 4.06 (d, 2H), 3.79 (t, 2H), 3.52 (d, 2H), 3.26-3.04 (m, 10H), 2.76 (m, 2H), 2.40 (s, 3H), 2.06 (m, 2H), 1.44 (t, 3H); MS (ESI) for C25H34ClN7O: 484 (MH+).
[0373] N'-{5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 2-methylphenyl}-N,N-diethylethane-l,2-diamine: 1H NMR (400 MHz, d4-methanol) δ 8.47 (s, IH), 6.55 (m, 2H), 4.31 (br s, 4H), 3.60 (t, 2H), 3.40 (t, 2H), 3.32 (4H buried under solvent), 3.22 (q, 2H), 3.07 (br s, 4H), 2.24 (s, 3H), 1.43 (t, 3H), 1.35 (t, 6H); MS (ESI) for C24H35C1N8: 471 (MET).
[0374] 4-{4-[5-chloro-2-methyl-3-(3-piperidin-l-ylpropyl)phenyl]piperazin-l-yl}-3- ethyl-lH-pyrazolo[3,4-d]ρyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.39 (s, IH), 7.03 (s, IH), 7.00 (s, IH), 4.14 (br s, 4H), 3.55 (d, 2H), 3.16 (m, 4H), 3.06 (br s, 4H), 2.94 (t, 2H), 2.74 (t, 2H), 2.38 (s, 3H), 2.06-1.95 (m, 4H), 1.85 (m, IH), 1.78 (m, 2H), 1.54 (m, IH), 1.43 (t, 3H); MS (ESI) for C26H36C1N7: 482 (MH*).
[0375] 4-[4-(3-bromo-2-chloro-5-fluorophenyl)piperazin-l-yl]-3-ethyl-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, CDC13) δ 11.21 (s, IH), 8.44 (s, IH), 7.12 (dd, IH), 6.76 (dd, IH), 3.95 (m, 4H), 3.18 (m, 4H), 3.02 (q, 2H), 1.41 (t, 3H); MS (ESI) for Cι7H17BϊClFN6: 439 (MET*).
[0376] 2-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- fluoro-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, d -methanol) δ 8.47 (s, IH), 6.44 (dd, IH), 6.34 (dd, IH), 4.32 (br s, 4H), 3.73 (m, 2H), 3.62 (t, 2H), 3.45 (t, 2H), 3.26 -3.11 (m, 8H), 2.16 (m, 2H), 2.04 (m, 2H), 1.41 (t, 3H); MS (ESI) for C23H30C1FN8: 473 (MET*).
[0377] 4-[4-(2,5-difluorophenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 13.31 (s, IH), 8.30 (s, IH), 7.19 (m, IH), 6.93 (m, IH), 6.78 (m, IH), 3.81 (m, 4H), 3.19 (m, 4H), 2.97 (q, 2H), 1.29 (t, 3H); MS (ESI) for C17H18F2N6: 345 (MBft).
[0378] 3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- [(phenylmethyl)oxy]-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.49 (s, IH), 7.41 (m, 2H), 7.35 (m, 2H), 7.30 (m, IH), 5.08 (s, 2H), 4.39 (br s, 4H), 3.71 (br s, 2H), 3.60 (t, 2H), 3.42 (t, 2H), 3.27-3.06 (m, 8H), 2.25 (s, 3H), 2.17 (br s, 2H), 2.05 (br s, 2H), 1.44 (t, 3H); MS (ESI) for QuHrøNsO: 542 (M+2).
[0379] methyl l-(3-chlorophenyl)-4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4- yl)piperazine-2-carboxylate trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.45 (s, IH), 7.21 (m, IH), 6.94 (s,lH), 6.87-6.79 (m, 2H), 5.11-5.04 (d, 2H), 4.64-4.56 (d, IH), 4.04-3.96 (d, 2H), 3.86-3.59 (m, 3H), 3.52 (s, 3H), 3.22-3.15 (m, 2H), 1.42-1.37 (m, 3H); MS (ESI) for C19H21ClN6O2: 401 (MIT).
[0380] l-(3-chlorophenyl)-4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2- carboxylic acid: 1H NMR (400 MHz, d6-DMSO) δ 13.34 (s, IH), 12.75 (s, IH), 8.30 (s, IH), 7.22-7.17 (m, IH), 6.91 (s, IH), 6.85 (d, IH), 6.75 (d, IH), 4.85 (s, IH), 4.66 (d, IH), 4.24 (d, IH), 3.71-3.64 (d, IH), 3.61-3.51 (m, 2H), 3.03-2.90 (m, 2H), 1.30-1.25 (m, 3H); MS (ESI) for C18H19ClN6O2: 387 (MH+). [0381] l-(3-chlorophenyl)-4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-N- methylpiperazine-2-carboxamide trifluoroacetate: 1H NMR (400 MHz, de-DMSO) δ 13.34 (s, IH), 12.75 (s, IH), 8.30 (s, IH), 7.20 (m, IH), 6.91 (s, IH), 6.85 (d, IH), 6.75 (d, IH), 4.85 (s, IH), 4.66 (d, IH), 4.24 (d, IH), 3.71-3.64 (d, IH), 3.61-3.51 (m, 2H), 3.03- 2.90 (m, 2H), 1.30-1.25 (m, 3H); MS (ESI) for C19H22ClN7O: 400 (MET*).
[0382] l-(3-chloroρhenyl)-N-[2-(dimethylamino)ethyl]-4-(3-ethyl-lH-pyrazolo[3,4- d]pyrimidin-4-yl)piperazine-2-carboxamide trifluoracetate: !H NMR (400 MHz, de- DMSO) δ 9.37 (s, IH), 8.50 (s, IH), 8.28 (s, IH), 7.25 (m, IH), 6.80 (m, 2H), 4.70-3.56 (m, 7H), 3.04-2.90 (m, 4H), 2.73 (d, 6H), 1.29-1.22 (m, 3H); MS (ESI) for C22H29ClN8O: 457 (MH+).
[0383] [l-(3-chlorophenyl)-4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-2- yljmethanol trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.48 (s, IH), 7.25-7.19 (m, IH), 6.96 (s, IH), 6.88 (d, IH), 6.80 (d, IH), 4.73 (br s, IH), 4.52 (br s, IH), 4.13 (br s, IH), 4.05-3.98 (m, IH), 3.69-3.57 (m, 2H), 3.53-3.41 (m, 2H), 3.27-3.20 (m, 2H), 1.45- 1.40 (m, 3H); MS (ESI) for C18H21ClN6O: 373 (MH*).
[0384] l-(3-chloroρhenyl)-4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(l- methylpiperidin-4-yl)piperazine-2-carboxamide trifluoroacetate: H NMR (400 MHz, d4- methanol) δ 8.43 (s, IH), 7.25 (m, IH), 6.90-6.78 (m, 3H), 4.80 (d, IH), 4.42 (s, IH), 4.38-4.27 (m, 2H), 4.07 (br s, IH), 3.85 (br s, 2H), 3.77-3.69 (m, IH), 3.49 (d, 2H), 3.24- 3.15 (m, 2H), 3.08-2.97 (m, 2H), 2.80 (s, 3H), 1.91 (br s, 2H), 1.80-1.64 (m, 2H), 1.42-
1.36 (m, 3H); MS (ESI) for C24H31ClN8O: 484 (MH*).
[0385] l-(3-chlorophenyl)-4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(2- moφholin-4-ylethyl)piperazine-2-carboxamide trifluoracetate: 1H NMR (400 MHz, d - methanol) δ 8.40 (s, IH), 7.17 (m, IH), 6.85 (s, IH), 6.77 (d, 2H), 4.77 (d, IH), 4.52 (s, IH), 4.25 (m, 2H), 4.07 (m, IH), 3.88 (br s, 2H), 3.77-3.59 (m, 2H), 3.56-3.47 (m, 2H),
3.37 (m, 2H), 3.18-3.07 (m, 4H), 2.99 (br s, 2H), 1.33-1.28 (m, 3H); MS (ESI) for C24H31ClN8O2: 499 (MH*).
[0386] 4-[4-(5-chloro-2-methyl-3-{ [2-(l-methylpiperidin-4- yl)ethyl]oxy}phenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.44 (s, IH), 6.77 (s, IH), 6.72 (s, IH), 4.24 (br s, 4H), 4.06 (m, 2H), 3.52 (d, 2H), 3.17 (m, 2H), 3.06 (m, 4H), 2.99 (d, 2H), 2.86 (s, 3H), 2.21 (s, 3H), 2.08 (d, 2H), 1.85 (m, 3H), 1.52 (m, 2H), 1.43-1.37 (m, 3H); MS (ESI) for C2eH36ClN7O: 499 (MH*).
[0387] 4-[4-(5-chloro-2-methyl-3-{ [2-(4-methylρiperazin-l- yl)ethyl]oxy}phenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, αVmethanol) δ 8.44 (s, IH), 6.79 (s, IH), 6.75 (s, IH), 4.26 (br s, 4H), 4.15 (m, 2H), 3.47 (m, 2H), 3.25 (m, 2H), 3.18 (m, 2H), 3.13 (m, 2H), 3.07 (m, 4H), 3.00 (m, 4H), 2.88 (s, 3H), 2.22 (s, 3H), 1.43-1.38 (m, 3H); MS (ESI) for C25H35ClN8O: 500 (MH*).
[0388] 4-[4-(5-chloro-2-methyl-3-{ [(l-methylpiperidin-4- yl)methyl]oxy}phenyl)piperazin-l-yl]-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: MS (ESI) for C27H36ClN5O: 483 (MH*).
[0389] 4-(4- { 5-chloro-2-methyl-3-[3-(4-methylpiperazin- 1 - yl)propyl]phenyl}piperazin-l-yl)-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, dj-methanol) δ 8.48 (s, IH), 7.06 (s, IH), 6.99 (s, IH), 4.33 (br s, 2H), 3.87 (br s, 4H), 3.62 (br s, 4H), 3.36 (m, 2H), 3.21 (m, 4H), 3.09 (m, 2H), 3.02 (m, 2H), 2.76 (m, 2H), 2.39 (s, 3H), 2.12 (m, 2H), 1.45-1.38 (m, 3H), 1.35-1.27 (m, 3H); MS (ESI) for C26H37C1N8: 498 (MH*).
[0390] 5-bromo-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- methylaniline: 1HNMR (400 MHz, d6-DMSO) δ 13.29 (s, IH), 8.28 (s, IH), 6.58 (s, IH), 6.39 (s, IH), 5.13 (s, 2H), 3.79 (br s, 4H), 3.00-2.93 (m, 2H), 2.92-2.88 (m, 4H), 1.99 (s, 3H), 1.31-1.26 (m, 3H); MS (ESI) for Cι8H22BrN7: 417 (MH*).
[0391] 4-{4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-l-yl}-3-ethyl-lH- pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.44 (s, IH), 7.63 (d, IH), 7.41 (s, IH), 7.39 (d, IH), 4.26 (br s, 4H), 3.30 (m, 4H), 3.21-3.15 (m, 2H), 1.46-1.40 (m, 4H); MS (ESI) for C18Hι8ClF3N6: 411(MIT*).
[0392] 3-bromo-5-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4- methyl-N-phenylbenzamide trifluoroacetate: 1H NMR (400 MHz, d6-DMSO) δ 13.31 (s, IH), 10.22 (s, IH), 8.31 (s, IH), 7.94 (s, IH), 7.73-7.68 (d, 2H), 7.64 (s, IH), 7.37-7.31 (m, 2H), 7.12-7.07 (m, IH), 3.86 (br s, 4H), 3.07 (br s, 4H), 3.02-2.95 (m, 2H), 2.46 (s, 3H), 1.33-1.27 (m, 3H); MS (ESI) for C25H26BrN7O: 521 (MIT). [0393] 4-[4-(3-Ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)ρiperazin-l-yl]-6,7- bis(methyloxy)quinazoline hydrochloride H NMR (400 MHz, d -methanol) δ 8.83 (s, IH), 8.36 (s, IH), 7.49 (s, IH), 7.25 (s, IH), 4.37-4.32 (m, 4H), 4.07-4.02(m, 4H), 4.00 (s, 3H), 3.96 (s, 3H), 3.04-2.98 (q, 2H), 1.30-1.26 (t, 3H); MS (ESI) for C2ιH24N8O2: 421 (MET*).
[0394] EXAMPLE 6: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-propyl-lH- pyrazolo[3 ,4-d]pyrimidine
[0395] To a suspension of sodium hydride (60% in mineral oil, 2.0 g, 50.0 mmol) in anhydrous THF (35 mL) was added dropwise a solution of malononitrile (3.0 g, 45.4 mmol) in THF (5 mL) at 0 °C. The reaction was stirred at room temperature for 20 min, then cooled to 0 °C. A solution of butyryl chloride (4.84 g, 45.4 mmol) in THF (10 mL) was added dropwise over 1 h, and the reaction mixture was stirred at room temperature for an additional 16 h. The reaction was concentrated, acidified with 2 N hydrochloric acid (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were dried over magnesium sulfate, and concentrated to give crude (1- hydroxybutylidene)propanedinitrile (3.12 g) as a brown oil.
[0396] To a solution of (l-hydroxybutylidene)propanedinitrile (288 mg, 2.12 mmol) in diethyl ether (1.5 mL) and methanol (1.5 mL) was added dropwise a solution of TMS- diazomethane in hexanes (2.0M, 483 mg, 4.24 mmol) at 0 °C. The reaction was stirred at 0 °C for 3 h, and then quenched with glacial acetic acid (0.5 mL). The solution was basified with saturated sodium bicarbonate (100 mL), and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexanes: ethyl acetate 1:1) afforded [1- (methyloxy)-butylidene]propanedinitrile (128 mg) as a tan oil.
[0397] A mixture of [l-(methyloxy)-butylidene]propanedinitrile (128 mg, 1.87 mmol) and hydrazine hydrate (187 mg, 3.74 mmol) in ethanol (3 mL) was stirred at 80 °C for 3 h, and then concentrated to give 5-amino-3-propyl-lH-pyrazole-4-carbonitrile (115 mg) as a tan oil. 1H NMR (400 MHz, d6-DMSO) δ 5.87 (br s, IH), 3.85 (s, IH), 2.48-2.44 (m, 2H), 1.62-1.57 (m, 2H), 0.90-0.87 (m, 3H); MS (ESI) for C7H10N4: 151 (MH+).
[0398] A solution of 5-amino-3-propyl-lH-pyrazole-4-carbonitrile (115 mg, 0.77 mmol) in formic acid (4 mL) was heated at 110 °C for 4 h. The solution was concentrated, ethyl acetate (5 mL) was added, and the precipitate was filtered, and dried to afford 3- propyl-lH-pyrazolo[3,4-d]pyrimidin-4-ol (43.0 mg) as a tan solid.
[0399] A suspension of 3-propyl-lH-pyrazolo[3,4-d]pyrimidin-4-ol (43.0 mg, 0.24 mmol) in thionyl chloride (5 mL) and DMF (0.05 ml) was refluxed for 2 h under nitrogen. The solution was concentrated, added into saturated sodium bicarbonate (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with 5% lithium chloride (50 mL), dried with sodium sulfate, and concentrated to give 4- chloro-3-propyl-lH-pyrazolo[3,4-d]pyrimidine (37 mg). 1H NMR (400 MHz, d6-DMSO) δ 8.76 (s, IH), 7.93 (br s, IH), 3.03-2.99 (m, 2H), 1.82-1.73 (m, 2H), 0.99-0.95 (m, 3H); MS (ESI) for C8H9C1N4: 197 (MH*).
[0400] A solution of 4-chloro-3-propyl-lH-pyrazolo[3,4-d]pyrimidine (35 mg, 0.18 mmol), diisopropylethylamine ( 24 mg, 0.19 mmol), and l-(5-chloro-2- methylphenyl)piperazine (40 mg, 0.19 mmol) in THF (5 mL) was stirred at 50 °C for 2 h. The mixture was concentrated, and the remaining solid washed with methanol and dried to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-propyl-lH-pyrazolo[3,4- d]pyrimidine (6 mg) as an off-white solid. 1H NMR (400 MHz, αVmethanol) δ 8.31 (br s, IH), 7.19 (d, IH), 7.04 (s, IH), 6.99 (d, IH), 3.95-3.92 (m, 4H), 3.05 (m, 4H), 3.00 (d, 2H), 2.34 (s, 3H), 1.87-1.77 (m, 2H), 1.00-0.96 (m, 3H); MS (ESI) for C19H23C1N6: 371 (MH+).
[0401] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0402] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(l-methylethyl)-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 13.38 (br s, IH), 8.37 (s, IH), 7.22 (d, IH), 7.05 (m, 2H), 3.80 (br s, 4H), 3.38 (m, IH), 3.02 (m, 4H), 2.29 (s, 3H), 1.34 (d, 6H); MS (ESI) for C19H23C1N6: 371 (MH*).
[0403] 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-l-ylethyl)oxy]phenyl}piperazin-l- yl)-3-cyclopropyl-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: !H NMR (400 MHz, d4- methanol) δ 8.42 (s, IH), 6.84 (m, 2H), 4.40 (br s, 4H), 4.34 (t, 2H), 3.78 (m, 2H), 3.71 (t, 2H), 3.25 (m, 2H), 3.10 (m, 4H), 2.31 (m, IH), 2.28 (s, 3H), 2.21 (m, 2H), 2.06 (m, 2H), 1.24 (m, 2H), 1.12 (m, 2H); MS (ESI) for C25H32ClN7O: 482 (MH*).
[0404] 5-chloro-3-[4-(3-cyclopropyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline trifluoroacetate: 1H NMR (400 MHz, dj- methanol) δ 8.41 (s, IH), 6.54 (m, 2H), 4.40 (br s, 4H), 3.72 (m, 2H), 3.56 (t, 2H), 3.46 (t, 2H), 3.15 (m, 2H), 3.06 (br s, 4H), 2.30 (m, IH), 2.21 (s, 3H), 2.16 (m, 2H), 2.03 (m, 2H),
1.23 (m, 2H), 1.11 (m, 2H); MS (ESI) for C25H33C1N8: 481 (MH*).
[0405] 4-[4-(5-chloro-2-methylphenyl)piperazin- 1 -yl] -3-(phenylmethyl)- 1H- pyrazolo[3,4-d]pyrimidine: Η NMR (400 MHz, d6-DMSO) δ 13.5 (s, IH), 8.33 (s, IH), 7.34-7.26 (m, 2H), 7.24-7.17 (m, 4H), 7.07-7.00 (m, IH), 6.99-6.96 (m, IH), 4.39 (s, 2H), 3.75 (br s, 4H), 2.82 (br s, 4H), 2.24 (s, 3H); MS (ESI) for C23H23C1N6: 419(MH*).
[0406] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(2-methylpropyl)-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 13.38 (s, IH), 8.32 (s, IH),
7.24 (s, IH), 7.04 (m, 2H), 3.83-3.77 (br s, 4H), 3.03-2.98 (br s, 4H), 2.83 (d, 2H), 2.29 (s, IH), 2.19-2.08 (m, IH), 0.89-0.84 (d, 6H); MS (ESI) for C22H27C1N4: 383 (MH*).
[0407] 5-chloro-2-methyl-3-{4-[3-(2-methylpropyl)-lH-pyrazolo[3,4-d]pyrimidin-4- yl]piperazin-l-yl}-N-(2-pyrrolidin-l-ylethyl)aniline trifluoroacetate: 1H NMR (400 MHz, c nethanol) δ 8.41 (s, IH), 6.53 (s, 2H), 4.29-4.01 (br s, 4H), 3.75-3.68 (m, 2H), 3.59- 3.54 (m, 2H), 3.48-3.42 (m, 2H), 3.21-3.11 (m, 2H), 3.04-2.96 (m, 6H), 2.21 (s, 3H), 2.19- 2.14 (d, 2H), 2.10 (m, IH), 2.06-1.99 (m, 2H), 0.93-0.89 (d, 6H); MS (ESI) for C26H37C1N8: 498 (MH*).
[0408] 4-(4- { 5-chloro-2-methyl-3-[(2-pyrrolidin- 1 -ylethyl)oxy]phenyl Jpiperazin- 1 - yl)-3-(2-methylpropyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-πιethanol) δ 8.44-8.39 (s, IH), 6.87-6.84 (s, IH), 6.81-6.78 (s,lH), 4.36-4.30 (m, 2H), 4.21-4.09 (br s, 4H), 3.82-3.74 (m, 2H), 3.73-3.69 (m, 2H), 3.08-3.03 (m, 6H), 3.01- 2.96 (d, 2H), 2.30-2.27 (s, 3H), 2.24-2.18 (m, 2H), 2.15-2.00 (m, 3H), 0.94-0.89 (d, 6H); MS (ESI) for C26H36ClN7O: 499 (MH*).
[0409] 4-(4- { 5-chloro-2-methyl-3-[(2-pyrrolidin- 1 -ylethyl)oxy]phenyl Jpiperazin- 1- yl)-3-(l-methylethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.42 (s, IH), 6.85 (s, IH), 6.81 (s,lH), 4.35 (m, 2H), 4.20-4.11 (br s, 4H), 3.83-3.75 (m, 2H), 3.72 (m, 2H), 3.58-3.49 (m, IH), 3.30-3.24 (m, 2H), 3.10-3.05 (m, 4H), 2.29 (s, 3H), 2.26-2.17 (m, 2H), 2.13-2.04 (m, 2H), 1.48-1.43 (d, 6H); MS (ESI) for C25H34ClN7O: 485 (MET).
[0410] 5-chloro-2-methyl-3-{4-[3-(l-methylethyl)-lH-pyrazolo[3,4-d]pyrimidin-4- yl]piperazin- 1 -yl } -N- (2-pyrrolidin- 1 -ylethyl)aniline trifluoroacetate : !H NMR (400 MHz, d4-methanol) δ 8.41 (s, IH), 6.54 (d, 2H), 4.29-4.00 (br s, 4H), 3.78-3.68 (m, 2H), 3.62- 3.44 (m, 5H), 3.58-3.49 (m, IH), 3.23-3.13 (m, 2H), 3.08-2.99 (br s, 4H), 2.23 (s, 3H), 2.21-2.15 (m, 2H), 2.09-2.01 (m, 2H), 1.48-1.42 (d, 6H); MS (ESI) for C25H35C1N8: 484 (MH*).
[0411] EXAMPLE 7: 4-[4-(5-chloro-2-methylphenyl)piρerazin-l-yl]-3-({[2-
(methyloxy)ethyl]oxy}methyl)-lH-pyrazolo[3,4-d]pyrimidine
[0412] To a suspension of sodium hydride (60% in mineral oil, 1.21 g, 30.3 mmol) in THF (20 mL) was added dropwise a solution of malononitrile (1.00 g, 15.1 mmol) in THF (5 mL) at 0 °C. The resulting mixture was stirred at room temperature for 1 h, and then cooled to 0 °C. A solution of 2-(2-methoxyethoxy)acetyl chloride (2.31 g, 15.1 mmol) in THF (5 mL) was added slowly. The reaction mixture was stirred at room temperature for another 3 h, then added into IN hydrochloric acid (50 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (25 mL), and brine (25 mL), dried with sodium sulfate, and concentrated to give (l-hydroxy-2-{[2- (methyloxy)ethyl]oxy}ethylidene)propanedinitrile (3.03 g) as a brown oil. !H NMR (400 MHz, d6-DMSO) δ 4.03 (s, 2H), 3.52 (m, 2H), 3.43 (m, 2H), 3.23 (s, 3H).
[0413] To a suspension of sodium hydride (60% in mineral oil, 0.27 g, 6.75 mmol) in DMF (5 mL) was added dropwise a solution of (l-hydroxy-2-{[2-(methyloxy)ethyl]oxy}- ethylidene)propanedinitrile (1.23 g, 6.75 mmol) in DMF (5 mL) at 0 °C. The resulting mixture was stirred at room temperature for 30 min, and then cooled to 0 °C. A solution of dimethylsulfate (0.85 g, 6.75 mmol) in DMF (5 mL) was added slowly, and the reaction mixture was stirred at room temperature for 24 h. More dimethylsulfate (0.85 g, 6.75 mmol) was added, and the reaction mixture was stirred at 50 °C for 12 h, and then at room temperature for 3 d. The resulting suspension was added into IN hydrochloric acid (100 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with 5% lithium chloride (50 mL), water (50 mL), and brine (50 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (hexanes: ethyl acetate 1:1) afforded impure (l-(methyloxy)-2-{[2-(methyloxy)ethyl]oxy}ethylidene)- propanedinitrile (0.44 g) as a brown oil. 1H NMR (400 MHz, de-DMSO) δ 4.57 (s, 2H), 4.17 (s, 3H), 3.66 (m, 2H), 3.50 (m, 2H), 3.26 (s, 3H).
[0414] A solution of (l-(methyloxy)-2-{[2-
(methyloxy)ethyl]oxy}ethylidene)propanedinitrile (436 mg, 2.22 mmol) and hydrazine monohydrate (206 mg, 4.12 mmol) in ethanol (5 mL) was stirred at room temperature for 19 h, and then concentrated to give crude 5-amino-3-({[2-(methyloxy)ethyl]oxy}methyl)- lH-pyrazole-4-carbonitrile.
[0415] A solution of 5-amino-3-({[2-(methyloxy)ethyl]oxy}methyl)-lH-pyrazole-4- carbonitrile in formic acid (5 mL) was refluxed for 24 h, and then concentrated to afford crude 3-({[2-(methyloxy)ethyl]oxy}methyl)-lH-pyrazolo[3,4-d]pyrimidin-4-ol.
[0416] Crude 3-({ [2-(methyloxy)ethyl]oxy }methyl)-lH-pyrazolo[3,4-d]pyrimidin-4-ol was suspended in thionyl chloride (5 mL), DMF (188 mg, 2.57 mmol) was added, and the reaction mixture was refluxed for 90 min. The mixture was concentrated, the residue added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford crude 4-chloro-3- ({ [2-(methyloxy)ethyl]oxy}methyl)-lH-pyrazolo[3,4-d]pyrimidine (36 mg).
[0417] A solution of 4-chloro-3-({ [2-(methyloxy)ethyl]oxy }methyl)-lH-pyrazolo[3,4- d]pyrimidine (36 mg), diisopropylethylamine ( 22 mg, 0.17 mmol), and l-(5-chloro-2- methylphenyOpiperazine (30 mg, 0.14 mmol) in THF (5 mL) was stirred at 50 °C for 3 h. The mixture was concentrated, and the remaining solid washed with methanol and dried to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-({[2-(methyloxy)ethyl]oxy}- methyl)-lH-pyrazolo[3,4-d]pyrimidine (6 mg) as an off-white solid. !H NMR (400 MHz, de-DMSO) δ 8.28 (s, IH), 7.17 (d, IH), 7.05 (d, IH), 6.98 (dd, IH) 4.81 (s, 2H), 4.11 (m, 4H), 3.67 (m, 2H), 3.55 (m, 2H), 3.31 (s, 3H), 3.05 (m, 4H), 2.35 (s, 3H); MS (ESI) for C20H25C1N6O2: 417 (MH*).
[0418] EXAMPLE 8: 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo [3 ,4-d]pyrimidine
[0419] To 3-bromo-4-chloro-lH-pyrazolo[3,4-d]pyrimidine (200 mg, 0.86 mmol, T.Y.H. Wu, P.G. Schultz, S.Ding, Org. Lett. 2003, 5, 3587-3590) in anhydrous dioxane (5 mL) was added triethylamine ( 0.17 mL, 1.20mmol) and l-(5-chloro-2-methylphenyl)- piperazine (254 mg, 1.20 mmol). The reaction mixture was stirred at 85 °C for 30 min, concentrated, and the solid residue was suspended in 2-propanol. The solid was filtered, washed with water and 2-propanol, and dried to provide 3-bromo-4-[4-(5-chloro-2- methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine (150 mg, 43% yield) as a white solid. 1H NMR (400 MHz, de-DMSO) δ 8.37 (s, IH), 7.22 (d, IH), 7.08-7.03 (m, 2H), 3.94 (m, 4H), 3.05 (m, 4H), 2.29 (s, 3H); MS (ESI) for Cι6H16BrClN6: 407 (MH*). [0420] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0421] N'-{3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-chloro- 2-methylphenyl}-N,N-dimethylethane-l,2-diamine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.32 (s, IH), 6.58 (d, IH), 6.54 (d, IH), 4.07 (br s, 4H), 3.57 (t, 2H), 3.40 (t, 2H), 3.03 (m, 4H), 2.96 (s, 6H), 2.20 (s, 3H); MS (ESI) for C20H26BrClN8: 495 (MH*).
[0422] N'- { 3-[4-(3-bromo- lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -5-chloro- 2-methylphenyl}-N-methyl-N-(l-methylethyl)ethane-l,2-diamine hydrochloride: *H NMR (400 MHz, d -methanol) δ 8.44 (s, IH), 6.58 (m, 2H), 4.28 (br s, 4H), 3.68 (m, IH), 3.59 (m, 2H), 3.47 (m, IH), 3.24 (m, IH), 3.11 (m, 4H), 2.87 (s, 3H), 2.22 (s, 3H), 1.37 (d, 3H), 1.32 (d, 3H); MS (ESI) for C22H30BrClN8: 523 (MH*).
[0423] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- [(cyclopropylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, αVmethanol) δ 8.20 (s, IH), 4.12 (br s, 4H), 3.51 (d, 2H), 3.43 (m, 2H), 3.33 (m, 2H), 3.20 (m, 2H), 3.10 (br s, 4H), 2.86 (m, 2H), 1.97 (s, 3H), 1.85 (m, 2H), 1.74 (m, 2H), 0.90 (m, IH), 0.28 (m, 2H), 0.01 (m, 2H); MS (ESI) for C26H35BrN8O: 555, 557 (MH*).
[0424] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- [(3-methylbutyl)oxy]-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.49 (s, IH), 4.40 (br s, 4H), 4.00 (t, 2H), 3.74 (m, 2H), 3.63 (t, 2H), 3.50 (t, 2H), 3.38 (br s, 4H), 3.16 (m, 2H), 2.26 (s, 3H), 2.17 (m, 2H), 2.06 (m, 2H), 1.83 (m, IH), 1.64 (m, 2H), 0.96 (d, 6H); MS (ESI) for C27H39BrN8O: 551, 553 (MH+).
[0425] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- [(cyclohexylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: XH NMR (400 MHz, d4-methanol) δ 8.45 (s, IH), 4.32 (br s, 4H), 3.76 (m, 4H), 3.60 (t, 2H), 3.48 (t, 2H), 3.17 (m, 2H), 2.23 (s, 3H), 2.18 (m, 2H), 2.07 (m, 2H), 1.87 (m, 2H), 1.76 (m, 4H), 1.30 (m, 4H), 1.10 (m, 2H); MS (ESI) for HJHHBΓNSO: 597, 599 (MH*).
[0426] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- [(cyclopentylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: !H NMR (400 MHz, CDC13) δ 8.44 (s, IH), 6.11 (d, IH), 6.05 (d, IH), 4.09 (br s, 4H), 3.80 (d, 2H), 3.28 (m, 2H), 3.06 (br s, 4H), 2.85 (m, 2H), 2.62 (br s, 4H), 2.14 (m, IH), 2.10 (s, 3H), 1.82 (m, 6H), 1.61 (m, 4H), 1.35 (m, 2H); MS (ESI) for C28H39BrN8O: 583, 585 (MH*). [0427] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (3-phenyl-l,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, CDC13) δ 8.46 (s, IH), 8.18 (m, 2H), 7.51 (m, 3H), 7.39 (s, IH), 7.24 (s, IH), 4.65 (s, IH), 4.12 (br s, 4H), 3.40 (br s, 2H), 3.17 (m, 4H), 2.91 (m, 2H), 2.65 (br s, 4H), 2.25 (s, 3H), 1.84 (br s, 4H); MS (ESI) for C30H33BrNιoO: 629, 631 (MH*).
[0428] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (3-methyl-l,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, CDC13) δ 8.44 (s, IH), 7.29 (s, IH), 7.12 (s, IH), 4.72 (s, IH), 4.08 (br s, 4H), 3.39 (br s, 2H), 3.13 (m, 4H), 2.94 (br s, 2H), 2.68 (br s, 4H), 2.47 (s, 3H), 2.25 (s, 3H), 1.86 (br s, 4H); MS (ESI) for C25H31BrN10O: 567, 569 (MH*).
[0429] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- (ethylsulfonyl)-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, CDC13) δ 8.46 (s, IH), 7.01 (s, IH), 6.88 (s, IH), 4.75 (s, IH), 4.08 (br s, 4H), 3.30 (m, 2H), 3.11 (m, 6H), 2.86 (m, 2H), 2.61 (br s, 4H), 2.21 (s, 3H), 1.83 (br s, 4H), 1.30 (t, 3H); MS (ESI) for C24H33BrN8O2S: 577, 579 (MET).
[0430] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (methylsulfonyl)-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, CDC13) δ 8.46 (s, IH), 7.05 (s, IH), 6.91 (s, IH), 4.80 (s, IH), 4.09 (br s, 4H), 3.32 (m, 2H), 3.11 (m, 4H), 3.05 (s, 3H), 2.88 (m, 2H), 2.63 (br s, 4H), 2.21 (s, 3H), 1.83 (br s, 4H); MS (ESI) for C23H31BrN8O2S: 563, 565 (MH*).
[0431] 5-bromo-3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- methyl-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, CDC13) δ 8.44 (s, IH), 6.63 (d, IH), 6.55 (s, IH), 4.56 (s, IH), 4.08 (br s, 4H), 3.26 (br s, 2H), 3.05 (m, 4H), 2.86 (br s, 2H), 2.61 (br s, 4H), 2.11 (s, 3H), 1.84 (br s, 4H); MS (ESI) for C22H28Br2N8: 565 (MH*).
[0432] 3-bromo-4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-l- yl)ethyl]oxy}phenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.48 (s,lH), 6.89 (m, IH), 6.85 (m, IH), 4.53-4.46 (m, 2H), 4.41-4.31 (m, 4H), 4.07-3.64 m, 10H), 3.23-3.16 (m, 4H), 3.05 (s, 3H), 2.31 (s, 3H); MS (ESI) for C23H30BrClN8O: 549 (MET).
[0433] 3-bromo-4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-l-yl)ethyl]oxy}-2- methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, αVmefhanol) δ 8.49 (s,lH), 6.90 (m, IH), 6.86 (m, IH), 4.55-4.44 (m, 2H), 4.42-4.30 (m, 4H), 4.16-3.52 (m, 10H), 3.44-3.35 (m, 2H), 3.24-3.12 (m, 4H), 2.33 (s, 3H), 1.51-1.33 (m, 3H); MS (ESI) for C24H32BrClN8O: 563 (MH*).
[0434] 3- [4-(3 -bromo- 1 H-pyrazolo[3 ,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -5- [(2- ethylbutyl)oxy]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, c -methanol) δ 8.37 (s,lH), 6.20 (br m, IH), 6.12 (br m, IH), 4.48-3.93 (m, 4H), 3.85 (d, 2H), 3.81-3.63 (m, 2H), 3.58 (t, 2H), 3.46 (t, 2H), 3.24-3.03 (m, 6H), 2.25-1.96 (m, 8H), 1.66-1.36 (m, 5H), 0.95 (t, 6H); MS (ESI) for C28H41BrN8O: 585 (MET*).
[0435] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-[(2- ethylbutyl)oxy]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.50 (s,lH), 4.67-4.14 (br m, 4H), 3.98 (t, 2H), 3.81-3.68 (br m, 2H), 3.64 (t, 2H), 3.50 (t, 2H), 3.45-3.33 (m, 4H), 3.23-3.09 (m, 2H), 2.27 (s, 3H), 2.24-1.97 (m, 4H), 1.73 (m, 2H), 1.49 (m, 2H), 0.97 (t, 3H); MS (ESI) for C26H37BrN8O: 557 (MH+).
[0436] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-[(2,2- dimethylpropyl)oxy]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, CDC13) δ 8.40 (s,lH), 6.10 (m, IH), 6.04 (m, IH), 4.57-3.73 (br m, 4H), 3.56 (br m, 2H), 3.38-3.29 (br m, 2H), 3.12-2.99 (br m, 4H), 2.95-2.85 (br m, 2H), 2.77-2.63 (br m, 4H), 2.10 (s, 3H), 1.91-1.78 (br m, 4H), 1.32-1.16 (br m, IH), 1.02 (m, 9H); MS (ESI) for C27H39BrN8O: 571 (MH*).
[0437] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N- (2-pyrrolidin-l-ylethyl)-5-[(tetrahydrofuran-2-ylmethyl)oxy]aniline acetate: 1H NMR (400 MHz, d4-methanol) δ 8.30 (s,lH), 6.14 (m, IH), 6.09 (m, IH), 4.29-3.72 (m, 10H), 3.42 (t, 2H), 3.14-2.93 (m, lOH), 2.16-1.84 (m, 12H), 1.83-1.71 (m, IH); MS (ESI) for C27H37BrN8O2: 585 (MH*).
[0438] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- {[2-(methyloxy)ethyl]oxy}-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.32 (s,lH), 6.12 (m, IH), 6.05 (m, IH), 4.24-3.83 (m, 6H), 3.74-3.54 (m, 6H), 3.48 (t, 2H), 3.37 (t, 2H), 3.32 (s, 3H), 3.17-2.90 (m, 5H), 2.17-1.86 (m, 6H); MS (ESI) for C25H35BrN8O2: 559 (MH*).
[0439] l-[3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl- 5-[(2-pyrrolidin-l-ylethyl)amino]phenyl}pentan-l-one: 1H NMR (400 MHz, dj-mefhanol) δ 8.31 (s,lH), 7.16 (m, IH), 7.05 (m, IH), 4.41-3.76 (m, 4H), 3.49-3.43 (m, 2H), 3.15- 3.04 (m, 4H), 3.03-2.96 (m, 4H), 2.93-2.83 (m, 4H), 2.26 (s, 3H), 2.00-1.85 (m, 4H), 1.72- 1.60 (m, 2H), 1.46-1.34 (m, 2H), 0.95 (t, 3H), MS (ESI) for C27H37BrN8O: 569 (MH*).
[0440] {3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-5- [(2-pyrrolidin-l-ylethyl)amino]phenyl}(phenyl)methanone trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.32 (s,lH), 7.80-7.76 (m, 2H), 7.67-7.60 (m,lH), 7.56-7.49 (m, 2H), 6.92 (m, 2H), 4.25-3.93 (m, 4H), 3.78-3.67 (m, 2H), 3.61 (t, 2H), 3.47 (t, 2H), 3.22- 3.10 (m, 2H), 3.09-3.00 (m, 4H), 2.34 (s, 3H), 2.26-1.94 (m, 4H); MS (ESI) for C29H33BrN8O: 589 (MH*).
[0441] l-{3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl- 5-[(2-pyrrolidin-l-ylethyl)amino]phenyl}propan-l-one acetate: !H NMR (400 MHz, i-U- methanol) δ 8.26 (s,lH), 7.19 (br s, IH), 7.05 (br s, IH), 4.36-3.81 (br m, 4H), 3.56 (t, 2H), 3.25 (t, 2H), 3.21-3.12 (m, 4H), 3.11-2.96 (m, 6H), 2.27 (s, 3H), 2.04-1.98 (m, 4H), 1.91 (s, 3H), 1.16 (t,3H); MS (ESI) for C25H33BrN8O: 541 (MH*).
[0442] l-[3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl- 5-[(2-pyrrolidin-l-ylethyl)amino]phenyl}butan-l-one: 1H NMR (400 MHz, d4-methanol) δ 8.32 (s,lH), 7.16 (br s, IH), 7.05 (br s, IH), 4.41-3.71 (br m, 4H), 3.46 (t, 2H), 3.16-3.04 (m, 4H), 3.03-2.92 (m, 4H), 2.91-2.80 (m, 4H), 2.25 (s, 3H), 1.99-1.86 (m, 4H), 1.79-1.63 (m, 2H), 0.99 (t,3H); MS (ESI) for C26H35BrN8O: 555 (MH+).
[0443] 3- [4-(3 -bromo- 1 H-pyrazolo [3 ,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -N,4- dimefhyl-N-(methyloxy)-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide: !H NMR (400 MHz, dVmethanol) δ 8.31 (s,lH), 6.80 (br s, IH), 6.70 (br s, IH), 4.37-3.77 (br m, 4H), 3.6 (s, 3H), 3.49 (t, 2H), 3.33 (s, 3H), 3.23-2.97 (m, 10H), 2.24 (s, 3H), 2.03-1.94 (m, 4H); MS (ESI) for C25H34BrN9O2: 572 (MIT).
[0444] 1 - { 3-[4-(3-bromo- lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -4-methyl- 5-[(2-pyrrolidin-l-ylethyl)amino]phenyl}ethanone trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.34 (s,lH), 7.23 (s, IH), 7.07 (s, IH), 4.36-3.88 (br m, 4H), 3.79-3.69 (m, 2H), 3.65 (t, 2H), 3.50 (t, 2H), 3.24-3.03 (m, 6H), 2.59 (s, 3H), 2.30 (s, 3H), 2.24-1.96 (m, 4H); MS (ESI) for C24H31BrN8O: 527 (MH*).
[0445] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-{[(2,2- difluorocyclopropyl)methyl]oxy}-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: !H NMR (400 MHz, d4-methanol) δ 8.21 (s,lH), 6.04 (s, IH), 5.99 (s, IH), 4.05-3.95 (m, IH), 3.88- 3.77 (m, IH), 3.31 (t, 2H), 3.02-2.77 (m, 10H), 2.06-1.90 (m, 4H), 1.89-1.82 (m, 4H), 1.56-1.41 (m, IH), 1.27-1.13 (m, IH); MS (ESI) for C26H33BrF2N8O: 591 (MH*).
[0446] 1 - { 3-[4-(3-bromo- lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -4-methyl- 5- [(2-pyrrolidin- 1 -ylethyl)amino]phenyl } -4,4,4-trifluorobutan- 1 -one hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.39 (s,lH), 7.27 (m, IH), 7.09 (m, IH), 4.51-3.88 (m, 4H), 3.80-3.71 (m, 2H), 3.67 (t, 2H), 3.52 (t, 2H), 3.36-3.29 (m, 2H), 3.24-3.08 (m, 6H), 2.69-2.51 (m, 2H), 2.33 (s, 3H), 2.27-1.96 (m, 4H); MS (ESI) for C26H32BrF3N8O: 609 (MET).
[0447] {3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-5- [(2-pyrrolidin-l-ylethyl)amino]ρhenyl}(cyclopropyl)methanone trifluoroacetate: !H NMR (400 MHz, dft-methanol) δ 8.33 (s,lH), 7.33 (s, IH), 7.08 (s, IH), 4.42-3.85 (br m, 4H), 3.78-3.68 (m, 2H), 3.65 (t, 2H), 3.50 (t, 2H), 3.23-3.05 (m, 6H), 2.91-2.78 (m, IH), 2.31 (s, 3H), 2.24-1.94 (m, 4H), 1.18-1.00 (m, 4H); MS (ESI) for C26H33BrN8O: 553(MH*).
[0448] 3-bromo-4-[4-(5-chloro-2-methyl-3-{[(l-methylρiperidin-4- yl)methyl]oxy}phenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.36 (s, IH), 6.76 (m, 2H), 4.14 (br s, 4H), 3.93 (d, 2H), 3.60 (d, 2H), 3.10 (m, 6H), 2.90 (s, 3H), 2.23 (s, 3H), 2.17 (m, 3H), 1.72 (q, 2H); MS (ESI) for C23H29BrClN7O: 536 (MH*).
[0449] 3-bromo-4-[4-(5-chloro-2-methyl-3-{[2-(l-methylpiperidin-4- yl)ethyl]oxy}phenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.41 (s, IH), 6.76 (m, 2H), 4.22 (br s, 4H), 4.07 (t, 2H), 3.53 (m, 2H), 3.12 (m, 4H), 3.03 (m, 2H), 2.87 (s, 3H), 2.22 (s, 3H), 2.10 (m, 2H), 2.04- 1.83 (m, 3H), 1.53 (m, 2H); MS (ESI) for C24H31BrClN7O: 550 (MH*).
[0450] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-chloro-5- fluoro-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, α -methanol) δ 8.47 (s, IH), 6.45 (dd, IH), 6.38 (dd, IH), 4.31 (br s, 4H), 3.73 (m, 2H), 3.62 (t, 2H), 3.45 (t, 2H), 3.26 (m, 4H), 3.15 (m, 2H), 2.17 (m, 2H), 2.03 (m, 2H); MS (ESI) for C21H25BrClFN8: 523 (MH*).
[0451] 3-bromo-4-[4-(2,5-difluorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.35 (s, IH), 7.19 (m, IH), 6.93 (m, IH), 6.79 (m, IH), 3.94 (m, 4H), 3.22 (m, 4H); MS (ESI) for C15H13F2N6: 397 (MH*). [0452] 3-({3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)ρiperazin-l-yl]-5- chloro-2-methylphenyl}oxy)-N,N-diethylpropan-l -amine hydrochloride: 1H NMR (400 MHz, αVmefhanol) δ 8.41 (s, IH), 6.74 (s, IH), 6.71 (s, IH), 4.11-4.08 (t, 2H), 3.98-3.93 (m, 4H), 3.55-3.35 (m, 4H), 3.28-3.16 (m, 4H), 3.01-3.00 (t, 2H), 2.24-2.17 (m, 5H), 1.39- 1.35 (t, 6H); MS (ESI) for C23H31BrCl N7O: 536 (MET).
[0453] 3-Bromo-4-(4- { 5-chloro-2-methyl-3-[(3-ρyrrolidin- 1 - ylpropyl)oxy]phenyl}piperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.47 (s, IH), 6.80 (s, 2H), 6.71 (s, IH), 4.37-4.33 (m, 4H), 4.13-4.10 (t, 2H), 3.77-3.72 (m, 2H), 3.46-3.32 (m, 2H), 3.18-3.14 (m, 6H), 2.31-2.20 (m, 7H), 2.11-2.03 (m, 2H); MS (ESI) for C23H29BrCl N7O: 534 (MH*).
[0454] 3-Bromo-4-[4-(5-chloro-2-methyl-3-{[3-(4-methylpiρerazin-l- yl)propyl]oxy}phenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: !H NMR (400 MHz, d4-methanol) δ 8.45 (s, IH), 6.81-6.79 (m, 2H), 4.33-4.27 (m, 4H), 4.15- 4.13 (t, 2H), 4.00-3.45 (m,12H), 3.17-3.14 (t, 4H), 3.05 (s, 3H), 2.39-2.33 (m, 2H), 2.26 (s, 3H); MS (ESI) for C2 H32BrCl N8O: 563 (MET*).
[0455] 3-Bromo-4-[4-(5-chloro-3-{[3-(4-efhylpiperazin-l-yl)propyl]oxy}-2- methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.45 (s, IH), 6.81-6.79 (m, 2H), 4.34-4.29 (m, 4H), 4.15-4.13 (t, 2H), 4.00-3.48 (m,8H), 3.40-3.35 (q, 2H), 3.27-3.25 (m, 2H), 3.17 -3.14 (t, 4H), 2.39- 2.33 (m, 2H), 2.26 (s, 3H), 1.45-1.42 (t, 3H); MS (ESI) for C25H34BrCl N8O: 577 (MET*).
[0456] 3-bromo-5-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4- methyl-N-phenylbenzamide: 1H NMR (400 MHz, d6-DMSO) δ 10.26 (s, IH), 8.39 (s, IH), 7.97 (s, IH), 7.74 (d, 2H), 7.67 (s, IH), 7.39-7.33 (m, 2H), 7.14-7.09 (m, IH), 4.05- 3.95 (br s, 4H), 3.15-3.09 (m, 4H), 2.47 (s, 3H); MS (ESI) for C23H21Br2N7O: 572 (MH*).
[0457] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- [(cyclobutylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, CDC13) δ 8.43 (s, IH), 6.11 (s, IH), 6.05 (s, IH), 4.40-4.32 (br s, IH), 4.16-4.09 (m, 2H), 3.93-3.89 (d, 2H), 3.30-3.22 (br s, 2H), 3.09-3.03 (m, 2H), 2.87-2.80 (br s, 2H), 2.79-2.71 (m, IH), 2.64-2.53 (br s, 4H), 2.19-2.12 (m, 2H), 2.11-2.09 (s, 3H), 1.97-1.87 (m, 2H), 1.84-1.78 (m, 4H), 1.29-1.24 (m, 2H); MS (ESI) for C27H37BrN8O: 570 (MH+).
[0458] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-(ethyloxy)- 2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, d - methanol) δ 8.31 (s, IH), 6.10 (s, IH), 6.05 (s, 1 H), 4.10-3.94 (m, 6H), 3.04-2.98 (br s, 4H), 2.89-2.85 (m, 2H), 2.77-2.72 (br s, 4H), 2.11 (s, 3H), 1.90-1.86 (m, 4H), 1.37-1.31 (m, 3H); MS (ESI) for C24H33BrN8O: 530 (MET*).
[0459] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- [(l-methylethyl)oxy]-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: MS (ESI) for C25H35BrN8O: 544 (MH*).
[0460] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (propyloxy)-N-(2-pyrrolidin-l-ylethyl)aniline acetate: 1H NMR (400 MHz, d4-methanol) δ 8.30 (s, IH), 6.14 (s, IH), 6.07 (s, IH), 4.28-3.91 (br s, 4H), 3.90-3.86 (m, 2H), 3.45- 3.39 (m, 2H), 3.12-3.06 (m, 2H), 3.06-2.96 (m, 8H), 2.13-2.12 (s, 3H), 1.99-1.93 (m, 4H), 1.80-1.70 (m, 2H), 1.05-1.00 (m, 3H); MS (ESI) for C25H35BrN8O: 544 (MH+).
[0461] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (phenylethynyl)-N-(2-pyrrolidin-l-ylethyl)aniline: !H NMR (400 MHz, d4-methanol) δ 8.32 (s, IH), 7.49-7.46 (d, 2H), 7.36-7.32 (m, 3H), 6.76 (s, IH), 6.69 (s, IH), 3.78-3.66 (m, 4H), 3.63-3.59 (m, 2H), 3.50-3.45 (m, 2H), 3.26-3.19 (m, 4H), 3.09-3.04 (m, 4H), 2.27 (s, 3H), 2.14-2.07 (m, 4H); MS (ESI) for C30H33BrN8: 586 (MH+).
[0462] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-ethynyl-2- methyl-N-(2-pyrrolidin-l-ylethyl)aniline trifluoroacetate: 1H NMR (400 MHz, άV methanol) δ 8.32 (s,lH), 6.72 (s, IH), 6.63 (s, IH), 4.17-3.95 (br s, 4H), 3.75-3.69 (br s, 2H), 3.59-3.55 (m, 2H), 3.49-3.44 (m, 2H), 2.28 (s, IH), 3.20-3.12 (m, 2H), 3.07-3.01 (br s, 4H), 2.24 (s, 3H), 2.21-2,14 (m, 2H), 2.07-2.00 (m, 2H); MS (ESI) for C24H29BrN8: 510 (MH*).
[0463] 3-[4-(3-bromo-lH-ρyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-(3,3- dimethylbut- 1 -yn- 1 -yl)-2-methyl-N-(2-pyrrolidin- 1 -ylethyl)aniline trifluoracetate : 1H NMR (400 MHz, d4-methanol) δ 8.32 (s,lH), 6.59 (s, IH), 6.50 (s, IH), 4.30-3.86 (br s, 4H), 3.76-3.68 (br s, 2H), 3.59-3.54 (m, 2H), 3.49-3.43 (m, 2H), 3.21-3.12 (m, 2H), 3.05- 2.98 (br s, 4H), 2.22 (s, 3H), 2.19-2.13 (m, 2H), 2.07-1.98 (m, 2H), 1.31-1.28 (s, 9H); MS (ESI) for C28H37BrN8: 566 (MH*).
[0464] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-(3,3- dimethylbutyl)-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, αV methanol) δ 8.32 (s,lH), 6.42 (s, IH), 6.34 (s, IH), 4.30-3.84 (br s, 4H), 3.75-3.67 (m, 2H), 3.54 (m, 2H), 3.35 (m, 2H), 3.25-3.19 (m, 2H), 3.03 (br s, 4H), 2.53-2.47 (m, 2H), 2.19 (s, 3H), 2.06 (m, 4H), 1.52-1.45 (m, 2H), 0.97 (s, 9H); MS (ESI) for
Figure imgf000084_0001
570 (MH+).
[0465] 3- [4-(3 -bromo- 1 H-pyrazolo[3 ,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -5-ethyl-2- methyl-N-(2-pyrrolidin-l-ylethyl)aniline trifluoroacetate: XH NMR (400 MHz, d4- methanol) δ 8.34 (s, IH), 6.49 (s, IH), 6.40 (s, IH), 4.22-3.90 (br s, 4H), 3.80-3.67 (br s, 2H), 3.62-3.56 (m, 2H), 3.54-3.48 (m, 2H), 3.22-3.06(m, 4H), 2.62-2.50 (m, 2H), 2.19 (s, 3H), 2.07-2.00 (m, 4H), 1.22-1.19 (m, 3H); MS (ESI) for C24H33BrN8: 514 (MET*).
[0466] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N- (2-pyrrolidin-l-ylethyl)-5-[2-(trimethylsilyl)ethyl]aniline trifluouroacetate: 1H NMR (400 MHz, άVmethanol) δ 8.39 (s, IH), 6.47 (s, IH), 6.41 (s, IH), 4.22-3.90 (br s, 4H), 3.80- 3.65 (m, 2H), 3.50-3.46 (m, 2H), 3.15 (br s, 6H), 2.60 (m, 2H), 2.21 (s, 3H), 2.20-2.00 (m, 4H), 0.84-0.81 (m, 2H), 0.02 (s, 9H); MS (ESI) for
Figure imgf000084_0002
586 (MET*).
[0467] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (2-phenylethyl)-N-(2-pyrrolidin-l-ylethyl)aniline acetate: 1H NMR (400 MHz, d4- methanol) δ 8.29 (s, IH), 7.23-7.17 (m, 2H), 7.12-7.09 (m, 3H), 6.29 (s, IH), 6.24 (s, IH), 4.18-3.77 (br s, 4H), 3.35-3.32 (m, 2H), 2.97-2.78 (m, 14H), 2.13 (s, 3H), 1.93-1.88 (m, 4H); MS (ESI) for C30H37BrN8: 590 (MH ).
[0468] 3-bromo-5-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N- (2-pyrrolidin-l-ylethyl)aniline acetate: 1H NMR (400 MHz, d4-mefhanol) δ 8.30 (s, IH), 6.48 (s, IH), 6.35 (s, IH), 6.21 (s, IH), 4.03-3.98 (m, 4H), 3.42-3.37 (m, 2H), 3.36-3.32 (m, 4H), 3.14-3.06 (m, 6H), 2.02-1.96 (m, 4H); MS (ESI) for C21H26Br2N8: 551 (MH*).
[0469] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-chloro-N- (2-pyrrolidin-l-ylethyl)aniline acetate: 1H NMR (400 MHz, d4-methanol) δ 8.31 (s, IH), 6.32 (s, IH), 6.17 (s, 2H), 4.03-3.99 (m, 4H), 3.35-3.32 (m, 4H), 2.88 (m, 2H), 2.80-2.77 (m, 4H), 1.91-1.87 (m, 6H); MS (ESI) for C21H2eBrClN8: 506 (MH+).
[0470] l-{3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-[(2- pyrrolidin-l-ylethyl)amino]phenyl}butan-l-one acetate: 1H NMR (400 MHz, dV methanol) δ 8.24 (s, IH), 6.91 (s, IH), 6.72 (s, IH), 6.48 (s, IH), 4.54 (br s, 2H), 3.99-3.94 (m, 4H), 3.48-3.42 (m, 2H), 3.34-3.24 (m, 8H), 2.89-2.84 (m, 2H), 2.01-1.93 (br s, 4H), 1.67-1.57 (m, 2H, 0.92-0.86 (m, 3H); MS (ESI) for C25H33BrN8O: 542 (MH*). [0471] 3-[4-(3-bromo-lH-pyrazolo[3,4-d]ρyrimidin-4-yl)piperazin-l-yl]-2-methyl-N- (2-pyrrolidin-l-ylethyl)-5-[(3,3,3-trifluoropropyl)oxy]aniline: XH NMR (400 MHz, dj- methanol) δ 8.30 (s, IH), 6.10 (s, IH), 4.19-4.15 (m, 2H), 3.41-3.36 (m, 2H), 3.02 (br s, 4H), 2.83-2.79 (m, 2H), 2.71-2.59 (m, 6H), 2.11 (s, 3H), 1.88-1.84 (m, 4H), 1.29 (m, 2H), 0.91-0.82 (m, 2H); MS (ESI) for C25H32BrF3NgO: 598 (MH*).
[0472] EXAMPLE 9: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-phenyl-lH- pyrazolo [3 ,4-d]pyrimidine
[0473] A solution of 5-amino-3-phenyl-lH-pyrazole-4-carbonitrile (341mg, 1.85 mmol, R.J. Bantems, J.D. Anderson, D.F. Smee, A. Jin, H.A. Alaghamandan, B.S. Sharma, W.B. Jolley, R.K. Robins, H.B. Cottam, /. Med. Chem. 1990, 33, 2174-2178) in formic acid (5 mL) was refluxed for 12 h. After cooling to room temperature, methanol (5 mL) was added, the precipitate was filtered, washed with methanol (2 3 mL), and dried to give 3-phenyl-lH-pyrazolo[3,4-d]pyrimidin-4-ol (190 mg, 48% yield) as a tan solid. !H NMR (400 MHz, d6-DMSO) δ 13.90 (br s, IH), 12.21 (br s, IH), 8.36 (d, 2H), 8.05 (s, IH), 7.50-7.36 (m, 3H); MS (ESI) for CnH8N4O: 213 (MH*).
[0474] A mixture of 3-phenyl-lH-pyrazolo[3,4-d]pyrimidin-4-ol (95 mg, 0.45 mmol) and DMF (0.5 mL) in 5 ml of thionyl chloride was refluxed for 3 h. The reaction mixture was concentrated, the residue was added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford 4-chloro-3-phenyl-lH-pyrazolo[3,4-d]pyrimidine (104 mg, 100% yield) as a brown solid. *H NMR (400 MHz, d6-DMSO) δ 8.86 (s, IH), 7.78 (m, 2H), 7.54 (m, 3H); MS (ESI) for CUH7C1N4: 231 (MH*).
[0475] A mixture of 4-chloro-3-phenyl-lH-pyrazolo[3,4-d]pyrimidine (100 mg, 0.43 mmol), diisopropylethylamine (67 mg, 0.52 mmol), and l-(5-chloro-2-methylphenyl)- piperazine (91 mg, 0.43 mmol) in dry THF (5 mL) was stirred at 50 °C for 5 h, and then concentrated. The remaining solid was washed with methanol and dried to provide 4-[4- (5-chloro-2-methylphenyl)piperazin-l-yl]-3-phenyl-lH-pyrazolo[3,4-d]pyrimidine (90 mg, 51% yield) as a pale yellow solid. 1H NMR (400 MHz, de-DMSO) δ 13.91 (br s, IH), 8.44 (s, IH), 7.70 (m, 2H), 7.55 (m, 2H), 7.46 (m, IH), 7.15 (d, IH), 7.00 (dd, IH), 6.92 (d, IH), 3.53 (m, 4H), 2.74 (m, 4H), 2.15 (s, 3H); MS (ESI) for C22H21C1N6: 405 (MH*). [0476] EXAMPLE 10: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-N-phenyl-lH- pyrazolo[3,4-d]pyrimidin-3-amine
[0477] A mixture of 4-hydroxy-N-phenyl-lH-pyrazolo[3,4-d]pyrimidin-3-amine (102 mg, 0.45 mmol, Y. Tominaga, Y. Honkawa, M. Hara, A. Hosami, /. Heterocycl. Chem. 1990, 27, 775-783) and phosphoryl chloride (5 mL) was refluxed for 2 h. The reaction mixture was concentrated, the residue was added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine (30 mL), dried with sodium sulfate, and concentrated to afford 4- chloro-N-phenyl-lH-pyrazolo[3,4-d]pyrimidin-3-amine (67 mg, 61% yield) as a yellow solid. 1H NMR (400 MHz, de-DMSO) δ 13.60 (s, IH), 8.70 (s, IH), 8.20 (s, IH), 7.59 (m, 2H), 7.29 (m, 2H), 6.91 (m, IH); MS (ESI) for CnH8ClN5: 246 (MH*).
[0478] A mixture of 4-chloro-N-phenyl-lH-pyrazolo[3,4-d]pyrimidine-3-amine (60 mg, 0.24 mmol), diisopropylethylamine (37 mg, 0.29 mmol), and l-(5-chloro-2- methylphenyl)piperazine (50 mg, 0.24 mmol) in anhydrous THF (5 mL) was stirred at 50 °C for 2 h. The reaction mixture was concentrated, and the remaining solid washed with methanol and purified by reverse phase HPLC to provide 4-[4-(5-chloro-2-methylphenyl)- piperazin-l-yl]-N-phenyl-lH-pyrazolo[3,4-d]pyrimidine-3-amine (18 mg, 17% yield) as a yellow solid. 1H NMR (400 MHz, d6-DMSO) δ 13.14 (s, IH), 8.63 (s, IH), 8.29 (s, IH), 7.20 (m, 3H), 7.00 (dd, IH), 6.93 (d, 2H), 6.82 (t, IH), 6.76 (d, IH), 3.87 (br s, 4H), 2.59 (m, 4H), 2.19 (s, 3H); MS (ESI) for C22H22C1N7: 420 (MH+).
[0479] EXAMPLE 11: 4-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidin-3-yl}phenol
[0480] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidine (50.0 mg, 0.12 mmol), 4-hydroxyphenylboronic acid (51.0mg, 0.37 mmol), [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1:1) (20mg, 0.025 mmol), and triethylamine (0.051 mL, 0.37 mmol) in dry DMF (1 mL) was stirred at 140 °C for 16 h. The reaction mixture was cooled, diluted with ethyl acetate (10 mL), and filtered over celite. The filtrate was washed with water and brine, dried over sodium sulfate, and concentrated. The oily residue was purified by reverse phase HPLC. The product containing fraction was concentrated and isolated as the hydrochloride salt by evaporating three times with a solution of 4N hydrochloric acid in dioxane to give 4-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]- pyrimidin-3-yl}phenol hydrochloride (25 mg, 44% yield) as a white solid. *H NMR (400 MHz, d6-DMSO) δ 9.73 (br s, IH), 8.41 (s, IH), 7.52 (d, 2H), 7.16 (d, IH), 7.02-6.97 (dd, IH), 6.94-6.90 (m, 3H), 3.55 (m, 4H), 2.78 (m, 4H), 2.17 (s, 3H); MS (ESI) for C22H2,ClN6O: 421 (MH+).
[0481] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds ofthe invention were prepared:
[0482] 3 - {4- [4-(5-chloro-2-methylphenyl)piperazin- 1 -yl] - 1 H-pyrazolo [3 ,4- d]pyrimidin-3-yl}phenol hydrochloride: Η NMR (400 MHz, αVmethanol) δ 8.45 (s, IH), 7.39 (t, IH), 7.13 (dd, 2H), 7.07 (m, IH), 6.96 (m, 3H), 3.75 (m, 4H), 2.81 (m, 4H), 2.22 (s, 3H); MS (ESI) for C22H2ιClN6O: 421 (MH+).
[0483] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-{3-
[(phenylmethyl)oxy]phenyl} - 1 H-pyrazolo [3, 4-d]pyrimidine hydrochloride: Η NMR (400 MHz, t-methanol) δ 8.45 (s, IH), 7.52 (t, IH), 7.44 (d, IH), 7.36-7.21 (m, 6H), 7.14 (d, IH), 6.98 (dd, IH), 6.92 (d, IH), 5.20 (s, 2H), 3.77 (br s, 4H), 2.78 (m, 4H), 2.22 (s, 3H); MS (ESI) for C29H27ClN6O: 511 (MH+).
[0484] 3-(l,3-benzodioxol-5-yl)-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidine hydrochloride: Η NMR (400 MHz, d6-DMSO) δ 8.45 (s, IH), 7.26 (d, IH), 7.17 (d, 2H), 7.12 (d, IH), 02 (dd, IH), 6.94 (d, IH), 6.11 (s, 2H), 3.58 (m, 4H), 2.80 (m, 4H), 2.19 (s, 3H); MS (ESI) for C23H2ιClN602: 449 (MH+).
[0485] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(2-tlιienyl)-lH-pyrazolo[3,4- d]pyrimidine hydrochloride: Η NMR (400 MHz, d6-DMSO) δ 8.45 (s, IH), 7.68 (d, IH), 7.44 (d, IH), 7.26 (t, IH), 7.17 (d, IH), 7.01 (dd, IH), 6.97 (d, IH), 3.61 (m, 4H), 2.84 (m, 4H), 2.12 (s, 3H); MS (ESI) for C20Hι9ClN6S: 411 (MH+).
[0486] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}aniline hydrochloride: Η NMR (400 MHz, d -methanol) δ 8.96 (br s, 2H), 8.52 (s, IH), 7.52 (t, IH), 7.20 (d, IH), 7.12 (d, IH), 7.08 (d, IH), 7.02 (dd, IH), 6.97 (m, 2H), 3.88 (m, 4H), 2.83 (m, 4H), 2.22 (s, 3H); MS (ESI) for C22H22C1N7: 420 (MH+).
[0487] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}benzoic acid hydrochloride: Η NMR (400 MHz, d -methanol) δ 8.51 (s, IH), 8.37 (s, IH), 8.20 (d, IH), 7.99 (d, IH), 7.72 (t, IH), 7.11 (d, IH), 6.97-6.90 (m, 2H), 3.77 (m, 4H), 2.81 (m, 4H), 1.93 (s, 3H); MS (ESI) for C23H2,ClN6O2: 449 (MH+). [0488] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(4-methylphenyl)-lH- pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, α -methanol) δ 8.53 (s, IH), 7.56 (d, 2H), 7.45 (d, 2H), 7.12 (d, IH), 6.97 (dd, IH), 6.92 (d, IH), 3.89 (m, 4H), 2.81 (m, 4H), 2.22 (s, 6H); MS (ESI) for C22H23C1N6: 421 (MBft).
[0489] N-(4-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}phenyl)acetamide hydrochloride: 1H NMR (400 MHz, d -methanol) δ 8.52 (s, IH), 7.83 (d, 2H), 7.63 (d, 2H), 7.12 (d, IH), 6.96 (dd, IH), 6.93 (d, IH), 3.89 (m, 4H), 2.82 (m, 4H), 2.22 (s, 3H), 2.16 (s, 3H); MS (ESI) for C24H24ClN7O: 462 (MET*).
[0490] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3 { 4-[2-moφhholin-4- ylethyl)oxy]phenyl}-lH-pyrazolo[3,4-d] pyrimidine: 1H NMR (400 MHz, t-methanol) δ 8.47 (s, IH), 7.70 (s, IH), 7.68 (s, IH), 7.26 (s, IH), 7.24 (s, IH), 7.13 (d, IH), 6.97 (dd, IH), 6.94 (s, IH), 4.48 (t, 4H), 4.04 (s, 2H), 3.76 (s, 4H), 3.68 (t, 4H), 2.80 (s, 4H), 2.12 (s, 3H); MS (ESI) for C28H32ClN7O2 : 534 (MET*).
[0491] 3-[(4-[4-[4-(5-chloro-2-methylphenyl)ρiperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}phenyl)oxy]-NN-dimethylpropan-l-amine: 1HNMR (400 MHz, αV methanol) δ 8.48 (s, IH), 7.65 (s, IH), 7.63 (s, IH), 7.20 (s, IH), 7.18 (s, IH), 7.13 (d, IH), 6.97 (dd, IH), 6.93 (d, IH), 4.21 (t, 4H), 3.38 (t, 2H), 2.95 (s, 6H), 2.81 (s, 4H), 2.27 (m, 3H), 2.22 (s, 4H); MS (ESI) for C27H32ClN7O: 506 (MH*).
[0492] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(l,2,3,6-tetrahydropyridin-4- yl)-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d4-methanol) δ 8.42 (s, IH), 7.17 (d, IH), 7.00 (m, 2H), 6.23 (s, IH), 3.98 (s, 6H), 3.53 (t, 4H), 3.00 (t, 4H); MS (ESI) for C21H24C1N7: 411 (MH+).
[0493] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(piperidin-4-ylmethyl)-lH- pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, 04-methanol) δ 8.32 (s, IH), 7.09 (d, IH), 6.97-6.89 (m, 2H), 4.03 (br.s, 4H), 3.32-3.24 (m, 2H), 3.07-2.95 (m, 6H), 2.89 (t, 2H), 2.26 (s, 3H), 2.16-2.00 (m, IH), 1.83-1.68 (m, 2H), 1.46-1.30 (m, 2H), MS (ESI) for C22H28C1N7: 426(MH*).
[0494] 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-3-[4-(methyloxy)phenyl]-lH- pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, αVmethanol) δ 8.51 (s, IH), 7.60 (d, 2H), 7.17 (d, 2H), 7.12 (d, IH), 6.98-6.95 (d,d IH), 6.92 (s IH), 3.93-3.88 (m, 4H), 3.89 (s, 3H), 2.87-2.82 (m, 4H), 2.24 (s, 3H); MS (ESI) for C23H23C1 N6O: 435 (MH*). [0495] 4-[4-(5-Chloro-2-methylphenyl)piρerazin-l-yl]-3-(4-fluorophenyl)-lH- ρyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d -methanol) δ 8.54 (s, IH), 7.73 (m, 2H), 7.41-7.36 (m, 2H), 7.13 (d, IH), 6.98-6.95 (d,d IH), 6.92 (s IH), 3.93- 3.89 (m, 4H), 2.86-2.81 (m, 4H), 2.23 (s, 3H); MS (ESI) for C22H20C1 FN6: 423 (MET).
[0496] 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-3-[4-(phenyloxy)phenyl]-lH- ρyrazolo[3,4-d]pyrimidine hydrochloride: !H NMR (400 MHz, αVmethanol) δ 8.53 (s, IH), 7.65 (d, 2H), 7.38-7.35 (m, 2H), 7.20-7.14 (m, 4H), 7.06 (m, IH), 6.99 (d,d IH), 6.93 (s IH), 3.98-3.88 (m, 4H), 2.89-2.83 (m, 4H), 2.27 (s, 3H); MS (ESI) for C28H25C1 N6O: 497 (MH*).
[0497] 4- [4-(5 -Chloro-2-methylphenyl)piperazin- 1 -yl] -3- [ 4- [(piperidin-4- ylmethyl)oxy]phenyl}-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: H NMR (400 MHz, αVmethanol) δ 8.50 (s, IH), 7.63-7.60 (d, 2H), 7.18 (d, 2H), 7.13 (d, IH), 6.97 (d,d, IH), 6.92 (d, IH), 4.02 (d, 2H), 3.94-3.84 (m, 4H), 3.47-3.44 (d, 2H), 3.09-3.03 (t,d, 2H), 2.87- 2.80 (m, 4H), 2.24 (s, 3H), 2.23-2.18 (m, IH), 2.14-2.10 (d, 2H), 1.71-1.06 (q,d, 2H); MS (ESI) for C28H32C1 N7O: 518 (MH+).
[0498] 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-3-[2-(methyloxy)phenyl]-lH- pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, αVmethanol) δ 8.40 (s, IH), 7.53-7.48 (d, d, d, IH), 7.45-7.43 (d,d, IH), 7.14-7.10 (d, IH), 7.10-7.06 (t,d, IH), 7.01 (d,d, IH), 6.87-6.84 (d,d, IH), 6.80 (d, IH), 3.82-3.74 (m, 7H), 2.88-2.81 (m, 4H), 2.11 (s, 3H); MS (ESI) for C23H23C1 N6O: 435 (MH+).
[0499] 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-3-pyridin-4-yl-lH- pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.82 (b, 2H), 8.40 (s, IH), 8.26 (d, 2H), 7.01 (d, IH), 6.86-6.83 (m, 2H), 3.69-3.63 (m, 4H), 2.79- 2.74 (m, 4H), 2.14 (s, 3H); MS (ESI) for C21H20C1 N7: 406 (MH*).
[0500] 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-3-[3-(methyloxy)phenyl]-lH- pyrazolo[3,4-d]pyrimidine trifluoroacetate: Η NMR (400 MHz, d4-methanol) δ 8.53 (s, IH), 7.56-7.52 (t, IH), 7.24-7.17 (m, 3H), 7.13 (d,d IH), 6.99-6.96 (d,d, 2H), 6.93 (d, IH), 3.94-3.88 (m, 7H), 2.86-2.78 (m, 4H), 2.23 (s, 3H); MS (ESI) for C23H23C1 N6O: 435 (MET*).
[0501] 4-[4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}benzonitrile trifluoroacetate: 1H NMR (400 MHz, d -methanol) δ 8.53 (s, IH), 7.99-7.96 (d, 2H), 7.89 (d, 2H), 7.12 (d, IH), 6.98-6.93 (m, 2H), 3.88-3.81 (m, 4H), 2.87-2.82 (m, 4H), 2.24 (s, 3H); MS (ESI) for C23H20C1 N7O: 430 (MET*).
[0502] 4-[4-(5-Chloro-2-methylphenyl)piρerazin-l-yl]-3-(3-fluoropyridin-4-yl)-lH- pyrazolo[3,4-d]pyrimidine trifluoroacetate: !H NMR (400 MHz, άVmethanol) δ 8.63 (s, IH), 8.53 (d, IH), 8.37 (s, IH), 7.73 (t, IH), 7.03 (d, IH), 6.88-6.85 (d,d, IH), 6.83 (d, IH), 3.74-3.69 (m, 4H), 2.73-2.69 (m, 4H), 2.13 (s, 3H); MS (ESI) for C21H19C1F N7: 424 (MH*).
[0503] 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-3-(3-chloropyridin-4-yl)-lH- pyrazolo[3,4 d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.83 (s, IH), 8.70 (d, IH), 8.45 (s, IH), 7.75 (d, IH), 7.12 (d, IH), 6.98-6.95 (d,d, IH), 6.91 (d, IH), 3.78-3.71 (m, 4H), 2.80-2.74 (m, 4H), 2.22 (s, 3H); MS (ESI) for C21H19C12 N7: 440 (MH+).
[0504] EXAMPLE 12: 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidin-3-yl Jpropan- 1 -ol trifluroacetate
[0505] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidine (0.50 g, 1.2 mmol), p-toluenesulfonic acid monohydrate (0.49 g, 2.6 mmol), and dihydropyran (0.18 g, 2.1 mmol) in DMF (3 mL) was stirred at 90 °C for 15 h. The reaction mixture was cooled, diluted with ethyl acetate (30 mL), washed with saturated sodium bicarbonate, water, and brine (30 mL each), dried with sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 85:15 to 7:3) gave 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazolo[3,4-d]pyrimidine (0.30 g, 50% yield). 1H NMR (400 MHz, CDC13) δ 8.43 (s, IH), 7.13 (d, IH), 7.00 (m, 2H), 5.98 (d,d, IH), 4.14 (m, IH), 4.03-3.98 (m, 4H), 3.82-3.76 (m, IH), 3.07 (m, 4H), 2.60-2.51 (m, IH), 2.32 (s, 3H), 2.12 (m, IH), 1.95-1.92 (m, IH), 1.81-1.73 (m, 2H), 1.61 (m, IH); MS (ESI) for C2ιH24BrClN6O: 491 (MH*).
[0506] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidine (0.26g, 0.52 mmol), potassium phosphate (0.56 g, 2.6 mmol), tert-butyl acrylate (0.30 g, 2.3 mmol), and [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichlormethane (0.86g, 0.11 mmol) in DMF (3 mL) was degassed with nitrogen for 5 min, and then stirred at 90 °C for 15 h. The reaction mixture was cooled, diluted with ethyl acetate (30 mL), filtered through celite, and the filtrate was washed with water and brine (30 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 85:15 to 7:3) provided 1,1-dimethylethyl (2£)-3-[4-[4-(5-chloro-2- methylphenyl)piperazin- 1 -yl] - 1 -(tetrahydro-2H-pyran-2-yl)- lH-pyrazolo[3 ,4-d]pyrimidin- 3-yl]ρrop-2-enoate (0.13 g, 0.23 mmol, 43% yield). 1H NMR (400 MΗz, CDC13) δ 8.48 (s, 1Η), 7.75-7.71 (d, 1Η), 7.10 (d, 1Η), 6.97 (m, 2Η), 6.72 (d, 1H),6.04-6.01 (d,d, IH), 4.14-4.01 (m, IH), 3.96-3.92 (m, IH), 3.86-3.81 (m, 4H), 3.07-3.02 (m, 4H), 2.60-2.51 (m, IH), 2.29 (s, 3H), 2.12 (m, IH), 1.95-1.92 (m, IH), 1.81-1.73 (m, 2H), 1.53 (s, 9H),1.61 (m, IH); MS (ESI) for C28H35ClN6O3: 539 (MH*).
[0507] A solution of 1,1-dimethylethyl (2£)-3-[4-[4-(5-chloro-2- methylphenyl)piperazin-l-yl]-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-rf]pyrimidin- 3-yl]prop-2-enoate (20 mg, 0.037 mmol) in 4N hydrogen chloride in dioxane (1.0 mL) was stirred at 60 °C for 15 min. The reaction mixture was concentrated, and the residue partitioned between sodium bicarbonate and ethyl acetate. The organic layer was concentrated and the residue was purified by reverse phase ΗPLC to give 1,1- dimethylethyl (2E)-3-{ 4-[4-(5-chloro-2-methylphenyl)piperazin- 1 -yl] - lΗ-pyrazolo[3,4- d]pyrimidin-3-yl}prop-2-enoate trifluoroacetate (8.6 mg, 40% yield). 1H NMR (400 MHz, de-DMSO) δ 8.44 (s, IH), 7.69-7.65 (d, IH), 7.21 (d, IH), 7.05-7.02 (m, 2H), 6.57-6.63 (d, IH), 3.75-3.72 (m, 4H), 3.06-3.03 (m, 4H), 2.27 (s, 3H), 1.48 (s, 9H); MS (ESI) for C23H27ClN6O2: 455 (MH*).
[0508] A solution of 1,1-dimethylethyl (2£)-3-[4-[4-(5-chloro-2- methylphenyl)piperazin- 1 -yl]- 1 -(tetrahydro-2H-pyran-2-yl)- lH-pyrazolo[3,4-d]pyrimidin- 3-yl]prop-2-enoate (100 mg, 0.19 mmol) in trifluroacetic acid was stirred at room temperature for 1 h. The reaction mixture was concentrated and the residue was purified by reverse phase ΗPLC to yield (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]- lΗ-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoic acid trifluoroacetate (36 mg, 48% yield). 1H NMR (400 MHz, de-DMSO) δ 8.42 (s, IH), 7.72-7.68 (d, IH), 7.20 (d, IH), 7.02 (m, 2H), 6.57-6.63 (d, IH), 3.78-3.75 (m, 4H), 3.03-2.99 (m, 4H), 2.26 (s, 3H); MS (ESI) for Cι9H19ClN6O2: 399 (MH+).
[0509] Sodium borohydride (90 mg, 2.4 mmol) was added to a mixture of the 1,1- dimethylethyl (2£)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazolo[3,4-rf]pyrimidin-3-yl]prop-2-enoate (127 mg, 0.24 mmol) and cobalt(U) chloride (310 mg, 2.4 mmol) in methanol (5 mL), and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (5 mL), concentrated, and ethyl acetate (5 mL) was added. The organic layer was washed with water, and brine (5 mL each), dried over sodium sulfate, and concentrated. The residue was dissolved in trifluoroacetic acid and stirred at room temperature for 15 min. The solution was concentrated and the residue was purified by reverse phase HPLC to provide 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidin-3- yl}propanoic acid trifluroacetate (30 mg, 31% yield). 1H NMR (400 MHz, d6-DMSO) δ 8.41 (s, IH), 7.18 (d, IH), 7.05 (d, IH), 7.02-6.99 (d,d, IH), 4.24-4.21(m, 4H), 3.43-3.39 (t , 2H), 3.12-3.09 (m, 4H), 2.89-2.85 (t, IH), 2.37 (s, 3H); MS (ESI) for C19H21ClN6O2: 401 (MH*).
[0510] Sodium borohydride (14 mg, 0.37 mmol) was added to a mixture of the 1,1- dimethylethyl (2E)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazolo[3,4-< |pyrimidin-3-yl]prop-2-enoate (20 mg, 0.037 mmol) and cobalt(II) chloride (49mg, 0.37 mmol) in methanol (5 mL), and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (5 mL), concentrated, diluted with ethyl acetate (5 mL), washed with water and brine solution (5 mL each), dried over sodium sulfate, and concentrated. The residue was dissolved in TΗF (2 mL), and a solution of lithium aluminum hydride in TΗF (1.0 M, 37 uL, 0.037 mmol) was added. The resulting mixture was stirred at room temperature for 1 h, and then quenched with 2N aqueous sodium hydroxide (0.2 mL), diluted with ethyl ether (10 mL), and filtered through celite. The filtrate was washed with brine (2 mL), dried over sodium sulfate, and concentrated. The residue was dissolved in trifluoroacetic acid (1 mL), stirred at room temperature of 15 min, and then concentrated. The residue was purified by reverse phase ΗPLC to give 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lΗ- pyrazolo[3,4-d]pyrimidin-3-yl}propan-l-ol trifluroacetate (5.2 mg, 35% yield). !H NMR (400 MHz, de-DMSO) δ 8.33 (s, IH), 7.08-7.06 (d, IH), 6.94-6.93 (d, IH), 6.91-6.88 (d,d, IH), 4.16-416 (m, 4H), 3.54-3.51 (t, 2H), 3.16-3.12 (m, 2H), 3.01-2.98. (m, 4H), 2.89-2.85 (t, IH), 2.56 (s, 3H), 1.92-1.85 (m, 2H); MS (ESI) for C19H23ClN6O: 387 (MH*).
[0511] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:
[0512] methyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate: 1H NMR (400 MHz, de-DMSO) δ 8.42 (s, IH), 7.82-7.76 (d, IH), 7.20 (d, IH), 7.05-7.01 (m, 2H), 6.64 (d, IH), 3.78-3.74 (m, 7H), 3.03-2.99 (m, 4H), 2.27 (s, 3H); MS (ESI) for C2oH21ClNeO2: 413 (MH*). [0513] 3-{4-[4-(5-chloro-2-methylphenyl)piρerazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}-N,N-diethylpropan-l-amine trifluoroacetate: 1H NMR (400 MHz, d4- methanol) δ 8.37 (s, IH), 7.19 (d, IH), 7.06 (d, IH), 7.00 (dd, IH), 4.02 (m, 4H), 3.28- 3.18 (m, 8H), 3.07 (m, 4H), 2.35 (s, 3H), 2.27 (m, 2H), 1.32 (t, 6H); MS (ESI) for C23H31C1N7: 442 (MH*).
[0514] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(3-pyrrolidin-l-ylpropyl)-lH- pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, αVmethanol) δ 8.41 (s, IH), 7.19 (d, IH), 7.08-6.99 (m, 2H), 4.11 (br s, 4H), 3.68 (br s, 2H), 3.37 (m, IH), 3.27 (m, IH), 3.21 (t, 2H), 3.13-3.07 (m, 6H), 2.35 (s, 3H), 2.27 (m, 2H), 2.15 (br s, 2H), 2.02 (br s, 2H).
[0515] 3-(azetidin-3-ylidenemethyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]- lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d6-DMSO) δ 8.40 (s, IH), 7.23 (d, IH), 7.11-7.08 (m, IH), 7.05 (dd, IH), 6.67-6.63 (m, IH), 5.20-4.48 (m, 5H), 3.83 (br.m, 4H), 3.02 (br.m, 4H), 2.29 (s, 3H), MS (ESI) for C20H22C1N7: 396(Mir*).
[0516] Phenylmethyl (3aR,6aS)-5-({4-[4-(5-chloro-2-methylphenyl)ρiρerazin-l-yl]- lH-pyrazolo[3,4-d]pyrimidin-3-yl}methylidene)hexahydrocyclopenta[c]pyrrole-2(lH)- carboxylate trifluoroacetate: !H NMR (400 MHz, d4-methanol) δ 8.44 (s, IH), 7.27-7.12 (m, 6H), 7.00 (m, 2H), 5.19 (s, IH), 4.95-4.83 (br s, 2H), 4.22-4.10 (m, 4H), 3.88 (m, 2H), 3.68-3.63 (m, IH), 3.46-3.36 (m, 3H), 3.02-2.93 (m, 6H), 2.73-2.68 (d,d, IH), 2.33-2.31 (d, 3H), 2.20-2.16 (d,d, IH); MS (ESI) for C32H34C1 N7O2: 584 (MET*).
[0517] 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-3-[(E)-(3aR,6aS)-hexahydro- cyclopenta[c]pyrrol-5(lH)-ylidenemethyl]-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.42 (s, IH), 7.19 (d, IH), 7.05-7.00 (m, 2H), 5.27 (s, IH), 4.13-4.08 (m, 4H), 3.92 (m, 2H), 3.64-3.59 (m, IH), 3.48-3.42 (d,d, IH), 3.34 (m, IH), 3.16 (m, 2H), 3.07-3.03 (m, 5H), 2.78-2.71 (m, IH), 2.35 (s, 3H), 2.34 (m, IH); MS (ESI) for C24H28C1 N7: 450 (MET*).
[0518] EXAMPLE 13: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(3- pyrrolidin-l-ylprop-l-yn-l-yl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate
[0519] To a solution of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidine (150 mg, 0.305 mmol) in DMF (3 mL) and triethylamine (0.45 mL) was added (l,l-dimethylethyl)(dimethyl)(prop-2-yn- l-yloxy)silane (156 mg, 0.915 mmol), copper(I) iodide (17.5 mg, 0.092 mmol) and tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.036 mmol). The mixture was stirred in a sealed tube at 105 °C for 3 h, then cooled to room temperature and concentrated. Column chromatography on silica (hexanes:ethyl acetate 3:2) provided 4-[4-(5-chloro-2- methylρhenyl)piperazin-l-yl]-3-(3-{[(l,l-dimethylethyl)(dimethyl)silyl]oxy}prop-l-yn-l- yl)-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidine (164 mg, 93% yield) as an orange oil. 1H NMR (400 MHz, CDC13) δ 8.29(s, IH), 7.16 (s, IH), 7.01 (m, IH), 6.89-6.86 (m, 2H), 5.91 (dd, IH), 4.54 (s, 2H), 4.08 (m, 4H), 4.02 (m, IH), 3.69 (m, IH), 2.95 (m, 4H), 2.47 (m, IH), 2.22 (s, 3H), 2.03 (m, IH), 1.82 (m, IH), 1.67 (m, 2H), 1.51 (m, IH), 0.78 (s, 9H), 0.00 (s, 6H).
[0520] To a solution of 4-[4-(5-chloro-2-methylρhenyl)piperazin-l-yl]-3-(3-{[(l,l- dimethylethyl)(dimethyl)silyl] oxy }prop- 1 -yn- 1 -yl)- 1 -(tetrahydro-2H-pyran-2-yl)- 1H- pyrazolo[3,4-d]pyrimidine (164 mg, 0.28 mmol) in THF (2 mL) was added tetrabutyl- ammonium fluoride in THF (1.0 M, 340 μL, 0.34 mmol). The mixture was stirred at room temperature for 80 min, then diluted with ethyl acetate, washed with water, and brine, dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexane:ethyl acetate 1:1) afforded 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-l-ol (118 mg, 90% yield) as a colorless syrup. 1H NMR (400 MHz, CDC13) δ 8.41 (s, IH), 7.11 (d, IH), 6.99 (m, 2H), 6.01 (dd, IH), 4.54 (s, 2H), 4.16 (m, 4H), 4.09 (m, IH), 3.79 (m, IH), 3.03 (m, 4H), 2.71 (br s, IH), 2.53 (m, IH), 2.31 (s, 3H), 2.10 (m, IH), 1.93 (m, IH), 1.75 (m, 2H), 1.60 (m, IH).
[0521] To a solution of 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-l-ol (85 mg, 0.18 mmol) in dichloromethane (4 mL) was added triethylamine (38 μL, 0.27 mmol) and methanesulfonyl chloride (18 μL, 0.23 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature over 1 h before diluting with dichloromethane. The organic solution was washed with 10% citric acid followed by saturated sodium bicarbonate. The organic layer was dried over magnesium sulfate, and concentrated to give 3-[4-[4-(5- chloro-2-methylphenyl)piperazin- 1 -yl] - 1 -(tetrahydro-2H-pyran-2-yl)- 1 H-pyrazolo[3 ,4-d] - pyrimidin-3-yl]prop-2-yn-l-yl methanesulfonate (86.5 mg, 88% yield) as a white solid. !H NMR (400 MHz, CDC13) δ 8.40 (s, IH), 7.11 (m, IH), 6.98 (m, 2H), 6.02 (d, IH), 5.09 (s, 2H), 4.18 (m, 4H), 4.13 (m, IH), 3.79 (m, IH), 3.09 (s, 3H), 3.04 (m, 4H), 2.54 (m, IH), 2.33 (s, 3H), 2.13 (m, IH), 1.92 (m, IH), 1.77 (m, 2H), 1.63 (m, IH). [0522] To a solution of 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-l-yl methanesulfonate (43 mg, 0.08 mmol) in DMF (1 mL) was added pyrrolidine (33 μL, 0.4 mmol). The mixture was stirred for 1 h at room temperature, and then concentrated to provide 4- [4-(5-chloro-2-methylphenyl)piperazin- 1 -yl] -3-(3-pyrrolidin- 1 -ylprop- 1 -yn- 1 - yl)-l-(tetrahydro-2H-ρyran-2-yl)-lH-pyrazolo[3,4-d]ρyrimidine. 1H NMR (400 MHz, CDC13) δ 8.40 (s, IH), 7.13 (d, IH), 7.01 (d, IH), 6.98 (m, IH), 6.01 (dd, IH), 4.21 (m, 4H), 4.12 (m, IH), 3.80 (m, IH), 3.74 (s, 2H), 3.33 (m, 4H), 3.04 (m, 4H), 2.57 (m, IH), 2.32 (s, 3H), 2.13 (m, IH), 2.01 (m, 4H), 1.93 (m, IH), 1.77 (m, 2H), 1.61 (m, IH).
[0523] A solution of 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(3-pyrrolidin-l- ylprop- 1 -yn- 1 -yl)- 1 -(tetrahydro-2H-pyran-2-yl)- lH-pyrazolo[3,4-d]pyrimidine in methanol (2 mL) and 4M hydrochloric acid in dioxane (2 mL) was stirred at 60 °C for 30 min and then concentrated. Purification by reverse phase HPLC provided 4-[4-(5-chloro- 2-methylphenyl)piperazin-l-yl]-3-(3-pyrrolidin-l-ylprop-l-yn-l-yl)-lH-pyrazolo[3,4-d]- pyrimidine trifluoroacetate as a yellow syrup. !H NMR (400 MHz, αVmethanol) δ 8.39 (s, IH), 7.18 (d, IH), 7.07 (d, IH), 7.00 (dd, IH), 4.54 (s, 2H), 4.32 (m, 4H), 3.53 (br s, 4H), 3.11 (m, 4H), 2.37 (s, 3H), 2.16 (br s, 4H); MS (ESI) for C23H25C1N7: 436 (MH*).
[0524] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:
[0525] N-(3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}prop-2-yn-l-yl)acetamide: 1H NMR (400 MHz, d6-DMSO) δ 8.47 (t, IH), 8.34 (s, IH), 7.23 (d, IH), 7.10 (d, IH), 7.04 (dd, IH), 4.18 (d, 2H), 4.12 (br s, 4H), 3.04 (m, 4H), 2.31 (s, 3H), 1.77 (s, 3H); MS (ESI) for C21H22ClN7O: 424 (MH*).
[0526] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}-N,N-diethylprop-2-yn-l-amine trifluoroacetate: 1H NMR (400 MHz, de-DMSO) δ 9.97 (br s, IH), 8.34 (s, IH), 7.21 (d, IH), 7.05 (m, IH), 7.02 (d, IH), 4.54 (br s, 2H), 4.14 (m, 4H), 3.26 (m, 4H), 3.03 (m, 4H), 2.30 (s, 3H), 1.26 (t, 6H); MS (ESI) for C23H28C1N7: 438 (MH*).
[0527] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidin-3-yl}prop-2-yn-l-ol: 1H NMR (400 MHz, d6-DMSO) δ 8.31 (s, IH), 7.20 (d,lH), 7.05 (d, IH), 7.02 (dd, IH), 4.37 (s, 2H), 4.11 (m, 4H), 3.04 (m, 4H), 2.29 (s, 3H); MS (ESI) for C19H19ClN6O: 383 (MIT*). [0528] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-[3-(4-methylpiperazin-l- yl)prop-l-yn-l-yl]-lH-ρyrazolo[3,4-d]ρyrimidine trifluoroacetate: 1H NMR (400 MHz, dVmethanol) δ 8.47 (s, IH), 7.20 (d, IH), 7.08 (d, IH), 7.02 (dd, IH), 4.45 (m, 4H), 3.85 (s, 2H), 3.16 (m, 4H), 3.00 (br s, 8H), 2.89 (s, 3H), 2.37 (s, 3H); MS (ESI) for
Figure imgf000096_0001
[0529] EXAMPLE 14: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-piperazin-l- yl-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate
[0530] To 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin- 1 -yl]- 1 -(tetrahydro-2H- pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidine (50 mg, 0.11 mmol) in anhydrous toluene (0.4 mL) was added Pd2(dba)3 (10 mg, 0.011 mmol), 2-(di-t-butylphosphino-l, l'-binaphthyl (10 mg, 0.033mmol), sodium tert-butoxide (15 mg, 0.15mmol), and Boc-piperazine (25 mg, 0.13 mmol). The reaction mixture was stirred at 100 °C for 16 h under nitrogen, and then concentrated. Column chromatography on silica (hexanes:ethyl acetate 2:1) provided 1 , 1 -dimethylethyl 4- [4- [4-(5-chloro-2-methylphenyl)piperazin- 1 -yl] - 1 -(tetrahydro-2H- pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-3-yl]piperazine-l-carboxylate (14 mg, 21% yield). MS (ESI) for C30H41C1N8O3: 597 (MIT).
[0531] To 1,1-dimethylethyl 4-[4-[4-(5-chloro-2-methylphenyl)ρiperazin-l-yl]-l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-3-yl]piperazine-l-carboxylate (14 mg, 0.023 mmol) in methanol (1 mL) was added 4N hydrogen chloride in dioxane (0.1ml), and the mixture was refluxed for 2 min. Purification by reversed phase HPLC yielded 4-[4-(5-chloro-2-methylphenyl)piperazin- 1 -yl] -3-piperazin- 1 -yl- 1 H-pyrazolo [3,4- d]pyrimidine trifluoroacetate (6 mg, 49% yield) as a white solid. 1H NMR (400 MHz, άV methanol) δ 8.30 (s, IH), 7.17 (d, IH), 7.04-7.01 (m, IH), 6.99 (dd, IH), 4.16 (br s, 4H), 3.58-3.37 (m, 8H), 3.08-2.96 (m, 4H), 2.34 (s, 3H); MS (ESI) for C20H25C1N8: 413 (MH*).
[0532] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:
[0533] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(4-methylpiperazin-l-yl)-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d4-methanol) δ 8.29 (s, IH), 7.16 (d, IH), 7.03 (m, IH), 6.99 (dd, IH), 4.14 (br s, 4H), 3.90-3.79 (m, 2H), 3.65-3.53 (m, 2H), 3.45- 3.34 (m, 2H), 3.28-3.16 (m, 2H), 3.06-3.00 (m, 4H), 2.98 (s, 3H), 2.34 (s, 3H); MS (ESI) for C2ιH27ClN8: 427 (MH÷). [0534] EXAMPLE 15: 2-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-lH- pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-l-yl}phenyl)oxy]-N,N-diethylethanamine trifluoroacetate
[0535] A mixture of ethyl 2-cyano-4,4,4-trifluoro-3-oxobutanoate (18.2 g, 78 mmol, EP 1067121A2), tert-butylhydrazine hydrochloride (17.4g, 140 mmol), trifluoroacetic acid (12.3 mL, 160 mmol), molecular sieves (3A, 28 g) and dimethyl carbonate (165 mL) was stirred at 80 °C for 18 h. The reaction mixture was cooled, diluted with ethyl acetate (200 mL), and filtered. The filtrate was concentrated and ethyl acetate (200 mL) was added. The organic layer was washed with 5% bicarbonate, 5% sodium hydroxide, water and brine (100 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 95:5 to 4:1) gave ethyl 5-amino-l-(l,l-dimethyl- ethyl)-3-(trifluoromethyl)-lH-pyrazole-4-carboxylate (7.3g, 33% yield); MS (ESI) for CnH16F3N3O: 280 (MET*).
[0536] A mixture of ethyl 5-amino-l-(l,l-dimethylethyl)-3-(trifluoromethyl)-lH- pyrazole-4-carboxylate (16.0, 57 mmol) and ammonium carbonate (5.4g, 69 mmol) in formamide (48 mL) was stirred at 170 °C for 3 d. The reaction mixture was cooled, diluted with ethyl acetate (200 mL), washed with water and brine (200 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes :ethyl acetate 65:35 to 3:1) provided l-(l,l-dimethylethyl)-3-(trifluoromethyl)-lH-pyrazolo[3,4- ^pyrimidin-4-ol (7.3g, 52% yield); MS (ESI) for Cι0ΗnF3N4O2: 261 (MH+).
[0537] DMF (3.0 mL, 38 mmol) was added drop wise to a mixture of 4- hydroxypyrazolopyrimidine (5.0, 19 mmol) and thionyl chloride (50 mL). The resulting mixture was stirred at 75 °C for 2 h. The reaction mixture was cooled, concentrated, and partitioned between aqueous sodium bicarbonate (100 mL) and ethyl acetate (100 mL). The organic layer was washed with water and brine (100 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 95:5) afforded 4-chloro- 1 -( 1 , 1 -dimethylethyl)-3 -(trifluoromethyl)- 1 H-pyrazolo[3 ,4- ]pyrimidine (5.0g, 95% yield); !Η NMR (400 MHz, CDC13) δ 8.80 (s, IH), 1.85 (m, 9H); MS (ESI) for C10H10C1F3N4: 279 (MIT*).
[0538] A mixture of 4-chloro-l-(l,l-dimethylethyl)-3-(trifluoromefhyl)-lH- pyrazolo[3,4-rf]pyrimidine (85 mg, 0.31 mmol), 2-[(5-chloro-2-methyl-3-piperazin-l- ylphenyl)oxy]-N,N-diethylethanamine (200mg, 0.61 mmol), and triethylamine (0.21 mL, 1.5 mmol), in dioxane (5 mL) was stirred at 75 °C for 18 h. The reaction mixture was cooled, diluted with ethyl acetate (50 mL), washed with water and brine (30 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane: methanohammonia 95:4:1) gave 2-[(5-chloro-3-{4-[l-(l,l- dimethylemyl)-3-( fluoromethyl)-lH-pyrazolo[3,4-6πpyrimidin-4-yl]piperazin-l-yl}-2- methylphenyl)oxy]-N,N-diethylethanamine (105 mg, 61% yield). 1H ΝMR (400 MΗz, d4- methanol) δ 8.42 (s, 1Η), 6.83 (s, 1Η), 6.79 (s, 1Η), 4.36-4.33 (t, 2Η), 3.92-3.89 (m, 4H), 3.68-3.66 (t, 2H), 3.41-3.37 (q,d, 4H), 3.01-2.98 (t, 4H), 2.24 (s, 3H), 1.81 (m, 9H), 1.42- 1.38 (t, 6H); MS (ESI) for C27H37ClF3Ν7O: 568 (MH*).
[0539] A mixture of 2-[(5-chloro-3-[4-[l-(l,l-dimethylethyl)-3-(trifluoromethyl)-lH- pyrazolo[3,4- ]pyrimidin-4-yl]piperazin-l-yl}-2-methylphenyl)oxy]-N,N- diethylethanamine (105 mg, 0.19 mmol) and methanesulfonic acid (1.0 mL) was stirred at 55 °C for 2 h, then poured into ice (10 g), and basified with solid sodium bicarbonate to pΗ 8. The aqueous layer was extracted with ethyl acetate (3x10 mL). The organic layer was washed with water and brine (20 mL each), dried over sodium sulfate, and concentrated. The residue was purified by reverse phase ΗPLC to give 2-[(5-chloro-2-methyl-3-{4-[3- (trifluoromethyl)-lΗ-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-l-yl}phenyl)oxy]-Ν,Ν- diethylethanamine trifluoroacetate (85 mg, 74% yield). 1H NMR (400 MHz, αVmethanol) δ 8.40 (s, IH), 6.74 (s, IH), 6.71 (s, IH), 4.11-4.09 (t, 2H), 3.96-3.93 (m, 4H), 3.03-2.99 (m, 6H), 2.79-2.74 (q, 4H), 2.02 (s, 3H), 1.17-1.14 (t, 6H); MS (ESI) for C23H29C1 F3N7O: 512 (MH*).
[0540] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0541] 4-(4-{5-Chloro-2-methyl-3-[(2-pyrrolidin-l-ylethyl)oxy]phenyl}piperazin-l- yl)-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.42 (s, IH), 6.83 (s, IH), 6.79 (s, IH), 4.34-4.32 (t, 2H), 3.97-3.93 (m, 4H), 3.69-3.66 (m, 2H), 3.72-3.70 (t, 2H), 3.26-3.23 (m, 2H), 3.02-2.99 (t, 4H), 2.26 (s, 3H), 2.23-2.19 (m, 2H), 2.09-2.05 (m, 2H); MS (ESI) for C23H27ClF3N7O: 510 (MET*).
[0542] 4-(4-{5-Chloro-2-methyl-3-[(3-moφholin-4-ylpropyl)oxy]phenyl}piperazin-l- yl)-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, άVmethanol) δ 8.32 (s, IH), 6.67 (s, IH), 6.64 (s, IH), 4.03-4.00 (t, 4H), 3.89-3.85 (m, 4H), 3.70-3.64 (t, 2H), 3.50-3.47 (d, 2H), 3.33-3.29 (d,d, 2H), 3.16-3.11 (t, d, 2H), 2.91-2.89 (t, 4H), 2.22-2.17 (m, 2H), 2.12 (s, 3H); MS (ESI) for C24H29C1 F3N7O2: 540 (MH*).
[0543] 4-(4-{5-Chloro-2-methyl-3-[(2-moφholin-4-ylethyl)oxy]phenyl}piperazin-l- yl)-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: *H NMR (400 MHz, αVmethanol) δ 8.41 (s, IH), 6.83 (s, IH), 6.79 (s, IH), 4.39 (t, 2H), 4.10-4.07 (m, 2H), 3.97-3.93 (m, 4H), 3.88 (m, 2H), 3.69 (t, 2H), 3.64-3.61 (m, 2H), 3.36-3.33 (m, 2H), 3.25 (m, 2H), 3.01-2.99 (t, d, 4H), 2.24 (s, 3H); MS (ESI) for C23H27C1 F3N7O2: 526 (MH*).
[0544] 4-(4-{5-Chloro-2-methyl-3-[(2-piperidin-l-ylethyl)oxy]phenyl}piperazin-l- yl)-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, t-methanol) δ 8.51 (s, IH), 6.85 (s, IH), 6.80 (s, IH), 4.39-4.37 (t, 2H), 4.11-4.07 (m, 4H), 3.68-3.60 (m, 4H), 3.17-3.12 (t,d, 2H), 3.07-3.05 (t, 4H), 2.26 (s, 3H), 2.01-1.97 (m, 2H), 1.87-1.81 (m, 3H), 1.60-1.56 (m, IH); MS (ESI) for C24H29C1 F3N7O: 524 (MH*).
[0545] 4-(4-{5-Chloro-2-methyl-3-[(3-pyrrolidin-l-ylpropyl)oxy]phenyl}piperazin-l- yl)-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: H NMR (400 MHz, d4-methanol) δ 8,41 (s, IH), 6.76 (s, IH), 6.73 (s, IH), 4.12-4.09 (t, 2H), 3.98-3.94 (m, 4H), 3.76-3.70 (m, 2H), 3.46-3.42 (d,d, 2H), 3.18-3.13 (m, 2H), 3.02-2.99 (t, 4H), 2.29-2.19 (m, 7H), 2.09-2.04 (m, 2H); MS (ESI) for C24H29ClF3N7O: 524 (MET*).
[0546] 4-(4-{5-Chloro-2-methyl-3-[(3-piperidin-l-ylpropyl)oxy]phenyl}piperazin-l- yl)-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.41 (s, IH), 6.76 (s, IH), 6.73 (s, IH), 4.12-4.09 (t, 2H), 3.98-3.94 (m, 4H), 3.63-3.60 (m, 2H), 3.02-2.98 (m, 6H), 2.31-2.25 (m, 2H), 2.29-2.19 (s, 3H), 2.02- 1.96 (m, 2H), 1.90-1.70 (m, 4H), 1.58-1.50 (m, 2H); MS (ESI) for C25H31C1 F3N7O: 538 (MIT).
[0547] 4-[4-(5-Chloro-2-methyl-3-{ [3-(4-methylpiperazin-l- yl)propyl]oxy}phenyl)piperazin-l-yl]-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, d4-methanol) δ 8.41 (s, IH), 6.74(s, IH), 6.71 (s, IH), 4.11-4.08 (t, 2H), 3.98-3.94 (m, 4H), 3.52-3.36 (m, 8H), 3.26-3.22 (d,d, 2H), 3.01- 2.99 (m, 4H), 2.95 (s, 3H), 2.26-2.20 (m, 5H); MS (ESI) for C25H32ClF3N8O: 553 (MIT).
[0548] 4-[4-(5-Chloro-3-{[3-(4-ethylpiperazin-l-yl)propyl]oxy}-2- methylphenyl)piperazin-l-yl]-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.41 (s, IH), 6.74(s, IH), 6.71 (s, IH), 4.11-4.08 (t, 2H), 3.98-3.94 (m, 4H), 3.52-3.36 (m, 8H), 3.26-3.21 (t, 2H), 3.19-3.17 (d,d, 2H), 3.02-2.99 (m, 4H), 2.22 (m, 5H), 1.39-1.35 (t, 3H); MS (ESI) for C26H34C1 F3N8O: 567 (MH*).
[0549] N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidin- 4-yl]piperazin-l-yl}phenyl)-N,N-dimethylethane-l,2-diamine hydrochloride: 1H NMR (400 MHz, αVmethanol) δ 8.50 (s, IH), 6.58-6.53 (m, 2H), 4.36-3.79 (br m, 4H), 3.58 (t, 2H), 3.40 (t, 2H), 3.09-2.98 (m, 4H), 2.96 (s, 6H), 2.22 (s, 3H); MS (ESI) for C21H26C1F3N8: 483(MH*).
[0550] 3-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidin- 4-yl]piperazin-l-yl}phenyl)oxy]-N,N-diethylpropan-l-amine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.40 (s, IH), 6.69 (d, IH), 6.65 (d, IH), 4.04-3.95 (m, 6H), 3.29 (m, 2H), 2.95 (t, 4H), 2.16 (m, 2H), 2.13 (s, 3H), 1.27 (t, 6H); MS (ESI) for C24H3ιClF3N7O: 526(MH*).
[0551] 4-[4-(5-chloro-2-methyl-3-{ [2-(4-methylpiperazin-l- yl)ethyl]oxy}phenyl)piperazin-l-yl]-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.55 (s, IH), 6.86 (m, IH), 6.81 (m, IH), 4.52-4.45 (m, 2H), 4.24-4.14 (m, 4H), 4.09-3.60 (m, 10H), 3.15-3.08 (m, AW), 3.05 (s, 3H), 2.30 (s, 3H); MS (ESI) for C24H30C1F3 N8O: 539(MH*).
[0552] 4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-l-yl)ethyl]oxy}-2- methylphenyl)piperazin-l-yl]-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.57 (s, IH), 6.88 (br s, IH), 6.81 (br s, IH), 4.55-4.42 (m, 2H), 4.26-4.12 (br s, 4H), 4.11-3.49 (m, 10H), 3.37 (q, 2H), 3.17- 3.04 (m, 4H), 2.29 (s, 3H), 1.43 (t, 3H); MS (ESI) for C25H32C1F3 N8O: 553(MH*).
[0553] 3-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidin- 4-yl]piperazin-l-yl}phenyl)-N,N-diethylpropan-l-amine trifluoroacetate: !H NMR (400 MHz, d4-methanol) δ 8.42 (s, IH), 7.02 (br s, IH), 6.97 (br s, IH), 4.09-3.84 (m, 4H), 3.28-3.15 (m, 6H), 3.02-2.94 (m, 4H), 2.73 (t, 2H), 2.35 (s, 3H), 2.02-1.89 (m, 2H), 1.30 (t, 6H); MS (ESI) for C24H3ιClF3 N7: 510(MH+).
[0554] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(trifluoromethyl)-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR(400 MHz, d4-methanol) δ 8.30 (s, IH), 7.06 (d, IH), 6.91 (d, IH), 6.88 (d, IH), 6.86 (d, IH), 3.86 (t, 4H), 2.92 (t, 4H), 2.24 (s, 3H); MS (ESI) for C17H16C1F3N6: 399 (MET).
[0555] 4-[4-(5-chloro-2-methyl-3-{ [(l-methylpiperidin-4- yl)methyl]oxy}phenyl)piperazin-l-yl]-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d4-methanol) δ 8.42 (s, IH), 6.74 (d, IH), 6.72 (d, IH), 3.98 (br s, 4H), 3.92 (d, 2H), 3.60 (d, 2H), 3.08 (m, 2H), 3.01 (m, 4H), 2.90 (s, 3H), 2.22 (s, 3H), 2.17 (m, 3H), 1.72 (m, 2H); MS (ESI) for C^H^ClFaN,©: 524 (MH*).
[0556] 4-[4-(5-chloro-2-methyl-3-{ [2-(l-methylρiperidin-4- yl)ethyl] oxy }phenyl)piperazin- 1 -yl] -3-(trifluoromethyl)- lH-pyrazolo[3 ,4-d]pyrimidine : 1H NMR (400 MHz, d4-methanol) δ 8.43 (s, IH), 6.74 (d, IH), 6.70 (d, 2H), 4.06 (t, 2H), 3.99 (br s, 4H), 3.52 (m, 2H), 3.05-2.98 (m, 6H), 2.87 (s, 3H), 2.21 (s, 3H), 2.11 (m, 2H), 1.91-1.82 (m, 3H), 1.52 (m, 2H); MS (ESI) for C25H3ιCl F3N7O: 538 (MH*).
[0557] N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidin- 4-yl]piperazin-l-yl}phenyl)-N,N-diethylethane-l,2-diamine hydrochloride: H NMR (400 MHz, cVmethanol) δ 8.57 (s, IH), 6.60 (s, IH), 6.58 (s,lH), 4.28-4.14 (br s, 4H), 3.63- 3.58 (m, 2H), 3.42-3.38 (m, 2H), 3.36-3.30 (m, 4H), 3.15-3.09 (br s, 4H), 2.24-2.22 (s, 3H), 1.37-1.32 (m, 6H); MS (ESI) for C25H32C1F3N6: 510 (MH*).
[0558] 5-chloro-2-methyl-N-(2-pyrrolidin- 1 -ylethyl)-3- { 4-[3-(trifluoromethyl)- 1H- pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-l-yl}aniline: !H NMR (400 MHz, d4-methanol) δ 8.58 (s, IH), 6.58 (s, 2H), 6.58 (s, IH), 4.28-4.14 (br s, 4H), 3.77-3.70 (m, 2H), 3.61- 3.56 (m, 2H), 3.48-3.44 (m, 2H), 3.19-3.09 (m, 6H), 2.25-2.23 (s, 3H), 2.19-2.13 (m, 2H), 2.09-2.01 (m, 2H); MS (ESI) for C23H28C1F3N8: 509 (MH*).
[0559] 4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-l-ylpropyl)phenyl]piperazin-l-yl}-3- (trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride: !H NMR (400 MHz, d - methanol) δ 8.51 (s, IH), 7.03 (s, IH), 6.99 (s, IH), 4.15-4.07 (br s, 4H), 3.69-3.62 (m, 2H), 3.28-3.23 (m, 2H), 3.13-3.02 (m, 6H), 2.77-2.17 (m, 2H), 2.37-2.35 (s, 3H), 2.19- 2.12 (m, 4H), 2.04-1.96 (m, 4H); MS (ESI) for C24H29C1F3N7: 508 (MH*).
[0560] 4-(4-{ 5-chloro-2-methyl-3-[3-(4-methylpiperazin-l- yl)propyl]phenyl}piperazin-l-yl)-3-(trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C24H29C1F3N7: 538 (MH*).
[0561] 4-{4-[5-chloro-2-methyl-3-(3-piperidin-l-ylpropyl)phenyl]piperazin-l-yl}-3- (trifluoromethyl)-lH-pyrazolo[3,4-d]pyrimidine trifluoroacetate: 1H NMR (400 MHz, άV methanol) δ 8.41 (s, IH), 7.01 (s, IH), 6.97 (s,lH), 4.04-3.91 (br s, 4H), 3.58-3.53 (m, 2H), 3.18-3.13 (m, 2H), 3.02-2.98 (m, 4H), 2.97-2.89 (m, 2H), 2.76-2.70 (m, 2H), 2.37- 2.35 (s, 3H), 2.04-1.94 (m, 4H), 1.89-1.82 (m, 2H), 1.80-1.67 (m, 2H); MS (ESI) for C25H31C1F3N7: 523 (MIT*).
[0562] EXAMPLE 16: 4-[4-(5-Chloro-2-methylphenyl)piperazin-l-yl]-6-methyl-lH- pyrazolo[3,4-d]pyrimidine
[0563] 3-Amino-4-pyrazolecarboxamide hemisulfate salt (250 mg, 1.4 mmol.) was taken into 1:1 polyphosphoric acid and glacial acetic acid (2 mL) and the mixture was heated at 120 °C over six hours. The mixture was cooled to room temperature then taken into water (10 mL) and the pΗ adjusted to approximately 5 by dropwise addition of 50% aqueous sodium hydroxide. The resulting white precipitate was collected by filtration and washed with additional water. The solid was then suspended in methanol and collected by filtration then washed with ethyl ether. Drying in vacuo afforded 6-methyl-l,5-dihydro- pyrazolo[3,4-d]pyrimidin-4-one (154 mg) as a colorless solid. 1H-NMR (400MΗz, de- DMSO): 13.55 (s, IH), 11.95 (s, IH), 8.03 (s, IH), 2.34 (s, 3H).
[0564] 6-Methyl-l,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one (134 mg, 0.89 mmol.) was taken into thionyl chloride (3 mL) followed by addition of DMF (0.2 mL) and the mixture was brought to reflux over 30 minutes. The resulting solution was concentrated and the residue partitioned with ethyl acetate and saturated aqueous sodium bicarbonate. The organic phase was washed with brine then dried over anhydrous sodium sulfate, filtered and concentrated to afford a yellow oil. The oil was taken into THF (3 mL) followed by addition of l-(5-Chloro-2-mefhylphenyl)-piperazine (390 mg, 1.87 mmol.) and catalytic DMAP then the mixture was brought to reflux over one hour. The resulting suspension was filtered and the filtrate was then concentrated. The residue was then suspended in methanol, filtered again and the resulting methanolic solution purified by preparative reverse phase HPLC. The pure fraction were combined and lyophilized to give 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-6-methyl-lH-pyrazolo[3,4- d]pyrimidine (10.7 mg) as a colorless solid. MS (ESI) for Cι7Η19ClN6: 343 (MET*).
[0565] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0566] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-6-ethyl-lH-pyrazolo[3,4- d]pyrimidine: MS (ESI) for C18H21C1N6: 357 (MH*). [0567] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-6-(l-methylethyl)-lH- pyrazolo[3,4-d]pyrimidine: MS (ESI) for C19H23C1N6: 371 (MH*).
[0568] 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-methyl-6-phenyl-lH- pyrazolo[3,4-d]pyrimidine: !H NMR (400 MHz, de-DMSO) δ 8.41 (m, 2H), 7.52 (m, 3H), 7.23 (d, IH), 7.10 (d, IH), 7.05 (dd, IH), 4.01 (br s, 4H), 3.08 (m, 4H), 2.62 (s, 3H), 2.32 (s, 3H); MS (ESI) for C23H23C1N6: 419 (MH*).
[0569] EXAMPLE 17: l-(3-chlorophenyl)-l,4-diazepane
[0570] A mixture of l-chloro-3-iodobenzene (240 mg, 1 mmol), homopiperazine (600 mg, 6 mmol), sodium tert-butoxide (135 mg, 1.4 mmol), Pd2(dba)3 (23 mg, 0.025 mmol), and XANTPHOS (29 mg, 0.05 mmol) in dioxane (3 mL) was heated to 60 °C for 6 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. Concentration in vacuo and column chromatography of the residue (dichloromethane methanol 8:2 to 7:3) gave l-(3-chlorophenyl)-l,4- diazepane (46 mg, 22% yield) as a yellow-brown film. 1H NMR (400 MHz, CDC13) δ 7.11 (t, IH), 6.64 (m, 2H), 6.56 (m, IH), 3.61 (m, 2H), 3.56 (m, 2H), 3.10 (m, 2H), 2.93 (m, 2H), 2.89 (br s, IH), 2.04-1.98 (m, 2H).
[0571] EXAMPLE 18: 2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane
[0572] A mixture of 3-bromo-l-chlorobenzene (191 mg, 1.0 mmol), 2,5- diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (240 mg, 1.2 mmol), sodium tert-butoxide (135 mg, 1.4 mmol), Pd2(dba)3 (27 mg, 0.03 mmol), and BINAP (56 mg, 0.09 mmol) in toluene (3 mL) was heated to 110 °C for 15 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. The solvents were removed in vacuo. Column chromatography on silica (hexanes:ethyl acetate 4:1) of the residue afforded 5-(3-chlorophenyl)-2,5- diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (240 mg, 78% yield) as a yellow solid. 1H NMR (400 MHz, CDC13, mixture of rotamers) δ 7.10 (q, IH), 6.65 (d, IH), 6.50 (m, IH), 6.40 (d, IH), 4.62 (s, 0.5H), 4.48 (s, 0.5H), 3.53 (m, IH), 3.47-3.67 (m, 2H), 3.20-3.08 (dd, IH), 1.98-1.91 (m, 2H), 1.45 (s, 4.5H), 1.41(s, 4.5H).
[0573] To 5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert- butyl ester (240 mg, 0.78 mmol) was added 4N HCI in dioxane (3 mL). The mixture was heated with a heat gun for two minutes, cooled to room temperature, and concentrated to provide 2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane hydrochloride as a yellow solid, which was used without further purification. !H NMR (400 MHz, df-methanol) δ 7.18 (t, IH), 6.69 (m, 2H), 6.60 (m, IH), 4.66 (s, IH), 4.50 (s, IH), 3.71 (m, 2H), 3.40- 3.33 (m, 2H), 2.27 (d, IH), 2.10 (d, IH).
[0574] EXAMPLE 19: 4-[2-(2-chloro-4-piperazin-l-ylphenoxy)ethyl]moφholine hydrochloride
[0575] A mixture of 4-bromo-2-chlorophenol (5.0 g, 24 mmol), cesium carbonate (15.7 g, 48 mmol), and benzyl bromide in DMF (50 mL) was stirred at room temperature for 30 min. Water was added and the resulting mixture was extracted with ether. The organic layer was washed with water and brine, dried over magnesium sulfate, and concentrated. The residue was triturated with hexanes to provide l-benzyloxy-4-bromo-2- chlorobenzene (5.91 g, 83% yield) as a white solid. JH NMR (400 MHz, CDC13) δ 7.52 (d, IH), 7.45-7.27 (m, 6H), 6.84-6.82 (d, IH), 5.14 (s, 2H).
[0576] A mixture of l-benzyloxy-4-bromo-2-chlorobenzene (300 mg, 1 mmol), piperazine (517 mg, 6 mmol), sodium tert-butoxide (135 mg, 1.4 mmol), Pd2(dba)3 (23 mg, 0.025 mmol), and BINAP (62 mg, 0.1 mmol) in toluene (3 mL) was heated to 110 °C for 14 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. The filtrate was concentrated. Column chromatography of the residue (dichloromethane methanol 4:1) afforded l-(4-benzyloxy- 3-chlorophenyl)piperazine (147 mg, 48% yield) as a yellow film. 1H NMR (400 MHz, CDC13) δ 7.45 (m, 2H), 7.40-7.35 (m, 2H), 7.30 (m, IH), 6.98 (d, IH), 6.88 (d, IH), 6.73 (dd, IH), 5.08 (s, 2H), 3.03-2.98 (m, 8H), 1.73 (br s, IH).
[0577] A mixture of l-(4-benzyloxy-3-chlorophenyl)piperazine (147 mg, 0.48 mmol) in trifluoroacetic acid (1 mL) was stirred at 65 °C for 2 h, and then concentrated. The residue was dissolved in ethyl acetate, and washed with saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, and concentrated to give 2-chloro-4-piperazin-l-yl-phenol as a brown sticky film, which was used without further purification. 1H NMR (400 MHz, αVmethanol) δ 7.12 (m, IH), 6.86 (m, 2H), 3.34 (m, 4H), 3.25 (m, 4H).
[0578] A solution of 2-chloro-4-piperazin-l-yl-phenol (0.47 mmol) and Boc- anhydride (110 mg, 0.5 mmol) in THF (5 mL) was stirred at room temperature for 3 d. Concentration and column chromatography on silica (hexanes:ethyl acetate 3:2) provided 1,1-dimethylethyl 4-(3-chloro-4-hydroxyphenyl)-piperazine-l-carboxylate (112 mg, 75% yield) as a yellow sticky film. 1H NMR (400 MHz, αVmethanol) δ 6.95 (m, IH), 6.85- 6.79 (m, 2H), 3.53 (m, 4H), 2.97-2.94 (m, 4H), 1.47 (S, 9H). To a mixture of 1,1-dimethylethyl 4-(3-chloro-4-hydroxyphenyl)-piperazine-l- carboxylate (56 mg, 0.18 mmol) and cesium carbonate (176 mg, 0.54 mmol) in DMF (1.8 mL) was added N-(2-chloroethyl)-moφholine hydrochloride (67 mg, 0.36 mmol). The suspension was stirred at 60 °C for 4 h, and then cooled to room temperature. Water and ethyl acetate were added, and the layers were separated. The organic phase was washed with brine, dried over magnesium sulfate, and concentrated to provide 1,1-dimethylethyl 4- [3 -chloro-4-(2-moφholin-4-yl-ethoxy)phenyl]piperazine-l -carboxylate (68 mg, 89% yield) as an orange oil. 1H ΝMR (400 MHz, CDC13) δ 6.97 (d, IH), 6.88 (d, IH), 6.78 (dd, IH), 4.12 (t, 2H), 3.73 (m, 4H), 3.56 (m, 4H), 3.01 (m, 4H), 2.86 (t, 2H), 2.63 (m, 4H), 1.48 (s, 9H).
[0579] A solution of 1,1-dimethylethyl 4-[3-chloro-4-(2-moφholin-4-yl- ethoxy)phenyl]piperazine-l -carboxylate (68 mg, 0.16 mmol) in 4Ν hydrochloric acid in dioxane was refluxed for 2 min, and then concentrated to give 4-[2-(2-chloro-4-piperazin- l-ylphenoxy)ethyl]moφholine hydrochloride as a yellow film. !H NMR (400 MHz, d4- methanol) δ 7.38 (m, IH), 7.22 (m, 2H), 4.50 (m, 2H), 4.08 (m, 2H), 3.92-3.85 (m, 2H), 3.72-3.66 (m, 4H), 3.55-3.49 (m, 8H), 3.42-3.35 (m, 2H).
[0580] EXAMPLE 20: 1,1-dimethylethyl 4-(3-chlorophenyl)-3-{[(2-moφholin-4- ylethyl)amino]carbonyl }piperazine- 1 -carboxylate
[0581] To l-(l,l-dimethylethyl) 3-methyl piperazine-l,3-dicarboxylate (l.OOg, 4.09 mmol) in dry toluene (15 mL) was added 3-bromo-chlorobenzene (653 mg, 3.41 mmol), Pd2(dba)3 (93.0 mg, 0.102 mmol), BINAP (191 mg, 0.307 mmol), and cesium carbonate (1.11 g, 4.77 mmol). The reaction mixture was stirred at 100 °C for 42 h, then cooled to room temperature and filtered through celite. The filter cake was washed with ethanol, and the filtrate was concentrated. Column chromatography on silica (hexanes: ethyl acetate 3:1) provided l-( 1,1-dimethylethyl) 3-methyl 4-(3-chlorophenyl)piperazine-l,3- dicarboxylate (310 mg, 21% yield) as a colorless oil. 1H NMR (400 MHz, CDC13) δ 7.20- 7.13 (t, IH), 6.84-6.79 (m, 2H), 6.73-6.78 (d, IH), 4.63-4.50 (br s, IH), 4.41-4.32 (br s, IH), 4.24-4.02 (br s, 2H), 3.71-3.65 (s, 3H), 3.55-3.46 (br s, IH), 3.42-3.26 (br s, IH), 3.16-2.97 (br s, IH), 1.49-1.42 (s, 9H); MS (ESI) for C17H23ClN2O4: 355 (MH*). [0582] To l-(l,l-dimethylethyl) 3-methyl 4-(3-chlorophenyl)piperazine-l,3- dicarboxylate (184 mg, 0.519 mmol) in methanol (6 mL) was added IM potassium hydroxide (3 mL). The reaction mixture was stirred at 50 °C for 5 h. The pH was adjusted to 5, and the mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated to provide l-(3-chlorophenyl)-4-{[(l,l- dimethylethyl)oxy]carbonyl}piperazine-2-carboxylic acid (159 mg, 76% yield) as a colorless oil. MS (ESI) for C16H21ClN2O4: 341 (MH*).
[0583] To l-(3-chlorophenyl)-4-{ [(l,l-dimethylethyl)oxy]carbonyl}piperazine-2- carboxylic acid (67 mg, 0.291 mmol) in DMF (4 mL) was added 2-moφholin-4-yl- ethylamine (379 mg, 2.91 mmol), HATU (111 mg, 0.291 mmol), HOAt (48 mg, 0.349 mmol), and N-methyl moφholine (0.170 ml, 1.45 mmol). The reaction mixture was stirred at 25 °C for 21 h. Water and saturated sodium bicarbonate were added, and the solution was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. The residue was suspended in acetonitrile and filtered. The filtrate was concentrated to provide 1,1-dimethylethyl 4-(3-chlorophenyl)-3- {[(2-moφholin-4-ylethyl)amino]carbonyl}piperazine-l-carboxylate (81 mg, 62% yield) as a colorless oil. MS (ESI) for C22H33ClN4O4: 453 (MH+).
[0584] To 1,1-dimethylethyl 4-(3-chlorophenyl)-3-{[(2-moφholin-4- ylethyl)amino]carbonyl}piperazine-l-carboxylate (81 mg, 0.18 mmol) in methanol (5 mL) was added 4N hydrochloric acid in dioxane (0.1 mL). The reaction mixture was refluxed for 2 min, and then concentrated to provide l-(3-chlorophenyl)-N-(2-moφholin-4- ylethyl)piperazine-2-carboxamide hydrochloride (69 mg, 100% yield) as a colorless oil. MS (ESI) for C17H25ClΝ4O2: 353 (MH*).
[0585] Using the same or analogous synthetic techniques and/or substitution with alternative reagents, the following compounds of the invention were prepared:
[0586] l-(3-chlorophenyl)-N-(l-methylpiperidin-4-yl)piperazine-2-carboxamide: MS (ESI) for C17H25ClN4O: 337 (MH+).
[0587] [l-(3-chlorophenyl)piperazin-2-yl]methanol: MS (ESI) for CπHι5ClN2O: 227
(MH4).
[0588] l-(3-chlorophenyl)-N-[2-(dimethylamino)ethyl]piperazine-2-carboxamide: MS (ESI) for Cι5H23ClN4O: 311 (MH+). [0589] l-(3-chlorophenyl)-N-methylpiperazine-2-carboxamide: MS (ESI) for C12Hι6ClN3O: 254 (MH+).
[0590] methyl 4-(3-chlorophenyl)piperazine-2-carboxylate: MS (ESI) for Cι2H15ClN2O2: 255 (MH+).
[0591] 4-(3-chlorophenyl)-N-methylpiperazine-2-carboxamide: MS (ESI) for C12H16ClΝ3O: 254 (MH*).
[0592] EXAMPLE 21: 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(3- methylbut-2-en-l-yl)-lH-pyrazolo[3,4-d]pyrimidine hydrochloride
[0593] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-lH- pyrazolo[3,4-cf]pyrimidine (20 mg, 0.050 mmol), 3-methyl-2-butenyltributylstannane (19 mg, 0.055 mmol), [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichlormethane (8.0 mg, 0.010 mmol), and hexamethylphosphoramide (lmL) was de-gassed with nitrogen for 5 min, and then stirred at 140 °C for 18 h. The reaction mixture was cooled, and diluted with ethyl acetate (10 mL). The organic layer was washed with water (3 x 5 mL), and brine (5 mL), dried over sodium sulfate, and concentrated. The residue was purified by reversed phase ΗPLC to give a powder, which was azoetroped with a mixture of 4M hydrogen chloride in dioxane:methanol 95:5 (3 x 1 mL) to give 4-[4-(5-chloro-2-methylphenyl)piperazin-l-yl]-3-(3-methylbut-2-en-l-yl)-lΗ- pyrazolo[3,4-d]pyrimidine hydrochloride (3.1 mg, 16% yield). 1H NMR (400 MHz, d4- methanol) δ 8.39 (s, IH), 7.18 (d, IH), 7.03 (d, IH), 7.00 (d, d, IH), 5.35 (t, IH), 4.17- 4.08 (m, 4H), 3.84 (d, IH), 3.07-3.02 (m, 4H), 2.34 (s, 3H), 1.78 (s, 3H), 1.75 (s, 3H); MS (ESI) for C2ιH25Cl N6: 397 (MH*).
[0594] EXAMPLE 22: [5-chloro-3-[4-(3-ethyl-lH-ρyrazolo[3,4-d]pyrimidin-4- yl)piperazin-l-yl]-2-(methyloxy)phenyl]methanol
[0595] To a degassed solution of methyl 3-bromo-5-chloro-2-(methyloxy)benzoate (1.57 g, 5.64 mmol) in toluene (60 mL) was added cesium carbonate (2.57 g, 7.89 mmol), BINAP (351 mg, 0.564 mmol), txis(dibenzylideneacetone)dipalladium(0) (130 mg, 0.141 mmol), and Boc-piperazine (1.4 g, 7.33 mmol). The mixture was refluxed for 24 h, then cooled to room temperature, and filtered through celite. The filtrate was concentrated and the residue was purified by column chromatography on silica (hexanes:ethyl acetate 4:1) to afford of 1,1-dimethylethyl 4-{5-chloro-2-(methyloxy)-3-
[(methyloxy)carbonyl]phenyl}piperazine-l-carboxylate (1.13g, 52% yield) as a white solid. 1H NMR (400 MHz, CDC13) δ 7.37 (d, IH), 6.97 (d, IH), 3.90 (s, 3H), 3.87 (s, 3H), 3.58-3.56 (m, 4H), 3.06-3.03 (m, 4H), 1.48 (s, 9H); MS (ESI) for C18H25ClN2O5: 385 (MH*).
[0596] A solution of l,l-dimethylethyl-4-{5-chloro-2-(methyloxy)-3-
[(methyloxy)carbonyl]phenyl}piperazine-l -carboxylate (300mg, 0.78 mmol) in THF (8 mL) was cooled to 0 °C, and lithium aluminum hydride (1.17 mL, 1.17 mmol) was added. The solution was stirred at 0 °C for 1 h, followed by the addition of water (150 μL), 15% sodium hydroxide (150 μL), and finally water (300 μL). The mixture was stirred at 0 °C for 10 min, then filtered through celite and concentrated. Column chromatography on silica (hexanes:ethyl acetate 3:2) gave l,l-dimethylethyl-4-[5-chloro-3-(hydroxymethyl)- 2-(methyloxy)phenyl]piperazine-l -carboxylate (264 mg, 95% yield) as a white solid. 1H NMR (400 MHz, CDC13) δ 7.00 (d, IH), 6.82 (d, IH), 4.65 (d, 2H), 3.87 (s, 3H), 3.60- 3.57 (m, 4H), 3.05-3.02 (m, 4H), 1.48 (s, 9H); MS (ESI) for Cι7H25ClN2O4: 357 (MH*).
[0597] A solution of l,l-dimethylethyl-4-[5-chloro-3-(hydroxymethyl)-2- (methyloxy)phenyl]piperazine-l -carboxylate (40 mg, 0.11 mmol) in dioxane (2 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 3 min, and then concentrated. The solid residue was dissolved in THF (5 mL), and triethylamine (50 μl, 0.34 mmol) and 4-chloro-3-ethyl-lH-pyrazolo[3,4- ]pyrimidine (20 mg, 0.11 mmol) were added. The solution was stirred at 50 °C for 24 h, then cooled to room temperature and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5 to 9:1) afforded [5- chloro-3-[4-(3-ethyl-lΗ-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- (methyloxy)phenyl]methanol (7.3 mg, 16% yield) as a white solid. 1H NMR (400 MHz, CDC13) δ 3.31 (s, IH), 8.30 (s, IH), 7.04 (d, IH), 6.88 (d, IH), 5.19 (t, IH), 4.49 (d, 2H), 3.85-3.78 (m, 7H), 3.21-3.16 (m, 4H), 2.97 (q, 2H), 1.29 (t, 3H); MS (ESI) for Cι9H2 ClN6O2: 403 (MH*).
[0598] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:
[0599] methyl 5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]-2-(methyloxy)benzoate: !H NMR (400 MHz, CDC13) δ 13.35 (s, IH), 8.30 (s, IH), 7.22 (d, IH), 7.19 (d, IH), 3.85-3.81 (m, 10H), 3.23-3.20 (m, 4H), 2.97 (q, 2H), 1.30 (t, 3H); MS (ESI) for C20H23C1N6O3; 431 (MH*). [0600] EXAMPLE 23: 5-chloro-N-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-lH- pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-(methyloxy)benzamide
[0601] To a solution of l,l-dimethylethyl-4-{5-chloro-2-(methyloxy)-3-[(methyloxy)- carbonyl]phenyl}piρerazine-l -carboxylate (Example 22, 290 mg, 0.75 mmol) in methanol (6 mL) was added IN aqueous potassium hydroxide (3.75 mL, 3.75 mmol). The solution was stirred at 60 °C for 15 h, then cooled to 0 °C and acidified to pH 2 using aqueous IN hydrochloric acid. The solution was diluted with water, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated to afford 5-chloro-3-(4-{[(l,l-dimefhylefhyl)oxy]carbonyl}piperazin-l-yl)-2- (methyloxy)benzoic acid (268 mg, 96% yield) as a yellow solid. 1H NMR (400 MHz, t- methanol) δ 7.26 (br s, IH), 7.08 (d, IH), 3.88 (s, 3H), 3.61-3.57 (m, 4H), 3.06-3.03 (m, 4H), 1.48 (s, 9H); MS (ESI) for C17H23ClN2O5: 393 (M+Na+).
[0602] To a solution of 5-chloro-3-(4-{[(l,l-dimethylethyl)oxy]carbonyl}piperazin-l- yl)-2-(methyloxy)benzoic acid (95 mg, 0.26 mmol) in DMF (5 mL) was added N,N- dimethylethylenediamine (25 μl, 0.23 mmol), triethylamine (75 μl, 0.51 mmol), and HATU (146 mg, 0.38 mmol). The solution was stirred at room temperature for 17 h, and then partitioned between ethyl acetate and 5% aqueous lithium chloride. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5) provided 1,1-dimethylethyl 4- [5-chloro-3-({[2-(dimethylamino)ethyl]amino}carbonyl)-2-(methyloxy)phenyl]piperazine- 1-carboxylate (108 mg, 96% yield) as a white solid. 1H NMR (400 MHz, CDC13) δ 8.63 (br s, IH), 7.71 (d, IH), 7.00 (d, IH), 3.93 (s, 3H), 3.66-3.63 (m, 2H), 3.62-3.58 (m, 4H), 3.04-3.01 (m, 4H), 2.90-2.87 (m, 2H), 2.58 (s, 6H), 1.49 (s, 9H); MS (ESI) for C21H33ClN4O4: 441 (MH*).
[0603] A solution of 1,1-dimethylethyl 4-[5-chloro-3-({ [2-
(dimethylamino)ethyl] amino } carbonyl)-2- (methyloxy)phenyl]piperazine- 1 -carboxylate (108 mg, 0.25 mmol) in dioxane (2 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 3 min and then concentrated. The residue was dissolved in THF (3 mL), and triethylamine (103 μl, 0.75 mmol) and 4-chloro-3-ethyl-lH-pyrazolo[3,4-^pyrimidine (45 mg, 0.25 mmol) were added. The mixture was stirred at 50 °C for 24 h, then cooled to room temperature and concentrated. The residue was diluted with sodium bicarbonate, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 85:15) yielded 5-chloro-N-[2-(dimethylamino)ethyl]- 3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-(methyloxy)benzamide (15 mg, 13% yield) as a white solid. 1H NMR (400 MHz, d6-DMSO) δ 13.32 (br s, IH), 8.37-8.34 (m, IH), 8.30 (s, IH), 7.22 (d, IH), 7.12 (d, IH), 3.85-3.81 (m, 7H), 3.22-3.20 (m, 4H), 2.39 (q, 2H), 2.19 (s, 6H), 1.99 (t, 3H); MS (ESI) for C23H3ιClN8O2: 488 (MIT*).
[0604] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0605] 4-(4-{ 5-chloro-2-(methyloxy)-3-[(4-methylpiperazin-l- yl)carbonyl]phenyl}piperazin-l-yl)-3-ethyl-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 13.31 (br s, IH), 8.30 (s, IH), 7.03 (d, IH), 6.87 (d, IH), 3.85-3.75 (m, 7H), 3.64-3.58 (m, 2H), 3.18-3.10 (m, 4H), 2.96 (q, 2H), 2.36-2.30 (m, 2H), 2.23-2.19 (m, 5H), 1.30 (t, 3H); MS (ESI) for C24H3ιClN8O2: 499 (MH*).
[0606] 2-(dimethylamino)ethyl 5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin- 4-yl)piperazin-l-yl]-2-(methyloxy)benzoate: !H NMR (400 MHz, d6-DMSO) δ 13.32 (br s, IH), 8.30 (s, IH), 7.19 (m, 2H), 4.30 (t, 2H), 3.84-3.80 (m, 7H), 3.25-3.20 (m, 4H), 2.99 (q, 2H), 2.58 (t, 2H), 2.19 (s, 6H), 1.29 (t, 3H); MS (ESI) for C23H30C1N7O3: 488 (MH+).
[0607] EXAMPLE 24: l-[5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4- yl)piperazin-l-yl]-2-(methyloxy)phenyl]-N,N-dimethylmethanamine
[0608] To a solution of l,l-dimethylethyl-4-[5-chloro-3-(hydroxymethyl)-2- (methyloxy)phenyl]piperazine-l -carboxylate (82 mg, 0.23 mmol) in dichloromethane (5 mL) was added Dess-Martin periodinane (117 mg, 0.28 mmol). The solution was stirred at room temperature for 1 h, followed by the addition of a 10% aqueous sodium thiosulfate pentahydrate solution (10 mL) and saturated sodium bicarbonate (10 mL). The mixture was stirred at room temperature for 15 minutes, the layers were separated, and the aqueous layer was extracted with more dichloromethane. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 4:1) afforded 1,1-dimethylethyl 4-[5-chloro-3-formyl-2- (methoxy)phenyl]piperazine-l -carboxylate (69 mg, 85% yield) as a yellow oil. 1H NMR (400 MHz, CDC13) δ 10.35 (s, IH), 7.44 (d, IH), 7.08 (d, IH), 3.97 (s, 3H), 3.63-3.60 (m, 4H), 3.09-3.06 (m, 4H), 1.49 (s, 9H); MS (ESI) for C17H23ClN2O4: 377 (M+Na+).
[0609] To a solution of 1,1-dimethylethyl 4-[5-chloro-3-formyl-2- (methoxy)phenyl]piperazine-l-carboxylate (95 mg, 0.27 mmol) in ethanol (2 mL) was added triethylamine (75 μl, 0.54 mmol), dimefhylamine hydrochloride (44 mg, 0.54 mmol), and Titanium(IV) isopropoxide (160 μl, 0.54 mmol). The mixture was stirred at room temperature for 15 h. Sodium borohydride (16 mg, 0.42 mmol) was added, and the mixture was stirred at room temperature for additional 3 h. The mixture was quenched by the addition of a 2N ammonia solution (3 mL), and the resulting precipitate was filtered and washed with dichloromethane. The filtrate was partitioned between water and dichloromethane, and the aqueous layer was extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate, and concentrated to give 1,1- dimethylethyl 4-[5-chloro-3-[(dimethylamino)methyl]-2-(methoxy)phenyl]piperazine-l- carboxylate (59 mg, 57% yield) as a white solid. 1H NMR (400 MHz, CDC13) δ 7.01 (d, IH), 6.75 (d, IH), 3.80 (s, 3H), 3.60-3.52 (m, 4H), 3.38 (s, 2H), 3.06-2.99 (m, 4H), 2.24 (s, 6H), 1.48 (s, 9H); MS (ESI) for Cι9H30ClN3O3: 384 (MH+).
[0610] To a solution of 1,1-dimethylethyl 4-[5-chloro-3-[(dimethylamino)methyl]-2- (mefhoxy)phenyljpiperazine-l-carboxylate (59 mg, 0.15 mmol) in dioxane (2 mL) was added 4N hydrochloric acid in dioxane (1 mL). The solution was refluxed for 2 min, and then concentrated. The residue was dissolved in THF (5 mL) and triethylamine (65 μl, 0.46 mmol) and 4-chloro-3-ethyl-lH-pyrazolo[3,4-ιflpyrimidine (28 mg, 0.15 mmol) were added. The solution was stirred at 50 °C for 24 h, cooled to room temperature and concentrated. The residue was added into saturated sodium bicarbonate, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane :mefhanol 85:15) yielded l-[5-chloro-3-[4-(3-ethyl-lΗ-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- (methyloxy)phenyl]-N,N-dimethylmethanamine (21 mg, 33% yield) as a white solid. 1H NMR (400 MHz, d6-DMSO) δ 13.31 (br s, IH), 8.30 (s, IH), 6.99 (d, IH), 6.89 (d, IH), 3.82-3.78 (m, 7H), 3.37 (s, 2H), 3.22-3.17 (m, 4H), 2.97 (q, 2H), 2.16 (s, 6H), 1.30 (t, 3H); MS (ESI) for C21H28ClN7O: 430 (MH*).
[0611] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:
[0612] N'-{[5-chloro-3-[4-(3-ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]- 2-(methyloxy)ρhenyl]methyl}-N,N-dimethylethane-l,2-diamine: !H NMR (400 MHz, CD3OD) δ 8.30 (s, IH), 7.02 (d, IH), 6.93 (d, IH), 3.97-3.93 (m, 7H), 3.76 (s, 2H), 3.27- 3.24 (m, 4H), 3.06 (q, 2H), 2.69 (t, 2H), 2.48 (t, 2H), 2.22 (s, 6H), 1.38 (t, 3H); MS (ESI) for C23H33ClN8O: 474 (MH*). [0613] EXAMPLE 25: l-[5-chloro-2-methyl-4-(methyloxy)phenyl]piperazine trifluoroacetate
[0614] A mixture of 2-chloro-5-methyl-4-nitrosophenol (11.6 g, 67.9 mmol, M.E. Falugh, T.A. Crowell, J.A. Clemens, B.D. Sawyer, /. Med. Chem. 1979, 22, 63-69), benzyl bromide (11.6 g, 67.9 mmol), and potassium carbonate (14.1 g, 102.2 mmol) in DMSO was stirred at 60 °C for 6 h. The reaction mixture was partitioned between water and ethyl acetate, filterd through celite, and the layers were separated. The organic layer was washed with saturated sodium bicarbonate, water, and brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes: ethyl acetate 97:3) afforded l-chloro-4-methyl-5-nitroso-2-[(phenylmethyl)oxy]benzene (1.55 g, 9% yield).
[0615] A mixture of l-chloro-4-methyl-5-nitroso-2-[(phenylmethyl)oxy]benzene (1.55 g, 5.92 mmol) and tin(II) chloride (5.05 g, 22.38 mmol) in ethanol was refluxed for 4 h. The reaction mixture was concentrated and the residue partitioned between ethyl acetate and saturated sodium bicarbonate. The layers were separated, the organic layer was washed with water, and brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 9:1) gave l-chloro-4-methyl-2-[(phenyl- methyl)oxy] aniline (1.32 g, 90% yield).
[0616] A mixture of l-chloro-4-methyl-2-[(phenylmethyl)oxy] aniline (1.10 g, 4.44 mmol), bis(2-chloroethyl)amine hydrochloride(0.79 g, 4.43 mmol), and potassium carbonate (0.61 g, 4.42 mmol) in diglyme was refluxed for 18 h. The reaction mixture was diluted with hexanes, decanted, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5 to 92:9) provided l-{5-chloro-2-methyl-4-[(phenyl- methyl)oxy]phenyl}piperazine (0.23 g, 16% yield).
[0617] A solution of l-{5-chloro-2-methyl-4-[(phenylmethyl)oxy]phenyl}piperazine (0.23 mg, 0.73 mmol) in trifluoroacetic acid (3 mL) was refluxed for 3 h and then concentrated. The residue was dissolved in ethyl acetate, treated with activated charcoal, and filtered. Concentration gave 2-chloro-5-methyl-4-piperazine-l-ylphenol (159 mg, 96% yield).
[0618] A solution of 2-chloro-5-methyl-4-piperazine-l-ylphenol (49 mg, 0.22 mmol) and Boc-anhydride (48 mg, 0.22 mmol) in ethyl acetate was stirred at 50 °C for 2 h. Concentration and column chromatography on silica (dichloromethane :mefhanol 95:5 to 9:1) afforded 1,1-dimethylethyl 4(5-chloro-4-hydroxy-2-methylphenyl)piperazine-l- carboxylate (49 mg, 68% yield).
[0619] A mixture of 1,1-dimethylethyl 4(5-chloro-4-hydroxy-2- methylphenyl)piperazine-l -carboxylate (16 mg, 0.05 mmol), methyl iodide (14 mg, 0.10 mmol), and cesium carbonate (32 mg, 0.10 mmol) in DMF was stirred at 60 °C for 5 h. The reaction mixture was diluted with ethyl acetate, washed with water, IN sodium hydroxide, and water, dried over sodium sulfate, and concentrated. The residue was dissolved in dichloromethane/trifluoroacetic acid/water (75:20:5) and stirred at room temperature for 12 h. Concentration provided l-[5-chloro-2-methyl-4-(methyloxy)- phenyl]piperazine trifluoroacetate (8 mg, 47% yield), which was used without further purification.
[0620] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0621] 3- [(2-chloro-5-methyl-4-piperazin- 1 -ylphenyl)oxy] -N,N-dimethylpropan- 1 - amine
[0622] 2-[(2-chloro-5-methyl-4-piperazin-l-ylphenyl)oxy]-N,N-dimethylethanamine
[0623] EXAMPLE 26: 2-{[5-chloro-2-(methyloxy)-3-ρiρerazin-l-ylphenyl]oxy}- N,N-dimethylethanamine
[0624] To a solution of methyl 3-bromo-5-chloro-2-(methyloxy)benzoate (2.86 g, 10.6 mmol) in THF (30 mL) was added methanol (620 μL, 15.3 mmol) followed by 2 M lithium borohydride in THF (7.7 mL, 15.4 mmol). The resulting mixture was heated to 50 °C for 2 h. The residual hydride was quenched with IM hydrochloric acid at 0 °C. The mixture was diluted with ethyl acetate and neutralized with sodium bicarbonate. The layers were separated, the organic layer was dried over magnesium sulfate, and concentrated to give [3-bromo-5-chloro-2-(methyloxy)phenyl]methanol as a white solid. 1H NMR (400 MHz, CDC13) δ 7.47 (d, IH), 7.34 (d, IH), 4.71 (d, 2H), 3.85 (s, 3H), 2.03 (t, IH).
[0625] A biphasic mixture of [3-bromo-5-chloro-2-(methyloxy)phenyl]methanol, potassium bromide (122 mg, 1.02 mmol), and TEMPO (16 mg, 0.10 mmol) in dichloromethane (25 mL) and water (10 mL) was cooled to 0 °C. A solution of bleach saturated with sodium bicarbonate (5% sodium hypochlorite, 18.7 mL, 12.5 mmol) was added, and the mixture was stirred for 20 min. Water was then added followed by dichloromethane. Ill The layers were separated, and the aqueous layer was extracted with dichloromethane. The organic extracts were combined, dried over magnesium sulfate, and concentrated to afford 3-bromo-5-chloro-2-(methyloxy)benzaldehyde (2.2 g, 87% yield over 2 steps) as a pale yellow solid. 1HNMR (400 MHz, CDC13) δ 10.26 (s, 2H), 7.78 (d, IH), 7.75 (d, IH), 3.97 (s, 3H).
[0626] A mixture of 3-bromo-5-chloro-2-(methyloxy)benzaldehyde (1.22 g, 4.9 mmol), and 3-chloroperbenzoic acid (2.4 g, 9.8 mmol) in dichloromethane (20 mL) was refluxed for 26 h, and then concentrated. The residue was dissolved in ethyl acetate, washed twice with saturated sodium bicarbonate, dried over magnesium sulfate, and concentrated. The residue was dissolved in methanol, and IM potassium hydroxide (5 mL) was added. The mixture was stirred for 1 h at room temperature, and then acidified with IM hydrochloric acid (5 mL). The methanol was removed in vacuo, and the resulting mixture was extracted with ethyl acetate. The organic extracts were dried with magnesium sulfate, and concentrated. Silica gel column chromatography (hexanes :ethyl acetate 4:1) provided 3-bromo-5-chloro-2-(methyloxy)phenol (123 mg, 11% yield) as a colorless oil. 1H NMR (400 MHz, CDC13) δ 7.08 (d, IH), 6.94 (d, IH), 3.89 (s, 3H).
[0627] To a solution of 3-bromo-5-chloro-2-(methyloxy)phenol (123 mg, 0.52 mmol) in DMF (1 mL) was added cesium carbonate (678 mg, 2.08 mmol) and 2-chloro-N,N- dimethylethylamme hydrochloride (150 mg, 1.04 mmol). The mixture was stirred at room temperature for 4 h and then at 70 °C for additional 2 h. After cooling to room temperature, water and ethyl acetate were added. The layers were separated, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated to give crude 2-{[3-bromo-5-chloro-2-(methyloxy)phenyl]oxy}-N,N-dimethylethanamine as a yellow film, which was used without further purification. 1H NMR (400 MHz, CDC13) δ 7.14 (d, IH), 6.86 (d, IH), 4.09 (t, 2H), 3.84 (s, 3H), 2.78 (t, 2H), 2.35 (s, 6H).
[0628] To a solution of crude 2-{[3-bromo-5-chloro-2-(methyloxy)phenyl]oxy}-N,N- dimethylethanamine in toluene (2 mL) was added tri(dibenzylideneacetone)dipalladium(0) (12 mg, 0.013 mmol), BINAP (16 mg, 0.026 mmol), sodium tert-butoxide (70 mg, 0.73 mmol), and piperazine (270 mg, 3.12 mmol). The resulting mixture was refluxed for 5 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. The filtrate was concentrated and the residue purified by column chromatography on silica (dichloromethane:methanol:aqueous ammonia 80:19:1) to provide 2-{[5-chloro-2-(methyloxy)-3-piperazin-l-ylphenyl]oxy}-N,N- dimethylethanamine (84.3 mg, 52% yield for 2 steps) as a yellow film. 1H NMR (400 MHz, CDC13) δ 6.57 (d, IH), 6.50 (d, IH), 4.05 (t, 2H), 3.79 (s, 3H), 3.02 (m, 8H), 2.75 (t, 2H), 2.34 (s, 6H); MS (ESI) for C15H24ClN3O2: 314 (MH+).
[0629] EXAMPLE 27: 3-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N,N- dimethylprop-2-yn- 1 -amine hydrochloride
[0630] A mixture of 5-chloro-l-iodo-2-methyl-3-nitrobenzene (3.0 g, 10.1 mmol) and tin(II) chloride dihydrate (9.1 g, 40.4 mmol) in acetic acid (10 mL) was stirred for 1 h at room temperature, and was then diluted with ether. The mixture was cooled to 0 °C and 50% aqueous sodium hydroxide was added slowly. A clumpy white solid formed, and was removed by filtration. The filtrate was concentrated and the residue purified by column chromatography on silica (hexane:ethyl acetate 4:1) to provide 5-chloro-3-iodo-2- methylaniline (1.81 g, 67% yield) as a pale yellow solid. 1H ΝMR (400 MHz, CDC13) δ 7.25 (d, IH), 6.64 (d, IH), 3.78 (br s, 2H), 2.28 (s, 3H).
[0631] To a solution of 5-chloro-3-iodo-2-methylaniline (1.32 g, 4.9 mmol) in diglyme (5 mL) was added potassium carbonate (677 mg, 4.9 mmol) and bis(2-chloroethyl)amine hydrochloride (875 mg, 4.9 mmol). The mixture was refluxed for 24 h and then cooled to room temperature. Water and ethyl acetate were added. The layers were separated, the organic layer was dried over sodium sulfate, filtered, and concentrated. Column chromatography on silica (dichloromethane:methanol 4:1) provided l-(5-chloro-3-iodo-2- methylphenyl)piperazine as a white solid (660 mg, 40% yield). 1H ΝMR (400 MHz, CDC13) δ 7.56 (d, IH), 6.97 (d, IH), 3.03 (m, 4H), 2.83 (m, 4H), 2.39 (s, 3H), 1.73 (br s, IH); MS (ESI) for CnH14CHN2: 337 (MH+).
[0632] A mixture of l-(5-chloro-3-iodo-2-mefhylphenyl)piperazine (660 mg, 2.0 mmol) and Boc-anhydride (437 mg, 2.0 mmol) in THF (20 mL) was stirred at room temperature for 15 h, and then concentrated to give 1,1-dimethylethyl 4-(5-chloro-3-iodo- 2-methylphenyl)piperazine-l -carboxylate (784 mg, 92% yield) as a pale yellow syrup. H ΝMR (400 MHz, CDC13) δ 7.56 (d, IH), 6.93 (d, IH), 3.55 (br s, 4H), 2.80 (m, 4H), 2.38 (s, 3H), 1.48 (s, 9H).
[0633] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-iodo-2- methylphenyl)piperazine-l -carboxylate (106 mg, 0.24 mmol) in THF (1 mL) was added bis(triphenylphosphine)palladium(II) chloride (35 mg, 0.012 mmol), 3-dimethylamino-l- propyne (40 μL, 0.36 mmol), triethylamine (50 μL, 0.36 mmol), and copper® iodide (5 mg, 0.024 mmol). The mixture was stirred at room temperature for 20 h, and then concentrated. Column chromatography on silica (dichloromethane methanol 95:5) provided 1,1-dimethylethyl 4-{5-chloro-3-[3-(dimethylamino)prop-l-yn-l-yl]-2- methylphenyl}ρiperazine-l-carboxylate (41.1 mg, 44% yield) as a yellow film. 1H NMR (400 MHz, CDC13) δ 7.14 (d, IH), 6.89 (d, IH), 3.56 (br s, 4H), 3.52 (s, 2H), 2.80 (m, 4H), 2.37 (s, 6H), 2.36 (s, 3H), 1.48 (s, 9H); MS (ESI) for C21H30C1N3O2: 392 (MH*).
[0634] A mixture of 1,1-dimethylethyl 4-{5-chloro-3-[3-(dimethylamino)prop-l-yn-l- yl]-2-methylphenyl}piperazine-l -carboxylate (41.1 mg, 0.105 mmol) in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 2 min and then concentrated to provide 3-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N,N-dimethylprop-2-yn-l-amine hydrochloride as a solid. MS (ESI) for Cι6H22ClN3: 292 (MH*).
[0635] EXAMPLE 28: N'-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N,N- dimethylethane- 1 ,2-diamine hydrochloride
[0636] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-iodo-2- methylphenyl)piperazine-l -carboxylate (92 mg, 0.21 mmol) in dioxane (1 mL) was added sodium tert-butoxide (28 mg, 0.29 mmol), tri(dibenzylideneacetone)dipalladium(0) (6 mg, 0.006 mmol), XANTPHOS (8 mg, 0.013 mmol), and N,N-dimethylethylenediamine (28 μL, 0.25 mmol). The mixture was refluxed for 5 h, then cooled to room temperature and concentrated. Column chromatography on silica (dichloromethane: methanol 9:1) gave 1 , 1 -dimethylethyl 4-(5-chloro-3- { [2-(dimethylamino)ethyl]amino } -2-methylphenyl)- piperazine-1-carboxylate (33.3 mg, 0.084 mmol, 40% yield) as a yellow film. 1H ΝMR (400 MHz, CDC13) δ 6.43 (d, IH), 6.38 (d, IH), 4.43 (br s, IH), 3.56 (br s, 4H), 3.15 (m, 2H), 2.79 (br s, 4H), 2.62 (m, 2H), 2.28 (s, 6H), 2.07 (s, 3H), 1.48 (s, 9H); MS (ESI) for C20H33C1Ν4O2: 397 (MH*).
[0637] A solution of 1,1-dimethylethyl 4-(5-chloro-3-{ [2-
(dimethylamino)ethyl] amino }-2-methylphenyl)piperazine-l -carboxylate (33.3 mg, 0.084 mmol) in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 2 min and then concentrated to provide N'-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N,N- dimethylethane-l,2-diamine hydrochloride as a solid. MS (ESI) for C15H25C1N4: 297 (MH*).
[0638] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared: [0639] N'-(5-chloro-2-methyl-3-ρiperazin-l-ylρhenyl)-N-methyl-N-(l- methylethyl)ethane-l,2-diamine: MS (ESI) for Cι7H29ClN4: 325 (MH*).
[0640] N'-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N-ethyl-N-methylethane-l,2- diamine: MS (ESI) for C16H27C1N4: 311 (MH*).
[0641] l-(3-bromo-2-chloro-5-fluorophenyl)piperazine: MS (ESI) for C10HπBrClFN2: 295 (MH+)
[0642] 2-chloro-5-fluoro-3-piperazin- 1 -yl-N-(2-pyrrolidin- 1 -ylethyl)aniline: MS
(ESI) for C16H24C1FN4: 327 (MH+).
[0643] N-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N,N',N'-trimethylethane-l,2- diamine: MS (ESI) for C16H27C1N4: 311 (MH*).
[0644] 5-bromo-2-methyl-3-piperazin- 1 -yl-N-(2-pyrrolidin- 1 -ylethyl)aniline hydrochloride: MS (ESI) for C17H27BrΝ4: 368 (MH*).
[0645] 5-chloro-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: MS (ESI) for C17H27C1Ν4: 323 (MH*).
[0646] EXAMPLE 29: 3-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)-N,N- diethylpropan- 1 -amine hydrochloride
[0647] To a solutionl,l-dimethylefhyl 4-(5-chloro-3-iodo-2-methylphenyl)piperazine- 1-carboxylate (111 mg, 0.25 mmol) in DMF (0.5 mL) was added tetrabutylammonium chloride (70 mg, 0.25 mmol), sodium bicarbonate (53 mg, 0.63 mmol), palladium(II) acetate (1 mg, 0.005 mmol), and allylalcohol (26 μL, 0.38 mmol). The resulting mixture was heated to 50 °C for 4 h before cooling to room temperature. Brine and ethyl acetate were added, the organic layer was dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexane:ethyl acetate 4:1) afforded 1,1-dimethylethyl 4- [5-chloro-2-mefhyl-3-(3-oxopropyl)phenyl]piperazine-l-carboxylate (63.0 mg, 69% yield) as a colorless film. 1H ΝMR (400 MHz, CDC13) δ 9.82 (m, IH), 6.88-6.85 (m, 2H), 3.56 (br s, 4H), 2.91 (t, 2H), 2.78 (m, 4H), 2.73 (m, 2H), 2.22 (s, 3H), 1.48 (s, 9H).
[0648] To a solution of 1,1-dimethylethyl 4-[5-chloro-2-methyl-3-(3- oxopropyl)phenyl]piperazine-l-carboxylate (31 mg, 0.085 mmol) in 1,2-dichloroethane (1 mL) was added diethylamine (44 μL, 0.43 mmol) and sodium triacetoxyborohydride (36 mg, 0.17 mmol). The mixture was stirred for 45 min at room temperature. The residual hydride was quenched with IN hydrochloric acid, and water and dichloromethane were added. The mixture was neutralized with sodium bicarbonate. The organic layer was dried over magnesium sulfate, and concentrated to provide 1,1-dimethylethyl 4-{5-chloro- 3-[3-(diethylamino)propyl]-2-methylphenyl}piperazine-l-carboxylate (27.5 mg, 76% yield) as a colorless film. 1H NMR (400 MHz, CDC13) δ 6.92 (d, IH), 6.89 (d, IH), 3.56 (br s, 4H), 2.79 (br s, 4H), 2.60-2.49 (m, 8H), 2.22 (s, 3H), 1.70 (m, 2H), 1.49 (s, 9H), 1.03 (t, 6H).
[0649] A solution of 1,1-dimethylethyl 4-{5-chloro-3-[3-(diethylamino)propyl]-2- methylphenyl}piperazine-l-carboxylate (27.5 mg, 0.065 mmol) in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 4 min and then concentrated to provide 3-(5-chloro-2-mefhyl-3-piperazin- 1 -ylphenyl)-N,N-diethylpropan- 1 -amine hydrochloride as a solid. MS (ESI) for C18H30C1N3: 324 (MH+).
[0650] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:
[0651] l-[5-chloro-2-methyl-3-(3-pyrrolidin-l-ylpropyl)phenyl]piperazine: MS (ESI) for C18H28C1N3: 295 (MH*).
[0652] l-[3-(5-chloro-2-methyl-3-piperazin-l-ylphenyl)propyl]-4-methylpiperazine hydrochloride: MS (ESI) for C19H31C1N4: 351 (MH*).
[0653] EXAMPLE 30: 2-[(5-chloro-2-methyl-3-piperazin-l-ylphenyl)oxy]-N,N- dimethylethanamine hydrochloride
[0654] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-iodo-2- methylphenyl)piperazine-l-carboxylate (384 mg, 0.88 mmol) in DMSO (5 mL) was added potassium acetate (259 mg, 2.64 mmol), bis(pinacolato)diboron (226 mg, 0.97 mmol), and [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (72 mg, 0.088 mmol). The mixture was stirred at 80 °C for 24 h, and cooled to room temperature. Water and ethyl acetate were added, and the suspension was filtered through celite. The layers were separated, the organic layer was washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexane: ethyl acetate 9:1) provided 1,1- dimethylethyl 4-[5-chloro-2-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl]piperazine-l-carboxylate (185 mg, 48% yield) as a pale yellow oil. 1H NMR (400 MHz, CDC13) δ 7.43 (d, IH), 7.01 (d, IH), 3.55 (br s, 4H), 2.79 (m, 4H), 2.44 (s, 3H), 1.48 (s, 9H), 1.34 (s, 12H). [0655] To a solution of 1,1-dimethylethyl 4-[5-chloro-2-methyl-3-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]piperazine-l-carboxylate (185 mg, 0.42 mmol) in THF (5 mL) was added 7.5 M sodium hydroxide (170 μL, 1.26 mmol) and 30% hydrogen peroxide solution (242 μL, 2.52 mmol) at 0 °C. The mixture was stirred for 30 min before adding 10% citric acid and ethyl acetate. The layers were separated, the organic layer was dried over magnesium sulfate, and concentrated to give 1,1- dimethylethyl 4-(5-chloro-3-hydroxy-2-methylphenyl)piperazine-l-carboxylate (139 mg, 100% yield) as a yellow solid. !H NMR (400 MHz, CDC13) δ 6.61 (d, IH), 6.53 (d, IH), 6.23 (br s, IH), 3.56 (br s, 4H), 2.79 (m, 4H), 2.13 (s, 3H), 2.13 (s, 3H), 1.49 (s, 9H).
[0656] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-hydroxy-2- methylphenyl)piperazine-l -carboxylate (45 mg, 0.122 mmol) in DMF was added 2- chloro-N,N-dimethylethylamine hydrochloride (35 mg, 0.244 mmol) and cesium carbonate (159 mg, 0.488 mmol). The mixture was stirred at room temperature for 16 h. Water was added and the resulting aqueous mixture was extracted twice with ethyl acetate. The organic extracts were combined, washed with water and brine, dried over magnesium sulfate, and concentrated to afford 1,1-dimethylethyl 4-(5-chloro-3-{[2- (dimethylamino)ethyl]oxy}-2-methylphenyl)piperazine-l -carboxylate as a colorless film which was used without further purification. !H NMR (400 MHz, CDC13) δ 6.61 (d, IH), 6.59 (d, IH), 4.06 (t, 2H), 3.55 (br s, 4H), 2.80 (m, 6H), 2.39 (s, 6H), 2.11 (s, 3H), 1.48 (s, 9H).
[0657] A solution of 1,1-dimethylethyl 4-(5-chloro-3-{[2-(dimethylamino)ethyl]oxy}- 2-methylphenyl)piperazine-l-carboxylate in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 4 min and then concentrated to provide 2-[(5-chloro-2- methyl-3-piperazin-l-ylphenyl)oxy]-N,N-dimethylethanamine hydrochloride as a solid. MS (ESI) for C15H24ClN3O: 298 (MH*).
[0658] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:
[0659] l-[5-chloro-2-methyl-3-(methyloxy)phenyl]piperazine: MS (ESI) for
C12H17ClN2O: 241 (MH*).
[0660] 2-[(5-chloro-2-memyl-3-piperazin-l-ylphenyl)oxy]-N,N-diethylethanamine: MS (ESI) for C17H28ClN3O: 326 (MET*). [0661] l-{5-chloro-2-methyl-3-[(2-pyrrolidin-l-ylethyl)oxy]phenyl}piperazine: MS (ESI) for C17H26ClN3O: 324 (MH+).
[0662] 4-{2-[(5-chloro-2-methyl-3-piρerazin-l-ylphenyl)oxy]ethyl}moφholine: MS (ESI) for C17H26ClN3O2: 340(MH+).
[0663] l-{5-chloro-2-methyl-3-[(2-piperidin-l-ylethyl)oxy]phenyl}piperazine: MS (ESI) for C18H28ClN3O: 338(MH+).
[0664] l-{2-[(5-chloro-2-methyl-3-piperazin-l-ylphenyl)oxy]ethyl}-4- ethylpiperazine: MS (ESI) for Cι9H31ClN4O: 367(MH*).
[0665] 4-{3-[(5-chloro-2-methyl-3-piperazin-l-ylphenyl)oxy]propyl}moφholine: MS (ESI) for Cι8H28ClN3O2: 354(MH*).
[0666] l-{5-chloro-2-methyl-3-[(3-pyrrolidin-l-ylpropyl)oxy]phenyl}piperazine: MS (ESI) for C18H28ClN3O: 338(MH+).
[0667] l-{3-[(5-chloro-2-methyl-3-piperazin-l-ylphenyl)oxy]propyl}-4- methylpiperazine: MS (ESI) for C19H31ClN4O: 367 (MH+).
[0668] l-{5-chloro-2-methyl-3-[(3-piperidin-l-ylpropyl)oxy]phenyl}piperazine: MS (ESI) for C19H30C1N3O: 352 (MH+).
[0669] 1 - { 3-[(5-chloro-2-methyl-3-piperazin- 1 -ylphenyl)oxy]propyl } -4- ethylpiperazine: MS (ESI) for C20H33C1N4O: 381 (MH*).
[0670] 3-[(5-chloro-2-methyl-3-piperazin-l-ylphenyl)oxy]-N,N-diethylpropan-l- amine: MS (ESI) for C18H30C1Ν3O: 340 (MH*).
[0671] 1 - { 2-[(5-chloro-2-methyl-3-piperazin- 1 -ylphenyl)oxy] ethyl } -4- methylpiperazine hydrochloride: MS (ESI) for C18H29ClN4O: 353 (MH*).
[0672] EXAMPLE 31: N,N-diethyl-2-[(3-piperazin-l-ylphenyl)oxy]ethanamine hydrochloride
[0673] A mixture of 3-hydroxyphenylpiperazine (0.41g, 2.25 mmol) and Boc- anhydride (0.49g, 2.25 mmol) in dry THF (15 mL) was stirred at room temperature for 5 h. The reaction mixture was concentrated to provide 1,1-dimethylethyl 4-(3- hydroxyphenyl)piperazine-l -carboxylate (100% yield) as a beige solid. MS (ESI) forCι5H22N2O3: 223 (M-56). [0674] A mixture of 1,1-dimethylethyl 4-(3-hydroxyphenyl)ρiperazine-l-carboxylate (0.13g, 0.46 mmol), potassium carbonate (256 mg, 1.9 mmol), and 2-(diethylamino)ethyl chloride hydrochloride (0.16g, 0.92 mmol) in DMF (3 mL) was stirred at 110 °C for 1 h. The reaction mixture was poured into ice water, and extracted several times with ether. The organic layer was washed with water, dried over sodium sulfate, and concentrated to give crude 1,1-dimethylethyl 4-(3-{[2-(diethylamino)ethyl]oxy]phenyl)piperazine-l- carboxylate. MS (ESI) for C21H35N3O3 : 378 (MH*).
[0675] A solution of 1,1-dimethylethyl 4-(3-{[2-
(diethylamino)ethyl]oxy}phenyl)piperazine-l -carboxylate ( 0.17 g, 0.45 mmol) in MeOH (2 mL) and 4N hydrochloric acid in dioxane (2 mL) was refluxed for 1 min. The reaction mixture was concentrated, the residue was triturated with ether, and dried to afford N,N- diethyl-2-[(3-piperazin-l-ylphenyl)oxy]ethanamine hydrochloride (100% yield) as an oil. MS (ESI) for Cι6H27N3O: 278 (MH+).
[0676] EXAMPLE 32: N,N-diethyl-2-[(2-methyl-3-piperazin-l- ylphenyl)oxy]ethanamine hydrochloride
[0677] A mixture of 2-methyl-3-nitrophenol (672 mg, 4.4 mmol), cesium carbonate (2.1 g, 6.44 mmol), and benzyl bromide (751 mg, 4.4 mmol) in DMF (6 mL) was stirred at room temperature for 3 h. The reaction mixture was poured into ice water. The light yellow precipitation was filtered off, washed several times with water, and dried, to provide l-nitro-2-methyl-3-[(phenylmethyl)oxy]benzene (930 mg, 87% yield). 1HNMR (400 MHz, d4-methanol): δ 7.47 (d, IH), 7.45 (s, IH), 7.40 (s, IH), 7.39 (d, IH), 7.37 (d, IH), 7.34 (m, IH), 7.32 (s, IH), 7.29 (d, IH), 4.90 (s, 2H), 2.35 (s, 3H).
[0678] • To a solution of l-nitro-2-methyl-3-[(phenylmethyl)oxy]benzene (0.92g, 3.8 mmol) in ethyl acetate (50 mL) was added tin(II) chloride monohydrate (3.5g, 15.2 mmol) and the reaction mixture was stirred at 70 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with ether (50 mL), and sodium bicarbonate was added until pH 8. The semi-solid byproduct was filtered off, washed with ethyl acetate, the organic layer was dried with sodium sulfate, and concentrated. Trituration with ether gave 2-methyl-3- [(phenylmethyl)oxy]aniline (0.35g, 44% yield) as a light yellow solid. MS (ESI) for Cι4H15NO: 214 (MH*).
[0679] A mixture of 2-methyl-3-[(phenylmethyl)oxy]aniline (0.34g, 1.6 mmol), potassium carbonate (0.44 g, 3.2 mmol), and bis(2-chloroethyl)amine hydrochloride (1.6 mmol) diglyme (5 mL) was refluxed for 4 h. The reaction mixture was cooled to room temperature, water was added, and the pH of the aqueous layer was adjusted to pH 13. The aqueous layer was extracted with ethyl acetate (3 x 20 mL), dried with sodium sulfate, and concentrated to provide l-{2-methyl-3-[(phenylmethyl)oxy]phenyl}piperazine (0.43g, 96% yield) as a dark oil. MS (ESI) for Cι8H22N2O: 283 (MH*).
[0680] A mixture of l-{2-methyl-3-[(phenylmethyl)oxy]phenyl}piperazine (0.42g 1.5 mmol) and Boc-anhydride (0.33g, 1.5 mmol) in THF (10 mL) was stirred at room temperature for 30 h. The reaction mixture was concentrated, diluted with ethyl acetate (30 ml), the organic layer was washed with water, brine, dried with sodium sulfate, and concentrated. Column chromatography on silica provided 1,1-dimethylethyl 4-{2-methyl- 3-[(phenylmethyl)oxy]phenyl}piperazine-l-carboxylate (0.18g, 32% yield). MS (ESI) for C23H3oN2O3: 384 (MH*) and 327 (MH-56).
[0681] To a solution of 1,1-dimethylethyl 4-{2-methyl-3-[(phenylmethyl)oxy]- phenyl}piperazine-l-carboxylate (0.18g, 0.5 mmol) in ethanol (15 mL) was added palladium on carbon (0.1 lg, 10%, contains 50% water), and the reaction mixture was stirred under an hydrogen atmosphere for 15 h. The reaction mixture was filtered through celite, and the filter cake was washed with ethanol. The filtrate was concentrated to give 1,1-dimethylethyl 4-(3-hydroxy-2-methylphenyl)piperazine-l-carboxylate (0.075g, 54% yield). MS (ESI) for C16H24N2O3: 293 (MH*).
[0682] A mixture of 1,1-dimethylethyl 4-(3-hydroxy-2-methylphenyl)piperazine-l- carboxylate (0.07g, 0.24 mmol), potassium carbonate (0.134g, 0.96 mmol), and 2- (diethylamino)ethylchloride hydrochloride (0.083g, 0.48 mmol) in DMF (2 mL) was stirred at 100 °C for 1 h. The reaction mixture was cooled to room temperature, poured into ice water, and extracted with ethyl acetate (3 x 20 ml). The organic layer was dried with sodium sulfate, and concentrated to afford 1,1-dimethylethyl 4-(3-{ [2- (diethylamino)ethyl]oxy}-2-methylphenyl)piperazine-l -carboxylate (0.07g, 76% yield). MS (ESI) for C22H37N3O3: 392 (MH+).
[0683] A solution of 1,1-dimethylethyl 4-(3-{[2-(diethylamino)ethyl]oxy}-2- methylphenyl)piperazine-l-caboxylate (0.07g, 0.18 mmol) in MeOH (2 mL) and 4N hydrochloric acid in dioxane (2 mL) was refluxed for 1 min. The reaction mixture was concentrated to give N,N-diethyl-2-[(2-methyl-3-piperazin-l-ylphenyl)oxy]ethanamine hydrochloride (0.04 g, 77% yield), which was used without further purification. MS (ESI) for C17H29N3O: 292 (MH*). [0684] EXAMPLE 33: 5-(ethylsulfonyl)-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin- l-ylethyl)aniline hydrochloride
[0685] To a solution of 3,5-dibromo-4-methylphenol (5.24 g, 19.70 mmol) in DMF (30 mL) was added sodium hydride (60% in mineral oil, 0.79 g, 19.75 mmol) at room temperature under nitrogen. The resulting mixture was stirred at 60 °C for 15 min, cooled to room temperature, and dimethythiocarbamoyl chloride (2.30 g, 18.61 mmol) was added. The resulting mixture was stirred at 60 °C for 1 h, and then diluted with ethyl acetate (100 mL). The organic layer was washed with IN sodium hydroxide (2 x 50 mL), water (50 mL), 5% lithium chloride (50 mL), and brine (50 mL), dried with sodium sulfate, and concentrated. Column cliromatography on silica (hexanes:ethyl acetate 9:1) afforded O- (3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (5.11 g, 78% yield) as a colorless solid. 1H NMR (400 MHz, CDC13) δ 7.28 (s, 2H), 3.44 (s, 3H), 3.32 (s, 3H), 2.55 (s, 3H).
[0686] O-(3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (4.00 g, 11.33 mmol) was stirred at 200 °C for 23 h under nitrogen. Column chromatography on silica (hexanes:ethyl acetate 9:1) gave S-(3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (3.05 g, 76% yield) as a colorless solid. 1H NMR (400 MHz, CDC13) δ 7.64 (s, 2H), 3.07 (br s, 3H), 3.03 (br s, 3H), 2.57 (s, 3H).
[0687] A solution of S-(3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (3.73 g, 10.56 mmol) in methanol (50 mL) and 2N sodium hydroxide (20 mL) was refluxed for 90 min. The reaction mixture was diluted with water (100 mL), acidified with IN hydrochloric acid to pH 3, and then extracted with ethyl acetate (100 mL). The organic layer was washed with water (50 mL), and brine (50 mL), dried with sodium sulfate, and concentrated to give 3,5-dibromo-4-methylbenzenethiol (2.85 g, 96% yield) as a colorless solid. 1H NMR (400 MHz, d6-DMSO) δ 7.61 (s, 2H), 6.94 (s, IH), 2.43 (s, 3H).
[0688] A mixture of 3,5-dibromo-4-methylbenzenethiol (0.88 g, 3.12 mmol), cesium carbonate (2.03 g, 6.24 mmol), and ethyl iodide (0.72 g, 4.63 mmol) in DMF (7 mL) mixture was stirred at 60 °C for 1 h, and then diluted with ethyl acetate (100 mL). The organic layer was washed with water (30 mL), 5% lithium chloride (2 x 30 mL), and brine (30 mL), dried with sodium sulfate, and concentrated to afford l,3-dibromo-5-(ethylthio)- 2-methylbenzene (0.90 g, 93% yield) as a pale yellow oil. 1H NMR (400 MHz, CDC13) δ 7.54 (s, 2H), 2.92 (q, 2H), 2.52 (s, 3H), 1.31 (t, 3H). [0689] To a solution of l,3-dibromo-5-(ethylthio)-2-methylbenzene (0.88 g, 2.84 mmol) in dichloromethane (30 mL) was added m-chloroperbenzoic acid (70%, 2.80 g) at 0 °C. The ice batch was removed and the resulting mixture was stirred at room temperate for 5 h. The mixture was diluted with ethyl acetate (200 mL), washed with saturated sodium bicarbonate (3 x 50 mL), and brine (30 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (hexanes: ethyl acetate 9:1) provided 1,3- dibromo-5-(ethylsulfonyl)-2-methylbenzene (0.57 g, 59% yield) as a colorless solid. 1H NMR (400 MHz, CDC13) δ 8.03 (s, 2H), 3.14 (q, 2H), 2.66 (s, 3H), 1.31 (t, 3H).
[0690] A mixture of l,3-dibromo-5-(ethylsulfonyl)-2-methylbenzene (400 mg, 1.17 mmol), Boc-piperazine (218 mg, 1.17 mmol), sodium tert-butoxide (160 mg, 1.66 mmol), Pd2(dba)3 (55 mg, 0.06 mmol), and BINAP (110 mg, 0.18 mmol) in toluene (5 mL) was stirred at 100 °C for 17 h. Column chromatography of the mixture on silica (hexanes: ethyl acetate 4:1) gave 1,1-dimethylethyl 4-[3-bromo-5-(ethylsulfonyl)-2- methylphenyl]piperazine-l -carboxylate (184 mg, 35% yield) as a yellow solid. !H NMR (400 MHz, CDC13) δ 7.82 (d, 3H), 7.43 (d, IH), 3.60 (br s, 4H), 3.11 (q, 2H), 2.18 (m, 4H), 2.46 (s, 3H), 1.49 (s, 9H), 1.29 (t, 3H).
[0691] A mixture of 1,1-dimethylethyl 4-[3-bromo-5-(ethylsulfonyl)-2-methylphenyl]- piperazine-1 -carboxylate (220 mg, 0.49 mmol), l-(2-aminoethyl)pyrrolidine (90 mg, 0.79 mmol), sodium tert-butoxide (95 mg, 0.98 mmol), Pd2(dba)3 (22 mg, 0.02 mmol), and BINAP (46 mg, 0.07 mmol) in toluene (3 mL) was stirred in a sealed pressure vessel at 100 °C for 2 h. Column chromatography of the mixture on silica (dichloromethane: methanol 95:5) afforded 1,1-dimethylethyl 4-{5-(ethylsulfonyl)-2-mefhyl-3-[(2-pyrrolidin- l-ylethyl)amino]phenyl}piperazine-l-carboxylate (158 mg, 67% yield) as a yellow oil. 1H NMR (400 MHz, d4-methanol) δ 6.95 (d, IH), 6.88 (d, IH), 3.58 (br s, 4H), 3.52 (t, 2H), 3.30 (m, 4H), 3.09 (br s, 4H), 2.84 (br s, 4H), 2.23 (s, 3H), 1.99 (m, 4H), 1.48 (s, 9H), 1.21 (t, 3H); MS (ESI) for C24H40 4O4S: 481 (MH*).
[0692] A mixture of 1,1-dimethylethyl 4-{5-(ethylsulfonyl)-2-methyl-3-[(2-pyrrolidin- l-ylethyl)amino]phenyl}piperazine-l -carboxylate (155 mg, 0.32 mmol), methanol (5 mL), and 4N hydrochloric acid in dioxane (5 mL) was refluxed for 1 min. The mixture was concentrated to 5-(ethylsulfonyl)-2-methyl-3-piperazin- 1 -yl-N-(2-pyrrolidin- 1-ylethyl)- aniline hydrochloride (170 mg, 100% yield) which was used without further purification. MS (ESI) for C19H32N4O2S: 381 (MH*). [0693] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:
[0694] 2-methyl-5-(methylsulfonyl)-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: MS (ESI) for C18H30N4O2S: 367 (MH*).
[0695] EXAMPLE 34: 5-bromo-2-methyl-3-piρerazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline hydrochloride
[0696] A mixture of 3,5-dibromo-4-methylbenzoic acid (6.3 g, 21.4 mmol), potassium carbonate (4.4 g, 32.1 mmol), and benzyl bromide (3.7 g, 21.7 mmol) in acetone (100 mL) was refluxed for 3 h. The resulting mixture was partitioned between ethyl acetate (300 mL) and water (100 mL). The organic layer was washed with water (2 x 100 mL), and brine (100 mL), dried with sodium sulfate, and concentrated to give phenylmethyl 3,5- dibromo-4-methylbenzoate (7.5 g, 91% yield) as a pale yellow solid. 1H NMR (400 MHz, CDC13) δ 8.18 (s, 2H), 7.41 (m, 5H), 5.35 (s, 2H), 2.62 (s, 3H).
[0697] A mixture of phenylmethyl 3,5-dibromo-4-methylbenzoate (7.50 mg, 19.53 mmol), Boc-piperazine (3.64 g, 19.53 mmol), cesium carbonate (8.91 g, 27.34 mmol), Pd2(dba)3 (0.89 g, 0.98 mmol), and BINAP (1.82 g, 2.93 mmol) in toluene (100 mL) was stirred at 100 °C for 16 h. The reaction mixture was filtered through celite and concentrated. Column chromatography on silica (hexanes: ethyl acetate 9:1) gave 1,1- dimethylethyl 4-(3-bromo-2-methyl-5-{ [(phenylmethyl)oxy]carbonyl }phenyl)piperazine- 1-carboxylate (4.04, 42% yield) as a yellow solid. !H NMR (400 MHz, CDC13) δ 8.00 (d, IH), 7.64 (d, IH), 7.40 (m, 5H), 5.35 (s, 2H), 3.58 (br s, 4H), 2.85 (m, 4H), 2.43 (s, 3H), 1.49 (s, 9H).
[0698] A mixture of 1,1-dimethylethyl 4-(3-bromo-2-methyl-5-{[(phenylmethyl)- oxy]carbonyl}phenyl)piperazine-l-carboxylate (2.10 g, 4.29 mmol), l-(2- aminoethyl)pyrrolidine (0.74 g, 6.44 mmol), cesium carbonate (2.80 g, 8.58 mmol), Pd2(dba)3 (0.20 g, 0.21 mmol), and BINAP (0.40 g, 0.64 mmol) in toluene (40 mL) was stirred at 100 °C for 16 h. The reaction mixture was filtered through celite and concentrated. Column chromatography on silica (dichloromethane: methanol 95:5 to 90 :10) afforded 1,1-dimethylethyl 4-{2-methyl-5-{[(phenylmethyl)oxy]carbonyl}-3-[(2- pyrrolidin-l-ylethyl)amino]phenyl}piperazine-l-carboxylate (0.91 g, 41% yield) as a brown foam. 1H NMR (400 MHz, CDC13) δ 7.40 (m, 5H), 7.20 (d, IH), 7.13 (d, IH), 5.35 (s, 2H), 4.41 (s, IH), 3.58 (br s, 4H), 3.26 (m, 2H), 2.83 (br s, 4H), 2.79 (t, 2H), 2.53 (m, 4H), 2.15 (s, 3H), 1.77 (m, 4H), 1.49 (s, 9H).
[0699] A solution of 1,1-dimethylethyl 4-{2-methyl-5-{[(phenylmethyl)- oxy]carbonyl}-3-[(2-pyrrolidin-l-ylefhyl)amino]phenyl}piperazine-l-carboxylate (3.94 g, 7.54 mmol) in dichloromethane (30 mL) and trifluoroacetic acid (30 mL) was stirred at room temperature for 90 min and then concentrated. Dichloromethane (60 mL) and diisopropylethylamine (10 mL) was added to the residue, and the resulting solution was cooled to 0 °C. Trifluoroacetic anhydride (3.56 g, 16.95 mmol) was added dropwise, and the mixture was stirred at 0 °C for 30 min and then at room temperature for 1 h. The reaction mixture was diluted with ethyl acetate (300 mL), washed with water (100 mL), saturated sodium bicarbonate (100 mL), water (100 mL), and brine (100 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane: methanol 97:3) provided phenylmethyl 4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoroacetyl)amino]- 5-[4-(trifluoroacetyl)piperazin-l-yl]benzoate (3.60 g, 78% yield) as a yellow foam. 1H NMR (400 MHz, CDC13) δ 7.79 (s, IH), 7.76 (s, IH), 7.40 (m, 5H), 5.39 (d, IH), 5.34 (d, IH), 4.43 (m, IH), 3.80 (br s, 4H), 3.13 (m, IH), 2.99 (m, 4H), 2.72 (m, IH), 2.61 (m, IH), 2.46 (m, 4H), 2.27 (s, 3H), 1.68 (br s, 4H).
[0700] A mixture of phenylmethyl 4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoro- acetyl)amino]-5-[4-(trifluoroacetyl)piperazin-l-yl]benzoate (3.60 g, 5.86 mmol) and palladium on carbon (0.60 g, 10%, contains 50% water) was stirred under an hydrogen atmosphere for 3 h. The raction mixture was filtered through celite, and concentrated to give 4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)- piperazin-l-yl]benzoic acid (3.13 g, 100% yield) as yellow semisolid. 1H NMR (400 MHz, CDC13) δ 7.91 (s, IH), 7.61 (s, IH), 4.48 (m, IH), 3.68 (br s, 4H), 3.51 (m, 2H), 3.25 (br s, 4H), 2.90 (m, 5H), 2.16 (s, 3H), 2.06 (m, 4H).
[0701] A solution of 4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoroacetyl)amino]-5-[4- (trifluoroacetyl)piperazin-l-yl]benzoic acid (0.98 g, 1.87 mmol) and pyridine (0.15 g, 1.85 mmol) in dichloromethane (10 mL) was cooled to 0 °C, and cyanuric fluoride (0.27 g, 2.01 mmol) was added dropwise. The mixture was stirred at 0 °C for 2.5 h, and then partitioned between dichloromethane (20 mL) and water (30 mL). The aqueous layer was extracted with more dichloromethane (2 x 20 mL), dried with sodium sulfate, and concentrated to afford 4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoroacetyl)amino]-5-[4- (trifluoroacetyl)piperazin-l-yl]benzoyl fluoride (1.05 g, 100% yield) as a yellow foam. MS (ESI) for C22H25F7N4O3: 527 (MH*).
[0702] A solution of 4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoroacetyl)amino]-5-[4- (trifluoroacetyl)piperazin-l-yl]benzoyl fluoride (1.05 g, 1.87 mmol) in dichloromethane (20 mL) was cooled to 0 °C, and sodium azide (1.20 g, 18.46 mmol) was added. The mixture was stirred at 0 °C for 3 h, and then partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted with more ethyl acetate (2 x 50 mL), washed with brine (50 mL), dried with sodium sulfate, and concentrated to give 4-methyl- 3- [(2-pyrrolidin- 1 -ylethyl)(trifluoroacetyl)amino] -5 - [4-(trifluoroacetyl)piperazin- 1 -yl] - benzoyl azide (0.88 g, 85% yield) as a yellow foam. 1H NMR (400 MHz, CDC13) δ 7.72 (s, IH), 7.69 (s, IH), 4.45 (m, IH), 3.87 (br s, 2H), 3.80 (m, 4H), 3.01 (m, 4H), 2.76 (br s, 4H), 2.29 (s, 3H), 1.88 (br s, 4H).
[0703] A solution of tert-butanol (2 mL) in toluene (20 mL) was heated to 100 °C, and a solution of 4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoroacetyl)amino]-5-[4-
(trifluoroacetyl)piperazin-l-yl]benzoyl azide (0.88 g, 1.60 mmol) and tert-butanol (2 mL) in toluene (20 mL) was added at that temperature. The mixture was stirred at 100 °C for 2 h, and then concentrated. Column chromatography on silica (dichloromethane: methanol 95:5) provided 1,1-dimethylethyl {4-methyl-3-[(2-pyrrolidin-l-ylethyl)(trifluoro- acetyl)amino]-5-[4-(trifluoroacetyl)piperazin-l-yl]phenyl}carbamate (0.42 g, 44% yield) as a yellow foam. 1H NMR (400 MHz, dVmethanol) δ 7.26 (s, IH), 7.18 (s, IH), 4.39 (m, IH), 3.82 (br s, 2H), 3.22 (m, IH), 2.96 (m, 4H), 2.80 (m, IH), 2.70 (m, IH), 2.61 (m, 4H), 2.17 (s, 3H), 1.80 (m, 4H), 1.51 (s, 9H).
[0704] A solution of 1,1-dimethylethyl {4-methyl-3-[(2-pyrrolidin-l-ylethyl)- (trifluoroacetyl)amino] -5- [4-(trifluoroacetyl)piperazin- 1 -yljphenyl } carbamate (0.42 g, 0.71 mmol) in dichloromethane (5 mL) and trifluoroacetic acid (5 mL) was stirred at room temperature for 3.5 h, and then concentrated. The residue was dissolved in ethyl acetate (50 mL), and washed with saturated sodium bicarbonate (50 mL). The aqueous layer was further extracted with ethyl acetate (2 x 30 mL), the combined organic layers were washed with brine (50 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane: methanol 95:5) gave N-{5-amino-2-mefhyl-3-[4-(trifIuoro- acetyl)piρerazin-l -yljphenyl }-2,2,2-trifluoro-N-(2-pyrrolidin-l-ylethyl)acetamide (0.23 g, 66% yield) as a yellow glass. 1H NMR (400 MHz, αVmethanol) δ 6.55 (d, IH), 6.39 (s, IH), 4.35 (m, IH), 3.80 (br s, 4H), 3.18 (m, IH), 2.93 (m, 4H), 2.77 (m, IH), 2.68 (m, IH), 2.58 (m, 4H), 2.08 (s, 3H), 1.80 (m, 4H).
[0705] A mixture of copper(II) bromide (120 mg, 0.54 mmol) and tert-butyl nitrite (76 mg, 0.66 mmol)in acetonitrile (8 mL) was cooled to 0 °C, and a solution of N-{5-amino- 2-methyl-3-[4-(trifluoroacetyl)piperazin-l-yl]phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-l- ylethyl)acetamide (220 mg, 0.44 mmol) in acetonitrile (2 mL) was added dropwise. The mixture was stirred at room temperature for 2 h, and then added into IN hydrochloric acid (100 mL). The aqueous layer was extracted with ethyl acetate (3 x 30 mL), washed with brine (30 mL), dried with sodium sulfate, and concentrated. Purification by reverse phase HPLC afforded N- { 5-bromo-2-methyl-3-[4-(trifluoroacetyl)piperazin- 1 -yljphenyl } -2,2,2- trifluoro-N-(2-pyrrolidin-l-ylethyl)acetamide (42 mg, 17% yield) as a yellow oil. MS (ESI) for C2ιH25BrF6N4O2: 559, 561 (MH*).
[0706] A mixture of N-{5-bromo-2-methyl-3-[4-(trifluoroacetyl)piperazin-l-yl]- phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-l-ylethyl)acetamide (42 mg, 0.08 mmol) and potassium carbonate (100 mg, 0.72 mmol) in methanol (5 mL) and water (0.5 mL) was stirred at 60 °C for 19 h, then concentrated and azeotroped with 2-propanol (2 x 5 mL) to give crude 5-bromo-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride, which was used without further purification. MS (ESI) for Cι7H27BrN4: 367, 369 (MET).
[0707] EXAMPLE 35: 2-[(3-chloro-5-piperazin-l-ylphenyl)oxy]-NN- diethylethanamine trifluoroacetate
[0708] A mixture of dichlorophenol (2.30 g, 14 mmol), cesium carbonate (7.00 g, 21 mmol), and benzyl bromide (2.43 g, 14 mmol) in DMF (20 mL) was stirred at room temperature for 4 h. The reaction mixture was poured into ice water,and extracted several times with ether. The organic layer was dried with sodium sulfate, and concentrated to provide l,3-dichloro-5-[(phenylmethyl)oxy]benzene (100% yield). 1H ΝMR (CDC13): δ 6.97 (s, IH), 6.88 (m, 2H), 5.03 (s, 2H).
[0709] A mixture of l,3-dichloro-5-[(phenylmethyl)oxy]benzene (0.56 g, 2.2 mmol), Boc-piperazine (0.5g, 2.64 mmol), sodium tert-butoxide (0.30 g, 3.12 mmol), Pd(dba)3 (0.02g, 1 mol%), and 2-(di-tert-butylphosphino)biphenyl (0.03g, 4 mol%) in toluene (4ml), was stirred at 90 °C for 15 h. Column chromatography on silica (ethyl acetate:hexanes 1: 8) afforded 1,1-dimethyl 4-{3-chloro-5- [(phenylmethyl)oxy]phenyl}ρiρerazine-l -carboxylate (0.70 g, 78% yield). MS (ESI) for C22H27ClN2O3: 347 (M-56).
[0710] A solution of 1,1-dimethylethyl 4-{3-chloro-5-
[(phenylmethyl)oxy]phenyl}piρerazine-l -carboxylate (190 mg, 0.47 mmol) in trifluoroacetic acid (4 mL) was refluxed for 5 h. The reaction mixture was concentrated to give 3-chloro-5-piperazin-l-ylρhenol (98 mg, 98% yield). MS (ESI) for C10H13C1N2O: 213 (MH*).
[0711] A solution of 3-chloro-5-piperazin-l-ylphenol (98 mg, 0.46 mmol) and Boc- anhydride (101 mg, 0.46 mmol) in THF (4 mL) was stirred at room temperature for 48 h. The reaction mixture was concentrated, the residue was dissolved in ethyl acetate, washed with water, and brine, dried with sodium sulfate, and concentrated to provide 1,1-dimethylethyl 4-(3-chloro-5-hydroxyphenyl)piperazine-l -carboxylate (150 mg, 100% yield). MS (ESI) for Cι5H2ιClN2O3 : 257 (M-56):
[0712] A mixture of 1,1-dimethylethyl 4-(3-chloro-5-hydroxyphenyl)piperazine-l- carboxylate (150 mg, 0.46 mmol), potassium carbonate (0.26 g, 1.84 mmol), and 2- (diethylamino)ethyl chloride hydrochloride (160 mg, 0.92 mmol) in DMF (3 mL) was stirred at 100 °C for 6 h. The reaction mixture was poured into ice water, and extracted several times with ethyl acetate. The organic layer was washed with water, brine, dried with sodium sulfate, and concentrated to give 1,1-dimethylethyl 4-(3-chloro-5-{[2- (diethylamino)ethyl]oxy}phenyl)piperazine-l -carboxylate yield (73 mg, 38% yield). MS (ESI) for C2ιH34ClN3O3: 412 (MH+).
[0713] A solution of 1,1-dimethylethyl 4-(3-chloro-5{ [2-
(diethylamino)ethyl]oxy}phenyl)piperazine-l-carboxylate (73 mg, 0.18 mmol) in trifluoroacetic acid (4 mL) was stirred at room temperature for 30 min. The reaction mixture was concentrated, and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, water, dried with sodium sulfate, and concentrated to afford 2-[(3-chloro-5-piperazin-l-ylphenyl)oxy]-N,N-diethylethanamine trifluoroacetate (100% yield). MS (ESI) for C16H26ClΝ3O: 312 (MH+).
[0714] Using the analogous synthetic techniques and substituting with alternative reagents, the following compound of the invention was prepared:
[0715] l-[3-chloro-5-(methyloxy)phenyl]piperazine: MS (ESI) for CnH15ClN2O: 228 (MIT). [0716] EXAMPLE 36: 5-[(2-ethylbutyl)oxy]-2-methyl-3-piperazin-l-yl-N-(2- pyrrolidin- 1 -ylethyl)aniline hydrochloride
[0717] A mixture of 3,5 dibromo-4-methylphenol (250 mg, 0.94 mmol), cesium carbonate (919 mg, 2.82 mmol) and 3-(bromomethyl)ρentane (197 μl, 1.41 mmol) were stirred in DMF (5 mL) at 60 °C for 16 h under nitrogen. The reaction mixture was diluted with ethyl acetate (50 mL), washed with water (20 mL), 5% lithium chloride (20 mL), and brine (20 mL), dried over sodium sulfate, and concentrated to give l,3-dibromo-5-[(2- ethylbutyl)oxy]-2-methylbenzene (300 mg, 91% yield) as a colorless oil. !H ΝMR (400 MHz, CDC13) δ 7.10-7.08 (br s, 2H), 3.80-3.77 (m, 2H), 2.48 (s, 3H), 1.69-1.57 (m, IH), 1.51-1.36 (m, 4H), 0.92 (t, 6H).
[0718] To l,3-dibromo-5-[(2-ethylbutyl)oxy]-2-methylbenzene (289 mg, 0.83 mmol) in dry toluene (3 mL) was added Pd2(dba)3 (76 mg, 0.083 mmol), BIΝAP (154 mg, 0.25 mmol), sodium tert-butoxide (109 mg, 1.16 mmol), and Boc-piperazine (163 mg, 0.87 mmol). The reaction mixture was stirred at 110 °C for 16 h under nitrogen, cooled to room temperature, diluted with ethyl acetate (30 mL), filtered, and concentrated. Column chromatography on silica (hexanes: ethyl acetate 95:5) provided 1,1-dimethylethyl 4-{3- bromo-5-[(2-ethylbutyl)oxy]-2-methylphenyl}piperazine-l-carboxylate (200 mg, 53% yield) as a yellow oil. !H ΝMR (400 MHz, CDC13) δ 6.87 (d, IH), 6.52 (d, IH), 3.78 (d, 2H), 3.64-3.47 (br m, 4H), 2.86-2.75 (br m, 4H), 2.30 (s, 3H), 1.68-1.59 (m, IH), 1.51- 1.38 (m, 13H), 0.92 (t, 6H).
[0719] To 1,1-dimethylethyl 4-{3-bromo-5-[(2-ethylbutyl)oxy]-2- methylphenyl}piperazine-l -carboxylate (193 mg, 0.42 mmol) in anhydrous toluene (2 mL) was added Pd2(dba)3 (39 mg, 0.042 mmol), BIΝAP (79 mg, 0.13 mmol), sodium tert- butoxide (56 mg, 0.59 mmol) and l-(2-aminoethyl)pyrrolidine (64 μl, 0.51 mmol). The reaction mixture was refluxed for 4 h under nitrogen, diluted with ethyl acetate (20 mL), filtered and concentrated. Column chromatography on silica (dichloromethane:methanol 94:6) gave 1,1-dimethylethyl 4-{5-[(2-ethylbutyl)oxy]-2-methyl-3-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l -carboxylate (147 mg, 53% yield) as a yellow oil. 1H ΝMR (400 MHz, CDC13) δ 6.06 (d, IH), 6.01 (d, IH), 3.81 (d, 2H), 3.73-3.35 (br m, 4H), 3.34-3.22 (m, 2H), 2.94-2.73 (m, 6H), 2.72-2.53 (m, 4H), 2.05 (s, 3H), 1.83 (m, 4H), 1.72- 1.56 (m, IH), 1.55-1.35 (m, 13H), 0.93 (t, 6H); MS (ESI) for CZSHJSΝ^: 489 (MH+). [0720] A solution of 1,1-dimethylethyl 4-{5-[(2-ethylbutyl)oxy]-2-methyl-3-[(2- pyrrolidin-l-ylethyl)amino]phenyl}piperazine-l-carboxylate (141 mg, 0.29 mmol) in methanol (2mL) and 4N hydrogen chloride in dioxane (0.3ml) was refluxed for 2 min, and then concentrated to yield 5-[(2-ethylbutyl)oxy]-2-methyl-3-piperazin-l-yl-N-(2- pyrrolidin-l-ylethyl)aniline hydrochloride (130 mg, 99% yield). MS (ESI) for C23H40N4O: 389(MH*).
[0721] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0722] 2-methyl-5-[(2-methylpropyl)oxy]-3-piperazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline hydrochloride: MS (ESI) for C2ιH36N4O: 361 (MH*).
[0723] 5-(butyloxy)-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: MS (ESI) for C2ιH36N O: 361(MH*).
[0724] 5-[(2,2-dimethylpropyl)oxy]-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline hydrochloride: MS (ESI) for C22H38N4O: 375 (MH*).
[0725] 2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)-5-[(tetrahydrofuran-2- ylmethyl)oxy]aniline hydrochloride: MS (ESI) for C22H36N4O2: 389 (MH+).
[0726] 2-methyl-5- { [2-(methyloxy)ethyl] oxy } -3-piperazin- 1 -yl-N- (2-pyrrolidin- 1 - ylethyl)aniline hydrochloride: MS (ESI) for C20H34N4O2: 363 (MH*).
[0727] 5-{[(2,2-difluorocyclopropyl)methyl]oxy}-2-methyl-3-piperazin-l-yl-N-(2- pyrrolidin-l-ylethyl)aniline hydrochloride: MS (ESI) for C21H32F2N4O: 395 (MH*).
[0728] 5-[(cyclopropylmethyl)oxy] -2-methyl-3-piperazin- 1 -yl-N-(2-pyrrolidin- 1 - ylethyl)aniline hydrochloride: MS (ESI) for C21H34N4O: 359 (MET).
[0729] 2-methyl-5-[(3-methylbutyl)oxy] - 3-piperazin- 1 -yl-N-(2-pyrrolidin- 1- ylethyl)aniline hydrochloride: MS (ESI) for C22H38N4O: 375 (MH+).
[0730] 5-[(cyclohexylmethyl)oxy]-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline hydrochloride: MS (ESI) for C24H40N4O: 401 (MH*).
[0731] 5-[(cyclopentylmethyl)oxy]-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline: MS (ESI) for C23H38N4O: 387 (MH*).
[0732] 2-methyl-5-[(phenylmethyl)oxy]-3-piperazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline: MS (ESI) for C^Hμ^O: 395 (MH+). [0733] 5-[(cyclobutylmethyl)oxy]-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline hydrochloride: MS (ESI) for C22H36Ν4O: 373 (MH*).
[0734] 5-(ethyloxy)-2-methyl-3-piperazin- 1 -yl-N-(2-pyrrolidin- 1 -ylethyl)aniline hydrochloride: MS (ESI) for C19H32Ν4O: 333 (MET*).
[0735] 2-methyl-5-[(l-methylethyl)oxy]-3-piperazin-l-yl-N-(2-pyrrolidin-l- ylethyl)aniline hydrochloride: MS (ESI) for C20H34Ν4O: 347 (MH*).
[0736] 2-methyl-3-piperazin-l-yl-5-(propyloxy)-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride: MS (ESI) for C20H34Ν4O: 347 (MH+).
[0737] 2-methyl-3-piperazin-l-yl-N-(2-ρyrrolidin-l-ylethyl)-5-[(3,3,3- trifluoropropyl)oxy]aniline hydrochloride: MS (ESI) for C20H31F3Ν4O: 401 (MH+).
[0738] EXAMPLE 37: 3-bromo-4-methyl-N-phenyl-5-piperazin-l-ylbenzamide hydrochloride
[0739] To 1,1-dimethylethyl 4-{3-bromo-2-methyl-5-
[(methyloxy)carbonyl]phenyl}piperazine-l -carboxylate (1.05 g, 2.54 mmol) in methanol (10 mL) and water (3 mL) was added potassium hydroxide (713 mg, 12.7 mmol). The reaction mixture was stirred at 60 °C for 2 hours. The pH was adjusted to 5 with 10% citric acid, and the mixtare was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and concentrated to give 3-bromo-5-(4-{[(l,l- dimethylethyl)oxy]carbonyl}piperazin-l-yl)-4-methylbenzoic acid (849 mg, 84% yield) as a white solid. MS (ESI) for C17H23BrΝ2O4: 400 (MET*).
[0740] To 3-bromo-5-(4-{[(l,l-dimethylethyl)oxy]carbonyl}piperazin-l-yl)-4- methylbenzoic acid (25 mg, 0.06 mmol) in DMF (3 mL) was added aniline (58 mg, 0.63 mmol), HATU (24 mg, 0.06 mmol), HOAT (11 mg, 0.08 mmol), and N-methyl moφholine (34 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 17 h, and then diluted with water. The pH was adjusted to 10 with saturated sodium bicarbonate. The mixture was extracted with diethyl ether, the organic layer was dried over magnesium sulfate, and concentrated to provide 1,1-dimethylethyl 4-{3-bromo-2- methyl-5-[(phenylamino)carbonyl]phenyl}piperazine-l -carboxylate (30 mg, 100% yield) as a colorless oil. MS (ESI) for C23H28BrN3O3: 475 (MH*).
[0741] To 1,1-dimethylethyl 4-{3-bromo-2-methyl-5-
[(phenylamino)carbonyl]phenyl}piperazine-l-carboxylate (106 mg, 0.22 mmol) in methanol (5 mL) was added 4N hydrochloric acid in dioxane (1 mL). The reaction mixture was refluxed for 3 min, and then concentrated to yield 3-bromo-4-mefhyl-N- phenyl-5-piρerazin-l-ylbenzamide hydrochloride (84 mg, 100% yield) as a colorless oil. MS (ESI) for C18H20BrΝ3O: 375 (MH*).
[0742] EXAMPLE 38: l-{4-methyl-3-piperazin-l-yl-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl } butan- 1 -one hydrochloride
[0743] To methyl-3,5 dibromo-4-methylbenzoate ( 7.13 g, 23.2 mmol) in dry toluene (90 mL) was added Pd2(dba)3 (1.06 g, 1.16 mmol), BINAP (2.17 g, 3.48 mmol), cesium carbonate (10.6 g, 32.5 mmol) and Boc-piperazine (4.36 g, 23.2 mmol). The reaction mixture was stirred at 110 °C for 16 h under nitrogen, cooled to room temperature, diluted with ethyl acetate (300 mL), filtered and concentrated. Column chromatography on silica (hexanes: ethyl acetate 9:1) provided 1,1-dimethylethyl 4-{3-bromo-2-methyl-5- [(methyloxy)carbonyl]phenyl}piperazine-l-carboxylate (5.5 g, 57% yield) as a light yellow oil. MS (ESI) for C18H25BrN2O4: 313 (MH+-100).
[0744] To 1,1-dimethylethyl 4-{3-bromo-2-methyl-5-
[(methyloxy)carbonyl]phenyl}piperazine-l-carboxylate (5.5 g, 13.3 mmol) in dry toluene (50 mL) was added Pd2(dba)3 (610 mg, 0.66 mmol), BINAP (1.24g, 2.0 mmol), cesium carbonate (6.06 g, 18.6 mmol) and l-(2-aminoethyl)pyrrolidine (2.02 mL, 16.0 mmol). The reaction mixture was stirred at 100°C for 16 h under nitrogen, diluted with ethyl acetate (200 mL), filtered and concentrated. Column chromatography on silica (dichloromethane:methanol 93:7) afforded 1,1-dimethylethyl 4-{2-methyl-5- [(methyloxy)carbonyl]-3-[(2-pyrrolidin- 1 -ylethyl)amino]phenyl Jpiperazine- 1 -carboxylate (3.0 g, 50% yield) as an orange solid. MS (ESI) for C24H38N4O4: 447 (MET*).
[0745] To 1,1-dimethylethyl 4-{2-methyl-5-[(methyloxy)carbonyl]-3-[(2-ρyrrolidin-l- ylethyl)amino]phenyl}piperazine-l-carboxylate (2.6 g, 5.8 mmol) in methanol (12 mL) was added 4N sodium hydroxide (4.4 ml, 17.5 mmol), and the reaction mixture was stirred at room temperatare for 16 h. To the solution was added 1.5N hydrogen chloride until pH 4, and the water layer was extracted with chloroform (2 x 100 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over sodium sulfate, and concentrated to yield 3-(4-{[(l,l-dimethylethyl)oxy]carbonyl}piperazin-l-yl)-4- methyl-5-[(2-ρyrrolidin-l-ylethyl)amino]benzoic acid (2.5 g, 99% yield). MS (ESI) for C23H36N4O4: 433 (MH*). [0746] To 3-(4-{ [(l,l-dimethylethyl)oxy]carbonyl}ρiρerazin-l-yl)-4-methyl-5-[(2- pyrrolidin-l-ylethyl)amino]benzoic acid (1.5 g, 3.47 mmol) in dry DMF (9 mL) was added N-methyl moφholine (1.53 mL, 13.90 mmol), N,O-dimethylhydroxylamine hydrochloride (406 mg, 4.16 mmol), HATU (1.32 g, 3.47 mmol) and HOAt (570 mg, 4.16 mmol). The reaction mixture was stirred at room temperature for 16 h, and then partitioned between ethyl acetate (100 mL) and water (50 mL). The organic layer was washed with 5% lithium chloride (50 mL), brine (50 mL), dried over sodium sulfate and concentrated. Column chromatography on silica (dichloromethane:methanol 93:7) gave 1,1-dimethylethyl 4-{2- methyl-5-{[methyl(methyloxy)amino]carbonyl}-3-[(2-pyrrolidin-l-ylethyl)amino]- ρhenyl}piperazine-l -carboxylate (919 mg, 56% yield). MS (ESI) for C 5H4ιN5O4: 476 (MH*).
[0747] A solution of 1,1-dimethylethyl 4-{2-methyl-5-
[ [methyl(methyloxy)amino]carbonyl } -3-[(2-pyrrolidin- 1 - ylethyl)amino]phenyl}piperazine-l -carboxylate (300 mg, 0.63 mmol) in anhydrous THF (3 mL) was cooled to 0 °C, and a 2M solution of propylmagnesium bromide in THF (1.6 ml, 3.16 mmol) was slowly added. The reaction mixture was allowed to warm to room temperatare and stirred for 3 h. The solution was cooled again to 0 °C and 1.5N hydrogen chloride was added until pH 2. Then, saturated sodium bicarbonate was added until basic pH. The water layer was extracted with ethyl acetate (2 x 50 mL), washed with brine (50 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5) yielded 1,1-dimethylethyl 4-{5-butanoyl-2-methyl-3- [(2-pyrrolidin-l-ylethyl)amino]phenyl}piperazine-l-carboxylate (196 mg, 68% yield). MS (ESI) for C26H42N4O3: 459 (MH*).
[0748] A mixture of 1,1-dimethylethyl 4-{5-butanoyl-2-methyl-3-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l -carboxylate (30 mg, 0.07 mmol) in methanol (2 mL) and 4N hydrogen chloride in dioxane (0.2 ml) was refluxed for 2 min, and then concentrated to afford l-{4-methyl-3-piperazin-l-yl-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl}butan-l-one hydrochloride (28 mg, 99% yield). MS (ESI) for C2ιH34N4O: 359 (MH*).
[0749] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0750] 1 - { 4-methyl-3-piperazin- 1 -yl-5 -[(2-pyrrolidin- 1 -ylethyl)amino]phenyl Jpentan- 1-one hydrochloride: MS (ESI) for C22H36N4O: 373 (MH*). [0751] {4-methyl-3-piperazin-l-yl-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl}(phenyl)methanone hydrochloride: MS (ESI) for C24H32N O: 393 (MH*).
[0752] 1 - { 4-methyl-3 -piperazin- 1 -yl-5 -[(2-pyrrolidin- 1 -ylethyl)amino]phenyl Jpropan- 1-one hydrochloride: MS (ESI) for C20H32N4O: 345 (MH*).
[0753] 1 - { 4-methyl-3 -piperazin- 1 -yl-5-[(2-pyrrolidin- 1 - ylethyl)amino]phenyl } ethanone
[0754] hydrochloride: MS (ESI) for C19H30N4O: 331 (MH*).
[0755] 4,4,4-trifluoro-l-{4-methyl-3-piperazin-l-yl-5-[(2-pyrrolidin-l-ylethyl)amino]- phenyl}butan-l-one hydrochloride: MS (ESI) for C21H31F3N4O: 413 (MH*).
[0756] cyclopropyl { 4-methyl-3 -piperazin- 1 -yl-5- [(2-pyrrolidin- 1 -ylethyl)amino] - phenyl }methanone hydrochloride: MS (ESI) for C2ιH32N4O: 395 (MH*).
[0757] EXAMPLE 39: 5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-l-yl-N-(2- pyrrolidin- 1 -ylethyl)aniline hydrochloride
[0758] To 3,5-dibromo-4-methylphenol (19.0 g, 71.4 mmol) in toluene (200 mL) was added 1,1-dimethylethyl piperazine-1 -carboxylate (11.9 g, 63.9 mmol), Pd2(dba)3 (1.63 g, 1.8 mmol), sodium tert-butoxide (19.3 g, 201 mmol), and BIΝAP (4.40 g, 7.1 mmol). The reaction mixture was heated to 110 °C in a sealed tube for 16 h, and then partitioned between with water and ethyl acetate. The organic layer was diluted with ether, filtered, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes: ethyl acetate 8:2) provided 1,1-dimethylethyl 4-(3-bromo-5-hydroxy-2-methylphenyl)- piperazine-1-carboxylate (9.75 g, 41.1% yield) as a white solid. MS (ESI) for C16H23BrΝ2O3: 372 (MH*).
[0759] To 1,1-dimethylethyl 4-(3-bromo-5-hydroxy-2-methylphenyl)piperazine-l- carboxylate (990 mg, 2.67 mmol) in toluene (5 mL) was added 2-pyrrolidin- 1-yl- ethylamine (623 mg, 5.33 mmol), sodium tert-butoxide (512 mg, 5.33 mmol), Pd2(dba)3 (123 mg, 0.13 mmol), and 2-(di-t-butylphosphino)biphenyl (159 mg, 0.53 mmol). The reaction mixture was stirred at 110 °C for 16 h, and filtered through celite. The filtrate was diluted with water, extracted with ethyl acetate, dried over sodium sulfate, and concentrated to give 1,1-dimethylethyl 4-{5-hydroxy-2-methyl-3-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l -carboxylate (1.08 g, 100% yield) as a brown oil, which was used without further purification. MS (ESI) for C22H36N4O3: 405 (MH*). [0760] To 1,1-dimethylethyl 4-{5-hydroxy-2-methyl-3-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l-carboxylate (1.08 g, 2.67 mmol) in methylene chloride (10 mL), was added triethylamine (540 mg, 5.34 mmol), and triflic anhydride (829 mg, 2.94 mmol) at -78 °C. The reaction mixture was stirred at -78 °C for 30 min and then at room temperature for 16 h. The reaction was quenched with water, extracted with methylene chloride, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane :methanol 9:1) afforded 1,1-dimethylethyl 4- (2-methyl-3-[(2-pyrrolidin-l-ylethyl)amino]-5-
{[(trifluoromethyl)sulfonyl]oxy}phenyl)piperazine-l -carboxylate (873 mg, 61% yield) as a light brown oil. MS (ESI) for C23H35F3N4O5S: 537 (MH*).
[0761] To 1,1-dimethylethyl 4-(2-methyl-3-[(2-pyrrolidin-l-ylethyl)amino]-5- { [(trifluoromethyl)sulfonyl]oxy}phenyl)piperazine-l-carboxylate (256 mg, 0.48 mmol) in DMF (3 mL) was added 3,3-dimethyl-but-l-yne (588 mg, 7.16 mmol), PdCl2(PPh3)2 (50 mg, 0.07 mmol), copper(I) iodide (41 mg, 0.22 mmol), and triethylamine (965 mg, 9.54 mmol). The reaction mixture was stirred in a sealed tube at 100 °C for 16 h, and filtered. The filtrate was diluted with water, extracted with ethyl acetate, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 9:1) provided 1 , 1 -dimethylethyl 4- { 5-(3,3-dimethylbut- 1-yn- 1 -yl)-2-methyl-3-[(2-pyrrolidin- 1 - ylethyl)amino]phenyl}piperazine-l-carboxylate (224 mg, 100% yield) as a pink oil. MS
Figure imgf000136_0001
[0762] To a solution of 1,1-dimethylethyl 4-{5-(3,3-dimethylbut-l-yn-l-yl)-2-methyl- 3-[(2-pyrrolidin-l-ylethyl)amino]phenyl}piperazine-l-carboxylate (200 mg, 0.43 mmol) in ethyl acetate (40 mL) arid glacial acetic acid (4 mL) was added palladium on carbon (100 mg, 10%, contains 50% water), and the reaction mixture was stirred under an hydrogen atmosphere for 3 h. The reaction mixture was filtered through celite, and concentrated. The filtrate was diluted with water, the pH adjusted to 10, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated to give 1,1-dimethylethyl 4-{5-(3,3-dimethylbutyl)-2-methyl-3-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l -carboxylate (202 mg, 100% yield) as a light tan oil. MS (ESI) for C28H48N4O2: 473 (MH*).
[0763] To 1,1-dimethylethyl 4-{5-(3,3-dimethylbutyl)-2-methyl-3-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l-carboxylate (210 mg, 0.44 mmol) in methanol (5 mL) was added 4N hydrochloric acid in dioxane (1 mL). The reaction mixture was refluxed for 3 min and then concentrated to provide 5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-l-yl- N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride (166 mg, 100% yield) as a colorless oil. MS (ESI) for C23H40Ν4: 373 (MH*).
[0764] Using the same or analogous synthetic techniques and/or substitution with alternative reagents, the following compounds of the invention were prepared:
[0765] 2-methyl-5-(phenylethynyl)-3-piperazin- 1 -yl-N-(2-pyrrolidin- 1 -ylethyl)aniline: MS (ESI) for C25H32Ν4: 389 (MH*).
[0766] 5-ethynyl-2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline: MS (ESI) for C19H28Ν4: 313 (MH*).
[0767] 5-(3,3-dimethylbut- 1-yn- 1 -yl)-2-methyl-3-piperazin- 1 -yl-N-(2-pyrrolidin- 1 - ylethyl)aniline: MS (ESI) for C23H36Ν4: 369 (MH*).
[0768] 5-ethyl-2-methyl-3-ρiperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline: MS (ESI) for C19H32Ν4: 317 (MH*).
[0769] 2-methyl-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)-5-[2- (trimethylsilyl)ethyl]aniline: MS (ESI) for C22H40Ν4Si: 389 (MH*).
[0770] 2-methyl-5-(2-phenylethyl)-3-piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline: MS (ESI) for C25H36Ν4: 393 (MH*).
[0771] EXAMPLE 40: 2-Methyl-5-(3-phenyl-l,2,4-oxadiazol-5-yl)-3-piperazin-l-yl- N-(2-pyrrolidin- 1 -ylethyl)aniline hydrochloride
[0772] To a solution of 3,5-dibromo-4-methylbenzoic acid (500 mg, 1.70 mmol) in DMF (10 mL) was added HATU (951 mg, 2.50 mmol), benzamidineoxime (272 mg, 2.00 mmol) and diisopropylethylamine (505 mg, 3.90 mmol). The reaction mixtare was stirred at room temperature for 3 h, then diluted with ethyl acetate (100 mL), washed with saturated sodium bicarbonate (50 mL), 5% lithium chloride (2 x 50 mL), and brine (50 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes :ethyl acetate 4:1) afforded N'-{[(3,5-dibromo-4-methylphenyl)carbonyl]oxy}- benzenecarboximidamide (630 mg, 90% yield) as a yellow solid. 1H NMR (400 MHz, de- DMSO) δ 8.39 (s, 2H), 7.75 (m, 2H), 7.50 (m, 3H), 7.16 (s, 2H), 2.60 (s, 3H).
[0773] To a solution of N'-{[(3,5-dibromo-4-methylphenyl)carbonyl]oxy}benzene- carboximidamide (620 mg, 1.50 mmol) in THF (10 mL) was added a 1.0 M solution of tetrabutylammonium fluoride in THF (1.50 mL). The reaction mixture was stirred at room temperature for 17 h, then diluted with ethyl acetate (100 mL), washed with water (50 mL), and brine (50 mL), dried over sodium sulfate, and concentrated. Tritaration with ethyl acetate provided 5-(3,5-dibromo-4-methylphenyl)-3-phenyl-l,2,4-oxadiazole (311 mg, 52% yield) as a colorless solid. !H NMR (400 MHz, d6-DMSO) δ 8.36 (s, 2H), 8.11 (m, 2H), 7.62 (m, 3H), 2.63 (s, 3H).
[0774] A mixture of 5-(3,5-dibromo-4-methylphenyl)-3-phenyl-l,2,4-oxadiazole (162 mg, 0.41 mmol), Boc-piperazine (76 mg, 0.41 mmol), sodium tert-butoxide (56 mg, 0.58 mmol), Pd2(dba)3 (19 mg, 0.02 mmol), and BINAP (38 mg, 0.06 mmol) in toluene (4 mL) was stirred at 110 °C for 16 h. Column chromatography of the mixtare on silica (hexanes: ethyl acetate 9:1) gave 1,1-dimethylethyl 4-[3-bromo-2-methyl-5-(3-phenyl-l,2,4-oxa- diazol-5-yl)phenyl]piperazine-l -carboxylate (76 mg, 37% yield) as a colorless solid. 1H NMR (400 MHz, CDC13) δ 8.17 (m, 3H), 7.78 (s, IH), 7.53 (m, 3H), 3.63 (br s, 4H), 2.95 (m, 4H), 2.49 (s, 3H), 1.50 (s, 9H).
[0775] A mixture of 1,1-dimethylethyl 4-[3-bromo-2-methyl-5-(3-phenyl-l,2,4- oxadiazol-5-yl)phenyl]piperazine-l -carboxylate (111 mg, 0.22 mmol), l-(2- aminoethyl)pyrrolidine (51 mg, 0.45 mmol), sodium tert-butoxide (49 mg, 0.51 mmol), Pd2(dba)3 (15 mg, 0.02 mmol), and BINAP (30 mg, 0.05 mmol) in toluene (4 mL) was stirred in a sealed pressure vessel at 100 °C for 12 h. Column chromatography of the mixture on silica (dichloromethane:methanol 95:5) gave 1,1-dimethylethyl 4-{2-methyl-5- (3-phenyl- 1 ,2,4-oxadiazol-5-yl)-3-[(2-pyrrolidin- l-ylethyl)amino]phenyl Jpiperazine- 1 - carboxylate (27 mg, 23% yield) as a yellow oil. !H NMR (400 MHz, d4-methanol) δ 8.13 (m, 2H), 7.95 (m, IH), 7.55 (m, 2H), 7.34 (s, IH), 7.27 (s, IH), 3.61 (m, 4H), 3.19 (br s, 4H), 2.90 (br s, 4H), 2.26 (s, 3H), 2.02 (m, 4H), 1.50 (s, 9H); MS (ESI) for oEUoNeO: 533 (MH*).
[0776] A mixture of 1,1-dimethylethyl 4-{2-mefhyl-5-(3-phenyl-l,2,4-oxadiazol-5- yl)-3-[(2-pyrrolidin-l-ylethyl)amino]phenyl}piperazine-l-carboxylate (27 mg, 0.05 mmol), methanol (2 mL), and 4N hydrochloric acid in dioxane (2 mL) was refluxed for 1 min. The mixture was concentrated to give 2-Methyl-5-(3-phenyl-l,2,4-oxadiazol-5-yl)-3- piperazin-l-yl-N-(2-pyrrolidin-l-ylethyl)aniline hydrochloride (31 mg, 100% yield) as a yellow oil, which was used without further purification. MS (ESI) for C2sH32N6O: 433 (MH*).
[0777] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared: [0778] 2-Methyl-5-(3-methyl-l,2,4-oxadiazol-5-yl)-3-ρiρerazin-l-yl-N-(2-pyrrolidin- l-ylethyl)aniline hydrochloride: MS (ESI) for C20H30NeO: 371 (MH*).
[0779] EXAMPLE 41: l-{3-piperazin-l-yl-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl }butan- 1 -one hydrochloride
[0780] To 1,1-dimethylethyl 4-{3-bromo-5-[(methyloxy)carbonyl]phenyl}piperazine- 1-carboxylate (2.65 g, 6.64 mmol) in toluene (70 mL) was added 2-tyrrolidin-l-yl-ethyl- amine (1.55 g, 13.3 mmol), cesium carbonate (8.65 g, 26.5 mmol), Pd2(dba)3 (486 mg, 0.531 mmol), and BINAP (992 mg, 1.59 mmol). The reaction mixtare was stirred at 110 °C in a sealed tube for 16 h, filtered, and concentrated. Column chromatography on silica (dichloromethane:methanol 9:1) gave 1,1-dimethylethyl 4-{3-[(methyloxy)carbonyl]-5- [(2-pyrrolidin-l-ylethyl)amino]phenyl}piperazine-l-carboxylate (1.53 g, 53% yield) as a tan oil. MS (ESI) for C23H36N4O4: 433 (MH*).
[0781] To 1,1-dimethylethyl 4-{3-[(methyloxy)carbonyl]-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l -carboxylate (924 mg, 2.13 mmol) in methanol (10 mL) and water (3 mL), was added potassium hydroxide (600 mg, 10.7 mmol). The reaction mixture was stirred at 60 °C for 1 h. The pH was adjusted to 4 with 10% citric acid. The reaction mixture was extracted with chloroform, and concentrated to provide 3- (4-{[(l,l-dimethylethyl)oxy]carbonyl}piperazin-l-yl)-5-[(2-pyrrolidin-l- ylethyl)amino]benzoic acid (262 mg, 29% yield) as a white solid. MS (ESI) for C22H34N4O4: 419 (MH*).
[0782] To 3-(4-{ [(l,l-dimethylethyl)oxy]carbonyl}piperazin-l-yl)-5-[(2-pyrrolidin-l- ylethyl)amino]benzoic acid (802 mg, 1.92 mmol), in DMF (5 mL) was added O,N- dimethyl-hydroxylamine (224 mg, 2.30 mmol), HATU (730 mg, 1.92 mmol), HOAT (313 mg, 2.30 mmol), and N-methyl moφholine (583 mg, 5.76 mmol). The reaction mixtare was stirred at 60 °C for 22 h, diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 92:8) gave 1,1-dimethylethyl 4-{3-{[methyl(methyloxy)amino]carbonyl}-5-[(2-pyrrolidin-l-ylethyl)amino]- phenyl}piperazine-l-carboxylate (316 mg, 36% yield) as an orange solid. MS (ESI) for C24H39N5O4: 462 (MH*).
[0783] To 1,1-dimethylethyl 4-{3-{[methyl(methyloxy)amino]carbonyl}-5-[(2- pyrrolidin-l-ylethyl)amino]phenyl}piperazine-l-carboxylate (150 mg, 0.33 mmol) in anhydrous THF (2 mL) was added propyl magnesium bromide (240 mg, 1.63 mmol). The reaction mixture was stirred at 0 °C for 10 min, and then at room temperatare for 2 h. Excess Grignard reagent was quenched with IN aqueous hydrogen chloride. The pH was adjusted to 10 with sodium bicarbonate, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 93:7) provided 1 , 1 -dimethylethyl 4- { 3-butanoyl-5-[(2-pyrrolidin- 1 -ylethyl)amino]phenyl } - piperazine-1 -carboxylate (20 mg, 14% yield) as a white solid. MS (ESI) for C25H4oN4O3: 445 (MH*).
[0784] To 1,1-dimethylethyl 4-{3-butanoyl-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl}piperazine-l -carboxylate (45 mg, 0.10 mmol) in methanol (5 mL) was added 4N hydrogen chloride in dioxane (1 mL). The reaction mixtare was refluxed for 3 min, and then concentrated to give l-{3-piperazin-l-yl-5-[(2-pyrrolidin-l- ylethyl)amino]phenyl}butan-l-one hydrochloride (35 mg, 100% yield) as a clear oil. MS (ESI) for C20H32N4O: 345 (MH*).
[0785] EXAMPLE 42: 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-l-yl- propyl)-phenyl] -piperazin- 1 -yl } - lH-pyrazolo[3 ,4-d]pyrimidine.
[0786] To a 50 mL recovery flask was added 4-(5-chloro-3-iodo-2-methyl-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester (1.25 g, 2.87 mmol, 1.0 eq.), tetra-n- butylammonium chloride (799 mg, 2.87 mmol, 1.0 eq.), sodium bicarbonate (604 mg, 7.18 mmol, 2.5 eq.), palladium (IT) acetate (13 mg, 0.02 eq.), and DMF (10 mL). Allyl alcohol (295 μL, 4.31 mmol, 1.5 eq.) was added and the reaction was heated at 50°C for 4h. The reaction mixture was filtered through Celite and the Celite cake was rinsed with EtOAc. The organic phase was washed with water (50 mL), 10% aq LiCI (2 x 50 mL), and saturated aq. sodium chloride (50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated to give black oil. The crude material was purified via column chromatography (20% EtOAc Hex) to give 4-[5-chloro-2-methyl-3-(3-oxo- propyl)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester as yellow oil (489 mg, 47%).
[0787] To a 25 mL recovery flask was added 4-[5-chloro-2-methyl-3-(3-oxo-propyl)- phenyl] -piperazine-1 -carboxylic acid tert-butyl ester (240 mg, 0.655 mmol, 1.0 eq.), pyrrolidine (274 μL, 3.28 mmol, 5.0 eq.), and 1,2-dichloroethane (5 mL). Upon stirring, NaBH(OAc)3 (278 mg, 1.31 mmol, 2.0 eq.) was added and the reaction was stirred at room temperature for lh. IN HCI (2 mL) was added and the reaction mixture was diluted with water (50 mL) and EtOAc (50 mL). The organic phase was washed with satarated aq. NaHCO3 (30 mL) and satarated aq. NaCl (30 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated to give 4-[5-chloro-2-methyl-3-(3- pyrrolidin-l-yl-propyl)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester as a gray paste that was used in the next step without further purification.
[0788] To a 25 mL recovery flask was added 4-[5-chloro-2-methyl-3-(3-pyrrolidin-l- yl-propyl)-phenyl] -piperazine-1 -carboxylic acid tert-butyl ester (278 mg, 0.665 mol, 1.0 eq.) and methanol (3 mL). 4N HCl/dioxane (4 mL) was added and the reaction was stirred for 2h at room temperature. LC/MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material of l-[5-chloro-2-methyl-3-(3-pyrrolidin-l-yl-propyl)-phenyl]-piperazine was used in the next reaction without further purification.
[0789] To a 25 mL recovery flask was added l-[5-chloro-2-methyl-3-(3-pyrrolidin-l- yl-propyl)-phenyl]-piperazine dihydrochlori.de (280 mg, 0.713 mmol, 1.1 eq.), 3-bromo-l- (tetrahydro-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-4-ol (193 mg, 0.648 mmol, 1.0 eq.), N-methylmoφholine (285 μL, 2.59 mmol, 4.0 eq.), and DMF (5 mL). With stirring, PyBOP (506 mg, 0.972 mmol, 1.5 eq.) was added whereupon the reaction was heated at 80°C overnight. The reaction mixture was diluted with with H2O (50 mL) and EtOAc (50 mL). The organic phase was washed with 10% aq. LiCI (2 x 30 mL) satarated aq. NaCl (30 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated. The crude material was purified via column chromatography (1% to 4% CH3OH CH2Cl2) to give 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-l-yl-ρroρyl)- phenyl] -piperazin- 1 -yl } - 1 -(tetrahydro-pyran-2-yl)- lH-pyrazolo[3,4-d]pyrimidine as a white solid (186 mg).
[0790] 3-Bromo-4-{ 4-[5-chloro-2-mefhyl-3-(3-pyrrolidin- 1 - ylpropyl)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4-d]pyrimidine. To a 25 mL recovery flask was added 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-l-yl-propyl)-phenyl]- piperazin-l-yl}-l-(tetrahydro-pyrari-2-yl)-lH-pyrazolo[3,4-d]pyrimidine (186 mg, 0.309 mol, 1.0 eq.) and methanol (7.5 mL). 4N HCl/dioxane (2.5 mL) was added and the reaction was stirred for 30 min at room temperature. LC MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material was purified via reverse-phase HPLC to give pure product, 3- bromo-4- { 4- [5-chloro-2-methyl-3 -(3-pyrrolidin- 1 -ylpropyl)phenyl]piperazin- 1 -yl } - 1H- pyrazolo[3,4-d]pyrimidine as the TFA salt (60 mg, 31%). 1H NMR (400 MHz, d6-DMSO) δ 10.55 (br s, IH), 8.38 (s, IH), 7.04 (s, IH), 7.00 (s, IH), 3.54-3.50 (m, 2H), 3.17-3.12 (m, 2H), 3.02-2.94 (m, 6H), 2.67-2.63 (t, 2H), 2.54 (s, 2H), 2.27 (s, 3H), 1.98-1.85 (m, 6H). MS (ESI) for C23H29BrClN7: 518 (MH*).
[0791] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0792] 3-[3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-chloro- 2-methylphenyl}-N,N-diethylρropan-l -amine: !H NMR (400 MHz, de-DMSO) δ 10.03 (br s, IH), 8.38 (s, IH), 7.07 (d, IH), 7.00 (d, IH), 3.14-3.05 (m, 6H), 3.02-3.00 (m, 4H), 2.66-2.62 (t, 2H), 2.27 (s, 3H), 1.89 (m, 2H), 1.20 (t, 6H). MS (ESI) for C23H31BrClN7: 520 (MH*).
[0793] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-moφholin-4- ylpropyl)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de- DMSO) δ 10.61 (br. s, IH), 8.39 (s, IH), 7.04 (s, IH), 7.00 (s, IH), 3.98 (d, 4H), 3.75 (t, 2H), 3.49 (m, 2H), 3.31 (m, 2H), 3.13 (m, 2H), 3.09 (m, 2H), 3.01 (m, 4H), 2.63 (t, 2H), 2.28 (s, 3H), 1.97 (m, 2H). MS (ESI) for C23H29BrClN7O: 536 (MH*).
[0794] 3-Bromo-4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-l- yl)propyl]phenyl [piperazin- l-yl)-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de- DMSO) δ 11.43 (br. s, IH), 8.36 (s, IH), 6.99 (s, IH) 7.02 (s, IH), 3.95 (m, 4H), 3.79 (m, 2H), 3.67 (m, 2H), 3.52 (m, 2H), 3.35 (m, 2H), 3.19 (m, 2H), 3.01 (m, 4H), 2.83 (s, 3H), 2.64 (m, 2H), 2.28 (s, 3H), 1.98 (m, 2H). MS (ESI) for C24H32BrClN8: 549 (MH*).
[0795] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-piperidin-l-ylpropyl)phenyl]piperazin- l-yl}-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 10.01 (br. s, IH), 8.40 (s, IH), 7.07 (s, IH), 7.02 (s, IH), 3.98 (m, 4H), 3.43 (d, 2H), 3.09 (m, 2H), 3.04 (m, 4H), 2.85 (m, 2H), 2.62 (t, 2H), 2.28 (s, 3H), 1.96 (m, 2H), 1.79 (m, 2H), 1.71 (m, 2H), 1.39 (m, 2H). MS (ESI) for C24H31BrClN7: 534 (MH*).
[0796] 4-{4-[5-Chloro-2-methyl-3-(3-pyrrolidin-l-ylpropyl)phenyl]piperazin-l-yl}- lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 9.43 (br. s, IH), 8.19 (s, IH), 6.99 (s, IH), 6.96 (s, IH), 4.03 (m, 2H), 3.31 (m, 2H), 3.10 (m, 2H), 2.93 (m, 4H), 2.58 (m, 2H), 2.43 (m, 2H), 2.40 (m, 2H), 2.21 (m, 3H), 1.93 (m, 2H), 1.81 (m, 4H). MS (ESI) for C23H30C1N7: 440 (MH*).
[0797] 3-Bromo-4-{4-[5-fluoro-2-methyl-3-(3-ρyrrolidin-l- ylpropyl)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de- DMSO) δ 9.80 (br. s, IH), 8.89 (s, IH), 6.72 (m, 2H), 3.88 (m, 4H), 3.08 (m, 2H), 2.92 (m, 6 H), 2.57 (m, 2H), 2.39 (m, 2H), 2.17 (s, 3H), 1.92 (m, 2H), 1.79 (m, 4H). MS (ESI) for C23H29BrFN7: 504 (MH*).
[0798] 3-Bromo-4- { 4- [4-methyl-3-(3-pyrrolidin- 1 -ylpropyl)phenyl]piperazin- 1 -yl } - lH-pyrazolo[3,4-d]pyrimidine. MS (ESI) for C23H30BrN7: 486 (MH*).
[0799] (2E)-3-(4-{4-[5-Chloro-2-methyl-3-(3-pyrrolidin-l-ylpropyl)phenyl]piperazin- l-yl}-lH-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-enoic acid: Η NMR (400 MHz, de- DMSO) δ 9.51 (br. s, IH), 8.47 (s, IH), 7.72 (d, IH), 7.05 (s, IH), 6.98 (s, IH), 6.60 (d, IH), 3.80 (m, 4H), 3.52 (m, 4H), 3.19 (m, 2H), 3.0 (m, 4H), 2.63 (m, 2H), 2.25 (s, 3H), 2.02 (m, 2H), 1.86 (m, 4H). MS (ESI) for C26H32ClN7O2: 510 (MH*).
[0800] 3-(4-{4-[5-Chloro-2-methyl-3-(3-pyrrolidin-l-ylpropyl)phenyl]piperazin-l- yl}-lH-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-yn-l-ol: 1H NMR (400 MHz, d6-DMSO) δ 9.51 (br. s, IH), 8.32 (s, IH), 7.05 (s, IH), 7.02 (s, IH), 4.40 (s, 2H), 4.13 (m, 2H), 3.50 (m, 2H), 3.20 (m, 2H), 3.02 (m, 6H), 2.65 (m, 2H), 2.28 (s, 3H), 2.03 (m, 2H), 1.89 (m, 4H). MS (ESI) for C26H32ClN7O: 494 (MH*).
[0801] EXAMPLE 43: 3τBromo-4-{4-[5-Chloro-2-methyl-3-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine.
[0802] 4-(5-Chloro-3-iodo-2-methyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester was synthesized as in a previous procedure.
[0803] To a pressure vessels was added 4-(5-chloro-3-iodo-2-methyl-phenyl)-Boc piperazine (4.0g, 9.2 mmol), dry DMSO (18.0 mL), potassium acetate (2.7g mg, 27.6 mmol), bis-(pinacolato)diboron (2.5 mg, 10.1 mmol), and Pd(dppf)Cl2 dichloromethane complex (751 mg, 0.92 mmol). The reaction was sealed and heated to 80°C overnight. The reaction was then cooled to rt, filtered through celite, and flushed with EtOAc. The combined organic flushes were washed with water, brine, and dried with Na2SO , and concentrated. Column chromatography on silica gel with 10:90 EtOAc: hexanes gave 2.3 g of 4-[5-chloro-2-methyl-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- piperazine-1 -carboxylic acid tert-butyl ester as an oil that crystallizes to 4-[5-chloro-2- methyl-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester as a white solid (57% yield). 1H NMR (400 MHz, CDC13) δ 7.49 (d, IH), 7.05 (d, IH), 3.60 (br s, 4H), 2.85 (br m, 4H), 2.42 (s, 3H), 1.50 (s, 9H), 1.4-1.2 (s, 12H). MS (ESI) for C22H34BClN2O4: 437 (MH*).
[0804] To a round bottom flask cooled to 0°C was added 4-[5-chloro-2-Methyl-3- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-piperazine-l-carboxylic acid tert- butyl ester (2.3g, 5.3 mmol), THF (50.0 mL), 12.5M NaOH (1.25mL, 15.8 mmol), and 30% aq H2O2 (3.03 mL mg, 31.6 mmol). The reaction was stirred at 0°C for 30 min (or until complete) before quenching with 10% citric acid and EtOAc. The reaction was partitioned, and the EtOAc layer was dried with Na2SO4, and concentrated to obtain 4-(5- chloro-3-Hydroxy-2-methyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester as a white solid (1.8g, 100% yield). 1H NMR (400 MHz, CDC13) δ 6.62 (d, IH), 6.58 (d, IH), 6.22 (br s, IH), 3.60 (br s, 4H), 2.80 (br m, 4H), 2.18 (s, 3H), 1.50 (s, 9H). MS (ESI) for C16H23BClN2O3: 327 (MH*).
[0805] To a round bottom flask was added 4-(5-chloro-3-hydroxy-2-methyl-phenyl)- piperazine-1-carboxylic acid tert-butyl ester (150 mg, 0.46 mmol), DMF (4.0 mL), l-(2- chloroethyl pyrrolidine) HCI (156 mg, 0.92 mmol), and Cs2CO3 (598 mg, 1.84 mmol). The reaction was stirred at 60°C for 5 hr (or until complete) before quenching with 10% LiCI and EtOAc. The reaction was partitioned, and the EtOAc layer was dried with Na2SO4, and concentrated to obtain 4-[5-chloro-2-methyl-3-(2-pyrrolidin-l-yl-ethoxy)- phenyl]-piperazine-l-carboxylic acid tert-butyl ester as a brown oil (279 mg, 100% yield) which was taken to the next step without further purification. 1H NMR, (400 MHz, CDC13) δ 6.62 (br d, 2H), 4.10 (t, 2H), 3.80 (br s, 4H), 2.80 (br t, 4H), 2.60 (m, 4H), 2.18 (s, 3H), 1.80 (br m, 4H), 1.50 (s, 9H). MS (ESI) for C22H34BClN3O3: 424 (MH*).
[0806] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(2-pyrrolidin-l-yl-ethoxy)-phenyl]- piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine: To a round bottom flask was added 4-[5- chloro-2-methyl-3-(2-pyrrolidin- 1 -yl-ethoxy)-phenyl] -piperazine- 1 -carboxylic acid tert- butyl ester (279 mg, 0.65 mmol), MeOH (4.0 mL), and 4M HCI in dioxane. The reaction was stirred at RT for 1 hr (or until complete) before concentrating to obtain free-base as brown oil. The brown oil was dissolved in DMF (4.0 mL) before adding N- methylmoφholine (0.31 mL, 2.8 mmol), PyBop (436 mg, 0.84 mmol), and 3-bromo-l- (tetrahydro-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-4-ol (229 mg, 0.77 mmol). The reaction was heated to 60°C overnight. The reaction was then quenched with 50 mL EtOAc and 5 mL 10% LiCI, partitioned, dried with Na2SO , concentrated and columned with 90:10 EtOAc: hexane to give 3-bromo-4-{4-[5-chloro-2-methyl-3-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine. The THP group was removed by dissolving in MeOH (7.5 mL) and 4M HCI in dioxanes (2.5 mL), and heating to 60°C for 15 min. The reaction was concentrated and prep purified, and then converted to the HCI salt to give 65 mg of 3-bromo-4-{4-[5-chloro-2-methyl-3-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine (65 mg). 1H NMR (400MHz, de-DMSO) δ 11.3 (br s, IH), 8.40 (s, IH), 6.81 (d, 2H), 4.20 (t, 2H), 4.0 (br s, 4H), 3.60 (br q, 4H), 3.00 (m, 6H), 2.18 (s, 3H), 1.80-2.0 (br m, 4H). MS (ESI) for C22H27BrClN7O: 518 (MH*).
[0807] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0808] (2-{ 3-[4-(3-Bromo-lH-pyrazolo[3,4-d] pyrimidin-4-yl)-piperazin-l-yl]-5- chloro-2-methyl-phenoxy}-ethyl)-diethyl-amine: 1H NMR (400MHz, d6-DMSO) δ 10.7 (br s, IH), 8.40 (s, IH), 6.81 (d, 2H), 4.20 (buried t, 2H), 3.8 (br q, 2H), 3.20 (m, 4H), 3.00 (br t, 4H), 2.18 (s, 3H), 1.25 (t, 6H). MS (ESI) for C22H29BrClN7O: 520 (MH*).
[0809] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(2-piperidin-l-yl-ethoxy)-phenyl]- piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine: !H NMR (400MHz, d6-DMSO) δ 9.9 (br s, IH), 8.40 (s, IH), 6.81 (d, 2H), 4.40 (t, 2H), 4.0 (br s, 4H), 3.6 (m, 4H), 3.00 (m, 8H), 2.18 (s, 3H), 1.80 (m, 6H). MS (ESI) for C23H29BrClN7O: 532 (MH*).
[0810] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(2-moφholin-4-yl-ethoxy)-phenyl]- piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine: 1H NMR (400MHz, de-DMSO) δ 10.8 (br s, IH), 8.40 (s, IH), 6.81 (d, 2H), 4.40 (br t, IH), 4.0 (br m, 4H), 3.8 (t, 2H), 3.4 (m, 6H), 3.00 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C22H27BrClN7O2: 536 (MH*).
[0811] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-piperidin-l-yl-propoxy)-phenyl]- piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine: 1H NMR (400MHz, de-DMSO) δ 9.4 (br s, IH), 8.40 (s, IH), 6.81 (d, 2H), 4.15 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 2H), 3.0 (br s, 4H), 2.8 (m, 4H), 2.18 (s, 3H), 1.80 (m,4H). MS (ESI) for C24H31BrClN7O: 548 (MH*).
[0812] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-moφholin-4-yl-propoxy)-phenyl]- piperazin-l-yl}-lH-pyrazolo[3,4-d] pyrimidine: 1H NMR (400MHz, d6-DMSO) δ 10.5 (br s, IH), 8.40 (s, IH), 6.81 (d, 2H), 4.15 (br t, 2H), 4.0 (br m, 4H), 3.8 (t, 2H), 3.21 (m, 2H), 3.0 (m, 8H), 2.18 (s, 3H), 1.80 (m,4H). MS (ESI) for C23H29BrClN7O2: 548 (MH*). [0813] 3-Bromo-4- { 4-[4-methyl-3-(2-pyrrolidin- l-yl-ethoxy)-phenyl] -piperazin- 1 -yl } - lH-ρyrazolo[3,4-d] pyrimidine: 1H NMR (400MHz, d6-DMSO) δ 10.4 (br s, IH), 8.40 (s, IH), 7.05 (d, IH), 6.75 (s, IH), 6.6 (d, IH), 4.15 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C22H28BrN7O: 486 (MH+).
[0814] 4-{4-[4-Methyl-3-(2-pyrrolidin-l-yl-ethoxy)-phenyl]-piρerazin-l-yl}-lH- pyrazolo[3,4-d] pyrimidine: !H NMR (400MHz, d6-DMSO) δ 7.9,7.4 (d, IH), 7.05 (d, IH), 6.75 (s, IH), 6.6 (d, IH), 4.20 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C22H29N7O: 406 (MH*).
[0815] 3-Methyl-4-[4-[4-methyl-3-(2-pyrrolidin-l-yl-ethoxy)-phenyl]-piperazin-l- yl}-lH-pyrazolo[3,4-d] pyrimidine: 1H NMR (400MHz, d6-DMSO) δ 8.5 (s, IH), 7.9,7.4 (d,lH), 7.05 (d, IH), 6.75 (s, IH), 6.6 (d, IH), 4.20 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 4H), 2.8 (m,4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C23H32N7O: 422 (MH*).
[0816] 4- { 4-[5-Chloro-2-methyl-3-(2-pyrrolidin- 1 -yl-ethoxy)-phenyl] -piperazin- 1 -yl } - lH-pyrazolo[3,4-d] pyrimidine: JH NMR (400MHz, d6-DMSO) δ 10.6 (br s, IH), 6.8 (d,2H), 4.40 (br t, 2H), 4.10 (br s, 4H), 3.8 (m, 4H), 3.2 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C2 H28ClN7O: 442 (MH*).
[0817] 4-{ 4-[5-Chloro-2-methyl-3-(2-pyrrolidin- 1 -yl-ethoxy)-phenyl] -piperazin- 1 -yl } - 3-methyl- lH-pyrazolo[3,4-d] pyrimidine: 1H NMR (400MHz, de-DMSO) δ 10.9 (br s, IH), 8.6(br s,lH), 6.8 (d, 2H), 4.20 (br t, 2H), 4.10 (br s, 4 H), 3.8 (m, 4H), 3.2 (m, 8H), 2.80 (br s, 2H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C23H30C1N7O: 456 (MH*).
[0818] EXAMPLE 44: 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]-5-chloro-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline.
[0819] To a 15 mL pressure vessel was added 4-(5-chloro-3-iodo-2-methyl-phenyl)- piperazine-1-carboxylic acid tert-butyl ester (450 mg, 1.03 mmol, 1.0 eq.), Xant phos (36 mg, 0.062 mmol, 0.06 eq.), 2-pyrrolidinoethylamine (157 μL, 1.24 mmol, 1.2 eq.), and dioxane (4 mL). The suspension was bubbled with N2 upon which Pd2(dba)3 (28 mg, 0.031 mmol, 0.03 eq.) and sodium tert-butoxide (139 mg, 1.44 mmol, 1.4 eq.) was added. The vessel was sealed and heated at 100°C overnight. The crude reaction mixture was concentrated and chromatographed (3% to 10% CH3OH/CH2Cl2) to afford pure product 4- [5-chloro-2-methyl-3-(2-pyrrolidin-l-yl-ethylamino)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester as an oil (312 mg, 72%). [0820] To a 25 mL recovery flask was added 4-[5-chloro-2-methyl-3-(2-pyrrolidin-l- yl-ethylamino)-phenyl] -piperazine-1 -carboxylic acid tert-butyl ester (308 mg, 0.729 mol, 1.0 eq.) and CH3OH (4 mL). 4N HCl/dioxane (4 mL) was added and the reaction was stirred for 2h at room temperature. LC/MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material of (5-chloro-2-methyl-3-piperazin-l-yl-phenyl)-(2-pyrrolidin-l-yl-ethyl)- amine was used in the next reaction without further purification.
[0821] To a 25 mL recovery flask was added (5-chloro-2-methyl-3-piperazin-l-yl- phenyl)-(2-pyrrolidin-l-yl-ethyl)-amine dihydrochloride (287 mg, 0.728 mmol, 1.1 eq.), 3- bromo-l-(tetrahydro-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-4-ol (197 mg, 0.662 mmol, 1.0 eq.), N-methylmoφholine (364 μL, 3.31 mmol, 5.0 eq.), and DMF (7 mL). With stirring, PyBOP (689 mg, 1.32 mmol, 2.0 eq.) was added whereupon the reaction was heated at 80°C overnight. The reaction mixtare was diluted with with H2O (50 mL) and EtOAc (50 mL). The organic phase was washed with 10% aq. LiCI (4 x 30 mL) satarated aq. NaCl (30 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated. The crude material of (3-{4-[3-bromo-l-(tetrahydro-pyran-2-yl)-lH- pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-l-yl}-5-chloro-2-methyl-phenyl)-(2-pyrrolidin- l-yl-ethyl)-amine was purified via column chromatography (2% to 5% CH3OH/CH2Cl2) to give a white solid (470 mg).
[0822] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-chloro-2- methyl-N-(2-pyrrolidin-l-ylethyl)aniline: To a 25 mL recovery flask was added (3-{4-[3- bromo- 1 -(tetrahydro-pyran-2-yl)- 1 H-pyrazolo[3 ,4-d]pyrimidin-4-yl] -piperazin- 1 -yl } -5- chloro-2-methyl-phenyl)-(2-pyrrolidin-l-yl-ethyl)-amine (438 mg, 0.727 mol, 1.0 eq.) and methanol (5 mL). 4N HCl/dioxane (5 mL) was added and the reaction was stirred for 30 min at room temperature. LC MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material was purified via reverse-phase HPLC to give pure product 3-[4-(3-bromo-lH- pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-l- ylethyl)aniline as the TFA salt (60 mg, 13%). 1H NMR (400 MHz, d6-DMSO) δlθ.76 (br s, IH), 8.38 (s, IH), 6.47 (d, 2H), 3.96 (br s, 3H), 3.61 (m, 2H), 3.51-3.48 (m, 2H), 3.34- 3.31 (m, 2H), 3.03-2.97 (m, 6H), 2.12 (s, 3H), 2.01-1.96 (m, 2H), 1.90-1.87 (m, 2H). MS (ESI) for C22H28BrClN8: 521 (MH*). [0823] Using the same or analogous synthetic techniques and/or substitating with alternative reagents, the following compounds of the invention were prepared:
[0824] N'-{3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- chloro-2-methylρhenyl}-N,N-diethylethane-l,2-diamine: 1H NMR (400 MHz, d6-DMSO) δ 10.43 (br s, IH), 8.38 (s, IH), 6.50 (s, IH), 6.46 (s, IH), 3.96 (m, 4H), 3.52 (t, 2H), 3.22- 3.16 (m, 6H), 2.97 (m, 4H), 2.10 (s, 3H), 1.22 (t, 6H). MS (ESI) for C22H30BrClN8: 523 (MH*).
[0825] 5-Chloro-2-methyl-3-[4-(lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N- (2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, de-DMSO) δ 10.64 (s, IH), 8.55 (s, IH), 6.48 (d, IH), 6.43 (s, IH), 4.19 (m, 4H), 3.51 (t, 2H), 3.34-3.31 (2H), 2.98 (m, 6H), 2.14 (s, 3H), 2.00 (m, 2H), 1.89 (m, 2H). MS (ESI) for C22H29C1N8: 441 (MH*).
[0826] 5-Chloro-2-methyl-3-[4-(3-methyl-lH-pyrazolo[3,4-d]pyrimidin-4- yl)piperazin-l-yl]-N-(2-pyrrolidin-l-ylethyl)aniline: !H NMR (400 MHz, d6-DMSO) δ 10.96 (s, IH), 8.57 (s, IH), 6.46 (d, IH), 6.40 (d, IH), 3.59 (m, 2H), 3.49 (m, 2H), 3.30 (m, 2H), 2.98 (m, 6H), 2.76 (s, 3H), 2.14 (s, 3H), 2.00 (m, 2H), 1.89 (m, 2H). MS (ESI) for C23H31C1N8: 455 (MH*).
[0827] 5-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N- (2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, d6-DMSO) δ 10.14 (br s, IH), 8.40 (d, IH), 6.94 (m, IH), 6.50 (m, 2H), 4.02 (m, 4H), 3.34 (m, 4H), 3.05 (m, 2H), 2.07 (m, 3H), 2.01 (m, 2H), 1.89 (m, 2H). MS (ESI) for C22H29BrClN8: 485 (MH*).
[0828] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-fluoro-2- methyl-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, d6-DMSO) δ 10.33 (br s, IH), 8.37 (s, IH), 6.27 (td, 2H), 3.95 (m, 4H), 3.46 (t, 4H), 3.31 (m, 2H), 3.02 (m, 2H), 2.95 (m, 3H), 2.09 (s, 3H), 2.00 (m, 2H), 1.89 (m, 2H). MS (ESI) for C22H28BrFN8: 505 (MH*).
[0829] 3-Bromo-4-(4-pyridin-2-ylpiperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: !H NMR (400 MHz, de-DMSO) δ 8.40 (s, IH), 8.07-8.05 (m, 2H), 7.43 (d, IH), 7.00 (t, IH), 4.07-4.04 (m, 4H), 3.97-3.94 (m, 4H). MS (ESI) for 4H14BrN7: 360 (MH*).
[0830] 3-Bromo-4-[4-(2,4-dimethylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.36 (s, IH), 7.00 (s, IH), 6.95 (s, IH), 3.94 (m, 4H), 2.97 (t, 4H), 2.27 (s, 3H), 2.22 (s, 3H). MS (ESI) for Cι7H19BrN6: 389 (MH*).
[0831] 3-Bromo-4-{4-[3-(methyloxy)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.44 (s, 1H), 7.29 (t, IH), 6.98-6.95 (m, 2H), 6.68 (d, IH), 4.14 (m, 4H), 3.77 (s, 3H), 3.54 (t, 4H). MS (ESI) for C16Hι7BrN6O: 391 (MH*).
[0832] 3-Bromo-4- { 4-[2-(methyloxy)phenyl]piperazin- 1 -yl } - lH-pyrazolo[3,4- d]pyrimidine: !H NMR (400 MHz, d6-DMSO) δ 8.37 (s, IH), 7.00-6.97 (m, 2H), 6.92- 6.90 (m, IH), 3.96 (m, 4H), 3.82 (s, 3H), 3.18 (m, 4H). MS (ESI) for Cι6Hι7BrN6O: 391 (MH*).
[0833] 3-[4-(3-Ethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-fluoro-2- methyl-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, d6-DMSO) δ 11.10 (s, IH), 8.57 (s, IH), 6.30 (dd, IH), 6.21 (dd, IH), 4.13 (br s, 4H), 3.49-3.48 (m, 2H), 3.51- 3.48 (m, 2H), 3.32-3.29 (m, 2H), 3.15-3.10 (m, 2H), 3.00-2.96 (m, 6H), 2.12 (s, 3H), 2.02- 1.97 (m, 2H), 1.91-1.87 (m, 2H), 1.31 (t, 3H). MS (ESI) for C24H33FN8: 453 (MH*).
[0834] 5-Fluoro-2-methyl-N-(2-pyrrolidin-l-ylethyl)-3-{4-[3-(trifluoromethyl)-lH- pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-l-yl}aniline: 1H NMR (400 MHz, d6-DMSO) HCI salt δ 10.49 (br s, IH), 8.48 (s, IH), 6.28 (dd, IH), 6.21 (dd, IH), 3.84 (m, 4H), 3.61- 3.59 (m, 2H), 3.48 (t, 2H), 3.32-3.29 (m, 2H), 3.02 (m, 2H), 2.89 (m, 4H), 2.09 (s, 3H), 2.03-1.97 (m, 2H), 1.93-1.87 (m, 2H). MS (ESI) for C23H28F4N8: 493 (MH*).
[0835] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N- [(cyclopropylmethyl)oxy]-4-methyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide: 1H
NMR (400 MHz, CDC13) δ 8.42 (s, IH), 7.26 (s, IH), 6.90 (s, IH), 6.81 (s, IH), 4.47 (s, IH), 4.12 (s, IH), 3.87 (s, 2H), 3.33 (s, 2H), 3.06 (s, 4H), 2.86 (s, 2H), 2.64 (s, 4H), 2.15 (s, 3H), 2.05 (s, IH), 1.83 (s, 4H), 1.26-1.20 (m, 2H), 0.60 (s, 2H), 0.33 (s, 2H). MS (ESI) for C27H36BrN9O2: 600 (MH*).
[0836] EXAMPLE 45: 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]-4-methyl-N-phenyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide.
[0837] To 4-[5-carboxy-2-methyl-3-(2-pyrrolidin-l-yl-ethylamino)-phenyl]- piperazine-1 -carboxylic acid tert-butyl ester (118 mg, 0.27 mmol) in DMF (3 mL) was added triethylamine (82 mg, 0.81 mmol), HOBT (93 mg, 0.68 mmol), EDCI (136 mg, 0.68 mmol) and phenylamine (46 mg, 0.49 mmol). After heating the reaction mixtare at 70°C for 1 hour the reaction was cooled to room temperatare. Ethyl Acetate was added and the organic layer was washed twice with water (50 ml), once with IN HCI (50 ml), twice with 5% LiCI (50 ml), and once with brine (50 ml). The organic layer was dried over sodium sulfate and the solvent was removed to yield 4-[2-methyl-5- phenylcarbamoyl-3-(2-pyrrolidin-l-yl-ethylamino)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester (133 mg, 96% yield). 1H NMR (400 MHz, de-DMSO) δ 8.91 (s, IH), 7.89 (d, 2H), 7.35 (t, 2H), 7.14 (m, 3H), 6.74 (d, IH), 4.60 (m, IH), 3.86 (m, 3H), 3.58 (br, s, IH), 3.24 (t, 3H), 2.84 (m, 6H), 2.17 (s, 3H), 2.10 (m, 5H), 1.49 (s, 9H), 1.28 (m, 3H), 0.90 (t, IH). MS (ESI) for C29H41N5O3: 508 (MH*).
[0838] To 4-[2-methyl-5-phenylcarbamoyl-3-(2-pyrrolidin- 1 -yl-ethylamino)-phenyl] - piperazine-1-carboxylic acid tert-butyl ester (106.1 mg, 0.21 mmol) in THF (3 mL) was added excess triethylamine and 3-Bromo-4-chloro-lH-pyrazolo[3,4-d]pyrimidine (60 mg, 0.25 mmol. The reaction was heated to reflux for lhour upon which the reaction was cooled to room temperature. Water 50ml was added and the product was extracted into ethyl acetate (50ml). After extraction the organic layer was washed once with water (50 ml) and once with brine (50ml). The organic layer was dried over sodium sulfate and the solvent removed under vacuum. Purification was carried out by column chromatography starting with straight DCM then a 5% MeOH/DCM solution and ending with a 10% MeOH/DCM solution. The product of 3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4- yl)piperazin-l-yl]-4-methyl-N-phenyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide was isolated and precipitated out of hexane (59.7 mg, 46% yield). 1H NMR (400 MHz, de- DMSO) δ 10.88 (br, s, IH), 10.15 (s, IH), 8.41 (s, IH), 7.78 (d, 2H), 7.34 (m, 3H), 7.08 (m, 3H), 4.07 (br, s, 3H), 3.64 (m, 4H), 3.38 (m, 2H), 3.07 (m, 6H), 2.24 (s, 3H), 2.01 (m, 2H), 1.88 (m, 2H). MS (ESI) for C29H34BrN9O: 602 (MH").
[0839] Using the same or analogous synthetic techniques and/or substitating with alternative reagents, the following compounds of the invention were prepared:
[0840] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N,N,4- trimethyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide. 1H NMR (400 MHz, d6-DMSO) δ 8.49 (s, IH), 6.62 (s, IH), 6.58 (s, IH), 3.78 (m, IH), 3.65 (s, IH), 3.61 (t, IH), 3.22 (s, 6H), 3.09 (br, s, 4H), 3.02 (br, s, 4H), 2.30 (s, 3H), 2.18 (m, 2H), 2.05 (m, 3H), 1.29, (t, 2H), 0.91 (t, 2H). MS (ESI) for C25H34BrN9O: 556 (MH*).
[0841] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (pyrrolidin-l-ylcarbonyl)-N-(2-pyrrolidin-l-ylethyl)aniline. !H NMR (400 MHz, d6- DMSO) δ 14.18 (br, s, IH), 10.42 (br, s, IH), 8.38 (s, IH), 6.58 (s, IH), 6.38 (s, IH), 3.61 (m, 3H), 3.51 (t, 2H), 3.42 (m, 4H), 3.33 (m, 3H), 2.99 (br, s, 7H), 2.17 (s, 3H), 2.01 (m, 2H), 1.83 (m, 4H), 1.76 (m, 3H). MS (ESI) for C27H36BrN9O: 582 (MH*).
[0842] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N,4- dimethyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide. 1H NMR (400 MHz, d6-DMSO) δ 8.36 (s, IH), 8.26 (m, IH), 6.92 (s, IH), 6.85 (s, IH), 4.91 (t, IH), 3.96 (br, s, 3H), 3.22 (m, 4H), 2.98 (m, 4H), 2.75 (d, 3H), 2.58 (m, 4H), 2.10 (s, 3H), 1.72 (m, 4H), 1.23 (m, 2H). MS (ESI) for C24H32BrN9O: 542 (MH*).
[0843] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N-(4- chlorophenyl)-4-methyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide. JH NMR (400 MHz, de-DMSO) δ 10.11 (s, IH), 8.37 (s, IH), 7.81 (d, 2H), 7.41 (d, 2H), 7.06 (s, IH), 6.97 (s, IH), 4.03 (m, 3H), 3.45 (m, 2H), 3.03 (m, 10H), 2.18 (s, 3H), 1.84 (m, 5H), 1.17 (m, 2H). MS (ESI) for C29H33BrClN9O: 638 (MH*).
[0844] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N-(2- chlorophenyl)-4-mefhyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide. 1H NMR (400 MHz, de-DMSO) δ 10.14 (s, IH), 8.45 (s, IH), 7.87 (s, 2H), 7.62 (d, IH), 7.39 (t, IH), 7.12 (d, IH), 7.03 (s, IH), 6.91 (s, IH), 5.09 (m, IH), 3.99 (m, 3H), 3.33 (m, 5H), 3.06 (m, 5H), 2.85 (m, 2H), 2.69 (m, 3H), 2.18 (s, 3H), 1.76 (m, 4H). MS (ESI) for C29H33BrClN9O: 638 (MH*).
[0845] Methyl-3-bromo-5-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin- l-yl]-4-methylbenzoate. 1H NMR (400 MHz, de-DMSO) δ 14.08 (br, s, IH), 8.38 (s, IH), 7.85 (s, IH), 7.61 (s, IH), 3.97 (br, s, 4H), 3.85 (s, 3H), 3.08 (br, s, 4H), 2.46 (s, 3H). MS (ESI) for Cι8H18Br2NeO2: 511 (MH*).
[0846] Methyl-3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4- methyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzoate. 1H NMR (400 MHz, CDC13) δ 8.45(s, IH), 7.22 (s, IH), 7.11 (s, IH), 4.50 (br, s, IH), 3.89 (s, 3H), 3.33 (m, 2H), 3.08 (m, 4H), 2.87 (m, 2H), 2.62 (m, 4H), 2.02 (s, 3H), 1.82 (m, 4H), 1.28 (m, 4H), 0.88 (t, 3H). MS (ESI) for C24H31BrN8O2: 543 (MH*).
[0847] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-N- (l-methylethyl)-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide. 1H NMR (400 MHz, de- DMSO) δ 8.35 (s, IH), 8.00 (d, IH), 6.84 (s, IH), 6.92 (s, IH), 4.89 (m, IH), 4.06 (m, IH), 4.00 (m, 4H), 3.26 (m, 2H), 2.96 (m, 4H), 2.77 (m, 2H), 2.61 (m, 4H), 2.10 (s, 3H), 1.72 (m, 4H), 1.13 (d, 6H). MS (ESI) for C26H36BrN9O: 570 (MH*).
[0848] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N,4- dimemyl-N-(l-methylemyl)-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide. 1H NMR (400 MHz, CDC13) δ 8.41 (s, IH), 6.50 (s, IH), 6.40 (s, IH), 4.49 (m, IH), 4.06 (m, 3H), 3.28 (m, 2H), 3.05 (m, 4H), 2.86 (m, 4H), 2.62 (m, 3H), 2.17 (s, 3H), 1.83 (m, 4H), 1.19 (m, 8H), 0.88 (m, 2H). MS (ESI) for C27H38BrN9O: 584 (MH*).
[0849] 3-[4-(3-Bromo- lH-pyrazolo[3,4-d]pyrimidin-4-yl)-2-oxopiperazin- 1 -yl]-4- methyl-N-phenylbenzamide: 1H NMR (400 MHz, d6-DMSO) δ 14.18 (br s, 1 H), 10.21 (s, 1 H), 8.43 (s, 1 H), 7.88 (m, 2 H), 7.75 (m, 2 H), 7.46 (m, 1 H), 7.35 (m, 2 H), 7.12 (m, 1 H), 4.59 (m, 2 H), 4.42 (m, 1 H), 4.25 (m, 1 H), 3.95 (m, 1 H), 3.68 (m, 1 H), 2.21 (s, 3 H). MS (ESI) for C23H20BrN7O2: 506 (MH*).
[0850] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N-(l,l- dimethylefhyl)-4-methyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide: 1H NMR (400 MHz, de-DMSO) δ 8.37 (s, IH), 7.52 (s, IH), 6.87 (s, IH), 6.79 (s, IH), 4.86 (m, IH), 3.26 (m, 6H), 2.99 (m, 4H), 2.72 (m, 2H), 2.55 (m, 4H), 2.10 (s, 3H), 1.72 (m, 4H), 1.36 (s, 9H). MS (ESI) for C27H38BrN9O: 584 (MH*).
[0851] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-N- pyridin-3-yl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide: 1H NMR (400 MHz, de- DMSO) δ 10.21 (s, IH), 8.89 (s, IH), 8.36 (d, IH), 8.29 (d, IH), 8.14 (d, IH), 7.38 (m, IH), 7.06 (s, IH), 6.97 (s, IH), 4.98 (m„ IH), 3.28 (m, 4H), 3.04 (m, 4H), 2.98 (m, 2H), 2.69 (m, 2H), 2.51 (m, 4H), 2.15 (s, 3H), 1.70 (m, 4H). MS (ESI) for C28H33BrNι0O: 605 (MH*).
[0852] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N-ethyl-4- methyl-5-[(2-pyrrolidin-l-ylethyl)amino]benzamide: 1H NMR (400 MHz, d6-DMSO) δ 8.34 (s, IH), 8.28 (m, IH), 6.91 (s, IH), 6.84 (s, IH), 4.86 (m, IH), 3.24 (m, 6H ), 2.97 (br s, 6H), 2.71 (t, 2H), 2.54 (br s, 4H), 2.10 (s, 3H), 1.71 (br s, 4H), 1.08 (t, 3H). MS (ESI) for C25H34BrN9O: 556 (MH*).
[0853] 3-[4-(3-Bromo-lH-ρyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-{[2- (dimethylamino)ethyl]amino}-4-methyl-N-phenylbenzamide: !H NMR (400 MHz, de- DMSO) δ 10.02 (s, IH), 8.32 (s, IH), 7.66 (d, 2H), 7.32 (t, 2H), 7.07 (t, IH), 7.01 (s, IH), 6.91 (s, IH), 4.90 (m, IH), 3.52 (m, 4H), 3.25 (m, 2H), 3.00 (br s, 4H), 2.63 (m, 2H), 2.28 (s, 6H), 2.12 (s, 3H). MS (ESI) for C27H32BrN9O: 578 (MH*).
[0854] 3-[4-(3-Bromo-lH-ρyrazolo[3,4-d]pyrimidin-4-yl)piρerazin-l-yl]-5-{[2- (dimethylarnino)ethyl]amino}-4-methyl-N-(l-methylethyl)benzamide: H NMR (400 MHz, de-DMSO) δ 8.32 (s, IH), 8.06 (d, IH), 6.90 (s, IH), 6.82 (s, IH), 4.82 (m, IH), 4.03 (m, IH), 3.21 (m, 4H), 2.95 (m, 4H), 2.90 (m, 2H), 2.61 (t, 2H), 2.27 (s, 6H), 2.08 (s, 3H), 1.11 (d, 6H). MS (ESI) for C24H34BrN9O: 544 (MH*).
[0855] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-5- [(2-pyrrolidin-l-ylethyl)amino]benzoic acid: 1H NMR (400 MHz, d6-DMSO) δ 9.58 (br s, IH), 8.33 (s, IH), 7.06 (s, IH), 6.95 (s, IH), 3.76 (br s, 4H), 3.59 (m, 2H), 3.46 (m, 2H), 3.35 (br s, 2H), 3.03 (m, 2H), 2.96 (br s, 4H), 2.15 (s, 3H), 2.00 (m, 2H), 1.85 (m, 2H). MS (ESI) for C23H29BrN8O: 529 (MH*).
[0856] 3-[(2S)-4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-l- yl]-4-methyl-N-phenylbenzamide: JH NMR (400 MHz, d6-DMSO) δ 10.1 (s, IH), 8.37 (s, IH), 7.81 (s, IH), 7.72 (m, 3H), 7.37 (m, 3H), 7.10 (t, IH), 4.48 (d, IH), 4.36 (d, IH), 3.58 (m, IH), 3.47 (m, IH), 3.23 (m, IH), 3.10 (m, IH), 2.88 (m, IH), 2.40 (s, 3H), 0.86 (d, 3H). MS (ESI) for C24H24BrN7O: 506 (MH*).
[0857] 3-[(2S)-4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-l- yl]-4-methyl-N-(phenylmethyl)benzamide: !H NMR (400 MHz, de-DMSO) δ 9.01 (t, IH), 8.37 (s, IH), 7.76 (s, IH), 7.63 (d, IH), 7.31 (m, 5H), 7.23 (m, IH), 4.47 (m, 3H), 4.34 (m, IH), 3.56 (m, IH), 3.41 (m, IH), 3.20 (m, IH), 3.05 (m, IH), 2.82 (t, IH), 2.37 (s, 3H), 0.83 (d, 3H). MS (ESI) for C25H26BrN7O: 520 (MH*).
[0858] 3-[(2R)-4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-2- (hydroxymethyl)piperazin-l-yl]-4-methyl-N-phenylbenzamide: 1H NMR (400 MHz, de- DMSO) δ 10.1 (s, IH), 8.34 (s, IH), 7.81 (m, IH), 7.70 (m, 4H), 7.33 (m, 4H), 7.08 (m, IH), 4.60 (m, IH), 4.48 (m, IH), 4.17 (m, IH), 3.73 (m, 2H), 3.52 (m, 2H), 3.20 (m, 3H), 2.95 (m, IH), 2.68 (m, IH). MS (ESI) for C24H24BrN7O2: 522 (MH*).
[0859] Methyl-3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4- methylbenzoate: 1H NMR (400 MHz, CDC13) δ 11.97 (IH, Br s), 8.45 (IH, s), 7.73 (IH, s), 7.72-7.70 (IH, d), 7.29-7.26 (IH, d), 4.10 (4H, m), 3.90 (3H, s), 3.15-3.02 (4H, m), 2.43 (3H, s). MS (ESI) for Cι8H19BrN6O2: 433 (MH*). [0860] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4- methylbenzoic acid: 1H NMR (400 MHz, d6-DMSO) δ 14.07 (IH, Br s), 12.84 (IH, Br s), 8.38 (IH, s), 7.60-7.57 (2H, m), 7.34-7.32 (IH, d), 3.95 (4H, m), 3.07-3.05 (4H, m), 2.38 (3H, s). MS (ESI) for C17H17BrN6O2: 417 (MH*).
[0861] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-N- phenylbenzamide: 1H NMR (400 MHz, de-DMSO) δ 14.11 (IH, Br s), 10.13 (IH, s), 8.38 (IH, s), 7.73-7.71 (2H, d), 7.61-7.59 (2H, m), 7.34-7.30 (3H, m), 7.09-7.05 (IH, t), 3.98 (4H, m), 3.11-3.09 (4H, m), 2.39 (3H, s). MS (ESI) for C23H22BrN7O: 492 (MH*).
[0862] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N,4- dimethylbenzamide: 1H NMR (400 MHz, d6-DMSO) δ 14.07 (IH, Br s), 8.38 (IH, s), 8.37-8.35 (IH, m), 7.53 (IH, s), 7.48-7.46 (IH, d), 7.28-7.26 (IH, d), 3.97 (4H, m), 3.06- 3.04 (4H, m), 2.76-2.75 (3H, d), 2.08 (3H, s). MS (ESI) for C18H20BrN7O: 430 (MH*).
[0863] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N,N,4- trimethylbenzamide: 1H NMR (400 MHz, de-DMSO) δ 14.07 (IH, Br s), 8.37 (IH, s), 7.26-7.24 (IH, d), 7.06 (IH, s), 7.03-7.01 (IH, d), 3.95 (4H, m), 3.06-3.04 (4H, m), 2.95 (3H, s), 2.91 (3H, s), 2.34 (3H, s). MS (ESI) for Cι9H22BrN7O: 444(MH*).
[0864] 3-[4-(3-Chloro-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-N- (2-methylpropyl)benzamide: 1H NMR (400 MHz, d6-DMSO) δ 13.96 (IH, Br s), 8.41- 8.38 (IH, t), 8.37 (IH, s), 7.54 (IH, s), 7.51-7.49 (IH, d), 7.28-7.26 (IH, d), 4.01 (4H, m), 3.07-3.04 (6H, m), 1.84-1.80 (lH,m ), 0.88-0.86 (6H, d). MS (ESI) for C2ιH26ClN7O: 428 (MH*).
[0865] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-N-[2- (dimethyla mino)ethyl]-4-methylbenzamide: !H NMR (400 MHz, de-DMSO) δ 14.75 (IH, Br s), 8.38 (IH, s), 8.37-8.29 (IH, t), 7.54 (IH, s), 7.50-7.47 (IH, d), 7.28-7.26 (IH, d), 3.97 (4H, m), 3.36 (2H, t), 3.05-3.04 (4H, m), 2.40 (2H, t), 2.36 (3H, s), 2.19 (6H, s). MS (ESI) for C2ιH27BrN8O: 487(MH*).
[0866] EXAMPLE 46: 3-Bromo-4-{4-[4-methyl-2'-(2-pyrrolidin-l-yl-ethoxy)- biphenyl-3-yl] -piperazin- 1 -yl }- lH-pyrazolo[3,4-d]pyrimidine.
[0867] 4-Bromo-l-methyl-2-nitro-benzene (3.76 g, 17.4 mmol), 2- benzyloxyphenylboronic acid (7.91 g, 34.7 mmol), and K3PO4 (13.1 g, 61.7 mmol) were combined in dry THF (20 mis) and the mixture sparged with N2 for 1 min. Biphenyl-2-yl- dicyclohexyl-phosphane (574 mg, 1.6 mmol) and palladium(II) acetate (206 mg, 0.92 mmol) were then added and the mixtare was stirred under N2 overnight at room temperature. The reaction was partitioned between H2O and EtOAc and the biphasic mixture was filtered through Celite with washing with H2O and EtOAc. The filtrate was transferred to a separatory funnel, the phases were separated and the organic phase was further washed with IN HCI (3x), H2O (lx), IN NaOH (3x), sat'd NaCl (lx), dried (Na2SO4), and conc'd in vacuo. The crude product was purified by flash chromatography (100% hexanes, followed by 5% EtOAc in hexanes) to give 2'-benzyloxy-4-methyl-3- nitro-biphenyl (5.51g, 99%). 1H NMR (400 MHz, CDC13) δ 8.26 (d, IH), 7.70 (dd, IH), 7.35 (complex multiplet, 8H), 7.05 (m, 2H), 5.11 (s, 2H), 2.63 (s, 3H).
[0868] 2'-Benzyloxy-4-methyl-3-nitro-biphenyl (5.5 lg, 17.2 mmol), toluene (50 mis), H2O (50 mis), iron powder (5.0 g, 89.5 mmol), and ammonium formate (10.0 g, 158 mmol) were combined and heated to reflux overnight. The cooled reaction mixture was filtered through Celite with washing with H2O and EtOAc. The filtrate was transferred to a separatory funnel and the phases were separated. The aqueous phase was further extracted with EtOAc (lx). The combined EtOAc extractions were washed with H2O (lx), sat'd NaCl (lx), dried (Na2SO4), and concentrated in vacuo. The crude product was purified by flash chromatography (9:1 hexane:EtOAc, followed by 4:1 hexane:EtOAc) to give 2'-benzyloxy-4-methyl-biphenyl-3-ylamine (3.99 g, 80%). 1H NMR (400 MHz, CDC13) δ 7.36 (m, 4H), 7.26 (m, 3H), 7.10 (d, IH), 6.98 (complex multiplet, 4H), 5.08 (s, 2H), 3.57 (br. s, 2H), 2.20 (s, 3H). MS (ESI) for C20H19NO: 290 (MH*).
[0869] 2'-Benzyloxy-4-methyl-biphenyl-3-ylamine (3.99 g, 13.8 mmol), bis-(2-chloro- ethyl)-amine hydrochloride (2.50 g, 14.0 mmol), K2CO3 (1.93 g, 13.9 mmol), and diglyme (25 mis) were combined and the mixture stirred at 145°C overnight. The cooled reaction mixture was diluted with IN HCI and EtOAc and stirred vigorously for several minutes. The resulting solid was washed with H2O and EtOAc and dried under vacuum to give crude l-(2'-benzyloxy-4-methyl-biphenyl-3-yl)-piperazine hydrochloride (5.60 g, 103%) which was used in the next reaction without further purification. 1H NMR (400 MHz, CDC13) δ 10.22 (br. s, IH), 7.76 (s, IH), 7.47 (d, IH), 7.27 (complex multiplet, 8H), 7.03 (m, 2H), 5.04 (s, 2H), 3.96 (br. m, 4H), 3.75 (br. m, 4H), 2.64 (s, 3H). MS (ESI) for C24H26N2O: 359 (MH*).
[0870] l-(2'-Benzyloxy-4-methyl-biphenyl-3-yl)-piperazine hydrochloride (5.60 g, 14.2 mmol) was dissolved in dioxane (40 mis) and 5N NaOH (8 mis), to which was added Boc anhydride (3.72 g, 17.0 mmol) and the mixtare stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and washed with H2O (lx), sat'd NaCl (lx), dried (Na2SO4), and conc'd in vacuo. The crude product was purified by flash chromatography (5%EtOAc in hexanes) followed by a second purification by flash chromatography (5% ether in hexanes) to give 4-(2'-benzyloxy-4-methyl-biphenyl-3-yl)- piperazine-1-carboxylic acid tert-butyl ester (2.84 g, 45%). 1H NMR (400 MHz, CDC13) δ 7.31 (m, 8H), 7.20 (m, 2H), 7.04 (m, 2H), 5.06 (s, 2H), 3.51 (m, 4H), 2.73 (m, 4H), 2.32 (s, 2H), 1.50 (s, 9H). MS (ESI) for C29H34N2O3: 459 (MH*).
[0871] 4-(2'-Benzyloxy-4-methyl-biphenyl-3-yl)-piperazine-l-carboxylic acid tert- butyl ester (2.84 g, 6.2 mmol), methanol (10 ml), ethyl acetate (10 ml), acetic acid (few drops) and 10% Pd/C (0.200 g) were agitated under hydrogen gas (40 psi) for 2 days. The mixture was diluted with methanol (200 ml) and ethyl acetate (100 ml), and heated to reflux, filtered through Celite and concentrated to give 4-(2'-hydroxy-4-methyl-biphenyl- 3-yl)-piρerazine-l-carboxylic acid tert-butyl ester (1.98 g, 88%). 1H NMR (400 MHz, CDC13) δ 7.31 (d, IH), 7.22 (m, 2H), 7.11 (d, IH), 7.07 (s, IH), 6.98 (m, 2H), 5.27 (br. s, IH), 3.61 (m 4H), 2.91 (m, 4H), 2.38 (s, 3H), 1.48 (s, 9H). MS (ESI) for C22H28N2O3: 369 (MH*).
[0872] 4-(2'-Hydroxy-4-methyl-biphenyl-3-yl)-piperazine-l -carboxylic acid tert-butyl ester (552 mgs, 1.5 mmol), K2CO3 (622 mgs, 4.5 mmol), and l-(2-chloro-ethyl)- pyrrolidine hydrochloride (273 mgs, 1.6 mmol) were combined in DMA (10 mis) and stirred at room temperature overnight. The reaction had proceeded only slightly at room temperature, so it was heated at 60C overnight to drive it to completion. The cooled reaction was partitioned between IN HCI and EtOAc. The phases were separated and the organic phase was further extracted with IN HCI (2x). The combined aqueous extractions were washed with EtOAc (lx), then basified with ice-cold ION NaOH and the resulting basic aqueous mixtare extracted with EtOAc (3x). The combined EtOAc extractions were washed with sat'd NaCl (lx), dried (Na2SO4), and conc'd in vacuo. The crude product was purified by flash chromatography (2% Et3N in EtOAc) to give 4-[4-methyl-2'-(2- pyrrolidin-l-yl-ethoxy)-biphenyl-3-yl]-piperazine-l-carboxylic acid tert-butyl ester (511 mg, 73%). 1H NMR (400 MHz, CDC13) δ 7.31 (m, 2H), 7.18 (m, 3H), 7.00 (m, 2H), 4.10 (t, 2H), 3.58 (m, 4H), 2.88 (m, 4H), 2.83 (t, 2H), 2.52 (m, 4H), 2.34 (s, 3H), 1.75 (m, 4H), 1.49 (s, 9H). MS (ESI) for C28H39N3O3: 466 (MH*). [0873] 4-[4-Methyl-2'-(2-pyrrolidin-l-yl-ethoxy)-biphenyl-3-yl]-piperazine-l- carboxylic acid tert-butyl ester (261 mgs, 0.56 mmol) was dissolved in DCM (5 mis) to which was added TFA (5 mis) and the mixtare stirred at room temperature for 2 hrs. The reaction mixture was concentrated in vacuo and dried under high vacuum for several hrs to give l-[4-methyl-2'-(2-pyrrolidin-l-yl-ethoxy)-biphenyl-3-yl]-piperazine trifluoroacetate (100%). MS (ESI) for C23H31N3O: 366 (MH*).
[0874] 3-Bromo-4-{4-[4-methyl-2'-(2-pyrrolidin-l-yl-ethoxy)-biρhenyl-3-yl]- piperazin-l-yl}-lH-pyrazolo[3,4-d]pyrimidine. l-[4-Methyl-2'- (2-pyrrolidin- 1-yl- ethoxy)-biphenyl-3-yl]-piperazine, di-TFA salt (0.56 mmol), Et3N (600 μl, 4.3 mmol), dry THF (10 mis), and 3-bromo-4-chloro-lH-pyrazolo[3,4-d]pyrimidine (146 mgs, 0.62 mmol) were combined and stirred at 40C overnight. The cooled reaction was diluted with EtOAc and washed with H2O (lx), sat'd NaHCO3 (2x), sat'd NaCl (lx), dried (Na2SO4), and conc'd in vacuo. The crude material was purified by flash chromatography (2.5% MeOH, 0.5% Et3N in DCM), followed by purification by preparative HPLC (solvent A = 0.05% ammonium acetate in H2O, Solvent B = 100% AcCN). Lyophilization of the pure HPLC fractions gave 3-bromo-4-{4-[4-methyl-2'-(2-pyrrolidin-l-yl-ethoxy)-biphenyl-3- yl]-piperazin-l-yl}-lH-pyrazolo[3,4-d]pyrimidine as the 0.5 AcOH salt (118 mg, 37%). 1H NMR (400 MHz, de-DMSO) δ 8.36 (s, IH), 7.30 (complex multiplet, 4H), 7.12 (m, 2H), 7.02 (t, IH), 4.12 (t, 2H), 3.98 (m, 4H), 3.06 (m, 4H), 2.92 (m, 2H), 2.58 (m, 4H), 2.35 (s, 3H), 1.91 (s, 1.5H, 0.5 AcOH), 1.62 (m, 4H). MS (ESI) for C28H32BrN7O: 562 (MH*).
[0875] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:
[0876] l-(3-[5-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4- methylbiphenyl-3-yl}propyl)pyridinium. JH NMR (400 MHz, d6-DMSO) δ 9.14 (d, 2H), 8.59 (t, IH), 8.22 (s, IH), 8.14 (t, 2H), 7.64 (d, 2H), 7.45 (t, 2H), 7.34 (t, IH), 7.20 (s, 2H), 4.73 (t, 2H), 3.86 (m, 2H), 3.07 (m, 4H), 2.73 (t, 2H), 2.30 (m, 4H), 1.80 (s, 3H). MS (ESI) for C30H3ιBrN7: 568 (MH*).
[0877] EXAMPLE 47: 3-Bromo-4-(4-{3'-fluoro-4-methyl-2'-[(2-pyrrolidin-l- ylethyl)oxy]biphenyl-3-yl}piperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine.
[0878] To a 150 mL pressure vessel was added 4-bromo-2-nitrotoluene (4.85 g, 22.4 mmol, 1.0 eq.), 3-fluoro-2-methoxy-phenylboronic acid (4.20 g, 24.7 mmol, 1.1 eq.), Pd(dppf)2Cl2 (CH2C12 complex, 917 mg, 2.24 mmol, 0.1 eq.), sodium carbonate (7.14 g, 67.4 mmol, 3.0 eq.), H2O (40 mL), and toluene (40 mL). The vessel was sealed and heated at 88°C overnight. GC/MS analysis indicated product is present as the major component. The reaction mixture was cooled and filtered through Celite, followed by a rinse of EtOAc. The organic phase was washed with H2O (100 mL) and saturated aq. NaCl (100 mL). The combined aqueous phases were extracted with EtOAc (2 x 100 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated to give black oil. The crude material was purified via column chromatography to afford 3-fluoro-2-methoxy-4'-methyl-3'-nitro-biphenyl as orange oil which later solidified upon standing (5.18 g, 88%).
[0879] To a 500 mL recovery flask was added 3-fluoro-2-methoxy-4'-methyl-3'-nitro- biphenyl (5.14 g, 19.6 mmol, 1.0 eq.) and CH2C12 (150 mL). Upon stirring, BBr3 (1.0 M in CH2C12, 58.6 mL, 58.6 mmol, 3.0 eq.) was added. Upon addition, the reaction mixture color turns light orange to dark red. After stirring for lh, the reaction color becomes lighter red. The reaction was stirred for 4h at room temperatare whereupon CH3OH was added to quench any excess BBr3. The reaction was concentrated and then taken up in CH2C12. The organic phase was washed with H2O (100 mL) and saturated aq. NaCl (100 mL). The combined aqueous phases were extracted with CH2C12 (2 x 100 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated to give a brown solid. The solid was suspended in 10% EtO Ac/Hex. The insoluble material was filtered to give 3-fluoro-4'-methyl-3'-nitro-biphenyl-2-ol as a tan solid. (4.08 g, 84%).
[0880] To a 150 mL pressure vessel was added 3-fluoro-4'-methyl-3'-nitro-biphenyl-2- ol (1.00 g, 4.04 mmol, 1.0 eq.), Cs2CO3 (3.69 g, 11.3 mmol, 2.8 eq.), l-(2-chloroethyl)- pyrrolidine hydrochloride (894 mg, 5.26 mmol, 1.3 eq.), and DMF (40 mL). The vessel was sealed and heated at 70°C overnight. The reaction mixture was cooled and was diluted with EtOAc (150 mL) and 10% aq. LiCI (50 mL). The organic phase was washed with 10% aq. LiCI (2 x 75 mL) and saturated aq. NaCl (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 75 mL). The combined organic phaseswere dried over anhydrous Na2SO , filtered, and concentrated to give brown oil. The crude material was purified via column chromatography (3% CH3OH CH2Cl2) to afford pure product l-[2-(3-fluoro-4'-methyl-3'-nitro-biphenyl-2-yloxy)-ethyl]-pyrrolidine as light-brown oil (1.39 g, 100%). [0881] To a 50 mL recovery flask was added l-[2-(3-fluoro-4'-methyl-3'-nitro- biphenyl-2-yloxy)-ethyl]-pyrrolidine (1.39 g, 4.04 mmol, 1.0 eq.), AcOH (8 mL), and tin (II) chloride dihydrate (3.64 g, 16.1 mmol, 4.0 eq.). The reaction was stirred vigorously at room temperatare. After 3h, LC/MS shows approximately 1:1 ratio of starting material to product. The reaction mixtare was heated at 75°C overnight, which drove the reaction to completion. The reaction mixture was cooled and poured into a 250 mL Erlenmeyer flask containing H2O (100 mL). 4N NaOH was added until the solution became alkaline. The thick mixtare was extracted with Et2O (5 x 75 mL). The organic phase was dried over Na2SO4, filtered, and concentrated to afford 3'-fluoro-4-methyl-2'-(2-pyrrolidin-l-yl- ethoxy)-biphenyl-3-ylamine as a brown oil which was used in the next reaction without further purification (1.25 g, 98%).
[0882] To a 48 mL pressure vessel was added 3'-fluoro-4-methyl-2'-(2-pyrrolidin-l-yl- ethoxy)-biphenyl-3-ylamine (333 mg, 1.06 mmol, 1.0 eq.), bis-(2-chloroefhyl)amine hydrochoride (189 mg, 1.06 mmol, 1.0 eq.), K2CO3 (146 mg, 1.06 mmol, 1.0 eq.), and diglyme (10 mL). The vessel was sealed and heated at 145°C overnight. The reaction was cooled and diluted with H2O (30 mL) and EtOAc (50 mL). The organic phase was washed with H2O (30 mL), satarated aq. NaHCO3 (30 mL), and brine (30 mL). The combined aqueous phases were extracted with EtOAc (4 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated to give black oil which still contained a large amount of diglyme. The crude mixture was purified by column chromatography (20% CH3OH/CH2Cl2 to 20% CH3OH/CH2Cl2 with 1% Et3N) to afford 1- [3'-fluoro-4-methyl-2'-(2-pyrrolidin-l-yl-ethoxy)-biphenyl-3-yl]-piperazine as black oil (257 mg, 62%).
[0883] 3-Bromo-4-(4-{3'-fluoro-4-methyl-2'-[(2-pyrrolidin-l-ylethyl)oxy]biphenyl-3- yl}piperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: To a 50 mL recovery flask was added l-[3'-fluoro-4-methyl-2'-(2-pyrrolidin-l-yl-ethoxy)-biphenyl-3-yl]-piperazine (255 mg, 0.665 mmol, 1.0 eq.), isopropanol (8 mL), z'-Pr2NEt (348 μL, 1.99 mmol, 3.0 eq.). Upon stirring, chloropyrimidine 7 (155 mg, 0.665 mmol, 1.0 eq.) was added and the reaction was heated at 65°C for lh and overnight while cooling to room temperatare. The reaction mixture was concentrated and then redissolved in EtOAc (100 mL). The organic phase was washed with H2O (2 x 50 mL) and brine (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated to give a brown solid. Column chromatography (3% to 10% CH3OH/CH2Cl2) afforded 3-bromo-4-(4-{3'-fluoro-4- methyl-2'-[(2-pyrrolidin-l-ylethyl)oxy]biphenyl-3-yl}piperazin-l-yl)-lH-pyrazolo[3,4- d]pyrimidine as an off-white solid (160 mg, 41%). 1H NMR (400 MHz, d6-DMSO) δ 10.29 (br s, IH), 8.38 (s, IH), 7.36-7.17 (m, 6H), 4.11 (t, 2H), 3.98 (m, 4H), 3.36-3.33 (m, 4H), 3.11-3.09 (m, 4H), 2.97-2.92 (m, 2H), 2.38 (s, 3H), 1.92 (m, 2H), 1.80 (m, 2H). MS(ESI) for C28H3ιFBrN7O: 582 (MH*).
[0884] Using the same or analogous synthetic techniques and/or substitating with alternative reagents, the following compounds of the invention were prepared:
[0885] 5-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl-N- (2-pyrrolidin-l-ylethyl)biphenyl-3-amine. 1H NMR (400 MHz, d6-DMSO) δ 8.69 (s, IH), 8.36 (s, IH), 7.61 (m, 2H), 7.41 (m, IH), 7.31 (m, IH), 6.68 (s, IH), 6.61 (s, IH), 4.97 (m, IH), 3-98 (m, 3H), 3.25 (m, 2H), 3.03 (m, 3H), 2.91 (br, s, 1), 2.76 (m, 3H), 2.57 (m, 4H), 2.13 (s, 2H), 1.19 (s, 2H), 1.78 (m, 3H). MS (ESI) for C28H33BrN8: 560 (MH*).
[0886] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N- (2-pyrrolidin-l-ylethyl)-5-(l,3-thiazol-2-yl)aniline. 1H NMR (400 MHz, de-DMSO) δ 8.38 (s, IH), 7.76 (d, 2H), 7.71 (d, IH), 6.99 (s, IH), 6.92 (s, IH), 6.61 (s, IH), 5.07 (t, IH), 4.01 (m, 3H), 2.73 (m, 4H), 2.67 (m, 2H), 2.55 (m, 4H), 2.45 (m, 2H), 2.13 (d, 3H), 2.07 (s, 2H), 1.75 (m, 3H). MS (ESI) for C25H30BrN9S: 568 (MH*).
[0887] l-[3-Bromo-lH-pyrazolo[3,4-J]pyrimidin-4-yl]-4-[2-methyl-4-[[3-(2- pyrrolidin-l-ylethoxy)]phenyl]phenyl]piperazine: 1H-NMR, (400 MΗz CDC13 ) δ 8.45 (s, 1Η), 7.22-7.33 (m, 4Η), 7.13 (d, /= ,8 Hz, IH), 7.08 (m, IH), 6.86 (dd, J= 1.5, J= 8 Hz), 4.20 (t, /= 6 Hz, 2H), 4.10 (m, 4H), 3.15 (m, 4H), 2.98 (t, /= 6 Hz, 2H), 2.70 (m, 4H), 2.40 (s, 3H), 1.84 (m, 4H). MS (ESI) for C28H32BrN7O: 564 (MH*).
[0888] 3-Bromo-4-(4-{4-methyl-2;-[(3-moφholin-4-ylpropyl)oxy]biρhenyl-3- yl}piperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ
8.36 (s, IH), 7.26 (m, 4H), 7.09 (m, 2H), 7.00 (t, IH), 4.00 (m, 6H), 3.44 (m, 4H), 3.07 (m, 4H), 2.35 (m, 5H), 2.25 (br s, 4H), 1.81 (m, 2H). MS (ESI) for C29H34BrN7O2: 592 (MH*).
[0889] 3-Bromo-4-(4- { 4-methyl-2'-[(2-moφholin-4-ylethyl)oxy]biphenyl-3- yl}piperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ
8.37 (s, IH), 7.26 (m, 4H), 7.13 (dd, 2H), 7.01 (t, IH), 4.09 (m, 2H), 3.98 (m, 4H), 3.49 (m, 4H), 3.07 (m, 4H), 2.62 (m, 2H), 2.35 (br s, 7H). MS (ESI) for C28H32BrN7O2: 578 (MH*).
[0890] 3-([3'-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4'- methylbiphenyl-2-yl}oxy)-N,N-dimethylpropan-l-amine: !H NMR (400 MHz, de- DMSO) δ 10.7 (s, IH), 8.40 (s, IH), 7.28 (m, 3H), 7.23 (s, IH), 7.18 (d, IH), 7.11 (d, IH), 7.03 (t, IH), 5.40 (m, 4H), 4.06 (m, 4H), 3.15 (s, 3H), 3.07 (m, 2H), 2.68 (m, 5H), 2.39 (s, 3H), 2.09 (m, 2H). MS (ESI) for C27H32BrN7O: 551 (MH*).
[0891] l-[2-({3'-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4'- methylbiphenyl-2-yl}oxy)ethyl]pyrrolidine-2,5-dione: 1H NMR (400 MHz, de-DMSO) δ 8.35 (s, IH), 7.30 (m, 2H), 7.20 (d, IH), 7.12 (s, IH), 7.04 (m, 3H), 4.10 (t, 2H), 3.97 (m, 4H), 3.69 (t, 2H), 3.35 (m, 4H), 3.09 (m, 4H), 2.35 (s, 3H). MS (ESI) for C28H28BrN7O3: 591 (MH*).
[0892] 3-Bromo-4-(4- { 4-chloro-2'-[(2-pyrrolidin- 1 -ylethyl)oxy]biρhenyl-3- yl}piperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 9.6 (br s, IH), 8.38 (s, IH), 7.49 (d, IH), 7.42 (m, 2H), 7.28 (d, IH), 7.20 (m, IH), 7.10 (t, IH), 4.70 (t, 2H), 3.98 (br q, 4H), 3.55 (br q, 2H), 3.45 (m, 2H), 3.22 (br q, 2H), 1.89 (br m, 2H), 1.75 (br m, 2H). MS (ESI) for C27H29BrClN7O: 582 (MH*).
[0893] 3-Bromo-4-(4-{4-chloro-4'-fluoro-2'-[(2-pyrrolidin-l-ylethyl)oxy]biphenyl-3- yl}piperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: *H NMR (400 MHz, d6-DMSO) δ 10.0 (br s, IH), 8.37 (s, IH), 7.49 (d, IH), 7.40 (t, IH), 7.25 (s, IH), 7.18 (dt, 2H), 6.94 (dt, IH), 4.35 (t, 2H), 3.98 (br s, 4H), 3.41 (m, 4H), 3.21 (br s, 4H), 2.93 (br q, 2H), 1.90 (br m, 2H), 1.75 (br m, 2H). MS (ESI) for C27H28BrClFN7O: 600 (MH*).
[0894] EXAMPLE 48: 6-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin- l-yl]-3,5-difluoro-N4-(3-methyl-butyl)-N2-(2-pyrrolidin-l-yl-ethyl)-pyridine-2,4-diamine.
[0895] To 2,3,4,5,6-pentafluoro-pyridine (770mg, 4.55 mmol) in dichloromethane (3mL) was added 3-mefhyl-butylamine (530 uL, 4.55 mmol) slowly. After the reaction mixtare was stirred at r.t. for 1 hr, it was concentrated to yield (3-methyl-butyl)-(2,3,5,6- tetrafluoro-pyridin-4-yl)-amine and used for next reaction. MS (ESI) for CioH12F4N2: 237 (MH*).
[0896] The mixture of (3-methyl-butyl)-(2,3,5,6-tetrafluoro-pyridin-4-yl)-amine and Boc-piperazine (4.35 mmol) was heated at 110°C for overnight. The product 4-[3,5,6- trifluoro-4-(3-methyl-butylamino)-pyridin-2-yl]-piperazine-l-carboxylic acid tert-butyl ester was purified by column chromatography (624 mg). MS (ESI) for C19H29F3N4O2: 401 (MH-).
[0897] The mixture of 4-[3,5,6-trifluoro-4-(3-methyl-butylamino)-pyridin-2-yl]- piperazine-1 -carboxylic acid tert-butyl ester (122 mg) and 2-amino-ethyl pyrrolidine (700 uL, 40eq.) in sealed tube was heated at 130°C for 3 days. The product 4-[3,5-difluoro-4- (3-methyl-butylamino)-6-(2-pyrrolidin- 1 -yl-ethylamino)-pyridin-2-yl] -piperazine- 1 - carboxylic acid tert-butyl ester was purified by column chromatography (91mg). MS (ESI) for C25H42F2N6O2: 497 (MH*).
[0898] 4-[3,5-Difluoro-4-(3-methyl-butylamino)-6-(2-ρyrrolidin- 1 -yl-ethylamino)- pyridin-2-yl] -piperazine-1 -carboxylic acid tert-butyl ester (4, 91 mg, 0.18 mmol) was treated with 4N-HCl-dioxane (2mL) in methanol (2mL) at r.t. for 1 hr. and gave 3,5- difluoro-N4-(3-methyl-butyl)-6-piperazin-l-yl-N2-(2-pyrrolidin-l-yl-ethyl)-pyridine-2,4- diamine hydrochloride. MS (ESI) for C20H34F2N6: 397 (MH*).
[0899] To the crude 3,5-difluoro-N4-(3-methyl-butyl)-6-ρiperazin-l-yl-N2-(2- pyrrolidin-l-yl-ethyl)-pyridine-2,4-diamine hydrochloride in THF (3mL), 3-bromo-4- chloro-lH-pyrazolo[3,4-d]pyrimidine (43 mg, 0.18 mmol), and triethylamine (150uL, 1.1 mmol) were added. The mixture was heated at 60°C for 2 hrs. After concentrated, the product was purified by HPLC and gave to 6-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin- 4-yl)-piperazin-l-yl]-3,5-difluoro-N4-(3-methyl-butyl)-N2-(2-pyrrolidin-l-yl-ethyl)- pyridine-2,4-diamine. 1H-NMR (400 MHz, CDC13) δ 8.4 (s, IH), 4.98(br s. IH), 4.04 (m, 4H), 3.58 (m, 2H), 3.48(m, 4H), 3.42(m, 2H), 2.84 (m, 2H), 2.73(br s, 4H), 1.85 (s, 4H), 1.68 (m, IH), 1.49 (m, 2H), 0.94(d, 6H). MS (ESI) for C25H35BrF2Nι0: 595 (MH*).
[0900] Using the same or analogous synthetic techniques and/or substitating with alternative reagents, the following compound of the invention was prepared:
[0901] 2-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-3,5,6- trifluoro-N-(3-methylbutyl)pyridin-4-amine: 1H-NMR (400 MHz, CDC13) δ 12.69 (br s, IH), 8.44 (s, IH), 4.18 (s, IH), 4.03 (m, 4H), 3.53 (m, 4H), 3.48 (m, 2H), 1.72 (m, IH), 1.53 (m, 2H), 0.94(m, 6H). MS (ESI) for C19H22BrF3N8: 501 (MH*).
[0902] EXAMPLE 49: [3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin- 1 -yl] -5-( 1 , 1 -difluoro-butyl)-2-methyl-phenyl] -(2-pyrrolidin- 1 -yl-ethyl)-amine.
[0903] To a round bottom flask was added l-(3,5-dibromo-4-methyl-phenyl)-butane- 1-one (1.0 g, 3.1 mmol), 1,2-efhanedithiol (0.52 mL, 6.2 mmol), and boron trifluoride acetic acid complex (0.43 mL, 3.1 mmol). The reaction was stirred vigorously at r.t. for 30 min before diluting with hexanes (20 mL). The organic solution was washed (3 X 20mL) with saturated NaHCO3, 15% NaOH, and finally with brine. The organic layer was dried with Na2SO4, and concentrated. Column chromatography with 10:90
EtOAc:Hexanes gave 2-(3,5-dibromo-4-methyl-phenyl)-2-propyl-[l,3]dithiolane as a clear oil that solidified upon standing (1.14 g, 90% yield). 1H NMR (400 MHz, CDC13) δ 7.82 (s, 2H), 3.40 (m, 2H), 3.20 (m, 2H), 2.58 (s, 3H), 2.25 (m, 2H), 1.30 (m, 2H), 0.90 (t, 3H).
[0904] To an oven dried round bottom flask was added dry l,3-dibromo-5,5- dimethylhydantoin (360 mg, 1.26 mmol), CH2CI2 (2.5mL), and hydrogen fluoride pyridine (0.62 mL, 2.73 mmol). The mixture was cooled to -78°C before adding dropwise a solution of 2-(3,5-Dibromo-4-methyl-phenyl)-2-propyl-[l,3]dithiolane (500 mg, 1.26 mmol) in 0.5 mL dry CH2C12. The reaction changed from yellow to orange to red in color. After 30 min at -78°C, the reaction was filtered through a 50mL polypropylene/polyethylene column packed with basic alumina. The column was rinsed with hexanes and then CH2C12. The combined organics were concentrated and columned with EtOAc: hexane (5:95) to give l,3-dibromo-5-(l,l-difluoro-butyl)-2-methyl-benzene as an oil (240 mg, 70% yield^H NMR (400 MHz, CDC13) δ 7.60 (m, 2H), 2.60 (m, 3H), 2.05 (m, 2H), 1.42 (m, 2H), 0.95 (t, 3H).
[0905] To a sealed tube was added l,3-dibromo-5-(l,l-difluoro-butyl)-2-methyl- benzene (235 mg, 0.68 mmol), toluene (3.0 mL), Boc-piperazine (115 mg, 0.62 mmol), NaOtBu (91.0 mg, 0.95 mmol), and BINAP (42.0 mg, 0.068 mmol). The reaction was purged with nitrogen before adding Pd2(dba)3 (15.0 mg, 0.017 mmol). The tube was sealed and heated to 110°C overnight. The reaction was then cooled to r.t., filtered through celite, rinsed with EtOAc, and concentrated. Column purification with 10:90 EtOAc: hexane gave 4-[3-bromo-5-(l,l-difluoro-butyl)-2-methyl-phenyl]-piperazine-l- carboxylic acid tert-butyl ester (200 mg, 66% yield). 1H NMR (400 MHz, CDC13) δ 7.40 (s, IH), 7.00 (s, IH), 3.60 (br s, 4H), 2.82 (br t, 4H), 2.40 (s, 3H), 2.05 (m, 2H), 1.50 (s, 9H), 1.45 (m, 2H), 0.95 (t, 3H).
[0906] To a sealed tube was added 4-[3-bromo-5-(l,l-difluoro-butyl)-2-methyl- phenyl] -piperazine-1 -carboxylic acid tert-butyl ester (200 mg, 0.44 mmol), dioxane (5.0 mL), NaOtBu (68.0 mg, 0.72 mmol), and xantphos (25.0 mg, 0.044 mmol). The reaction was purged with nitrogen before adding Pd2(dba)3 (20.0 mg, 0.022 mmol). The tube was sealed and stirred at RT for 10 min before adding l-(2-aminoefhyl)-pyrrolidine (75 mg, 0.66 mmol), sealed and heated to 100°C overnight. The reaction was then cooled to r.t., filtered through celite, rinsed with MeOH, and concentrated. Column purification with MeOH: CH2C12 (7:93) gave 4-5-(l,l-difluoro-butyl)-2-methyl-3-(2-pyrrolidin-l-yl- ethylamino)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester (130 mg, 62% yield). !H NMR (400 MHz, de-DMSO) δ 6.42 (d, 2H), 4.95 (br s, IH), 3.60 (s, 2H), 3.20 (m, 4H), 2.70 (m, 4H), 2.15 (m, 2H), 2.01 (s, 3H), 1.70 (br s, 4H), 1.42 (s, 9H), 1.40 (m, 2H), 0.93 (t, 3H). MS (ESI) for C26H42F2N4O2: 481 (MH*).
[0907] [3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-l-yl]-5-(l,l- difluoro-butyl)-2-methyl-phenyl] -(2-pyrrolidin- l-yl-ethyl)-amine: To a round bottom flask was added 4-5-(l,l-difluoro-butyl)-2-methyl-3-(2-pyrrolidin-l-yl-ethylamino)- phenyl]-piperazine-l-carboxylic acid tert-butyl ester (130 mg, 0.27 mmol), dry methanol (3.0 mL) and 4N HCI in dioxane (3.0 mL). The reaction was stirred at RT for 1 hr, then concentrated to remove trace HCI. The residue was then dissolved in THF (5.0 mL), and triethyl amine (0.156 mL, 1.08 mmol), before adding 3-bromo-4-chloro-lH-pyrazolo[3,4- d]pyrimidine (63.0 mg, 0.27 mmol). The reaction was stirred at 65°C for 30 min, concentrated and prep purified to give the TFA salt of [3-[4-(3-bromo-lH-pyrazolo[3,4- d]pyrimidin-4-yl)-piperazin- 1 -yl] -5-( 1 , 1 -difluoro-butyl)-2-methyl-phenyl] -(2-pyrrolidin- 1 - yl-ethyl)-amine. The salt was converted to the HCI salt by adding excess 4N HCI and lyophilizing in H2O/CH3CN to give [3-[4-(3-bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)- piperazin-l-yl]-5-(l,l-difluoro-butyl)-2-methyl-phenyl]-(2-pyrrolidin-l-yl-ethyl)-amine as a white solid (101 mg, 64% yield) : 1H NMR (400MHz, d6-DMSO) δ 9.60 (br s, IH), 8.40 (s, IH), 6.60 (d, 2H), 3.45 (m, 4H), 3.40 (m, 4H), 3.00 (m, 6H), 2.20 (s, 3H), 2.10 (m, 4H), 1.95 (m, 2H), 1.40 (m, 2H), 0.95 (t, 3H). MS (ESI) for C26H35BrF2N8: 577 (MH*).
[0908] Using the same or analogous synthetic techniques and/or substitating with alternative reagents, the following compound of the invention was prepared:
[0909] l-{3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-4-methyl- 5-[(2-pyrrolidin-l-ylethyl)amino]phenyl}butan-l-ol: 1H NMR (400 MHz, de-DMSO) δ 8.36 (s, IH), 6.47 (s, IH), 6.38 (s, IH), 4.39 (m, IH), 3.95 (br, 3H), 3.62 (br, 2H), 3.43 (m, 2H), 3.36 (m, 2H), 3.08 (br, 2H), 2.94 (s, 4H), 2.10 (s, 3H), 1.95 (br, 5H), 1.52 (m, 2H), 1.45 (m, IH), 1.25 (m, IH), 0.86 (t, 3H). MS (ESI) for C26H37BrN8O: 557 (MH*).
[0910] EXAMPLE 50: 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]-5-[(ethyloxy)methyl]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline. [0911] To a 500 mL recovery flask was added methyl 3,5-dibromo-4-methylbenzoate (26 g, 84.4 mmol, 1.0 eq.), anhydrous ethanol (300 mL), and NaBE (9.58 g, 253 mmol, 3.0 eq.). The reaction was stirred at reflux overnight. TLC analysis indicated that the reaction was complete. The reaction was concentrated and chromatographed (10% EtOAc Hex) to give (3,5-dibromo-4-methyl-phenyl)-methanol as a white solid (17.2 g, 73%).
[0912] To a 50 mL recovery flask was added (3,5-dibromo-4-methyl-phenyl)- methanol (0.50 g, 1.78 mmol, 1.0 eq.) and DMF (15 mL). NaH (60% dispersion in mineral oil, 143 mg, 3.57 mmol, 2.0 eq.) was added and the mixture was stirred at 70°C for 5 min. Bromoethane (400 μL, 5.36 mmol, 3.0 eq.) was added and the reaction was stirred overnight at 70°C. The reaction mixtare was diluted with EtOAc (100 mL) and the organic phase was washed with 10% aq. LiCI (2 x 50 mL) and saturated aq. sodium chloride (50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated. The crude oil was purified via column chromatography (5% EtO Ac/Hex) to give l,3-dibromo-5-ethoxymethyl-2-methyl-benzene as yellow oil (410 mg, 75%).
[0913] To a 48 mL pressure vessel was added l,3-dibromo-5-ethoxymethyl-2-methyl- benzene (1.24 g, 4.02 mmol, 1.0 eq.), Boc-piperazine (675 mg, 3.62 mmol, 0.9 eq.), BINAP (250 mg, 0.402 mmol, 0.1 eq.), and toluene (15 mL). The suspension was bubbled with N2 upon which Pd2(dba)3 (92 mg, 0.0100 mmol, 0.025 eq.) and sodium tert-butoxide (542 mg, 5.64 mmol, 1.4 eq.) was added. The vessel was sealed and heated at 110°C overnight. The crude mixture was filtered through Celite and the Celite cake was rinsed with EtOAc. The filtrate was concentrated and chromatographed (5% to 15% EtOAc Hex) to afford 4-(3-bromo-5-ethoxymethyl-2-methyl-phenyl)-piperazine-l- carboxylic acid tert-butyl ester as yellow oil (1.01 g, 61%).
[0914] To a 75 mL pressure vessel was added 4-(3-bromo-5-ethoxymethyl-2-methyl- phenyl)-piperazine-l -carboxylic acid tert-butyl ester (1.00 g, 2.42 mmol, 1.0 eq.), XantPHOS (84 mg, 0.145 mmol, 0.06 eq.), 2-pyrrolidinoethylamine (457 μL, 3.63 mmol, 1.5 eq.), and dioxane (25 mL). The suspension was bubbled with N2 upon which Pd2(dba)3 (66 mg, 0.0725 mmol, 0.03 eq.) and sodium tert-butoxide (349 mg, 3.63 mmol, 1.5 eq.) was added. The vessel was sealed and heated at 100°C overnight. The crude mixture was filtered through Celite and the Celite cake was rinsed with EtOAc. The filtrate was concentrated and chromatographed (5%-15% CH3OH CH2Cl2) to afford 4-[5- ethoxymethyl-2-methyl-3 -(2-pyrrolidin- 1 -yl-ethylamino)-phenyl] -piperazine- 1 -carboxylic acid tert-butyl ester as bronze oil (535 mg, 49%).
[0915] To a 50 mL recovery flask was added 4-[5-efhoxymethyl-2-methyl-3-(2- pyrrolidin-l-yl-ethylamino)-phenyl] -piperazine-1 -carboxylic acid tert-butyl ester (535 mg, 1.20 mol, 1.0 eq.) and methanol (8 mL). 4N HCl/dioxane (8 mL) was added and the reaction was stirred for 2h at room temperature. LC MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material of (5-ethoxymethyl-2-methyl-3-piperazin-l-yl-phenyl)-(2- pyrrolidin-l-yl-ethyl)-amine was used in the next reaction without further purification.
[0916] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5- [(ethyloxy)methyl]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: To a 50 mL recovery flask was added (5-ethoxymethyl-2-methyl-3 -piperazin- 1 -yl-phenyl)-(2-pyrrolidin- 1 -yl-ethyl)- amine (502 mg, 1.20 mmol, 1.0 eq.), isopropanol (15 mL), z-Pr2NEt (1.04 mL, 5.98 mmol, 5.0 eq.). Upon stirring, 3-bromo-4-chloro-lH-pyrazolo[3,4-d]pyrimidine (279 mg, 1.20 mmol, 1.0 eq.) was added and the reaction was heated at 65°C for lh. The reaction mixture was concentrated and then redissolved in EtOAc (100 mL). The organic phase was washed with H2O (2 x 50 mL) and brine (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated to give light-brown oil. Column chromatography (5% to 15% CH3OH/CH2Cl2) afforded pure product 3-[4-(3-bromo-lH- pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-5-[(ethyloxy)methyl]-2-methyl-N-(2- pyrrolidin-l-ylethyl)aniline as a light yellow oil (277 mg, 43%). H NMR (400 MHz, de- DMSO) δ 11.18 (br s, IH), 8.42 (s, IH), 6.62 (s, IH), 6.59 (s, IH), 4.37 (s, 2H), 4.09 (br s, 3H), 3.60 (m, 2H), 3.54 (t, 2H), 3.47 (q, 2H), 3.38 (m, 2H), 3.12 (m, 3H), 3.04 (m, 2H), 2.24 (s, 3H), 2.00 (m, 2H), 1.91 (m, 2H), 1.14 (t, 3H). MS(ESI) for C25H35BrN8O: 545 (MH*).
[0917] Using the same or analogous synthetic techniques and/or substitating with alternative reagents, the following compound of the invention was prepared:
[0918] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N- (2-pyrrolidin-l-ylethyl)-5-{[(2,2,2-trifluoroethyl)oxy]methyl}aniline: [0919] The key intermediate of l,3-dibromo-2-methyl-5-(2,2,2-trifluoro- ethoxymethyl)-benzene was synthesized by following method and further reactions were the same as the previous section.
[0920] To a 200 mL recovery flask was added (3,5-dibromo-4-methyl-phenyl)- methanol (1.50 g, 5.36 mmol, 1.0 eq.) and azodicarbonyldipiperidine (2.70 g, 10.7 mmol, 2.0 eq.). Benzene (60 mL) was added and the mixture was stirred at room temperature. Tri-n-butylphosphine (2.64 mL, 10.7 mmol, 2.0 eq.) was added at the reaction mixture was stirred for 10 minutes whereupon 2,2,2-trifluoroethanol (3.85 mL, 53.6 mmol, 10.0 eq.) was added. The reaction was stirred for 6 hours at room temperature. TLC analysis at 2 h and 6 h indicated the reaction progression had slowed and therefore the reaction was concentrated and chromatographed (100% CH2C12) to afford the product l,3-dibromo-2- methyl-5-(2,2,2-trifluoro-ethoxymethyl)-benzene as a white solid (1.11 g, 57%, 79% based on recovered starting material).
[0921] To a 50 mL recovery flask was added [2-methyl-3-piperazin-l-yl-5-(2,2,2- trifluoro-ethoxymethyl)-phenyl] -(2-pyrrolidin- l-yl-ethyl)-amine dihydrochloride (570 mg, 1.20 mmol, 1.0 eq.), isopropanol (15 mL), z'-Pr2NEt (1.05 mL, 6.02 mmol, 5.0 eq.). Upon stirring, 3-Bromo-4-chloro-lH-pyrazolo[3,4-d]pyrimidine (281 mg, 1.20 mmol, 1.0 eq.) was added and the reaction was heated at 65°C for lh. The reaction mixture was concentrated and then redissolved in EtOAc (100 mL). The organic phase was washed with water (2 x 50 mL) and brine (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated to give light-brown oil. Column chromatography (3% to 15% CH3OH/CH2Cl2) afforded 3-[4-(3-bromo-lH-pyrazolo[3,4- d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N-(2-pyrrolidin-l-ylethyl)-5-{ [(2,2,2- trifluoroethyl)oxy]methyl} aniline as a light yellow oil (258 mg, 36%). *H NMR (400 MHz, αVDMSO) δ 11.00 (br s, IH), 8.40 (s, IH), 6.55 (s, IH), 6.52 (s, IH), 4.56 (s, 2H), 4.09-4.02 (m, 5H), 3.59 (m, 2H), 3.51 (t, 2H), 3.34 (m, 2H), 3.04 (m, 6H), 2.19 (s, 3H), 2.00 (m, 2H), 1.90 (m, 2H). MS (ESI) for C25H32BrF3N8O: 599 (MH*).
[0922] EXAMPLE 51: [3-[4-(3-Bromo-lH-pyrazolo[3,4-^]pyrimidin-4-yl]-piperazin- l-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-(2-pyrrolidin-l-yl-ethyl)- amine.
[0923] To a pressure vessel was added 3,5-dibromo-4-methyl phenol (12.0g, 45 mmol), dry DMF (80 mL), cesium carbonate (35.4 g, 108.6mmol), and 2-(Bromomethyl)- 1,2,3-trifluoropropane (11.2g, 58 mmol). The reaction was sealed and heated to 80°C overnight. The reaction was then cooled to r.t. then partitioned between EtOAc and water. The organic layer was washed with brine, dried with Na2SO , and concentrated. Column chromatography on silica gel with 5:95 EtOAc: hexanes gave 15 g of l,3-dibromo-5-(2,3- difluoro-2-fluoromethyl-propoxy)-2-methyl-benzene as a white solid (89% yield). 1H NMR (400 MHz, CDC13) δ 7.10 (s, 2H), 4.70 (dd, 4H), 4.2 (d, 2H), 2.44 (s, 3H). MS (ESI) for CnHiiBr2F3O: 375 (MH*).
[0924] To a pressure vessel was added pure trifluoro ether l,3-dibromo-5-(2,3- difluoro-2-fluoromethyl-propoxy)-2-methyl-benzene (15.0 g, 40 mmol), toluene (100 mL), Boc piperazine (6.7g, 36.0 mmol), sodium t-butoxide (5.35g, 56.0 mmol), and BINAP (2.49 g, 4.0mmol). The vessel was then purged with N2 before adding Pd2(dba)3 (915 mg, 1.0 mmol), sealed and heated to 110°C overnight. The reaction was then cooled to r.t., filtered through celite, rinsed with EtOAc and concentrated. Column chromatography on silica gel with 10:90 EtOAc: hexane gave 12.7g of 4-[3-bromo-5-(2,3-difluoro-2- fluoromethyl-propoxy)-2-methyl-phenyl] -piperazine-1 -carboxylic acid t-butyl ester as a pale yellow solid (67% yield). 1H NMR (400 MHz, CDC13) δ 6.90 (s, IH), 6.60 (s, IH), 4.75 (dd, 4H), 4.2 (d, 2H), 3.60 (br s, 4H), 2.81 (br s, 4H), 2.34 (s, 3H), 1.45 (s, 9H). MS (ESI) for C20H28BrF3N2O3: 481 (MH*).
[0925] To a pressure vessel was added 4-[3-bromo-5-(2,3-difluoro-2-fluoromethyl- propoxy)-2-methyl-phenyl] -piperazine-1 -carboxylic acid t-butyl ester (6.8g, 14.2 mmol), dry dioxane (100 mL), sodium t-butoxide (2.2g, 22.7 mmol), and Xantphos (821 mg, 1.4mmol). The reaction was purged with N2 before adding Pd2(dba)3 (649 mg, 0.71 mmol). The reaction was stirred at rt for 5 min before adding l-(2-aminoethyl pyrrolidine) (2.7 mL, 21.3mmol). The reaction was then sealed and stirred at 90°C overnight. The reaction was cooled to rt, filtered through celite, rinsed with methanol, concentrated and column purified with silica gel and 10:90 MeOH: CH2C12 to give 4-[5-(2,3-difluoro-2- fluoromethyl-propoxy)-2-methyl-3-(2-pyrrolidin-l-yl-ethylamino)-phenyl]-piperazine-l- carboxylic acid t-butyl ester as a brown solid (6.2g, 85% yield). 1H NMR (400 MHz, de- DMSO) δ 6.00 (d, 2H), 4.80 (m, 4H), 4.2 (d, 2H), 3.50 (br s, 4H), 3.19 (q, 2H), 2.72 (br s, 4H), 2.70 (t, 2H), 2.44 (m, 4H), 2.00 (s, 3H), 1.70 (br s, 4H), 1.45 (s, 9H). MS (ESI) for C26H41F3N4O3: 515 (MH*).
[0926] [3-[4-(3-Bromo-lH-pyrazolo[3,4-cf]pyrimidin-4-yl]-piperazin-l-yl]-5-(2,3- difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl] -(2-pyrrolidin- 1 -yl-ethyl)-amine: To a round bottom flask was added 4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2- pyrrolidin-l-yl-ethylamino)-phenyl]-piperazine-l-carboxylic acid t-butyl ester (6.2 g, 12.0 mmol), dry MeOH (35 mL) and 4N HCI in dioxane (35 mL). The reaction was stirred at rt for 1 hr or until complete as monitored by LC/MS. The reaction was then concentrated, and placed on high vacuum for 1 hr before carrying onto the next step without further purification.
[0927] To the round bottom flask containing [5-(2,3-difluoro-2-fluoromethyl- propoxy)-2-methyl-3-piperazin-l-yl-phenyl]-(2-pyrrolidin-l-yl-ethyl)-amine was added in order: THF (60mL), triethyl amine (6.9mL, 48.0 mmol), and 3-bromo-4-chloro-lH- pyrazolo[3,4-d]pyrimidine (2.8g, 12.0 mmol). The reaction was stirred at 65°C for 1 hr or until complete as monitored by LC/MS. The reaction was then concentrated before adding EtOAc (200 mL). The organic layer was washed with saturated NaHCO3 (2X), water, brine, and then dried with Na2SO before concentrating. Column purification with silica gel and a gradient of 5:95 to 15:85 MeOH: CH2C12 gave [3-[4-(3-bromo-lH-pyrazolo[3,4- it]pyrimidin-4-yl]-piperazin-l-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl- phenyl]-(2-pyrrolidin-l-yl-ethyl)-amine (5.41 g, 73% yield). Conversion to the ΗC1 salt was achieved by dissolving [3-[4-(3-bromo-lH-pyrazolo[3,4-£πpyrimidin-4-yl]-piperazin- l-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-(2-pyrrolidin-l-yl-ethyl)- amine in 1:1 water: acetonitrile and adding 1.0 eq. of 4N ΗC1, and lyophilizing. The ΗC1 salt was then lyophilized again with water-acetonitrile. XΗ NMR (400MHz, d6-DMSO) δ 10.90 (br s, IH), 8.20 (s, IH), 6.19 (d, 2H), 4.85 (d sextet, 4H), 4.25 (d, 2H), 4.00 (br s, 4H), 3.80 (br s, 2H), 3.75 (br t, 2H), 3.25 (br s, 2H), 3.00 (br s, 4H), 2.10 (s, 3H), 1.95 (br m, 4H). MS (ESI) for C26H3 BrF3N8O: 609 (MH*).
[0928] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:
[0929] {3-[4-(3-Bromo-lH-pyrazolo[3,4-βT]pyrimidin-4-yl]-piperazin-l-yl]-5- isobutoxy-2-methyl-phenyl}-2-pyrrolidin-l-yl-ethyl)-amine: 1H NMR (400MΗz, de- DMSO) δ 10.85 (br s, IH), 8.40 (s, IH), 6.12 (d, 2H), 3.7 (d, 2H), 3.62 (br s, 2H), 3.45 (br t, 2H), 3.22 (br s, 4H), 3.00 (br s, 8H), 2.18 (s, 3H), 1.80 (m,4H), 1.00 (d, 6H). MS (ESI) for C26H37BrN8O: 557 (MH*).
[0930] N'-{3-[4-(3-Bromo-lH-pyrazolo[3,4-rf]pyrimidin-4-yl]-piρerazin-l-yl]-5- isobutoxy-2-methyl-phenyl}-N,N-diethyl-ethane-l,2-diamine: 1H NMR (400MΗz, de- DMSO) δ 12.2 (br s, IH), 10.20 (br s, IH), 8.20 (s, IH), 6.12 (d, 2H), 3.80 (d, 2H), 3.22 (m, 5H), 3.00 (br s, 2H), 2.18 (s, 3H), 1.90 (m, IH), 1.25 (t, 6H), 1.00 (d, 6H). MS (ESI) for C2eH39BrN8O: 558 (MH*).
[0931] N'-{3-[4-(3-Bromo-lH-pyrazolo[3,4-^pyrimidin-4-yl]-piperazin-l-yl]-5- isobutoxy-2-methyl-phenyl}-N,N-methyl-ethane-l,2-diamine: !Η NMR (400MHz, de- DMSO) δ 12.2 (br s, IH), 10.20 (br s, IH), 8.40 (s, IH), 6.02 (d, 2H), 3.70 (d, 2H), 3.60 (t, 2H), 3.30 (t, 2H), 3.00 (br s, 4H), 2.80 (s, 6H), 2.18 (s, 3H), 1.90 (m, IH), 1.00 (d, 6H). MS (ESI) for C24H35BrN8O: 531 (MH*).
[0932] [3-[4-(3-Bromo-lH-pyrazolo[3,4-c ]pyrimidin-4-yl]-piperazin-l-yl]-5-(2- fluoro-2-methyl-propoxy)-2-methyl-phenyl] -2-pyrrolidin- 1 -yl-efhyl)-amine : 1H NMR (400MHz, de-DMSO) δ 10.60 (br s, IH), 8.40 (s, IH), 6.12 (d, 2H), 4.0 (d, 4H), 3.60 (m, 4H), 3.00 (m, 8H), 2.18 (s, 3H), 1.80 (m,4H), 1.40 (d, 6H). MS (ESI) for C26H36BrFN8O: 555 (MH*).
[0933] N'-[3-[4-(3-Bromo-lH-pyrazolo[3,4-^]pyrimidin-4-yl]-ρiperazin-l-yl]-5-(2- fluoro-2-methyl-propoxy)-2-methyl-phenyl]-N,N-dimethyl-ethane-diamine: 1H NMR (400MHz, de-DMSO) δ 10.80 (br s, IH), 8.40 (s, IH), 6.12 (d, 2H), 4.0 (d, 4H), 3.30 (t, 2H), 3.00 (s, 2H), 2.80 (s, 6H), 2.18 (s, 3H), 1.40 (d, 6H). MS (ESI) for C24H34BrFN8O: 549 (MH*).
[0934] N'-[3-[4-(3-Bromo-lH-pyrazolo[3,4-rf]pyrimidin-4-yl]-piperazin-l-yl]-5-(2,3- difluoro-2-fluoromethylpropoxy)-2-methyl-phenyl] -N,N-dimethyl-ethane- 1 ,2diamine: XΗ NMR (400MHz, de-DMSO) δ 10.80 (br s, IH), 8.40 (s, IH), 6.19 (d, 2H), 4.90 (dq, 2H), 4.80 (dq, 2H), 4.25 (d, 2H), 4.00 (br s, 4H), 3.50 (t, 2H), 3.23 (t, 2H), 3.00 (br s, 4H), 2.80 (s, 6H), 2.12 (s, 3H). MS (ESI) for C24H32BrF3N8O: 585 (MH*).
[0935] 3-Bromo-4-{4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(3- pyrrolidin- 1 -yl-propyl)-phenyl] -piperazin- 1 -yl }- lH-pyrazolo[3,4--f]pyrimidine: 1H NMR (400MHz, de-DMSO) δ 10.60 (br s, IH), 8.40 (s, IH), 6.60 (s, 2H), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.25 (d, 2H), 3.80 (m, 6H), 3.19 (m, 2H), 3.00 (br m, 6H), 2.80 (m, 2H), 2.20 (s, 3H), 1.95 (m, 6H). MS (ESI) for C27H35BrF3N7O: 610 (MH*).
[0936] 3-Bromo-4- { 4- [5-isobutoxy-2-methyl-3 -(3 -pyrrolidin- 1 -yl-propyl)-phenyl] - piperazin-l-yl}-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400MΗz, d6-DMSO) δ 10.23 (br s, IH), 8.40 (s, IH), 6.60 (d, 2H), 4.00 (br s, 4H), 3.70 (d, 2H), 3.20 (m, 2H), 3.00 (br s, 6H), 2.60 (m, 2H), 2.20 (s, 3H), 1.95 (m, 6H). MS (ESI) for C27H38BrN7O: 556 (MH*). [0937] 3-Bromo-4-{4-[3-Bromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl- phenyl]-piperazin-l-yl}-lH-pyrazolo[3,4-^pyrimidine: 1H NMR (400MΗz, de-DMSO) δ 8.40 (s, IH), 7.05 (s, IH), 6.80 (s, IH), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.32 (d, 2H), 4.00 (br s, 4H), 3.00 (br s, 4H), 2.20 (s, 3H). MS (ESI) for C2oH2ιBr2F3N6θ: 579 (MH*).
[0938] 4-{4-[3-Bromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]- piperazin-l-yl}-3-ethyl-lH-pyrazolo[3,4-c ]pyrimidine: *Η NMR (400MHz, d6-DMSO) δ 8.40 (br s, IH), 7.05 (s, IH), 6.79 (s, IH), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.32 (d, 2H), 4.00 (br s, 4H), 3.00 (br s, 6H), 2.20 (s, 3H), 1.4 (t, 3H). MS (ESI) for C22H2eBrN6O: 526 (MH*).
[0939] {3-[4-(3-Bromo-lH-pyrazolo[3,4-rf]pyrimidin-4-yl]-piperazin-l-yl]-5- difluoromethoxy-2-methyl-phenyl}- (2-pyrrolidin- 1-yl-ethyl)- amine: 1H NMR (400MΗz, de-DMSO) δ 8.40 (s, IH), 7.25 (t, IH), 6.25 (d, 2H), 4.00 (br s, 4H), 3,60 (m, 2H), 3.45 (t, 2H), 3.31 ((br t, 2H), 3.00 (br s, 6H), 2.18 (s, 3H), 1.95 (m, 4H). MS (ESI) for C23H29BrF2N8O: 551 (MH*).
[0940] {3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-l-yl]-5- difluoromethoxymethyl-2-methyl-phenyl}- (2-pyrrolidin- 1-yl-ethyl)- amine: 1H NMR (400MHz, d6-DMSO) δ 10.95 (br s, IH), 8.40 (s, IH), 6.80 (t, IH), 6.60 (d, 2H), 4.00 (br s, 4H), 3.60 (m, 2H), 3.55 (m, 2H), 3.39 (m, 2H), 3.00 (br s, 6H), 2.18 (s, 3H), 1.95 (m, 4H). MS (ESI) for C24H31BrF2N8O: 565 (MH*).
[0941] 3-Bromo-4-{4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]- piperazin-l-yl}-lH-pyrazolo[3,4-^pyrimidine: 1H NMR (400MΗz, d6-DMSO) δ 8.40 (s, IH), 7.15 (d, IH), 6.70 (s,lH), 6.65 (dd, 2H), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.32 (d, 2H), 4.00 (br s, 4H), 3.00 (br s, 4H), 2.20 (s, 3H). MS (ESI) for C20H22F3BrNeO: 579 (MH*).
[0942] [3-[4-(3-Bromo-lH-pyrazolo[3,4-rf]pyrimidin-4-yl]-piperazin-l-yl]-4-methyl- 5-(2-ρyrrolidin-l-yl-ethylamino)-ρhenyl]-methanol: 1H NMR (400MΗz, d6-DMSO) δ 10.95 (br s, IH), 8.20 (s, IH), 6.60 (d, 2H), 4.50 (s, 2H), 3.80 (m, 8H), 3.10 (br s, 6H), 2.18 (s, 3H), 1.99 (m, 4H). MS (ESI) for C23H31BrN8O: 515 (MH*).
[0943] 5-{[2,3-Difluoro-2-(fluoromethyl)propyl]oxy}-3-[4-(3-ethyl-lH-pyrazolo[3,4- d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N-(2-pyrrolidin-l-ylethyl)aniline: *H NMR (400 MHz, de-DMSO) δ 9.58 (br s, IH), 8.37 (br s, IH), 6.08 (dd, 2H), 4.78 (m, 4H), 4.23 (d, 4H), 3.90 (br s, 4H), 3.65 (br s, 2H), 3.44 (t, 2H), 3.35 (br s, 2H), 3.01 (br m, 4H), 2.91 (br s, 4H), 2.06 (s, 3H), 1.89 (m, 4H), 1.29 (t, 3H). MS (ESI) for C28H39F3N8O: 561 (MH*).
[0944] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-N- (2-pyrrolidin-l-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]aniline: 1H NMR (400 MHz, de- DMSO) δ 8.38 (s, IH), 6.10 (s, IH), 6.03 (s, IH), 4.88 (t, 2H), 4.66 (q, 2H), 3.93 (m, 4H), 3.34 (m, 2H), 3.19 (q, 2H), 2.95 (q, 2H), 2.95 (m, 4H), 2.68 (t, 3H), 2.01 (s, 3H), 1.7 (m, 4H). MS (ESI) for C24H30BrF3N8O: 585 (MH*).
[0945] EXAMPLE 52: 4-[4-(3-Bromo-5-chloro-2-methyl-phenyl)-piperazin-l-yl]-lH- pyrazolo[3,4-rf]-pyrimidin-6-ylamine.
[0946] To a round bottom flask cooled to -78°C was added 2-amino-4,6-dichloro-5- formyl-pyrimidine (576 mg, 3.0 mmol), dry TΗF (30.0 mL), DIEA (0.96mL, 6.0 mmol), and l-(5-chloro-2-methyl-phenyl)piperazine (630 mg, 3.0 mmol). The reaction was then warmed to rt, and stirred for 3 hr. The yellow precipitate was then filtered out, and the supernatant containing crude product was then concentrated to give crude 2-amino-4- chloro-6-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-pyrimidine-5-carbaldehyde (1.0 g, 90% yield). 1H NMR, (400 MΗz, de-DMSO) δ 9.88 (s, 1Η), 7.65 (d, 2Η), 7.20 (d, IH), 7.00 (d, IH), 3.62 (m, 4H), 2.98 (m, 4H), 2.42 (s, 3H), 2.20 (s, 3H). MS (ESI) for C16H17Cl2N5O: 366 (MH*).
[0947] To a round bottom flask was added 2-amino-4-chloro-6-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-pyrimidine-5-carbaldehyde (364 mg, 1.0 mmol), isopropanol (6.0 mL), and hydrazine (0.080 mL, 1.4 mmol). The reaction was heated to 80°C overnight in a sealed tube before cooling to RT. Product precipitated out of the reaction mixture as a white solid, was filtered, rinsed with iPrOH and dried to give 4-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-lH-pyrazolo[3,4-<fl-pyrimidin-6-ylamine (220 mg, 64% yield): 1H NMR (400MHz, de-DMSO) δ 12.80 (br s, IH), 8.82 (s, IH), 7.25 (d, IH), 7.10 (m, 2H), 4.19 (m, 4H), 3.00 (br s, 4H), 2.30 (s, 3H). MS (ESI) for C16H18C1N7: 344 (MH*).
[0948] EXAMPLE 53: 4-[4-(3-bromo-5-chloro-2-methyl-phenyl)-piperazin-l-yl]-lH- pyrazolo[3,4-rf]-pyrimidin-6-ylamine.
[0949] 4-[4-(3-Bromo-5-chloro-2-methyl-phenyl)-piperazin-l-yl]-lH-pyrazolo[3,4-.f]- pyrimidin-6-ylamine: To a sealed tube was added 4-[4-(5-Chloro-2-methyl-phenyl)- piperazin-l-yl]-lH-pyrazolo[3,4-rf]-pyrimidin-6-ylamine (85 mg, 0.25 mmol), water (1.5 mL), and bromine (0.014 mL, 0.27 mmol). The reaction was heated to 110°C overnight in a sealed tube. Three compounds were detected by LC/MS: major portion was starting material, second one was unidentified, and third one was the desired product. The reaction was cooled to r.t.. The brown precipitate was filtered and rinsed with water and purified by prep-HPLC to give 4-[4-(3-bromo-5-chloro-2-methyl-phenyl)-piperazin-l-yl]-lH- pyrazolo[3,4-(t]-pyrimidin-6-ylamine (6.0 mg, 1.4%): 1H NMR (400MΗz, d6-DMSO) δ 12.70 (br s, IH), 8.82 (s, IH), 7.61 (s, IH), 7.23 (s, IH), 4.19 (m, 4H), 3.00 (br s, 4H), 2.30 (s, 3H). MS (ESI) for CιeHπBrClN7: 422 (MH*).
[0950] EXAMPLE 54: (2E)-3-[4-(4-{5-{[2,3-Difluoro-2-(fluoromethyl)propyl]oxy}- 2-methyl-3-[(2-pyrrolidin-l-ylethyl)amino]phenyl}piperazin-l-yl)-lH-pyrazolo[3,4- d]pyrimidin-3-yl]prop-2-enoic acid.
[0951] To a round bottom flask was added 4-[5-(2,3-difluoro-2-fluoromethyl- propoxy)-2-methyl-3-(2-pyrrolidin-l-yl-ethylamino)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester (539 mg, 1.04 mmol), dry MeOH (2.0 mL) and 4N HCI in dioxane (2.0 mL). The reaction was stirred at RT for 1 hr, then concentrated to remove trace HCI. The residue was then dissolved in THF (20.0 mL), and triethyl amine (0.69 mL, 4.8 mmol), before adding 3-bromo-l-(tetrahydro-pyran-2-yl)-4-[l,2,4]triazol-l-yl-lH-pyrazolo[3,4- d]pyrimidine (420.0 mg, 1.2 mmol). The reaction was then stirred at 65°C overnight, concentrated, extract with EtOAc and water, washed with saturated NaHCO3, brine, and dried with Na2SO4, concentrated and columned with 20:80 CH2C12 to give [3-{4-[3- bromo-l-(tetrahydro-pyran-2-yl)-lH-pyrazolo[3,4- ]-pyrimidin-4-yl}-5-(2,3-difluoro-2- fluoromethyl-propxy)-2-methyl-phenyl]-(2-pyrrolidin-l-yl-efhyl)-amine as a pale yellow solid (509 mg, 61% yield). 1H NMR, (400 MΗz, de-DMSO) δ 8.40 (s, 1Η), 6.08 (d, 2Η), 5.90 (dd, IH), 4.80 (m, 5H), 4.22 (d, 2H), 3.98 (m, 4H), 3.68 (m, IH), 3.19 (q, 2H), 2.98 (br s, 4H), 2.40 (dq, 2H), 2.0 (m, 5H), 1.80-1.60 (m, 8H). MS (ESI) for C31H42BrF3N8O2: 695 (MH*).
[0952] To a sealed tube was added [3-{4-[3-bromo-l-(tetrahydro-pyran-2-yl)-lH- pyrazolo[3,4-rf]-pyriniidin-4-yl}-5-(2,3-difluoro-2-fluoromethyl-propxy)-2-methyl- phenyl]-(2-pyrrolidin-l-yl-ethyl)-amine (130 mg, 0.19 mmol), DMF (3.0 mL), triethylamine (0.23 mL, 1.9 mmol), Cul (12 mg, 0.06 mmol), and tert-butyldimethyl-(2- propynyloxy)-silane (0.11 mL, 0.56 mmol). The reaction mixtare was purged with nitrogen before adding Pd(PPh3)4 (23 mg, 0.02 mmol). The tube was sealed and heated to 105°C overnight and cooled to RT, filtered through celite, rinsed with MeOΗ and columned with 5:95 MeOΗ: CΗ2C12 to give [3-{4-[3-[3-(tert-butyl-dimethyl-silanyloxy)- prop- 1 -ynyl] - 1 -(tetrahydro-pyran-2-yl)- lH-pyrazolo[3 ,4-rf]pyrimidin-4-yl)-piperazin- 1 - yl}-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-(2-pyrrolidin-l-yl-ethyl)- amine (113 mg, 65 % yield). MS (ESI) for C40Η59F3N8O3Si: 785 (MH*).
[0953] To a round bottom flask was added [3-{4-[3-[3-(tert-butyl-dimethyl- silanyloxy)-prop- 1 -ynyl] - 1 -(tetrahydro-pyran-2-yl)- lH-pyrazolo [3 ,4-c0pyrimidin-4-yl)- piperazin-l-yl}-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-(2-pyrrolidin- l-yl-ethyl)-amine (113 mg, 0.14 mmol), MeOΗ (2.0 mL), and 4N ΗC1 in dioxane (2.0 mL). The reaction was stirred at RT for 15 min, concentrated, prep purified and converted to the ΗC1 salt to give 3-(4-{4-[5-(2,3-difluoro-2-fluoromethyl-propxy)-2-methyl-3-(2- pyrrolidin- 1 -yl-ethylamino)-phenyl] -piperazin- 1 -yl } - lH-pyrazolo [3 ,4-d]pyrimidin-3-yl)- prop-2-yn-l-ol as a white solid (48.0 mg, 65% yield): 1H NMR (400MΗz, d6-DMSO) δ 10.60 (br s, IH), 8.40 (br s, IH), 6.10 (d, 2H), 4.83 (dq, 4H), 4.79 (dq, 4H), 4.40 (s, IH), 4.30 (d, 2H), 3.60 (m, 6H), 3.35 (br s, 4H), 3.00 (br s, 6H), 2.05 (s, 3H), 1.95 (m, 4H). MS (ESI) for C29H37F3N8O2: 587 (MH*).
[0954] EXAMPLE 55: (2E)-3-[4-(4-{5-{[2,3-Difluoro-2-(fluoromethyl)propyl]oxy}- 2-methyl-3- [(2-pyrrolidin- 1 -ylethyl)amino]phenyl [piperazin- 1 -yl)- lH-pyrazolo[3,4- d]pyrimidin-3-yl]prop-2-enoic acid.
[0955] To a sealed tube was added [3-{4-[3-bromo-l-(tetrahydro-pyran-2-yl)-lH- pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-l-yl}-5-(2,3-difluoro-2-fluoromethyl-propoxy)- 2-methyl-phenyl]-(2-pyrrolidin-l-yl-ethyl)-amine (250 mg, 0.36 mmol), DMF (3.0 mL), potassium phosphate tribasic (382 mg, 1.8 mmol), and t-butyl acrylate (0.29 mL, 1.44 mmol). The reaction mixture was purged with nitrogen before adding Pd(dppf)Cl2CH2Cl2 (59 mg, 0.072 mmol). The tube was sealed and heated to 120°C overnight and cooled to RT, filtered through celite, rinsed with MeOH and concentrated to give crude 3-[4-{4-[5- (2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2-pyιτolidin-l-yl-ethylamino)- phenyl]-piperazin-l-yl}-l-(tetrahydro-pyran-2-yl)-lH-pyrazolo[3,4- ]pyrimidin-3-yl]- acrylic acid tert-butyl ester which was carried to the next step without further purification. MS (ESI) for C38Η53F3N8O4: 743 (MH*).
[0956] To a round bottom flask was added 3-[4-{4-[5-(2,3-difluoro-2-fluoromethyl- propoxy)-2-methyl-3-(2-pyrrolidin- 1 -yl-ethylamino)-phenyl] -piperazin- 1 -yl } - 1 - (tetrahydro-pyran-2-yl)-lH-pyrazolo[3,4-(f]pyrimidin-3-yl]-acrylic acid tert-butyl ester (250 mg, 0.33 mmol), CΗ2C12 (2.0 mL), and TFA (2.0 mL). The reaction was stirred at r.t. for 2 hr, concentrated, prep purified and converted to the HCI salt to give (2E)-3-[4-(4- {5-{[2,3-difluoro-2-(fluoromethyl)ρropyl]oxy}-2-methyl-3-[(2-pyrrolidin-l- ylethyl)amino]phenyl }piperazin- 1 -yl)- 1 H-pyrazolo [3 ,4-d]pyrimidin-3-yl]prop-2-enoic acid as a yellow solid (102.0 mg, 51% yield over two steps): 1H NMR (400MHz, de- DMSO) δ 9.42 (br s, IH), 7.75 (d, 2H), 6.60 (d, 2H), 4.80 (m, 4H), 4.22 (d, 2H), 3.00 (m, 8H), 2.05 (s, 3H), 1.95 (m, 4H). MS (ESI) for C29H37F3N8O3: 603 (MH*).
[0957] Using the same or analogous synthetic techniques and/or substitating with alternative reagents, the following compounds of the invention were prepared:
[0958] 4-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- methylquinoline. !H NMR (400 MHz, de-DMSO) δ 8.40 (s, IH), 8.08 (d, IH), 7.88 (d, IH), 7.68 (t, IH), 7.52 (t, IH), 6.98 (s, IH), 4.10 (m, 4H), 3.35 (m, 4H), 2.58 (s, 3H). MS (ESI) for C19Hι8BrN7: 424 (MH*).
[0959] 3-Bromo-4-[4-(3,5-dichlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4- djpyrimidine: MS (ESI) for C15H13BrCl2N6: 429 (MH*).
[0960] 3-[4-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-l-methyl- 6-(trifluoromethyl)-lH-benzimidazol-2-yl]propan-l-ol: 1H NMR (400 MHz, CDC13) δ 8.42 (s, IH), 7.24 (s, IH), 6.89 (s, IH), 4.19 (m, 4H), 3.86 ((q, 2H), 3.79 (s, 3H), 3.70 (m, 4H), 3.12 (t, 2H), 2.20 (m, 2H). MS (ESI) for C ιH22BrF3N8O: 541 (MH*).
[0961] 3- [4-(3 -Bromo- 1 H-pyrazolo[3 ,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -2-methyl-N- (2-pyrrolidin-l-ylethyl)-5-[4,4,4-trifluoro-l,l-bis(methyloxy)butyl]aniline: H NMR (400 MHz, de-DMSO) δ 8.33 (s, IH), 6.45 (s, IH), 6.38 (s, IH), 4.8 (br. IH), 3.9 (br. 4H), 3.15 (q, 2H), 3.05 (s, 6H), 2.91 (br. 4H), 2.61 (t, 2H), 2.45 (m, 4H), 2.04 (s, 3H), 2.00 (m, 2H), 1.8 (m, 2H), 1.67 (br. 4H). MS (ESI) for C28H38BrF3N8O2: 657 (MH*).
[0962] 3-Bromo-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-l-yl}-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 14.12 (br. s, IH), 8.38 (m, 2 H), 7.19 (br s, IH), 6.95 (br d, J = 5.2 Hz, IH), 3.95 (m, 4H), 3.84 (m, 4H). MS (ESI) for C15H13BrF3N7: 430 (MH*).
[0963] 3-Bromo-4- { 4- [4-(trifluoromethyl)pyrimidin-2-yl] piperazin- 1 -yl } - 1 H- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 14.10 (br. s, IH), 8.75 (d, J = 4.8 Hz, 1 H), 8.38 (s, IH), 7.10 (d, J = 4.8 Hz, IH), 3.99 (m, 4H), 3.92 (m, 4H). MS (ESI) for Cι4Hι2BrF3N8: 431 (MH*). [0964] 2-({3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]pyrazin- 2-yl}oxy)-N,N-dimethylethanamine: 1H NMR (400 MHz, d6-DMSO) δ 14.10 (br s, IH), 8.38 (s, IH), 7.87 (d, J = 2.9 Hz, IH), 7.68 (d, J = 2.9 Hz, IH), 4.66 (m, 2H), 3.92 (4H), 3.67 (m, 4H), 3.61 (m, 2H), 2.91 (m, 6H). MS (ESI) for C17H22BrN9O: 430 (MH*).
[0965] 3-Bromo-4-{4-[3-(methyloxy)pyrazin-2-yl]piperazin-l-yl}-lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, d6- DMSO) δ 14.20 (s, IH), 8.37 (s, IH), 7.80 (d, J = 2.7 Hz, IH), 7.67 (d, J = 2.9 Hz, IH), 3.94 (s, 3H), 3.92 (m, 4H), 3.65 (m, 4H). MS (ESI) for Cι4H15BrN8O: 391 (MH*).
[0966] 4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-l-(5-chloro-2- methylphenyl)piperazin-2-one: 1H NMR (400 MHz, d6-DMSO) δ 14.12 (br s, IH), 8.42 (s, IH), 7.43 (br s, IH), 7.34 (m, 2H), 4.56 (m, 2H), 4.38 (m, IH), 4.21 (m, IH), 3.87 (m, IH), 3.63 (m, IH), 2.12 (s, 3H). MS (ESI) for C16H14BrClN6O: 421(MH*).
[0967] 3-({6-[4-(3-Bromo-lH-ρyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- chloro-5-methylpyrimidin-4-yl}oxy)-N,N-diethylpropan-l -amine: 1H NMR (400 MHz, CDC13) δ 8.37 (s, IH), 4.40 (t, 2H), 4.10 (m, 4H), 3.64 (m, 4H), 3.17 (m, 6H), 2.33 (m, 2H), 2.25 (s, 3H), 1.38 (t, 6H). MS (ESI) for C2ιH29BrClN9O: 538 (MH*).
[0968] 3-({4-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-6- chloro-5-methylpyrimidin-2-yl}oxy)-N,N-diethylpropan-l-amine: 1H NMR (400 MHz, d6-DMSO) δ 8.37 (s, IH), 4.35 (t, 2H), 3.91 (m, 4H), 3.56 ,(m, 4H), 3.08 (m, 6H), 2.07 (m, 5H), 1.15 (m, 6H). MS (ESI) for C21H29BrClN9O: 538 (MH*).
[0969] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2-methyl-5- (5-methyl-l,2,4-oxadiazol-3-yl)-N-(2-ρyrrolidin-l-ylethyl)aniline: !H NMR (400 MHz, de-DMSO) δ 8.38 (s, IH), 7.05 (s, IH), 6.99 (s, IH), 5.09 (t, IH), 3.97 (br s, 8H), 3.24 (m, 2H), 3.02 (br s, 4H), 2.69 (t, 2H), 2.64 (s, 3H), 2.14 (s, 3H), 1.71 (m, 4H). MS (ESI) for C25H3ιBrN10O: 567 (MH*).
[0970] 3-Bromo-4-[(3S)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.36 (s, IH), 7.25 (m, 2H), 7.11 (dd, IH), 4.38 (d, IH), 4.28 (d, IH), 3.56 (m, IH), 3.38 (m, IH), 3.23 (m, IH), 3.07 (m, IH), 2.80 (m, IH), 2.29 (s, 3H), 0.84 (d, 3H). MS (ESI) for C17Hι8BrClN6: 421 (MH*). [0971] 3-Bromo-4-[(3R)-4-(5-chloro-2-methylphenyl)-3-methylρiperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, CDC13) δ 12.2 (s, IH), 8.41 (s, IH), 7.09 (m, 3H), 4.57 (m, IH), 4.48 (m, IH), 3.60 (m, IH), 3.33 (m, IH), 3.28 (m, IH), 3.06 (m, IH), 2.88 (m, IH), 2.32 (s, 3H), 0.94 (d, 3H). MS (ESI) for C17H18BrClN6: 421 (MH*).
[0972] 2-({3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]phenyl}oxy)-N-ethylacetamide: 1H NMR (400 MHz, CDC13) δ 11.92 (br s, IH), 8.42 (s, IH), 7.21-7.19 (m, IH), 6.65-6.63 (m, IH), 6.56(m, IH,), 6.52 (s, IH), 6.45-6.43 (m, IH), 4.48 (s, 2H), 4.09-4.06 (m, 4H), 3.41-3.40 (m, 6H), 1.21-1.18 (t, 3H). MS (ESI) for C19H22BrN7O2: 460 (MH*).
[0973] 2- [4-(3 -Bromo- lH-pyrazolo [3 ,4-d]pyrimidin-4-yl)piperazin- 1 -yl] -N,N- diethylpyrimidin-4-amine: 1H NMR (400 MHz, CDC13) δ 12.10 (br s, IH), 8.40 (s, IH), 7.91-7.89 (d, IH), 5.82-5.80 (d, IH), 3.99-3.96 (m, 8H), 3.47 (m, 4H), 1.20-1.17 (t, 6H). MS (ESI) for C17H22BrN9: 432 (MH*).
[0974] 3-Bromo-4-[4-(3- { [(3-methylphenyl)methyl] oxy }phenyl)piperazin- 1 -yl] - 1H- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, CDC13) δ 11.35 ( br s, IH), 8.39 (s, IH), 7.39-7.37 (m, IH), 7.25-7.23 (m, IH), 7.22-7.19 (m, 2H), 6.94 (s, 4H), 4.99 (s, 2H), 4.09- 4.06 (m, 4H), 3.28-3.25 (m, 4H), 2.37 (s, 3H). MS (ESI) for C23H23BrN6O: 479 (MH+).
[0975] 3-Bromo-4-(4-{3-[(2-piperidin-l-ylethyl)oxy]phenyl}piperazin-l-yl)-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, CDC13) δ 8.43 (s, IH), 6.94-6.92 (d, 2H), 6.87-6.84 (d, 2H), 4.09-4.07 (m, 6H), 3.27-3.25 (m, 4H), 2.78-2.75 (t, 2H), 2.52 (m, 4H), 1.64-1.59 (m, 4H), 1.45 (m, 2H). MS (ESI) for C22H28 BrN7O: 486 (MH*).
[0976] 3-Bromo-4- [4-(4-furan-2-ylpyrimidin-2-yl)piperazin- 1 -yl] - 1 H-pyrazolo [3,4- djpyrimidine: 1H NMR (400 MHz, CDC13) δ 11.56 (br s, IH), 8.44 (s, IH), 8.40-8.39 (d, IH), 7.58-7.58 (m, IH), 7.22-7.21 (m, IH), 6.94-6.93 (d, IH), 6.57-6.56 (m, IH), 4.11- 4.09 (m, 4H), 4.05-4.03 (m, 4H). MS (ESI) for C17H15BrN8O: 427 (MH*).
[0977] 6-{2-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]pyrimidin- 4-yl}-2H-l,4-benzoxazin-3(4H)-one: 1H NMR (400 MHz, de-DMSO) δ 14.10 (br s, IH), 10.85 (s, IH), 8.46-8.44 (d, IH), 8.38 (s, IH), 7.79 (s, IH), 7.74-7.71 (d, IH), 7.14-7.13 (d, IH), 7.07-7.05 (d, IH), 4.66 (s, 2H), 4.05 (m, 4H), 3.94-3.92 (m, 4H). MS (ESI) for C21H18BrN9O2: 508 (MH*). [0978] 2-({3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]phenyl}oxy)-N-cyclopropylacetamide: *H NMR (400 MHz, CDC13) δ 8.32 (s, IH), 7.25-7.21 (m, IH), 6.68 (br s, IH), 6.65-6.63 (m, IH), 6.51-6.47 (m, 2H), 4.50 (s, 2H), 4.36-4.33 (m, 4H), 3.45-3.42 (m, 4H), 2.81-2.78 (m, IH), 0.88-0.83 (m, 2H), 0.61-0.57 (m, 2H). MS (ESI) for C2oH22BrN7O2: 472 (MH*).
[0979] 3-Bromo-4-(4-{3-[(2-piperidin-l-ylethyl)oxy]pyrazin-2-yl}piperazin-l-yl)-lH- pyrazoloP dJpyrimidine^H NMR (400 MHz, CDC13) δ 12.48 (br s, IH), 8.28 (s, IH), 7.82-7.81 (d, IH), 7.60-7.59 (d, IH), 4.86-4.84 (t, 2H), 4.26-4.23 (m, 4H), 3.79-3.72 (m, 6H), 3.51-3.48 (t, 2H), 2.77-2.71 (m, 4H), 2.06-1.98 (m, 2H), 1.91-1.89 (m, 2H). MS (ESI) for C20H26BrN9O: 488 (MH*).
[0980] 3-Bromo-4-[4-(2,4-dichlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.35 (s, IH), 7.57 (d, IH), 7.37 (dd, IH), 7.21 (d, IH), 3.94 (t, 4H), 3.14 (t, 4H). MS (ESI) for C15H13BrCl2N6: 427 (MH*)
[0981] 4-{4-[3,5-Bis-(methyloxy)phenyl]piperazin-l-yl}-3-bromo-lH-pyrazolo[3,4-d] pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.35 (s, IH), 6.19 (d, 2H), 6.02 (t, IH), 3.94 (t, 4H), 3.70 (s, 6H), 3.36 (t, 4H). MS (ESI) for C17H19BrN6O2: 419 (MH*).
[0982] 3-Bromo-4-[4-(3,4-dimethylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.35 (s, IH), 6.98 (d, IH), 6.84 (s, IH), 6.74 (d,lH), 3.91 (br s, 4H), 3.28 (br s, 4H), 2.18 (s, 3H), 2.12 (s, 3H). MS (ESI) for CπH19BrN6: 387 (MH*).
[0983] 3-Bromo-4-[4-(4-nitrophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.35 (s, IH), 8.07 (d, 2H), 7.05 (d, 2H), 3.96 (t, 4H), 3.71 (t, 4H). MS (ESI) for C15Hι4BrN7O2: 404 (MH*).
[0984] 3-Bromo-4-[4-(2,6-dimethylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.33 (s, IH), 6.97 (m, 3H), 3.91 (t, 4H), 3.18 (t, 4H), 2.39 (s, 6H). MS (ESI) for C17H19BrN6: 387 (MH*).
[0985] 3-Bromo-4- { 4-[4-(ethyloxy)phenyl]piperazin-l -yl } - lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, de-DMSO) δ 8.35 (s, IH), 6.97 (d, 2H), 6.84 (d, 2H), 3.95 (m, 4H), 3:25 (br t, 4H), 1.29 (t, 3H). MS (ESI) for C H19BrN6O: 403 (MH*).
[0986] 3-Bromo-4-[4-(2-ethylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.35 (s, IH), 7.23 (dd, IH), 7.14 (m, 2H), 7.04 (dt, IH), 3.95 (br s, 4H), 2.99 (t, 4H), 2.73 (q, 2H), 1.22 (t, 3H). MS (ESI) for C17H19BrN6: 387 (MH*).
[0987] 3-Bromo-4-[4-(2-nitrophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 8.35 (s, IH), 7.84 (dd, IH), 7.60 (dt, IH), 7.38 (dd, IH),
7.15 (dt, IH), 3.92 (t, 4H), 3.22 (t, 4H). MS (ESI) for C15Hι4BrN7O2: 404 (MH*).
[0988] 2-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrirnidin-4-yl)piperazin-l-yl]benzonitrile: 1H NMR (400 MHz, d6-DMSO) δ 8.36 (s, IH), 7.73 (d, IH), 7.61 (t, IH), 7.22 (d, IH), 7.12 (t, IH), 3.98 (br s, 4H), 3.33 (br s, 4H). MS (ESI) for C16Hι4BrN7: 384 (MH*).
[0989] 4-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]benzonitrile: 1H NMR (400 MHz, de-DMSO) δ 8.35 (s, IH), 7.60 (d, 2H), 7.05 (d, 2H), 3.93 (t, 4H), 3.58 (t, 4H). MS (ESI) for Cι6H14BrN7: 384 (MH*).
[0990] 3-Bromo-4- { 4-[4-(trifluoromethyl)phenyl]piperazin- 1 -yl } - lH-pyrazolo[3,4- d]pyrimidine: Η NMR (400 MHz, d6-DMSO) δ 8.36 (s, IH), 7.25 (d, 2H), 7.11 (d, 2H),
3.94 (t, 4H), 3.50 (t, 4H). MS (ESI) for C16Hι4BrF3N6: 427 (MH*).
[0991] 3-Bromo-4-(4- { 4-[(phenylmethyl)oxy]phenyl [piperazin- 1 -yl)- 1H- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.36 (s, IH), 7.40 (m, 5H),
6.95 (q, 4H), 5.04 (s, 2H), 3.93 (t, 4H), 3.46 (t, 4H). MS (ESI) for C22H2iBrN6O: 465 (MH*).
[1000] 2-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]pyridine-3- carbonitrile: 1H NMR (400 MHz, d6-DMSO) δ 8.42 (dd, IH), 8.35 (s, IH), 8.09 (dd, IH),
6.96 (q, IH), 3.93 (m, 4H), 3.46 (m, 4H). MS (ESI) for C15H13BrN8: 385 (MH*).
[1001] 3-Bromo-4-[4-(2,3-dichlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.37 (s, IH), 7.34 (m, 2H), 7.22 (m, IH), 3.97(t, 4H), 3.17 (t, 4H). MS (ESI) for C15H13BrCl2N6: 427 (MH*).
[1002] 3-Bromo-4-{4-[2-(trifluoromethyl)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.37 (s, IH), 7.68 (m, 3H), 7.37 (m, IH), 3.94 (br m, 4H), 3.05 (t, 4H). MS (ESI) for C16H14BrF3N6: 427 (MH*).
[1003] 2-({3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]phenyl}oxy)- N,N-diethylethanamine: 1H NMR (400 MHz, d6-DMSO) δ 9.40 (br s, IH), 8.35 (s, IH),
7.16 (t, IH), 6.64 (d, IH), 6.58 (s, IH), 6.45 (d, IH), 4.28 (t, 2H), 3.92 (br s, 2H), 3.49 (d, 4H), 3.35 (br s, 4H), 3.21 (q, 4H), 1.23 (t, 6H). MS (ESI) for C2ιH28BrN7O: 474 (MH*). [1004] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]ρyrimidin-4-yl)ρiperazin-l-yl]-2-methyl-5- (methyloxy)-N-(2-pyrrolidin-l-ylethyl)aniline: 1H NMR (400 MHz, d6-DMSO) δ 9.40 (br s, IH), 8.36 (s, IH), 6.06 (d, IH), 5.99 (d, IH), 3.85 (br m, 4H), 3.69 (s, 3H), 3.62 (br m, 4H), 3.43 (t, 2H), 3.35 (m, 2H), 3.05 (br s, 4H), 2.94 (br s, 4H), 2.05 (s, 3H), 1.85 (br m, 4H). MS (ESI) for C23H31BrN8O: 515 (MET*).
[1005] 3-Bromo-4-[4-(3',4',6-trifluoro-4-methylbiphenyl-3-yl)piperazin-l-yl]-lH- pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.37 (s, IH), 7.63 (m, IH), 7.52 (m, IH), 7.42 (br m, IH), 7.20 (d, IH), 7.18 (s, IH), 3.96 (br s, 4H), 3.07 (t, 4H), 2.36 (s, 3H). MS (ESI) for C22Hι8BrF3N6: 503 (MH*).
[1006] 3-Bromo-4-[4-(3,4-dichlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for Cι5H13BrCl2Ne: 428 (MH*).
[1007] 3-Bromo-4-[4-(3,4-difluorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C15Hι3BrF2N6: 394 (MH*).
[1008] 3-Bromo-4-[4-(3-chloro-4-fluorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.39 (s, IH), 7.29 (t, IH), 7.19 (m, IH), 7.02 (m, IH), 3.92 (t, 4H), 3.33 (t, 4H). MS (ESI) for C15H13BrClFN6: 412 (MH*).
[1009] l-{4-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l- yl]phenyl}ethanone: MS (ESI) for Cι7H BrN6O: 403 (MH*).
[1010] 3-Bromo-4-[4-(2,5-dichlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 8.39 (s, IH), 7.49 (d, IH), 7.26 (d, IH), 7.16 (dd, IH), 3.95 (m, 4H), 3.20 (m, 4H). MS (ESI) for Cι5H13BrCl2Ne: 428 (MH*).
[1011] 4-{4-[2,4-Bis(methyloxy)phenyl]piperazin-l-yl}-3-bromo-lH-pyrazolo[3,4- d]pyrimidine: MS (ESI) for Cι7H19BrN6O2: 421 (MH*).
[1012] 3-Bromo-4-(4-pyrazin-2-ylpiperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C13H13BrN8: 361 (MH*).
[1013] 3-Bromo-4-(4-pyrimidin-2-ylpiperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C13H13BrN8: 361 (MH*).
[1014] 4-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-l-yl]-2- (trifluoromethyl)quinoline: 1H NMR (400 MHz, d6-DMSO) δ 8.39 (s, IH) 8.21 (d, IH), 8.09 (d, IH), 7.84 (t, 3H), 7.73 (t, 3H), 7.34 (s, IH), 4.11 (m, 4H), 3.54 (m, 4H). MS (ESI) for C19Hι5BrF3N7: 480 (MH*). [1015] 3-[4-(3-Bromo-lH-pyrazolo[3,4-d]pyrimidin-4-yl)ρiperazin-l-yl]pyrazine-2- carbonitrile: MS (ESI) for C14H12BrN9: 386 (MH*).
[1016] 3-Bromo-4-[4-(3-chlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.38 (s, IH), 7.22 (t, IH), 7.01 (s, IH), 6.97 (d, IH), 6.81 (d, IH), 3.91 (t, 4H), 3.40 (t, 4H). MS (ESI) for C15Hι4BrClN6: 395 (MH*).
[1017] 3-Bromo-4-{4-[3-(trifluorpmethyl)pyridin-2-yl]piperazin-l-yl}-lH-pyrazolo[3,4- d]pyrimidine: MS (ESI) for C15Hι3BrF3N7: 429 (MH*).
[1018] 3-Bromo-4- { 4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin- 1 -yl } - 1H- pyrazolo[3,4-d]pyrimidine: MS (ESI) for C15H12BrClF3N7: 464 (MH*).
[1019] 3-Bromo-4-(4-phenylpiperazin-l-yl)-lH-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, de-DMSO) δ 8.38 (s, IH), 7.24 (t, 2H), 7.02 (d, 2H), 6.83 (t, IH), 3.94 (t, 4H), 3.37 (t, 4H). MS (ESI) for Cι5H15BrN6: 360 (MH*).
[1020] 3-Bromo-4-[4-(4-fluorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C15H14BrFN6: 378 (MET*).
[1021] 3-Bromo-4-[4-(4-chlorophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C15Hι4BrClN6: 395 (MH*).
[1022] 3-Bromo-4-{4-[3-(trifluoromethyl)phenyl]piperazin-l-yl}-lH-pyrazolo[3,4- djpyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.38 (s, IH), 7.42 (t, IH), 7.29 (d, IH), 7.25 (s, IH), 7.11 (d, IH), 3.94 (m, 4H), 3.43 (m, 4H). MS (ESI) for C16H14BrF3N6: 430 (MH*).
[1023] 3-Bromo-4-[4-(4-bromophenyl)piperazin-l-yl]-lH-pyrazolo[3,4-d]pyrimidine: MS (ESI) for Cι5H14Br2N6: 439 (MH*).
[1024] 3-Bromo-4-[3-methyl-4-(3-methylphenyl)piperazin-l-yl]-lH-pyrazolo[3,4- d]pyrimidine: 1H NMR (400 MHz, d6-DMSO) δ 8.39 (s, IH), 7.20 (m, IH), 6.92 (m, 2H), 6.76 (m, IH), 4.30 (m, 2H), 4.11 (m, 2H), 3.52 (m, 2H), 3.40 (m, IH), 2.38 (s, 3H), 0.94 (d, 3H). MS (ESI) for Cι7Hι9BrN6: 388 (MH*).
[1025] Additional examples of compounds that were made according to the methods and procedures described above are set forth in Table 1. Each of these compounds are further aspects of this invention.
Assays [1026] For assay of activity, generally p70S6K and/or AktK, or a compound according to the invention is non-diffusably bound to an insoluble support having isolated sample- receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble support may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Exemplary methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.
[1027] One measure of inhibition is Kj. For compounds with IC5o's less than 1 μM, the Kj or Kd is defined as the dissociation rate constant for the interaction of the agent with a p70S6K and/or AktK. Exemplary compositions have Kj's of, for example, less than about 100 μM, less than about 10 μM, less than about 1 μM, and further for example having Kj's of less than about 100 nM, and still further, for example, less than about 10 nM. The K; for a compound is determined from the IC50 based on three assumptions. First, only one compound molecule binds to the enzyme and there is no cooperativity. Second, the concentrations of active enzyme and the compound tested are known (i.e., there are no significant amounts of impurities or inactive forms in the preparations). Third, the enzymatic rate of the enzyme-inhibitor complex is zero. The rate data (i.e. compound concentration) are fitted to the equation: [1028] where V is the observed rate, V^, is the rate of the free enzyme, I0 is the inhibitor concentration, E0 is the enzyme concentration, and K is the dissociation constant of the enzyme-inhibitor complex.
[1029] Another measure of inhibition is GI50, defined as the concentration of the compound that results in a decrease in the rate of cell growth by fifty percent. Exemplary compounds have GI5o's of, for example, less than about 1 mM, less than about 10 μM, less than about 1 μM, and further, for example, having GI50's of less than about 100 nM, still further having GIso's of less than about 10 nM. Measurement of GI50 is done using a cell proliferation assay.
[1030] Tyrosine kinase activity is determined by 1) measurement of kinase-dependent ATP consumption by in the presence of a generic substrate such as polyglutamine, tyrosine (pEY), by luciferase/luciferin-mediated chemiluminescence or; 2) incoφoration of radioactive phosphate derived from 33P-ATP into a generic substrate which has been adsorbed onto the well surface of polystyrene microtiter plates. Phosphorylated substrate products are quantified by scintillation spectrometry. Luciferase-Coupled Chemiluminescence Assav Protocol
[1031] Kinase activity is measured as the percent of ATP consumed following the kinase reaction using luciferase-luciferin-coupled chemiluminescence. Reactions were conducted in 384-well white, medium binding microtiter plates (Greiner). Kinase reactions were initiated by combining test compounds, ATP and kinase in a 20 uL volume. The reaction mixture was incubated at ambient temperature for 3 hrs. For p70S6K and/or AktK, 2.5-5 nM of the enzyme was pre-incubated with compound in 20 mM Tris pH 7.5, 10 mM MgC12, 0.03% TX-100, and ImM DTT for 30 minutes at room temperatare. Following the kinase reaction, a 20 μL aliquot of luciferase-luciferin mix was added and the chemiluminescence signal measured using a Victor plate reader (Perkin Elmer). The luciferase-luciferin mix contained 50 mM HEPES, pH 7.8, 67 mM oxalic acid (pH 7.8), 5 (or 50) mM DTT, 0.4% Triton X-100, 0.25 mg/mL coenzyme A, 63 μM AMP, 28 μg/mL luciferin and 40,000 units/mL luciferase. Total ATP consumption was limited to 25-60% and the IC5o values correlate well with those determined by radiometric assays. 33P -Phosphoryl Transfer Kinase Assay Protocol II
[1032] Direct p70S6K and/or AktK activity was measured as incoφorated 33P in the method described below. Reactions were performed in a 96-well polypropylene V-bottom plate. Samples were incubated for 30 minutes and then transferred to a 96-well P81 Unifilter plate (Whatman). Each reaction contained 50 nM p70S6 and/or Akt kinase with 5 uM ATP and 33P-γ-ATP (3.3 μCi/nmol) in 20 mM Tris pH 7.5, 10 mM MgC12, 0.03% TX-100, and ImM DTT. Plates were washed 10 times with 0.075% phosphoric acid. 100 ul of scintillation fluid was added and incoφorated 33P was measured by liquid scintillation spectrometry using a MicroBeta scintillation counter (Perkin Elmer). Structure Activity Relationships [1033] Table 1 shows structure activity relationship data for selected compounds of the invention. Inhibition is indicated as IC50 with following key: A = ICs0 less than 100 nM, B = IC50 greater than 100 nM, but less than or equal to 1000 nM, C = IC50 greater than 1000 nM, but less than 10,000 nM, D = IC50 10,000 nM or greater. An empty cell indicates lack of data only. Table 1
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
[1034] As discussed above, the names of the compounds are generated using the nomenclature engine published by ACD Labs of Toronto Canada. In order to further describe the compounds of the present invention, a representative number of compounds set forth in Table 1 are provided below in Table 2, wherein the structure of the compound is provided as well as the name generated by the nomenclature engine. These examples are provided to further clarify the compounds of the present invention. Table 2
Figure imgf000200_0001
3-({3 4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1- yl]-4'-methylbiphenyl-2-yl}oxy)-N,N-dimethylpropan-1 -amine
3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]- 5-(1 ,1 -dif luorobutyl)-2-methyl-N-(2-pyrrolidin-1 -ylethyQaniline
3-bromo-4-(4-{4-methyl-2'-[(3-morpholin-4- ylpropyl)oxy]biphenyl-3-yl}piperazin-1 -yl)-1 H-pyrazolo[3,4- d]pyrimidine
3-bromo-4-(4-{4-methyl-2 (2-morpholin-4-ylethyl)oxy]biphenyl- 3-yl}piperazin-1 -yl)-1 H-pyrazolo[3,4-d]pyrimidine
Figure imgf000201_0001
3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]- 2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-{[(2,2,2- triflυoroethyl)oxy]methyl}aniline 1-[2-({344-(3-bromo-1 H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin- 1-yl]-4'-methylbiphenyl-2-yl}oxy)ethyl]pyrrolidine-2,5-dione
3-bromo-4-(4-{3'-fluoro-4-methyl-2'-[(2-pyrrolidin-1- ylethyl)oxy]biphenyl-3-yl}piperazin-1 -yl)-1 H-pyrazolo[3,4- d]pyrimidine
1 -{3-[4-(3-bromo-1 H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1 - yl]-5-[(2-pyrrolidin-i -ylethyl)amino]phenyl}butan-1 -one
3-[4-(3-bromo-1 H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]- 2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(3,3,3- trifluoropropyl)oxy]aniline
3-[4-(3-bromo-1 H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]- 2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2- trifluoroethyl)oxy]aniline
Figure imgf000202_0001
1-{3-[4-(3-bromo-1 H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1- yll-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-ol 3-bromo-4-(4-{4-chloro-24(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3- yl}piperazin-1 -yl)-1 H-pyrazolo[3,4-d]pyrimidine
3-[4-(4-{5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3- [(2-pyrrolidin-1 -ylethyl)amino]phenyl}piperazin-1 -yl)-1 H- pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol
Figure imgf000203_0001
3-bromo-4-(4-{4-chloro-4'-fluoro-2'-[(2-pyrrolidin-1- ylethyl)oxy]biphenyl-3-yl}piperazin-1 -yl)-1 H-pyrazolo[3,4- d]pyrimidine
3-bromo-4-(4-{4-methyl-34(2-pyrrolidin-1-ylethyl)oxy]biphenyl- 3-yl}piperazin-1 -yl)-1 H-pyrazolo[3,4-dlpyrimidine
Figure imgf000203_0002
(2E)-3-[4-(4-{5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2- methyl-3-[(2-pyrroπdin-1-ylethyl)amino]phenyl}piperazin-1-yl)- 1 H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid
[1035] The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the invention and that modifications may be made therein without departing from the spirit or scope of the invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

Claims

What is claimed is:
1. A compound of Formula I,
Figure imgf000205_0001
or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, X2ι is N or CR22; X22 is N or CR23; X23 is N or CR24, but when X22 is N then X23 is CR2 ; each of R2), R22, R23, R2 , R25, R26, R27, R2 , R29 and R30, and each R3 !, R32 and R33 is independently selected from -H, halogen, trihalomethyl, -CN, -NO2, -NR35R35a, -S(0)o-2R35, -SO2NR35R35a, -CO2R35, -C(O)NR35R35a, -N(R35)SO2R35, -N(R35)C(0)R35, -N(R35)CO2R35, -OR35, -C(0)R35) optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; R is selected from -H, halogen, trihalomethyl, -S(0)o-2R35, -SO2NR35R35a, -C02R35, -C(O)NR35R35a, -OR35, -C(O)R35, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or two of R25, R26, R27, R28, R29, R3o, R3ι or R32, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted spirocyclic ring system, optionally substituted fused ring system, and optionally substituted saturated bridged ring system; each of R35 and R35a is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substitated lower arylalkyl, optionally substitated lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or R35 and R35a, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl; and m is an integer from 0 to 5; n is an integer from 1 to 2; and with the provisos that when X22 is CR23 and X23 is N then R is not optionally substituted aryl, aralkyl or heteroaryl, and that when X22 is N and X23 is CR24 then R is not optional substitated aryl or heteroaryl and R21 is not -NR35R35a, and that when X22 is CR23 and X23 is CR2 then R2ι is not optionally substituted aryl, and that compounds with CAS Registration Nos. 732271-60-2, 565169-26-8, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-34-2, 47281-43-6, 37425-49-3, 37425-48-2, 24932-89-6 and 24932- 78-3 are not included in Formula I.
2. A compound of Claim 1, wherein In one example, the compound is according to Formula I, wherein n is 1.
3. A compound according to Claim 2, wherein X 1 is N.
4. A compound according to Claim 3, wherein X23 is N.
5. A compound according to Claim 4, wherein X22 is CR23.
6. A compound according to Claim 5, wherein R is -H.
7. A compound according to Claim 5, wherein R is optionally substituted alkyl.
8. A compound according to Claim 6, wherein R2ι is -H.
9. A compound according to Claim 6, wherein R21 is optionally substituted alkyl.
10. A compound according to Claim 8, wherein R25 and R 6 are -H.
11. A compound according to Claim 10, wherein R27 and R28 are -H.
12. A compound according to Claim 11, wherein R29 is -H.
13. A compound according to Claim 12, wherein R30 is -H.
14. A compound according to Claim 12, wherein R30 is optionally substituted alkyl.
15. A compound according to Claim 12, wherein R30 is -C(O)R35.
16. A compound according to Claim 12, wherein R30 is -C(O)NR35R35a.
17. A compound according to Claim 13, wherein R3ι is -H.
18. A compound according to Claim 17, wherein R3 is -H.
19 A compound according to Claim 17, wherein R32 is -C(O)R35.
20 A compound according to Claim 17, wherein R29, R30, R3ι, and R32 are -H.
21 A compound according to Claim 18, wherein R23 is optionally substituted alkyl.
22, A compound according to Claim 18, wherein R23 is halogen.
23 A compound according to Claim 22, wherein R23 is Br.
24 A compound according to Claim 18, wherein R23 is -H.
25 A compound according to Claim 18, wherein m is 2.
26 A compound according to Claim 18, wherein m is 3.
27, A compound according to Claim 18, wherein R33 is -H.
28, A compound according to Claim 18, wherein R33 is halogen.
29, A compound according to Claim 18, wherein R33 is optionally substitated alkyl.
30. A compound according to Claim 18, wherein R33 is -NR35R35a.
31. A compound according to Claim 18, wherein R33 is -C(O)R35.
32. A compound according to Claim 18, wherein R33 is trihalomethyl.
33. A compound of Formula II,
Figure imgf000207_0001
II or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, X2ι is N or CR22; X22 is N or CR23; X23 is N or CR24, but when X22 is N then X23 is CR24; each of R2), R22, R2 , R24, R25, R26, R27, R-28, R29 and R30 and each of R3ι, R32 and R 3 is independently selected from -H, halogen, trihalomethyl, -CN, -NO2, -NR35R35a, -S(O)0-2R35, -SO2NR35R35a, -CO2R35, -C(O)NR35R35a, -N(R35)S02R35, -N(R35)C(O)R35, -N(R35)CO2R35, -OR35, -C(O)R35, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; R is selected from -H, halogen, trihalomethyl, -S(O)o-2R35, -SO2NR3sR35a, -CO2R3s, -C(0)NR35R35a, -OR35, -C(O)R35, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or two of R25, R26, R27, R28, R29, R3o, R31 or R32, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted spirocyclic ring system, optionally substituted fused ring system, and optionally substituted saturated bridged ring system; each R35 and R35a is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or R35 and R3sa, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl; Qi optionally substituted heterocyclyl; n is an integer from 1 to 2; and with the provisos that when X22 is CR2 and X2 is N then R is not optionally substituted aryl, aralkyl or heteroaryl, and that when X22 is N and X23 is CR24 then R is not optional substituted aryl or heteroaryl and R2ι is not -NR 5R35a, and that when X22 is CR23 and X23 is CR24 then R2| is not optionally substituted aryl and
Figure imgf000208_0001
is N, and that compounds with CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908- 34-7, 537667-22-4, 252722-35-3, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 24932-90-9, and 24932-77-2 are not included in Formula II.
34. A compound of Claim 33, wherein n is 1.
35. A compound of Claim 34, wherein X 1 is N.
36. A compound of Claim 35, wherein X23 is N.
37. A compound of Claim 36, wherein X22 is CR23.
38. A compound of Claim 37, wherein R is -H.
39. A compound of Claim 37, wherein R is optionally substituted alkyl.
40. A compound of Claim 38, wherein R21 is -H.
41. A compound of Claim 38, wherein R 1 is optionally substitated alkyl.
42. A compound of Claim 40, wherein R25 and R26 are -H.
43. A compound of Claim 42, wherein R27 and R28 are -H.
44. A compound of Claim 43, wherein R29 is -H.
45. A compound of Claim 44, wherein R30 is -H.
46. A compound of Claim 44, wherein R30 is optionally substituted alkyl.
47. A compound of Claim 44, wherein R30 is -C(O)R35.
48. A compound of Claim 44, wherein R30 is -C(O)NR35R35a.
49. A compound of Claim 45, wherein R31 is -H.
50. A compound of Claim 49, wherein R3 is -H.
51. A compound of Claim 50, wherein R32 is -C(O)R35.
52. A compound of Claim 50, wherein R29, R30, R31, and R32 are -H.
53. A compound of Claim 50, wherein R23 is optionally substitated alkyl.
54. A compound of Claim 50, wherein R23 is halogen.
55. A compound of Claim 50, wherein R23 is -H.
56. A compound of Claim 50, wherein Qi is a substituted heterocyclyl wherein the heterocyclyl has at least one nitrogen.
57. A compound of Claim 55, wherein Qi is a substituted heterocyclyl wherein the heterocyclyl has at least one oxygen.
58. A composition comprising the compound of Claim 1 or 33, and at least one pharmaceutically acceptable carrier or excipient.
59. A metabolite of the compound of Claim 1 or 33.
60. A method of modulating the in vivo activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising at least one compound of Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425- 49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X22 is CR23 and X23 is N then R is optionally substitated aryl, aralkyl or heteroaryl, and when X22 is N and X23 is CR^ then R21 is - NR35R35, and when X22 is CR23 and X23 is CR24 then R21 is optionally substitated aryl and X 1 is N.
61. A method of Claim 60, wherein the kinase is p70S6 and/or Akt.
62. A method of Claim 61, wherein modulating the in vivo activity of p70S6K and/or AktK comprises inhibition of p70S6K and/or AktK.
63. A method of treating and/or inhibiting diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising at least one of the compound according to Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908- 34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X22 is CR23 and X23 is N then R is optionally substitated aryl, aralkyl or heteroaryl, and when X22 is N and X23 is CR2 then R21 is -NR35R35, and when X22 is CR23 and X23 is CR24 then R21 is optionally substituted aryl and X2ι is N.
64. A method of screening for modulator of a p70S6K and/or AktK, the method comprising combining at least one of the compound according to Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908- 34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X22 is CR23 and X23 is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X22 is N and X23 is CR24 then R21 is -NR35R35, and when X22 is CR23 and X23 is CR24 then R2ι is optionally substituted aryl and X2ι is N, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
65. A method of inhibiting prohferative activity in a cell or a plurality of cells, the method comprising administering an effective amount of at least one of the compound according to Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425- 49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X22 is CR23 and X23 is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X 2 is N and X23 is CR24 then R21 is - NR35R35, and when X22 is CR23 and X 3 is CR 4 then R21 is optionally substituted aryl and X21 is N, to said cell or plurality of cells.
PCT/US2005/013860 2004-04-23 2005-04-22 Kinase modulators and methods of use WO2005117909A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP20050804792 EP1750727A2 (en) 2004-04-23 2005-04-22 Kinase modulators and methods of use
AU2005249380A AU2005249380C1 (en) 2004-04-23 2005-04-22 Kinase modulators and methods of use
US11/568,173 US8076338B2 (en) 2004-04-23 2005-04-22 Kinase modulators and methods of use
JP2007509678A JP5213229B2 (en) 2004-04-23 2005-04-22 Kinase modulators and methods of use
CA2563699A CA2563699C (en) 2004-04-23 2005-04-22 Kinase modulators and method of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56490804P 2004-04-23 2004-04-23
US60/564,908 2004-04-23

Publications (2)

Publication Number Publication Date
WO2005117909A2 true WO2005117909A2 (en) 2005-12-15
WO2005117909A3 WO2005117909A3 (en) 2006-04-27

Family

ID=35463331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013860 WO2005117909A2 (en) 2004-04-23 2005-04-22 Kinase modulators and methods of use

Country Status (6)

Country Link
US (1) US8076338B2 (en)
EP (1) EP1750727A2 (en)
JP (1) JP5213229B2 (en)
AU (1) AU2005249380C1 (en)
CA (1) CA2563699C (en)
WO (1) WO2005117909A2 (en)

Cited By (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071819A1 (en) * 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006090261A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
WO2006124865A2 (en) * 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
WO2007117494A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
WO2007125321A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125325A1 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
JP2008517984A (en) * 2004-10-25 2008-05-29 アステックス、セラピューティックス、リミテッド Ortho-fused pyridine and pyrimidine derivatives (eg purines) as protein kinase inhibitors
WO2008075110A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety
WO2008118468A1 (en) 2007-03-23 2008-10-02 Amgen Inc. Heterocyclic compounds and their uses
WO2008140947A1 (en) 2007-05-11 2008-11-20 Eli Lilly And Company P70 s6 kinase inhibitors
WO2010056575A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and egfr inhibitor combination therapy
WO2010056574A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
JP2010521438A (en) * 2007-03-15 2010-06-24 ノバルティス アーゲー Organic compounds and uses thereof
US7880008B2 (en) 2005-05-31 2011-02-01 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
WO2011017009A1 (en) 2009-08-07 2011-02-10 Merck Patent Gmbh Novel azaheterocyclic compounds
US8003651B2 (en) 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8044041B2 (en) 2006-11-15 2011-10-25 Forest Laboratories Holdings Limited Phthalazine derivatives as inhibitors of protein kinase
WO2011141474A1 (en) * 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8101623B2 (en) 2007-10-11 2012-01-24 Astrazeneca Ab Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
WO2012013282A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2012027495A1 (en) * 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8148387B2 (en) 2008-11-11 2012-04-03 Eli Lilly And Company AKT and P70 S6 kinase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2012069146A1 (en) 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines
US20120157443A1 (en) * 2009-09-04 2012-06-21 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
US8232274B2 (en) * 2007-03-15 2012-07-31 Albany Molecular Research, Inc. Pyridazinone derivatives useful as glucan synthase inhibitors
CN101489559B (en) * 2006-04-25 2012-08-15 阿斯特克斯治疗有限公司 Purine and deazapurine derivatives as pharmaceutical compounds
US8247576B2 (en) 2003-12-23 2012-08-21 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2013040044A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
WO2013040059A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
US8436002B2 (en) 2009-10-23 2013-05-07 Eli Lilly And Company AKT inhibitors
US8497294B2 (en) 2007-03-14 2013-07-30 Astex Therapeutics Limited Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
WO2013128378A1 (en) 2012-02-28 2013-09-06 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as gpr agonists
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8637532B2 (en) 2009-02-11 2014-01-28 Merck Patent Gmbh Amino azaheterocyclic carboxamides
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2014078637A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
WO2014078634A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
WO2014096423A1 (en) * 2012-12-20 2014-06-26 Ucb Pharma S.A. Therapeutically active pyrazolo-pyrimidine derivatives
US8765949B2 (en) 2009-12-17 2014-07-01 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
CN102245607B (en) * 2008-10-14 2014-07-02 第一三共株式会社 Morpholinopurine derivative
CN104016985A (en) * 2013-03-01 2014-09-03 华东理工大学 Pyrazolo pyrimidine compound and application thereof
US8835440B2 (en) 2008-12-19 2014-09-16 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2014143612A1 (en) 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
CN104072499A (en) * 2013-03-29 2014-10-01 黄传满 Piperazine substituted pyrimidine compounds and applications thereof
WO2014039714A3 (en) * 2012-09-06 2014-10-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014160521A1 (en) * 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
CN104119343A (en) * 2013-04-25 2014-10-29 苏州科捷生物医药有限公司 2-trifluoromethyl thiadiazole compound and application thereof
CN104292242A (en) * 2014-09-18 2015-01-21 广州必贝特医药技术有限公司 Pyrantel compound and preparation, as well as preparation method and application of pyrantel compound and preparation
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
WO2015078799A1 (en) * 2013-11-27 2015-06-04 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
WO2015107494A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
WO2015107495A1 (en) * 2014-01-17 2015-07-23 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
US9108958B2 (en) 2011-07-15 2015-08-18 Boehringer Ingelheim International Gmbh Selective CCR2 antagonists
WO2015149909A1 (en) 2014-04-03 2015-10-08 Merck Patent Gmbh Combinations of cancer therapeutics
US9200002B2 (en) 2013-10-17 2015-12-01 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9402847B2 (en) 2011-04-01 2016-08-02 Astrazeneca Ab Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
US9409871B2 (en) 2008-07-18 2016-08-09 Novartis Ag Pyridazinyl derivatives as SMO inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2016170163A1 (en) * 2015-04-23 2016-10-27 Sentinel Oncology Limited Substituted quinoxalines and benzotriazine p70s6 kinase inhibitors
US9487525B2 (en) 2012-04-17 2016-11-08 Astrazeneca Ab Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
WO2017035354A1 (en) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
US9586961B2 (en) 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9610289B2 (en) 2011-04-01 2017-04-04 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9737540B2 (en) 2011-11-30 2017-08-22 Astrazeneca Ab Combination treatment of cancer
CZ306987B6 (en) * 2015-10-26 2017-11-01 Ústav experimentální botaniky AV ČR, v. v. i. 2,6-disubstituted purines for use as pharmaceuticals and pharmaceutical preparations containing them
WO2017200087A1 (en) 2016-05-20 2017-11-23 大鵬薬品工業株式会社 Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative
US10000496B2 (en) 2015-07-24 2018-06-19 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit and PDGFR
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10080753B2 (en) 2011-12-22 2018-09-25 Merck Patent Gmbh Heterocyclic carboxamides as modulators of kinase activity
CN108794480A (en) * 2017-04-28 2018-11-13 天津药物研究院有限公司 Azolopyrimidines, preparation method and use
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10213428B2 (en) 2015-07-02 2019-02-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10370379B2 (en) 2015-11-19 2019-08-06 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
WO2020028482A1 (en) * 2018-07-31 2020-02-06 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10618887B2 (en) 2012-06-08 2020-04-14 Sunesis Pharmaceuticals, Inc. Pyrimidinyl tyrosine kinase inhibitors
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US10829493B2 (en) 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
USRE48622E1 (en) 2012-12-20 2021-07-06 UCB Biopharma SRL Therapeutically active pyrazolo-pyrimidine derivatives
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
WO2024073502A1 (en) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
RU2817354C2 (en) * 2019-04-12 2024-04-15 Блюпринт Медисинс Корпорейшн COMPOSITIONS AND METHODS OF TREATING KIT- AND PDGFRα-MEDIATED DISEASES
US11964980B2 (en) 2019-04-12 2024-04-23 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
US12053470B2 (en) 2017-01-10 2024-08-06 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1599468T3 (en) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders associated therewith such as diabetes and hyperglycemia
JP5608097B2 (en) 2008-01-08 2014-10-15 アレイ バイオファーマ、インコーポレイテッド Pyrrolopyridine as a kinase inhibitor
CA2711741A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
CA2721919C (en) * 2008-04-21 2016-08-16 Lexicon Pharmaceuticals, Inc. Limk2 inhibitors, compositions comprising them, and methods of their use
US8367663B2 (en) 2009-01-08 2013-02-05 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
KR101771401B1 (en) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
UA107938C2 (en) * 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
JP5766820B2 (en) * 2011-02-09 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Heterocyclic compounds as PI3 kinase inhibitors
KR20180108848A (en) 2011-04-01 2018-10-04 쿠리스 인코퍼레이션 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
SG195085A1 (en) * 2011-06-07 2013-12-30 Pfizer Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
EP2548878A1 (en) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
JP2014156442A (en) * 2013-02-18 2014-08-28 Nippon Rikagaku Kogyo Kk Method of producing arylpiperazine derivatives or salts thereof
JP5719985B2 (en) * 2013-08-01 2015-05-20 株式会社ポーラファルマ Diphenylmethyl piperazine derivatives
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10227347B2 (en) * 2015-04-21 2019-03-12 Guizhou Bailing Group Pharmaceutical Co., Ltd. Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
BR112021004371A2 (en) 2018-09-11 2021-05-25 Curis Inc. therapy in combination with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1165283A (en) 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
CA2065434C (en) 1989-09-19 1999-11-30 Yasuji Sakuma Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and pharmaceutical preparation comprising the same as active ingredient
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
US6946449B2 (en) * 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
JP2005509612A (en) 2001-10-12 2005-04-14 アイアールエム エルエルシー Method for synthesizing substituted purines
SE0300457D0 (en) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1663962A4 (en) 2003-08-22 2007-08-22 Dendreon Corp Compositions and methods for the treatment of disease associated with trp-p8 expression
JP2007523938A (en) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー Condensed derivatives of pyrazole
GB0407723D0 (en) 2004-04-05 2004-05-12 Novartis Ag Organic compounds
JP5274842B2 (en) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド [1H-piperazo [3,4-d] pyrimidin-4-yl] -piperazine as a serine-threonine kinase modulator (p70S6K, Akt-1 and Akt-2) for the treatment of immune, inflammatory and proliferative disorders Or [1H-piperazo [3,4-d] pyrimidin-4-yl] -piperazine compounds

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
BOLEN, ONCOGENE, vol. 8, 1993, pages 2025 - 2031
GOODMAN; GILMAN ET AL.: "The Pharmacological Basis of Therapeutics", 1990, PERGAMON PRESS
MANNING ET AL., SCIENCE, vol. 298, 2002, pages 1912
PENDE ET AL., NATURE, vol. 408, 2000, pages 994 - 997
PLOWMAN ET AL., DN&P, vol. 7, no. 6, 1994, pages 334 - 339
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14, A.C.S. SYMPOSIUM SERIES
UM ET AL., NATURE, vol. 431, 2004, pages 200 - 205

Cited By (315)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283226B2 (en) 2003-12-23 2016-03-15 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US8247576B2 (en) 2003-12-23 2012-08-21 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US8691806B2 (en) 2003-12-23 2014-04-08 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
JP2008517984A (en) * 2004-10-25 2008-05-29 アステックス、セラピューティックス、リミテッド Ortho-fused pyridine and pyrimidine derivatives (eg purines) as protein kinase inhibitors
US8546407B2 (en) 2004-10-25 2013-10-01 Astex Therapeutics Limited Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors
WO2006071819A1 (en) * 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006090261A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US7705002B2 (en) 2005-05-19 2010-04-27 Vertex Pharmaceuticals Incorporated Biaryls useful as modulators of ion channels
WO2006124865A2 (en) * 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
WO2006124865A3 (en) * 2005-05-19 2007-01-11 Vertex Pharma Biaryls derivatives useful as modulators of ion channels
US7880008B2 (en) 2005-05-31 2011-02-01 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US8329702B2 (en) 2005-05-31 2012-12-11 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US8741912B2 (en) 2006-04-05 2014-06-03 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of Janus kinases
WO2007117494A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
CN101489559B (en) * 2006-04-25 2012-08-15 阿斯特克斯治疗有限公司 Purine and deazapurine derivatives as pharmaceutical compounds
JP2009534455A (en) * 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
EP3421471A1 (en) * 2006-04-25 2019-01-02 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125321A3 (en) * 2006-04-25 2007-12-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125321A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP3719018A1 (en) * 2006-04-25 2020-10-07 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125325A1 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US8853199B2 (en) 2006-07-06 2014-10-07 Array Biopharma, Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
US8846681B2 (en) 2006-07-06 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8003651B2 (en) 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8044041B2 (en) 2006-11-15 2011-10-25 Forest Laboratories Holdings Limited Phthalazine derivatives as inhibitors of protein kinase
WO2008075110A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety
US8497294B2 (en) 2007-03-14 2013-07-30 Astex Therapeutics Limited Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
JP2010521438A (en) * 2007-03-15 2010-06-24 ノバルティス アーゲー Organic compounds and uses thereof
US8232274B2 (en) * 2007-03-15 2012-07-31 Albany Molecular Research, Inc. Pyridazinone derivatives useful as glucan synthase inhibitors
WO2008118468A1 (en) 2007-03-23 2008-10-02 Amgen Inc. Heterocyclic compounds and their uses
EA017389B1 (en) * 2007-03-23 2012-12-28 Амген Инк. Heterocyclic compounds and their uses
US9873701B2 (en) 2007-03-23 2018-01-23 Amgen Inc. Heterocyclic compounds and their uses
EP3045458A1 (en) * 2007-03-23 2016-07-20 Amgen, Inc Heterocyclic compounds and their uses
US8586739B2 (en) 2007-03-23 2013-11-19 Amgen Inc. Heterocyclic compounds and their uses
US8901135B2 (en) 2007-03-23 2014-12-02 Amgen Inc. Heterocyclic compounds and their uses
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010526814A (en) * 2007-05-11 2010-08-05 イーライ リリー アンド カンパニー P70S6 kinase inhibitor
US8093383B2 (en) 2007-05-11 2012-01-10 Eli Lilly And Company P70 S6 kinase inhibitors
TWI423805B (en) * 2007-05-11 2014-01-21 Lilly Co Eli P70 s6 kinase inhibitors
WO2008140947A1 (en) 2007-05-11 2008-11-20 Eli Lilly And Company P70 s6 kinase inhibitors
AU2008251692B2 (en) * 2007-05-11 2012-10-11 Eli Lilly And Company P70 S6 kinase inhibitors
CN101679439B (en) * 2007-05-11 2013-09-11 伊莱利利公司 P70 s6 kinase inhibitors
EA016445B1 (en) * 2007-05-11 2012-05-30 Эли Лилли Энд Компани P70 s6 kinase inhibitors
CN101679439A (en) * 2007-05-11 2010-03-24 伊莱利利公司 P70 S6 kinase inhibitor
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US11236095B2 (en) 2007-10-11 2022-02-01 Astrazeneca Ab Protein kinase B inhibitors
CN101861321B (en) * 2007-10-11 2013-02-06 阿斯利康(瑞典)有限公司 Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
US10059714B2 (en) 2007-10-11 2018-08-28 Astrazeneca Ab Protein kinase B inhibitors
US8101623B2 (en) 2007-10-11 2012-01-24 Astrazeneca Ab Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
US10654855B2 (en) 2007-10-11 2020-05-19 Astrazeneca Ab Protein kinase B inhibitors
US9492453B2 (en) 2007-10-11 2016-11-15 Astrazeneca Ab Protein kinase B inhibitors
US11760760B2 (en) 2007-10-11 2023-09-19 Astrazeneca Ab Protein kinase B inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8420629B2 (en) 2008-03-11 2013-04-16 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US9409871B2 (en) 2008-07-18 2016-08-09 Novartis Ag Pyridazinyl derivatives as SMO inhibitors
CN102245607B (en) * 2008-10-14 2014-07-02 第一三共株式会社 Morpholinopurine derivative
WO2010056574A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
EA018624B1 (en) * 2008-11-11 2013-09-30 Эли Лилли Энд Компани P70 s6 kinase inhibitor and egfr inhibitor combination therapy
US8334293B2 (en) 2008-11-11 2012-12-18 Eli Lilly And Company P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
US8148387B2 (en) 2008-11-11 2012-04-03 Eli Lilly And Company AKT and P70 S6 kinase inhibitors
EA018824B1 (en) * 2008-11-11 2013-10-30 Эли Лилли Энд Компани P70 S6 KINASE INHIBITOR AND mTOR INHIBITOR COMBINATION THERAPY
WO2010056575A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and egfr inhibitor combination therapy
US8835440B2 (en) 2008-12-19 2014-09-16 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
US9067951B2 (en) 2008-12-19 2015-06-30 Boehringer Ingelheim International Gmbh Process and intermediates for the production of CCR2 antagonists
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
US8637532B2 (en) 2009-02-11 2014-01-28 Merck Patent Gmbh Amino azaheterocyclic carboxamides
US9040560B2 (en) 2009-02-11 2015-05-26 Merck Patent Gmbh Amino azaheterocyclic carboxamides
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US9023847B2 (en) 2009-08-07 2015-05-05 Merck Patent Gmbh Azaheterocyclic compounds
WO2011017009A1 (en) 2009-08-07 2011-02-10 Merck Patent Gmbh Novel azaheterocyclic compounds
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US9249146B2 (en) 2009-09-04 2016-02-02 Biogen Ma Inc. Bruton'S tyrosine kinase inhibitors
US10577374B2 (en) 2009-09-04 2020-03-03 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
US9790229B2 (en) * 2009-09-04 2017-10-17 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
AU2016202601B2 (en) * 2009-09-04 2017-12-07 Biogen Ma Inc. Bruton's Tyrosine Kinase Inhibitors
US20120157443A1 (en) * 2009-09-04 2012-06-21 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
US8785440B2 (en) 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
US20140309212A1 (en) * 2009-09-04 2014-10-16 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
US20230046457A1 (en) * 2009-09-04 2023-02-16 Viracta Therapeutics, Inc. Bruton's tyrosine kinase inhibitors
US8436002B2 (en) 2009-10-23 2013-05-07 Eli Lilly And Company AKT inhibitors
US10196402B2 (en) 2009-12-17 2019-02-05 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US8765949B2 (en) 2009-12-17 2014-07-01 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
US11731981B2 (en) 2009-12-17 2023-08-22 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US11046706B2 (en) 2009-12-17 2021-06-29 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US9670222B2 (en) 2009-12-17 2017-06-06 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en) * 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
US9586961B2 (en) 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
WO2012013282A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
US9586938B2 (en) 2010-07-29 2017-03-07 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
US8710044B2 (en) 2010-07-29 2014-04-29 Merck Patent Gmbh Bicyclic azaheterocyclic carboxamides
US10087166B2 (en) 2010-07-29 2018-10-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
WO2012027495A1 (en) * 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
WO2012069146A1 (en) 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines
US9585886B2 (en) 2010-12-16 2017-03-07 Calchan Limited ASK1 inhibiting pyrrolopyrimidine derivatives
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
US9717730B2 (en) 2011-04-01 2017-08-01 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
US10092567B2 (en) 2011-04-01 2018-10-09 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
US9610289B2 (en) 2011-04-01 2017-04-04 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
US9402847B2 (en) 2011-04-01 2016-08-02 Astrazeneca Ab Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9108958B2 (en) 2011-07-15 2015-08-18 Boehringer Ingelheim International Gmbh Selective CCR2 antagonists
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9662330B2 (en) 2011-09-12 2017-05-30 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
US9321760B2 (en) 2011-09-12 2016-04-26 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
US10080750B2 (en) 2011-09-12 2018-09-25 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
WO2013040044A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
WO2013040059A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
US9145392B2 (en) 2011-09-12 2015-09-29 Merck Patent Gmbh Imidazole amines as modulators of kinase activity
US9737540B2 (en) 2011-11-30 2017-08-22 Astrazeneca Ab Combination treatment of cancer
US10080753B2 (en) 2011-12-22 2018-09-25 Merck Patent Gmbh Heterocyclic carboxamides as modulators of kinase activity
WO2013128378A1 (en) 2012-02-28 2013-09-06 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as gpr agonists
US10039766B2 (en) 2012-04-17 2018-08-07 Astrazeneca Ab Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
US9487525B2 (en) 2012-04-17 2016-11-08 Astrazeneca Ab Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US10618887B2 (en) 2012-06-08 2020-04-14 Sunesis Pharmaceuticals, Inc. Pyrimidinyl tyrosine kinase inhibitors
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014039714A3 (en) * 2012-09-06 2014-10-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
US10287300B2 (en) 2012-11-16 2019-05-14 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
US9315517B2 (en) 2012-11-16 2016-04-19 Merck Patent Gmbh Imidazol-piperidinyl derivatives as modulators of kinase activity
WO2014078634A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
US9850255B2 (en) 2012-11-16 2017-12-26 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
WO2014078637A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
EP3299362A1 (en) 2012-11-16 2018-03-28 Merck Patent GmbH Imidazol-piperidinyl derivatives as modulators of kinase activity
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
US9440968B2 (en) 2012-11-29 2016-09-13 Merck Patent Gmbh Substituted pyrido[3,2-d]pyrimidines for treating cancer
US9981925B2 (en) 2012-11-29 2018-05-29 Merck Patent Gmbh Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors
US10233160B2 (en) 2012-11-29 2019-03-19 Merck Patent Gmbh Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors
US11370798B2 (en) 2012-12-07 2022-06-28 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10392391B2 (en) 2012-12-07 2019-08-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9650381B2 (en) 2012-12-07 2017-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10787452B2 (en) 2012-12-07 2020-09-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9718827B2 (en) 2012-12-07 2017-08-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11117900B2 (en) 2012-12-07 2021-09-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US20160194329A1 (en) * 2012-12-20 2016-07-07 Ucb Pharma S.A. Therapeutically Active Pyrazolo-Pyrimidine Derivatives
USRE48622E1 (en) 2012-12-20 2021-07-06 UCB Biopharma SRL Therapeutically active pyrazolo-pyrimidine derivatives
WO2014096423A1 (en) * 2012-12-20 2014-06-26 Ucb Pharma S.A. Therapeutically active pyrazolo-pyrimidine derivatives
EA027752B1 (en) * 2012-12-20 2017-08-31 Юсб Биофарма Спрл Therapeutically active pyrazolo-pyrimidine derivatives
CN105008360B (en) * 2012-12-20 2017-09-19 Ucb生物制药私人有限公司 The Pyrazolopyrimidine derivative of therapeutic activity
US9714248B2 (en) 2012-12-20 2017-07-25 Ucb Pharma S.A. Therapeutically active pyrazolo-pyrimidine derivatives
CN104016985A (en) * 2013-03-01 2014-09-03 华东理工大学 Pyrazolo pyrimidine compound and application thereof
CN104016985B (en) * 2013-03-01 2017-11-03 华东理工大学 A kind of Pyrazolopyrimidine compound and application thereof
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2014143612A1 (en) 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
US9458134B2 (en) 2013-03-11 2016-10-04 Merck Patent Gmbh Heterocycles as modulators of kinase activity
US9867826B2 (en) 2013-03-11 2018-01-16 Merck Patent Gmbh Heterocycles as modulators of kinase activity
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9994552B2 (en) 2013-03-15 2018-06-12 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014160521A1 (en) * 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
CN104072499A (en) * 2013-03-29 2014-10-01 黄传满 Piperazine substituted pyrimidine compounds and applications thereof
CN104119343A (en) * 2013-04-25 2014-10-29 苏州科捷生物医药有限公司 2-trifluoromethyl thiadiazole compound and application thereof
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US11827642B2 (en) 2013-10-17 2023-11-28 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
US10807985B2 (en) 2013-10-17 2020-10-20 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9884861B2 (en) 2013-10-17 2018-02-06 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9200002B2 (en) 2013-10-17 2015-12-01 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2706235C2 (en) * 2013-10-17 2019-11-15 Блюпринт Медсинс Корпорейшн Compositions suitable for treating disorders associated with kit
US9944651B2 (en) 2013-10-17 2018-04-17 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9994575B2 (en) 2013-10-17 2018-06-12 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2015078799A1 (en) * 2013-11-27 2015-06-04 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US10815239B2 (en) 2013-12-06 2020-10-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11485739B2 (en) 2013-12-06 2022-11-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
TWI657083B (en) * 2014-01-17 2019-04-21 瑞士商諾華公司 Compounds and compositions for inhibiting the activity of shp2
US10774065B2 (en) 2014-01-17 2020-09-15 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US11952386B2 (en) 2014-01-17 2024-04-09 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
US10077276B2 (en) 2014-01-17 2018-09-18 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
KR102501558B1 (en) 2014-01-17 2023-02-20 노파르티스 아게 N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
CN105899493B (en) * 2014-01-17 2019-03-29 诺华股份有限公司 For inhibiting the active 1- of SHP2 (triazine -3- base/pyridazine -3- base)-piperazine (- piperazine) piperidine derivatives and combinations thereof
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
CN105916845B (en) * 2014-01-17 2019-11-12 诺华股份有限公司 N- heteroaryl compound and composition for inhibiting the active N- azaspiro cycloalkanes of SHP2 to replace
US11401259B2 (en) 2014-01-17 2022-08-02 Novartis Ag 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
WO2015107494A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
US10968235B2 (en) 2014-01-17 2021-04-06 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
EA031573B1 (en) * 2014-01-17 2019-01-31 Новартис Аг N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
US10336774B2 (en) 2014-01-17 2019-07-02 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
CN105916845A (en) * 2014-01-17 2016-08-31 诺华股份有限公司 N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
CN105899491B (en) * 2014-01-17 2019-04-02 诺华股份有限公司 For inhibiting the active 1- pyridazine-of SHP2/triazine -3- base-piperazine (- piperazine)/pyridine/pyrrolidin derivatives and combinations thereof
WO2015107495A1 (en) * 2014-01-17 2015-07-23 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
KR20160103137A (en) * 2014-01-17 2016-08-31 노파르티스 아게 N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
US10301278B2 (en) 2014-01-17 2019-05-28 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
CN105899493A (en) * 2014-01-17 2016-08-24 诺华股份有限公司 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of SHP2
CN105899491A (en) * 2014-01-17 2016-08-24 诺华股份有限公司 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of SHP2
WO2015149909A1 (en) 2014-04-03 2015-10-08 Merck Patent Gmbh Combinations of cancer therapeutics
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10800781B2 (en) 2014-06-05 2020-10-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10093676B2 (en) 2014-06-05 2018-10-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US11254681B2 (en) 2014-08-04 2022-02-22 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10689383B2 (en) 2014-08-04 2020-06-23 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN104292242A (en) * 2014-09-18 2015-01-21 广州必贝特医药技术有限公司 Pyrantel compound and preparation, as well as preparation method and application of pyrantel compound and preparation
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2016170163A1 (en) * 2015-04-23 2016-10-27 Sentinel Oncology Limited Substituted quinoxalines and benzotriazine p70s6 kinase inhibitors
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US11147814B2 (en) 2015-07-02 2021-10-19 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US12076321B2 (en) 2015-07-02 2024-09-03 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US10213428B2 (en) 2015-07-02 2019-02-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US10568885B2 (en) 2015-07-02 2020-02-25 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-y1)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-citrate
US10000496B2 (en) 2015-07-24 2018-06-19 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit and PDGFR
US10017512B2 (en) 2015-08-26 2018-07-10 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
RU2744974C2 (en) * 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Compounds and compositions used for treatment of ntrk-related disorders
WO2017035354A1 (en) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
US11046697B2 (en) 2015-08-26 2021-06-29 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
CN108137607A (en) * 2015-08-26 2018-06-08 蓝图药品公司 Suitable for treating compound and composition with the relevant illnesss of NTRK
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CZ306987B6 (en) * 2015-10-26 2017-11-01 Ústav experimentální botaniky AV ČR, v. v. i. 2,6-disubstituted purines for use as pharmaceuticals and pharmaceutical preparations containing them
US11059827B2 (en) 2015-11-19 2021-07-13 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
US10370379B2 (en) 2015-11-19 2019-08-06 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
US10933065B2 (en) 2015-12-23 2021-03-02 Arqule Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020400B2 (en) 2015-12-23 2021-06-01 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10245263B2 (en) 2015-12-23 2019-04-02 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN109153681A (en) * 2016-05-20 2019-01-04 大鹏药品工业株式会社 Novel 5H- pyrrolo- [2,3-d] pyrimidine -6 (7H) -one derivative
US10538528B2 (en) 2016-05-20 2020-01-21 Taiho Pahrmaceutical Co., Ltd. 5H-pyrrolo[2,3-D]pyrimidin-6(7H)-one derivative
CN109153681B (en) * 2016-05-20 2021-06-04 大鹏药品工业株式会社 Novel 5H-pyrrolo [2,3-d ] pyrimidin-6 (7H) -one derivatives
WO2017200087A1 (en) 2016-05-20 2017-11-23 大鵬薬品工業株式会社 Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative
KR20180120777A (en) 2016-05-20 2018-11-06 다이호야쿠힌고교 가부시키가이샤 A novel 5H-pyrrolo [2,3-d] pyrimidin-6 (7H) -one derivative
EP3459953A4 (en) * 2016-05-20 2020-01-08 Taiho Pharmaceutical Co., Ltd. Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative
US11905283B2 (en) 2016-06-14 2024-02-20 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
US12053470B2 (en) 2017-01-10 2024-08-06 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN108794480A (en) * 2017-04-28 2018-11-13 天津药物研究院有限公司 Azolopyrimidines, preparation method and use
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
WO2020028482A1 (en) * 2018-07-31 2020-02-06 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity
US12060354B2 (en) 2019-04-12 2024-08-13 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
US10829493B2 (en) 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
US11999744B2 (en) 2019-04-12 2024-06-04 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
US11964980B2 (en) 2019-04-12 2024-04-23 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
RU2817354C2 (en) * 2019-04-12 2024-04-15 Блюпринт Медисинс Корпорейшн COMPOSITIONS AND METHODS OF TREATING KIT- AND PDGFRα-MEDIATED DISEASES
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
WO2024073502A1 (en) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors

Also Published As

Publication number Publication date
CA2563699A1 (en) 2005-12-15
AU2005249380A1 (en) 2005-12-15
JP5213229B2 (en) 2013-06-19
JP2007534687A (en) 2007-11-29
AU2005249380C1 (en) 2012-09-20
WO2005117909A3 (en) 2006-04-27
US20080076774A1 (en) 2008-03-27
AU2005249380B2 (en) 2012-05-10
US8076338B2 (en) 2011-12-13
CA2563699C (en) 2014-03-25
EP1750727A2 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
AU2005249380C1 (en) Kinase modulators and methods of use
AU2005322085B2 (en) [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
JP6932394B2 (en) Nitrogen-containing heterocyclic compounds, production methods, intermediates, pharmaceutical compositions and applications
JP6726677B2 (en) Substituted 2-H-pyrazole derivatives as anticancer agents
AU2004259012B2 (en) Anaplastic lymphoma kinase modulators and methods of use
CA2453881C (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
AU2003249212C1 (en) Receptor-type kinase modulators and methods of use
US8404692B2 (en) Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds
AU2007263017A1 (en) Pyridine and pyrazine derivatives as MNK kinase inhibitors
KR20190067913A (en) Aminopyrazolopyrimidine compounds used as inhibitors of tyrosine kinase receptors which are neurotrophic factors
EP3083625A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EP1773826A2 (en) C-met modulators and method of use
EP2320895A2 (en) Cdk modulators
TW200300350A (en) C-5 modified indazolylpyrrolotriazines
BRPI0614502A2 (en) COMPOUND, PROCESS TO PREPARE THE SAME, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
KR102603203B1 (en) Pyridopyrimidines as histamine H4-receptor inhibitors
JP2022538042A (en) CDK kinase inhibitor
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
TW202340175A (en) Parp7 inhibitors
AU2011202643A1 (en) Anaplastic lymphoma kinase modulators and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005249380

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2563699

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007509678

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2005249380

Country of ref document: AU

Date of ref document: 20050422

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005249380

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005804792

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005804792

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11568173

Country of ref document: US